













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
Cardiovascular risk factor prevalence, mortality and 
cardiovascular disease incidence in patients who initiated 
renal replacement therapy in childhood; systematic review 








Doctor of Philosophy  








I, Dinara Galiyeva, hereby declare that the thesis has been composed by me and is my 
own work. This work has not been submitted for any other degree or professional 
qualification. 
 

















Background. The incidence of starting renal replacement therapy (RRT) among 
young people (<20 years of age) in 2013 in Scotland was 7.7 per million (age-related) 
population. Little knowledge exists about cardiovascular risk factors (CVRFs), long-
term survival and cardiovascular disease (CVD) outcomes in patients who initiated 
RRT in childhood. The main source of routine data for these patients is available from 
the European Society of Paediatric Nephrology/European Renal Association-
European Dialysis and Transplant Association (ESPN/ERA-EDTA) registry. In 
Scotland nationally comprehensive data on patients receiving RRT is available from 
the Scottish Renal Registry (SRR). 
Aim and objectives. The overall aim of the thesis is to review relevant literature and 
conduct retrospective cohort studies describing CVRF prevalence, all-cause mortality 
and incidence of CVD outcomes in patients who initiated RRT in childhood. 
ESPN/ERA-EDTA registry data were used to describe the prevalence of anaemia, 
hypertension, dyslipidaemia and BMI categories and their association with all-cause 
and CV mortality. SRR data were used to describe all-cause mortality and CVD 
incidence and their association with age at start of RRT, sex, primary renal disease 
(PRD), type of RRT and period of start of RRT.  
Methods. Systematic searches were performed to identify relevant literature. For the 
ESPN/ERA-EDTA analyses patients who started RRT between 0 and 20 years of age 
and who had CVRF data were included. Patients were followed from date of first 
CVRF measurement until the earliest of death, loss to follow-up, reaching 20 years of 
age or the end of follow-up (December 31st 2012). Cox proportional hazard models 
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were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for 
mortality, comparing patients with and without each CVRF. For the SRR analyses, 
patients who started RRT under 18 years of age in the period from 1963 to 2013 were 
included in the analyses. To describe CVD incidence the SRR data were linked to 
national registers for death and CVD hospital admissions available from 1981 
onwards. These analyses, therefore, included patients who started RRT between 1981 
and 2013 with follow-up until first CVD event after start of RRT, end of follow-up 
period or censoring at death. Cox proportional hazard models were used to examine 
the association of age at initiation of RRT, sex, PRD, type of RRT and period of 
initiation of RRT with all-cause mortality and CVD incidence.  
Results. The systematic reviews revealed a gap in current knowledge about CVD 
incidence and the association of CVRFs with CVD outcomes in patients who initiated 
RRT in childhood. In total, 7,845 patients were included in the ESPN/ERA-EDTA 
registry analysis. The mean age of the patients was 9.5 (SE 0.06) years, 58.9% were 
male, and the most common PRD was congenital anomalies of kidney and urinary tract 
(CAKUT). The prevalence of dyslipidaemia, hypertension, anaemia 
overweight/obesity and underweight was 87.5%, 79.3%, 36.0%, 29.9% and 4.3%, 
respectively. During median follow-up of 3.7 (IQR 1.7-6.8) years 357 patients died. 
HRs for anaemia were 2.19 (95% CI 1.64-2.93) and 2.55 (95% CI 1.27-5.12) for all-
cause and CVD mortality, respectively. The HR for all-cause mortality for 
underweight was 1.81 (95% CI 1.30-2.53). No other studied CVRFs were statistically 
significantly associated with all-cause and CVD mortality. 
In total, 479 patients were included in the SRR analyses of all-cause mortality. The 
most common PRD was CAKUT and 55.3% of patients were male. During a median 
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follow-up of 18.3 (IQR 8.7-27.0 years) years 126 patients died. Twenty-year survival 
among patients initiated RRT in childhood was 77.6% (95% CI 73.8-81.3). Age at start 
of RRT, PRD and type of RRT were significantly associated with all-cause mortality. 
HR for all-cause mortality for patients who started RRT under 2 years of age was 2.50 
(95% CI 1.19-5.25) compared to patients who started RRT at 12 to 18 years old. HR 
for all-cause mortality for patients with PRD other than CAKUT or glomerulonephritis 
(GN) was 1.58 (95% CI 1.05-2.39) compared to patients with CAKUT. HRs for all-
cause mortality for patients who only received either HD or PD during follow-up were 
19.4 (95% CI 10.4-36.4 and 19.5 (9.65-39.7), respectively, compared to patients who 
received a renal transplant.  
In total, 381 patients were included in the SRR analyses of CVD incidence. During a 
median of 12.9 (IQR 5.6-21.5) years of follow-up after initiation of RRT 134 patients 
(35.2%) developed CVD. The overall crude CVD incidence was 2.6 (95% CI 2.2-3.0) 
per 100 person-years. HRs for CVD were 1.69 (95% CI 1.05-2.74) for males compared 
to females, 1.72 (95% CI 1.02-2.91) for PRD other than CAKUT or GN compared to 
CAKUT and 8.38 (95% CI 3.31-21.23) and 7.30 (95% CI 2.30-23.16) for patients who 
only received either HD or PD during follow-up, respectively, compared to patients 
who received a renal transplant. 
Conclusions. This thesis has contributed to knowledge about CVRF prevalence, 
longer-term survival and CVD outcomes in patients who initiated RRT in childhood 
by identifying high prevalence of CVRFs and that CVD is a common complication. 
This study did not investigate whether anaemia, hypertension, dyslipidaemia and 
obesity are associated with a higher risk of developing CVD after start of RRT. Future 
research is needed to study whether treatment of anaemia, hypertension, dyslipidaemia 
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and controlling body weight will reduce the risk of CVD and mortality in patients who 





















The overall aim of the thesis is to describe risk of dying and risk of heart disease in 
children with kidney failure. I used information collected in the European and Scottish 
registers of children with kidney failure. I found that risk factors for developing a heart 
disease, were common in European children with kidney failure. Children with low 
blood counts or who were underweight were more likely to die than children with 
normal blood counts or who were normal weight. Just over a quarter of the Scottish 
children died during the study period. The highest death rates were for children aged 
less than 2 years when their kidneys failed. Children born with kidney disease and who 
had a kidney transplant had lower risks of dying and of getting a heart disease than 
other groups of children with kidney disease. Over a third of children developed heart 
disease during the study period and the risk was slightly higher in boys than girls. This 
thesis has contributed to knowledge about heart disease and mortality in children with 
kidney failure. Future research is needed to study whether increasing blood count, 
controlling body weight and blood pressure will reduce the risk of  heart disease and 
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Chapter 1. Introduction 
Chronic kidney disease (CKD) is a serious condition as it can progress to end-stage 
renal disease (ESRD) which is the final stage of CKD. Treatment with renal 
replacement therapy (RRT) i.e. dialysis or kidney transplant, becomes necessary to 
sustain life when a patient reaches the final stage of CKD. The European Renal 
Association-European Dialysis and Transplant Association (ERA-EDTA) registry 
annually collects data on patients receiving RRT for ESRD from national and regional 
renal registries in Europe. In 2014, the total unadjusted incidence rate of RRT among 
all the registries reporting to the ERA-EDTA registry was 133 per year per million of 
the age-related population (MARP) (1). The incidence of RRT in children and 
adolescents is much lower than among adults. For Scotland, the ERA-EDTA registry 
reported the incidence rate of 12.0 per MARP among patients who initiated RRT from 
zero to 19 years old, while it was 55.1 per MARP for patients from 20 to 44 years old, 
143.3 per MARP from 45 to 64 years old, 254.1 per MARP from 65 to 74 years old 
and 230.8 per MARP for patients older than 75 years old (1).  
This “Introduction” chapter defines CKD and describes its classification, aetiology and 
epidemiology. This chapter also presents the background for this research, and the 





1.1 Definition of CKD in children and adults 
The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines define CKD 
according to the following criteria (2): 
1. Kidney damage for a period of three months or more, as defined by structural or 
functional abnormalities of the kidney, with or without decreased glomerular filtration 
rate (GFR), irrespective of the underlying diagnosis; or 
2. GFR <60 ml/min/1.73 m2 for a period of three months or more with or without 
kidney damage, irrespective of the underlying diagnosis.  
Markers of kidney damage include abnormalities in the composition of the blood or 
urine (microalbuminuria, proteinuria, haematuria), abnormalities in imaging tests 
(structural abnormalities of the kidneys demonstrated on ultrasound scanning or other 
radiological tests) or pathological abnormalities proven by biopsy test (2).  
1.2 Classification of CKD  
According to the K/DOQI guidelines (2), CKD in children and adults is divided into 
five stages, based on the level of estimated GFR (eGFR) with higher stages 
representing lower eGFR levels (Table 1). The term kidney failure or ESRD refers to 
an eGFR below 15 ml/min/1.73 m2. At this level of kidney function, a patient with 
reasonable life expectancy is generally referred for RRT (dialysis or kidney 





Table 1. Classification of stages of CKD according to K/DOQI guidelines 
Stage Description eGFR (ml/min/1.73 
m²) 
1 Kidney damage with normal or high eGFR ≥90 
2 Kidney damage with mild low eGFR 60-89 
3 Moderate low eGFR 30-59 
4 Severe low eGFR 15-29 
5 Kidney failure ≤15  
eGFR- estimated glomerular filtration rate  
1.3 Methods of assessing renal function 
GFR is considered the best marker of kidney function, which can be measured using 
renal clearance methods. There are several methods to measure GFR. The first method 
is assessing inulin clearance, which is the gold standard for measuring GFR, in both 
adults and children. Inulin is an exogenous filtration marker, which is freely filtered, 
not bound by protein, and is not secreted or metabolized by kidneys. However, this 
method requires continuous infusions of inulin and collection of timed urine samples 
using a urinary catheter, which makes it cumbersome and impractical for daily clinical 
practice (3). The second method to measure GFR is using radioisotopes, such as 
chromium-51 labelled ethylenediamine tetraacetic acid (51Cr EDTA), and non-
radioactive agents, such as iohexol. The plasma clearance of both 51Cr EDTA and 
iohexol have been shown to correlate well with the renal clearance of inulin (3). 
However, measuring GFR by using exogenous markers is technically difficult and time 
consuming. As a consequence, the preferred practice is to use an endogenous marker, 
such as serum creatinine, which remains the most widely used endogenous filtration 
marker for GFR estimation (4). Creatinine is a result of the degradation of creatine 
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synthesised in skeletal muscle (3) and, therefore, is highly dependent on age and 
muscle mass. Due to this fact, the K/DOQI guidelines advise against the use of serum 
creatinine alone in the assessment of GFR and, therefore, recommend the use of serum 
creatinine-based prediction equations for GFR estimation (5).  
1.3.1 Estimation of GFR in adults 
In adults, the formulas determined by the Modification of Diet in Renal Disease 
(MDRD) Study (6) and Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) (7) study are used for GFR estimation. However, both formulas have not been 
validated in patients aged less than 18 years of age (6), therefore, may provide highly 
inaccurate estimation of GFR (8). Another formula that is used to estimate GFR in 
adults, the Cockroft–Gault equation can be used in children older than 12 years of age, 
but not for younger children (8, 9).  
Cockroft-Gault=(140-age)(body weight in kg) (0.85 if female)/72x Serum creatinine 
in mg/dL. 
1.3.2 Estimation of GFR in children 
The K/DOQI guidelines recommend two formulas for the estimation of GFR in 
children, the Schwartz (10) and Counahan-Barratt equations (11) (Table 2). Both 
formulas are based on height and serum creatinine, however, the use of different assays 
to measure creatinine resulted in different constants cited in the Counahan-Barratt and 
the Schwartz formula. The Counahan-Barratt formula was developed using a measure 
of creatinine by an automated method (11), while the Schwartz formula used creatinine 
measured by a colorimetric reaction with alkaline picrate (10). 
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Table 2. Estimation of GFR in children using serum creatinine and height 
Author Equation 
Schwartz CCr (ml/min/1. 73m²)= k*Height (cm) / SCr (mg/dL) 
Counahan-Barratt CCr (ml/min/1. 73m²)= 0.43*Height (cm) / SCr 
(mg/dL) 
CCr indicates creatinine clearance and SCr, serum creatinine. In the Schwartz equation, the value k is 
0.45 for children <1 year of age, 0.55 for children from 1 to 12 years old and adolescent girls (13-21 
years) and 0.7 for adolescent boys (13 to 21 years). In Counahan-Barratt equation, the value k is constant 
regardless of age at 0.43. To convert serum creatinine from mmol/L to mg/dL, the value should be 
multiplied by 0.0113. 
 
Although, the estimation of GFR with the Schwartz and Counahan-Barratt equations 
are more practical for bedside use, these formulae have limitations. They are not 
recommended to be used in patients in whom height cannot accurately reflect muscle 
mass, for example in patients with limb amputation, severe obesity or malnourishment. 
Moreover, they can provide an inaccurate estimation of GFR in critically ill patients 
and in patients with acute renal failure when GFR is rapidly changing (3). 
Additionally, both formulae may overestimate the “true” GFR measured by gold 
standard. In the Chronic Kidney Disease in Children (CKiD) study, conducted in 
children with CKD stage 2-4, it was shown that the Schwartz equation overestimated 
GFR measured by the plasma disappearance of iohexol by approximately 12 
ml/min/1.73m2 (12). Moreover, Seikaly et al. reported that overestimation of GFR by 
the Schwartz formula was most pronounced in advanced stages of CKD (13). 
1.4 Renal replacement therapy 
There are two options for RRT when a patient`s kidney function fails, which are 
dialysis or kidney transplantation. Kidney transplantation is generally considered as 
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the therapy of choice for patients with ESRD, but availability of donor kidneys is 
limited. Children have a relatively high chance of a transplant due to the fact that a 
parent is often willing and able to donate a kidney and in most countries children get 
priority on the waiting list for a deceased donor kidneys. However, a kidney 
transplantation has often been delayed until the child weights 10 kg or is two years 
old. The primary reason for this delay is that a kidney transplantation is technically 
difficult in very young children (< two years old) due to the small size of the child 
compared to the relatively large (usually adult) donor kidney and the small blood 
vessel calibre of the recipient (14). Although pre-emptive kidney transplantation i.e. 
transplantation at the start of RRT, is recommended, in practice this only happens in 
10-20% of the children starting RRT (15). Therefore, the majority of paediatric 
patients receive dialysis while waiting for a renal transplant. Azar describes dialysis as 
“a procedure that is performed periodically in order to remove excess water from a 
patient and to cleanse the blood from metabolic toxins. The procedure is done by 
placing the patient’s blood in contact with a dialysate solution across a semi-permeable 
membrane” (16). There are two forms of dialysis: haemodialysis (HD) and peritoneal 
dialysis (PD). HD is a procedure in which a patient`s blood is filtered and toxins 
removed to the dialysis fluid of the HD machine (Figure 1). PD is a type of dialysis, 
in which excess fluid and toxins are removed from the patient`s blood through the 
peritoneal membrane of the patient`s abdomen into dialysis fluid. This fluid is then 
drained through the inserted catheter (Figure 2) (16). Even though the majority of 
paediatric patients start on dialysis, over time, kidney transplant becomes the most 
common modality, followed by HD and PD (17). The differences between HD and PD 
are covered in Table 3.  
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Figure 1. HD system 
 




Source of pictures: Ahmad Taher Azar “Modeling and Control of Dialysis Systems. Volume 1: 








Table 3. Differences between haemodialysis (HD) and peritoneal dialysis (PD) 
Characteristics HD PD 
Dialysis 
characteristics 
HD is intermittent. Fluid, 
wastes and chemicals build 
up between treatments. 
PD is continuous throughout 
the entire day. Changes in 
fluid build up and wastes are 
not so dramatic and 
noticeable.  
Frequency  Usually performed three 
times a week, but may be up 
to six times a week.  
 
Dialysis solution is exchanged 
four to five times every day, or 
several times during the night.  
 
Duration Each session lasts four hours 
if performed three times a 
week; two hours if 
performed six times a week. 
Each manual exchange of 
dialysis solution takes 30 to 45 
minutes; or 10 to 12 hours 
during the night using a cycler 
machine. 
Type of access Requires a vascular access, 
usually in arm. 
 
Requires a peritoneal catheter 
inserted in the abdomen 
 
Location Performed in a dialysis 
centre or at home. 
Many options, usually 
performed at home or work. 
Source of table: Ahmad Taher Azar “Modeling and Control of Dialysis Systems. Volume 1: Modeling 
Techniques of Hemodialysis Systems. Springer-Verlag Berlin Heidelberg 2013, page 33. 
 
1.5 Epidemiology of patients who initiated RRT in childhood 
1.5.1 Sources of paediatric renal data 
Most of the existing data on epidemiology of patients who initiated RRT for ESRD 
during childhood is available from national and international renal registries, mostly 
from high-income countries. These registries collect information about patients who 
receive RRT for ESRD. The main source of European data comes from the European 
Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 
registry which was established in 1960 (18). Until 2007 data collection on children and 
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young adults on RRT in Europe was limited to that of the ERA-EDTA registry. Within 
the ERA-EDTA registry data are collected from national and regional renal registries. 
As these do not always include paediatric patients, data on children have only been 
available from a limited part of Europe. In 2007 an additional registry specifically 
focusing at children was officially launched. The data collection on children was 
expanded not only to include more countries, but also to collect much more detailed 
data on different aspects of RRT. At the end of 2008 this registry was officially named 
as the European Society of Pediatric Nephrology/European Renal Association-
European Dialysis and Transplant Association (ESPN/ERA-EDTA). In 2014, 38 
paediatric registries contributed data to the ESPN/ERA-EDTA registry. The majority 
of the individual European registries cover 100% of the general population of the 
country, except the Czech Republic, Poland and Russia, which cover 99%, 98% and 
99% of the general population, respectively (18). High proportions of countries with 
national coverage reflects a good generalisability of the ESPN/ERA-EDTA registry to 
all RRT patients from zero to 20 years of the participating countries.  
In the United States (US), data are mainly available from two renal sources: the North 
American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry and 
the US Renal Data System (USRDS) registry. The NAPRTCS was initiated in 1987 to 
obtain the voluntary participation of all renal transplant centres in the US, Canada, 
Mexico, and Costa Rica. From 1992, this registry also includes paediatric patients (0-
18 years old) who receive HD or PD therapy. Since 1994 this registry also includes 
data on patients with earlier stages of CKD, defined as eGFR < 75 ml/min/1.73 m2. 
Currently, 120 centres in the US, Canada, Mexico, and Costa Rica voluntarily 
participate and annually provide data to NAPRTCS (19). However, this registry does 
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not cover complete populations of participating countries, which limits the 
generalisability of the results obtained by the NAPRTCS if included and not included 
patients are different.  
In contrast to the NAPRTCS, which only receives data voluntarily submitted by 
paediatric nephrology centres, the USRDS is a national data system created in 1988. 
The USRDS collects, analyses, and distributes information about all patients receiving 
RRT for ESRD in the US as participation of renal centres is mandatory. Specific type 
of analyses such as hospitalizations, costs, and clinical services, are restricted to 
Medicare patients. Medicare is a federal health insurance program for legal US citizens 
or legal residents, people 65 years old or older, people of any age with certain 
disabilities, people of any age with ESRD, requiring dialysis or a kidney transplant 
(20). However, insurance is not directly available and there is a waiting time of three 
month until patients become eligible. The USRDS reports that 92% of the patients with 
ESRD have Medicare insurance, therefore, it is likely that the results of the USRDS 
have a good generalisability to most RRT patients in the US (17).  
Data from Australia and New Zealand are collected by the ANZDATA registry which 
was established in 1978. The ANZDATA registry collects information on adults and 
children (0-17 years old) receiving HD, PD and kidney transplantation. All renal units 
in Australia and New Zealand participate in the registry (21). Therefore, the results of 
this registry are generalisable to all patients receiving RRT for ESRD in Australia and 
New Zealand.  
The International Pediatric Peritoneal Network (IPPN) gathers information on children 
and adolescents (0-18 years old) undergoing PD around the world (12 European 
39 
 
countries, US, Canada, Turkey, Chile, Korea, Argentina, China, Finland, Singapore, 
Finland, Macedonia, Nicaragua, and Uruguay). Participation in the IPPN registry, 
similarly to the NAPRTCS, is voluntary, resulting in differences in coverage of 
paediatric PD patients between countries (10% US; 19% Turkey; 31% European 
countries; 59 % Canada; 80%-90% Chile, Korea, Argentina; 100% China, Finland, 
Singapore, Macedonia, Nicaragua, Uruguay) (22). Therefore, results may have limited 
generalisability to those countries with low national coverage, such as the US, Turkey 
and European countries. Moreover, characteristics of patients in participating countries 
differ, therefore, the overall results are unlikely to be generalisable. 
All of the above described registries collect data on paediatric patients receiving RRT, 
therefore, do not include patients who have developed ERSD but are not treated by 
RRT. Therefore, the results of these registries are only generalisable to ESRD patients 
receiving RRT.  
1.5.2 Distribution of underlying primary renal disease in patients who 
initiated RRT in childhood 
The knowledge of distribution of underlying primary renal disease (PRD) in children 
and young adults receiving RRT primarily comes from national and international renal 
registries. According to the data from the USRDS, the ESPN/ERA-EDTA and the 
ANZDATA registries, the main underlying PRD are congenital anomalies of kidney 
and urinary tract (CAKUT), such as renal hypoplasia or dysplasia, and 
glomerulonephritis (GN). In a report from the USRDS the leading types of PRD in 
children and young people (aged 0-21 years) during 2009-2013 were: CAKUT 
(33.0%) and GN (24.6%) (17). Among patients < 15 years of age starting RRT in 2013 
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the most common types of PRD reported by the ESPN/ERA-EDTA registry were 
CAKUT (30%), GN (14.7%) and cystic kidney disease (11.6%) (18). In the 
ANZDATA registry, the leading type of PRD in children and adolescents (aged 0-17 
years) in 2006-2011 were GN (32%), renal hypoplasia or dysplasia (21%) and reflux 
nephropathy (7%) (21).  
1.5.3 Incidence and prevalence of CKD in children 
Only a small number of studies have provided information about the incidence and 
prevalence of the stages of CKD before ESRD in children. For example, an Italian 
population-based study, conducted between 1990 and 2000, reported a mean incidence 
of CKD (stages 2 to 4) of 12.1 cases per year per MARP during 1995–2000, with a 
point prevalence as of January 1, 2001 of 74.7 per MARP in children younger than 20 
years of age (23). Another national study was conducted in Swedish children under 18 
years of age during 1986-1994. The median annual incidence of more severe stages of 
CKD (stage 4 and 5) with an eGFR below 30 ml/min/1.73 m2 was 7.7 per MARP and 
the prevalence was 21 per MARP (24).  
More data are available on the prevalence and incidence of RRT compared to earlier 
stages of CKD. Data from the USRDS showed that in patients between 0 and 19 years 
old, the incidence of RRT in 2007 was 14.6 per MARP and the prevalence was 84.6 
per MARP (25). The ESPN/ERA-EDTA registry reported that the incidence of RRT 
in patients aged 0-14 years in Europe was 6.5 per MARP in the 2007 cohort and the 
prevalence was 33.6 per MARP in 2013 (26). The difference in the reported rates 
between the US and Europe might be partly explained by the higher proportion of 
black people in the US, who have a higher risk of developing ESRD compared to white 
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people (27). Additionally, the incidence and prevalence rates reported by the USRDS 
were adjusted for age, gender and race, while the ESPN/ERA-EDTA registry reported 
crude rates.  
There is also some knowledge available about the rate of progression to a more severe 
CKD stage. According to the NAPRTCS registry, 3.5% and 8.6% of children with 
CKD stage 2 and 3, respectively, develop ESRD within one year following 
registration, while 43% of all children with CKD stage 4 develop ESRD in the same 
time period. Younger age, African-American race, focal segmental 
glomerulosclerosis, hypertension, anaemia, hypocalcemia, hyperphosphataemia and 
hypoalbuminaemia were significantly associated with a higher risk for progression to 
ESRD (27). 
1.6 Mortality and cardiovascular disease in patients who initiated RRT in 
childhood 
Despite the fact that RRT for ESRD in children and young adults is rare these patients 
have an increased mortality compared to age- and sex-matched general population. 
The Australia and New Zealand Dialysis and Transplant (ANZDATA) registry 
examined the long-term survival of patients who initiated RRT at less than 20 years of 
age from 1963 to 2002. The results showed that the mortality rate for children 
receiving RRT was 30 times higher than in the age- and sex-matched general 
population (28). Cardiovascular disease (CVD) and infection are the main causes of 
death in patients who initiated RRT for ESRD in childhood. CVD accounted for 20-
45% of all deaths in different studies (29-31).  
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1.6.1. Traditional cardiovascular risk factors 
Due to high CV mortality in patients with ESRD, the K/DOQI guidelines for 
management of CVD in children and adults receiving RRT recommend that “all 
patients, regardless of symptoms, require assessment for CVD, as well as screening 
for traditional and non-traditional CVRFs” (32). The prevalence of traditional CVRFs, 
such as hypertension, obesity, and dyslipidaemia is much higher in patients who 
initiated RRT for ESRD in childhood compared to age- and sex-matched general 
population. The prevalence of CVRFs starts to increase in early stages of CKD and 
continues to persist in ESRD that is demonstrated in the following paragraphs. 
Hypertension is one of the most common traditional modifiable CVRF in patients who 
initiated RRT for ESRD in childhood. Hypertension defined as either systolic blood 
pressure (SBP) or diastolic blood pressure (DBP) ≥ 95th percentile for sex, age and 
height, is present in 48% of children with CKD stages 2 to 4 registered in the 
NAPRTCS registry (33), while it is only present in 4.2% (SE 0.7%), 3.3% (SE, 0.6%), 
and 4.6% (SE, 0.6%) among the general paediatric population of black, white, and 
Mexican American, respectively, defined as SBP or DBP ≥ 95th percentile (33). 
Hypertension is associated with progression to ESRD (27) and its prevalence is even 
higher after initiation of RRT. The ESPN/ERA-EDTA registry reported prevalence of 
hypertension, defined as a SBP or DBP SD scores (SDS) ≥ 95th percentile or use of 
antihypertensive medication, to be 69.7% in HD, 68.2% in PD and 66.5% in 
transplanted patients (zero to 17 years old) registered in the registry between 1999 and 
2010 (34).  
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Obesity is another important CVRF that is also common in patients who initiated RRT 
for ESRD in childhood and in earlier stages of CKD. The CKiD prospective cohort 
study reported that the prevalence of obesity was 15% in children with CKD stages 2 
to 4 (35), which is comparable to the prevalence among general paediatric population. 
Thus, overweight and obesity (body mass index (BMI) for age>85th and >95th 
percentile) were prevalent in 27.0% and 12.0% of the US children aged 2-5 years, 
while it was higher in the 6-19 year age group, 33.0% and 18.0%, respectively (36). 
The prevalence of obesity still persists after initiation of RRT. Obesity was present 
among 12.5% of all European patients initiating RRT from zero to 15 years old 
registered in the ESPN/ERA-EDTA registry from 1995 to 2010 (37). 
The CKiD study also reported an increased prevalence of dyslipidaemia in CKD 
patients. The authors reported an increasing prevalence of dyslipidaemia, defined as 
total cholesterol >200 mg/dl, or high-density lipoprotein (HDL) cholesterol<40 mg/dl, 
or non-HDL cholesterol >160 mg/dl, with decreasing eGFR. Dyslipidaemia was 
prevalent in 31.0% of children with eGFR 40-50 ml/min/1.73 m2, in 53.0% of children 
with eGFR 30-40 ml/min/1.73 m2 and 65.0% of children with eGFR less than 30 
ml/min/1.73 m2 (38), while it is lower in the general paediatric population. Overall 
dyslipidaemia, defined by at least one of the dyslipidaemic measures 
(hypertriglyceridaemia, or low HDL-cholesterol, or high non HDL-cholesterol), was 
prevalent among 23% of the US children aged 10-18 years with the most common type 
being elevated triglyceride (TG) levels (13.2%), defined as TG>130 mg/dl (1.5 
mmol/l) (39). The prevalence of dyslipidaemia remains high after initiation of RRT. 
Dyslipidaemia, defined as TG >100 mg/dL or HDL cholesterol <40 mg/dL, or non-
HDL cholesterol >145 mg/dL, was present in 68.0% of patients initiating RRT from 
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zero to 17 years old and registered in the ESPN/ERA-EDTA registry from 2000 to 
2012 (40). 
1.6.2. Uraemia-related cardiovascular risk factors 
According to the K/DOQI guidelines for management of CVD, another group of 
CVRFs that needs to be closely monitored is uraemia-related CVRFs that arise from 
impaired kidney function. Anaemia and abnormal mineral metabolism, defined as 
abnormal levels of serum Ca, serum P and parathyroid hormone (PTH) are one of the 
most common uraemia-related CVRFs (32).  
The prevalence of anaemia in paediatric patients with ESRD is high compared to the 
age- and sex-matched general population. Results from the NAPRTCS registry 
showed that 39.0% of children with CKD stage 2-4 are anaemic, while the prevalence 
is lower (16.7%) in the general paediatric population in children between zero to five 
years of age, defined as haemoglobin (Hb) level less than 11.0 g/dl (41). Anaemia has 
been shown to be associated with increased risk of progression to ESRD. Anaemic 
patients, defined as haematocrit (Ht) <33%, had a 52% increase in risk of progression 
to ESRD compared with the non-anaemic patients (hazard ratio (HR) 1.52; 95% 
confidence interval (CI) 1.36-1.69) (27). Anaemia continues to persist in patients 
receiving RRT. The ESPN/ERA-EDTA registry reported that the prevalence of 
anaemia, defined as Hb level less than 11.0 g/dl, is 31.2% in European patients from 
zero to 18 years old receiving dialysis (42).  
Abnormal mineral metabolism is also an important uraemia-related CVRF, which was 
also shown to be high in early stages of CKD and continues to persist after initiation 
of RRT. The prevalence of high PTH level was reported to be 47%, 
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hyperphosphataemia 28% and hypercalcaemia 15% in children with CKD stage 2-4. 
Abnormal serum Ca and serum P levels has been shown to be associated with 
progression to ESRD (27). The ESPN/ERA-EDTA registry reported the prevalence of 
mineral abnormalities among transplanted children; abnormal serum P levels were 
observed in 25%, altered serum Ca in 30%, and hyperparathyroidism in 41% of 
patients (43).  
1.7 Overall aim and specific objectives of the thesis  
In summary, ESRD in children and young adults is a rare condition. Mortality is much 
higher in these patients compared to the age- and sex-matched general population. 
CVD is one of the main causes of death and CVRFs are common in patients who 
initiated RRT for ESRD in childhood. The main aim of my thesis is to describe patterns 
of CVRFs, all-cause mortality and CVD outcomes in patients who initiated RRT in 
childhood. Two systematic reviews are performed to identify knowledge about longer-
term survival, CVD morbidity and the associations between traditional and uraemia-
related CVRFs with all-cause and CV mortality to inform my analyses. Two paediatric 
renal databases were used for the data analyses: the ESPN/ERA-EDTA registry and 
the Scottish Renal Registry (SRR), which are described in details in the relevant 
chapters.  
Through a systematic review of the literature and analyses of data from the 
ESPN/ERA-EDTA and the SRR registries I addressed the following specific 
objectives of this thesis: 
1. To conduct a systematic review to synthesise and critically appraise the relevant 
published research about the prevalence of traditional and uraemia-related CVRFs and 
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their associations with all-cause mortality and CVD outcomes in patients who initiated 
RRT for ESRD in childhood. Hypertension, abnormal BMI, dyslipidaemia and 
anaemia were the CVRFs addressed in this thesis. The rationale for selecting these 
particular CVRFs for study are explained in detail in Chapter 2.  
2. To describe the prevalence and patterns of traditional and uraemia-related CVRFs 
and their associations with all-cause and CV mortality in European patients who 
initiated RRT for ESRD between zero and 20 years of age. 
3. To conduct a systematic review to synthesise and critically appraise the relevant 
published research about long-term survival, CVD incidence and the association of 
age at start of RRT, sex, PRD, type of RRT and period of start of RRT with all-cause 
mortality and CVD outcomes in patients who initiated RRT for ESRD in childhood.  
4. To describe long-term survival, CVD incidence and the associations of age at start 
of RRT, sex, PRD, type of RRT and period of start of RRT with all-cause mortality 
and CVD incidence in patients who initiated RRT for ESRD in childhood in Scotland.  
1.8 Outline of the thesis 
Chapter 2 reports a literature review, which consists of two parts. The first is a 
literature review of the prevalence of CVRFs and the second is a systematic review of 
the association of CVRFs with all-cause mortality and CVD outcomes in patients who 
initiated RRT for ESRD in childhood. Chapter 3 describes the ESPN/ERA-EDTA 
registry data analyses of the prevalence of CVRFs and their association with all-cause 
and CV mortality. Chapter 4 presents a literature review of survival, CVD outcomes 
and the associations of age at start of RRT, sex, PRD, type of RRT and period of start 
of RRT with all-cause mortality and CVD outcomes in patients who initiated RRT for 
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ESRD in childhood. Chapter 5 and 6 are the SRR registry data analyses of all-cause 
mortality, survival, CVD incidence and the association of age at start of RRT, sex, 
PRD, type of RRT and period of start of RRT with all-cause mortality and CVD 
incidence. Chapter 7 is an overall discussion and conclusion chapter, which highlights 
the main findings, limitations and strengths of the current thesis. Additionally, it 
provides recommendations for future research and implications of the current findings 







Chapter 2. Prevalence and patterns of cardiovascular risk factors and 
their association with all-cause mortality and cardiovascular disease 
outcomes in patients who initiated RRT for ESRD in childhood; literature 
review 
2.1. Introduction 
CVD is one of the main causes of death in patients who initiated RRT for ESRD in 
childhood. The ESPN/ERA-EDTA registry reported that CV mortality was the main 
known cause of death (25.8%), followed by infection (17.0%) and malignancies 
(5.2%). However, the cause of death was missing in 26.1% of cases. The most common 
cause of CV death was cardiac arrest/sudden death (54.4%) (30). 
Previous studies showed a high prevalence of hypertension (44, 45), dyslipidaemia 
(46), obesity (47) and anaemia (48) in patients who initiated RRT for ESRD in 
childhood. It was also shown that these CVRFs start to occur from the early stages of 
CKD (49-52). Moreover, hypertension (53), obesity (54) and anaemia (55) were 
reported to be associated with higher risk of all-cause mortality in this specific 
population. 
Although the prevalence of CVRFs and their association with all-cause mortality in 
patients who initiated RRT in childhood has been described previously, the existing 
studies vary in the choice of study design and their selection of study participants. The 
results of some studies may suffer from selection bias that can lead to over- or 
underestimation of the effect. Furthermore, the information about the prevalence of 
different combinations of traditional and uraemia-related CVRFs is uncertain.  
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Several systematic reviews have been conducted in adult RRT populations. These 
generated the results that point to the association between Hb level and all-cause 
mortality (56, 57) and the association of BMI with risk of cardiac disease (58) and all-
cause mortality (59). However, no systematic reviews have yet been performed in 
patients with childhood-onset RRT that summarises and critically appraises results of 
the association between CVRFs and all-cause mortality and CVD outcomes.  
This literature review aims to identify, critically appraise and synthesise the relevant 
published research about the prevalence of single and multiple CVRFs and their 
association with all-cause and CV mortality and CV morbidity in patients who initiated 
RRT in childhood. 
The specific objectives of this literature review are: 
1. To identify, synthesise and critically appraise information about the prevalence of 
individual and multiple CVRFs in patients who initiated RRT in childhood. 
2. To identify, synthesise and critically appraise evidence for associations between 
individual CVRFs and all-cause mortality and/or CVD outcomes in patients who 
initiated RRT in childhood. 
The following CVRFs are considered in this literature review: hypertension, obesity, 
dyslipidaemia and anaemia. 
2.2 Methods  
A protocol for the systematic review was published in PROSPERO, an online 




2.2.1 Search strategy 
A literature search strategy was designed primarily to identify studies that were 
reporting associations of CVRFs with all-cause mortality and CVD outcomes. From 
the results of this search strategy I also identified studies reporting only the prevalence 
of CVRFs that did not report association of CVRFs with all-cause mortality and CVD 
outcomes. When the search was oriented on the prevalence of CVRFs it yielded over 
30,000 results. I had, therefore, chosen the above approach to yield a more manageable 
number of papers. Since the search for the prevalence of CVRFs was not systematic, 
it is a literature review. Therefore, this literature review is presented in two parts: 
1. The first part is a literature review that describes and critically appraises the 
information about the prevalence of CVRFs in patients who initiated RRT in 
childhood.  
2. The second part is a systematic review, which describes and critically appraises the 
studies reporting the associations between CVRFs and all-cause mortality and/or CVD 
outcomes (CVD morbidity and CVD mortality) in patients who initiated RRT in 
childhood. 
At my first year PhD review I was advised to limit the search strategy to hypertension, 
obesity, dyslipidaemia and anaemia. This is because preliminary literature searches 
performed in the first year of my PhD found no studies describing the association 
between abnormal mineral metabolism and all-cause mortality and CVD outcomes. 
Therefore, search terms for abnormal serum Ca, serum P and PTH, were not included 
in the search strategy. Nonetheless, this information was extracted and included in the 
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literature review from the identified studies. Other traditional CVRFs, such as diabetes 
and smoking, were not addressed as they are uncommon in children. 
Medline (1946 - July week 2, 2015) and Embase (1980 - July week 2, 2015) electronic 
literature databases were searched, using a comprehensive search strategy comprised 
of Medical Subject Heading terms and keywords for renal disease, CVRFs and the 
outcomes of interest (see Appendix 1, page 351). The reference lists of relevant articles 
were also perused to identify additional relevant references. Furthermore, annual 
reports of the national and international renal registries (the ERA-EDTA, the 
ESPN/ERA-EDTA, the USRDS, the NAPRTCS, the ANZDATA, the United 
Kingdom (UK) and the SRR registries) were searched.  
2.2.2 Inclusion and exclusion criteria for study identification for this 
review 
Inclusion criteria for literature review 
Randomised clinical trials (RCTs) and observational studies that included patients who 
initiated RRT for ESRD in childhood and that reported prevalence of anaemia, obesity, 
hypertension, and dyslipidaemia were included. 
Exclusion criteria for literature review 
Studies that reported prevalence of anaemia, obesity, hypertension, and dyslipidaemia 
in patients with adult-onset RRT for ESRD were excluded.  
Inclusion criteria for systematic review 
RCTs and observational studies among patients who initiated RRT for ESRD in 
childhood and that reported the association of anaemia, obesity, hypertension and 
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dyslipidaemia with all-cause mortality and CVD outcomes (fatal and/or non-fatal) 
were included.  
CVD outcomes in this systematic review included: endocarditis, heart failure 
pericarditis, coronary artery disease; cardiomyopathy; cardiac arrest; valvular heart 
disease; arrhythmias; myocardial ischaemia,  stroke, and peripheral vascular diseases 
such as thrombophlebitis. Congenital heart defects such as aortic coarctation, trilogy 
of Fallot, tricuspid atresia or tetralogy of Fallot were not included in this review.  
Exclusion criteria systematic review 
Studies that reported association of CVRFs with CV surrogate end-points (left 
ventricular hypertrophy (LVH), carotid intima-media thickness, coronary artery 
calcification or coronary intravascular ultrasound plaque volume) that were obtained 
from non-invasive imaging techniques were excluded. Studies that included patients 
with adult-onset RRT for ESRD were excluded.  
Both parts of the literature review excluded studies that were not written in English. 
2.2.3 Data extraction and assessment of risk of bias and confounding 
A single author - Dinara Galiyeva (DG) - screened the results of the search strategy to 
identify relevant studies for inclusion, first by abstract and then by full text. Data from 
relevant full-text studies were extracted for both parts of the review by DG. Data 
extraction tables were used to extract the following information from each study: 
author/s; year of publication; data sources and settings; study population; length of 
follow-up; definition of exposure; incident/prevalent RRT population; statistical 
techniques used; and results of the study analysis (crude/adjusted effect estimates and 
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CIs). Authors were contacted where necessary to request additional information that 
was lacking in the original paper. 
95% CIs were calculated around reported prevalence estimates using the following 
formulas: 
Standard error of the proportion (SE) =√ [P × (1 − P)]/N, where P-proportion, N total 
number of patients 
95% CI = P ± 1.96 × SE  
Since the aim is to publish the results of the systematic review, a second author Nynke 
Halbesma (NH), who is a co-supervisor of my PhD, was allocated. NH compared my 
extracted data against the articles included for the systematic review. DG and NH 
independently assessed the risk of bias and confounding factors in the included studies 
using the Critical Appraisal Skills Programme (CASP) checklist (60). Disagreements 
between authors over the extracted data and risk of bias and confounding were 
resolved by discussion, with no need to consult a third reviewer.  
The CASP checklist was chosen for assessment of the included studies because of its 
conceptual approach for assessing validity of the studies. The questions are organised 
to cover all three main epidemiological concepts of study assessment: conceptual 
validity, internal validity and external validity of the studies. This makes it easy to 
follow the structure of the questionnaire.  
The result of the literature and systematic reviews were summarised in a narrative 
synthesis since studies differed in terms of RRT population and methodology, so it 
was not feasible to pull the results together in meta-analysis. A meta-analysis is a 
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statistical technique that allows results from individual studies to be combined to give 
an overall measure of the effect (61).  
PRISMA guideline was used for reporting this literature review. A checklist of features 
that were followed and not followed are included in the Appendix 1, page 379 
 
2.3 Results 
The flow diagram of included and excluded studies is presented in Figure 3. In total, 
after excluding duplicate records, 9,365 records were identified through two database 
searches. After screening titles and abstracts 8,188 records were excluded, leaving 
1,177 relevant papers for full-text review. Ultimately, 1,155 full-text articles were 
retrieved and assessed for eligibility and 41 studies were included in this literature 
review. Thirty-eight studies were included in the literature review and seven studies 
were included in the systematic review. The combined number adds up to more than 
41 since some studies were included in both literature and systematic reviews1. 
Characteristics of 41 studies included in the literature and systematic reviews are 
presented in Table 4 (in the table the number in superscript refers to the study 
                                                 
1 Thirty-four studies were included exclusively in the literature review since they reported only the 
prevalence of CVRFs. Three studies were included exclusively in the systematic review since they 
reported only the associations of CVRFs with outcomes of interest without reporting the prevalence of 
CVRFs. Four studies were included in both parts of the review since they reported both prevalence of 




identifier). Studies in this table are organised by the year of publication in ascending 
order. Studies generally included patients up to 18 years of age. All studies reported a 
higher proportion of male patients compared to female. The most common underlying 
renal disease was CAKUT. Not all studies reported the distribution of race/ethnicity 
in their study population. The studies that did report race distribution showed that the 
population was predominantly white.  
Among 38 studies included in the literature review the prevalence of hypertension was 
described in almost half (19 studies) of the included studies. Ten studies were included 
for the prevalence of dyslipidaemia, nine for obesity, 10 for anaemia and three for 
abnormal mineral metabolism. Eight studies described prevalence of several CVRFs 
in the same study population and as a result papers are used in more than one section2.  
2.3.1 Characteristics of the studies included in the literature and 
systematic reviews  
Out of 38 studies included in the literature review 24 articles were single-centre and 
14 were multi-centre studies. Twenty-six studies included only patients after kidney 
transplantation. Nine studies included patients receiving HD or PD and three studies 
included both dialysis and transplanted patients. Twenty-five studies were cross-
sectional - a type of observational study that examines the relationship between 
diseases (or other health outcomes) and other variables of interest as they exist in a 
defined population at one particular time (62). Thirteen studies were cohort studies. A 
cohort study is an observational study in which subsets of a defined population can be 
identified who are, have been, or in the future may be exposed or not exposed –or 
                                                 
2 The final number of included studies in the literature review adds up to more than 38. 
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exposed in different degrees-to a factor or factors hypothesised to influence the 
occurrence of a given outcome (62). The combination of multiple CVRFs was 
described by three studies. 
All seven studies included in the systematic review were observational cohort studies, 
with no RCTs identified. Three studies reported associations with all-cause mortality 
for anaemia, two for BMI and two for hypertension. Only one study described the 
association between hypertension and cerebrovascular mortality. Six studies used data 
from national or multi-national renal registries and one was a single-centre study. 
Three studies included patients receiving dialysis, two studies included patients after 
kidney transplantation, two studies included both dialysis and transplanted populations 




Figure 3. Flow diagram of included studies of the prevalence and patterns of CVRFs 
and their association with all-cause mortality and CVD outcomes in patients who 



















1,895 duplicate records 
excluded 
11,260 records identified through 
database searching (4,563 in 
Medline and 6,697 in Embase) 
 
9,365 potentially relevant records 
included for screening titles and 
abstracts  
8,188 irrelevant records 
excluded after screening 




22 full-text articles could 
not be retrieved 
1,155 full-text articles retrieved  
1,177 full-text articles of 
potentially relevant abstracts 





1,126 full-text articles did 




1,168 full-text articles retrieved 
and assessed for eligibility 
41 articles in total were included in 
the review (38 and 7 studies included 




Table 4. Study characteristics of included studies in the literature and systematic reviews reporting the prevalence of CVRFs and their 
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47 (21) Tx Prevalent  13.6 (5.2) 52.0 White 76.0 
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Black 40.0 
Other 11.0 











N(n) Study population Studies 
































Cohort  141 (42)  Tx Incident   Median 
12.7 (range  
2.1-21.8) 







Wilson et al. 
(2010)82 












































































N(n) Study population Studies 



































Sinha et al. 
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Cohort 77 (1)  Tx Prevalent  
11.44 (5.4) 
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Cohort  210 (NR) Tx Prevalent  
6.9 (5.5) 
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41.0 Black 82.0 
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N-total number of patients in the study after exclusion of patients with missing data, (n)- excluded patients with missing data, RRT- renal replacement therapy; PRD-primary renal disease; HD-haemodialysis, 
PD-peritoneal dialysis; Tx-transplanted; GN-glomerulonephritis; CAKUT-congenital anomalies of kidney and urinary tract; HUS- haemolytic uraemic syndrome; FSGS-focal segmental glomerulosclerosis; EPO-
erythropoietin; Hb-haemoglobin; Ht-haemotocrit; BMI-body mass index; SBP-systolic blood pressure, DBP- diastolic blood pressure, BP-blood pressure; eGFR-estimated glomerular filtration rate; IQR-
Interquartile range. *All age values are means +/- SD, unless otherwise specified. LR-literature review, SR-systematic review. NR-not reported. Number is superscript refers to the study identifier   
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2.3.1 Part 1. The prevalence of cardiovascular risk factors in patients who 
initiated RRT in childhood.  Literature review 
This literature review presents results of the prevalence and patterns of CVRFs in 
patients who initiated RRT in childhood. According to the ESPN/ERA-EDTA registry, 
the prevalence of CVRFs significantly differs by treatment modality (dialysis and 
kidney transplantation) (37, 63, 64). Therefore, it was decided, where possible, to 
stratify the reported prevalence of CVRFs by treatment modality.  
2.3.1.1 Prevalence of anaemia in patients who initiated RRT in childhood  
Ten studies3 reported the prevalence of anaemia. Six were single-centre studies 
conducted in the USA (65-67), Israel (68, 69) and Australia (70). Four studies were 
from large international and national renal registries, such as the NAPRTCS (71), the 
USRDS (72), the ESPN/ERA-EDTA (42) and the IPPN Registries (22).  
The sample size of the studies ranged from 50 to 2,351 patients. The mean age of the 
patients in the included studies ranged from 10.2 to 16 years. The definition of anaemia 
differed across studies. Five out of ten studies used a single cut-off value for Hb to 
define anaemia (Hb<11g/dl or <10 g/dl) (22, 66, 67, 69, 72), while three studies used 
age-dependent cut-off values for Hb (42, 68, 70) and two studies used Ht values (Ht 
>2SD below published means for age or Ht <33 %) (65, 71). The use of erythropoietin 
(EPO) was included in the definition of anaemia in three studies (65, 68, 69).  
                                                 
3 Six cohort and four cross-sectional studies 
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The prevalence of anaemia among dialysis populations was reported by four multi-
centre studies conducted by the USRDS (72), the IPPN (22), the ESPN/ERA-EDTA 
(42), and the NAPRTCS (71) registries, and ranged from 26-68% (Figure 4).  
Figure 4. Prevalence of anaemia in studies that included a dialysis population. The 
number within the bars refers to the proportion of patients with anaemia; the number 
in parentheses refers to the reference number of the study 
 
Study reference (72) (42) (22) (71) 
Sample size 677 2,351 1,394 1,942 
95% CI 40-47 30-34 
29-33 
24-28 66-70 
CI-confidence interval around reported proportion of patients with anaemia presented in Figure 4. The 
order of multiple CIs in the table within the study correspond to the proportions presented in the figure 




The NAPRTCS (71) registry reported the highest prevalence of anaemia compared to 
other studies. In part, this may be explained by the use of Ht to define anaemia in this 
study, whilst other studies used Hb. As patients` fluid status influences Ht more than 
Hb (73), it is likely that the NAPRTCS study reported higher prevalence of anaemia 
due to low Ht values as a result of patients being hypervolemic.  
Among three studies that used Hb to define anaemia the USRDS registry reported the 
highest prevalence (72), while the IPPN registry showed the lowest (22). The 
difference between the two studies may be explained by the variation in treatment 
practices and different cut-off values of Hb. The USRDS study (72) used higher cut-
off values of Hb that may partly explain the higher prevalence of anaemia in this study 
compared to the IPPN study (22). The USRDS registry study (72) included HD 
patients, while the IPPN study included PD patients (22). Volume overload is more 
common among HD patients compared to PD patients (74). As Hb/Ht values are 
affected by patients fluid status and hypervolaemic patients may have lower Hb/Ht 
values (73) the USRDS study might have been expected to report a higher prevalence 
of anaemia compared to the IPPN study.  
The ESPN/ERA-EDTA study (42) reported the overall prevalence of anaemia among 
both HD and PD patients stratified by age, since the authors used age-dependent cut-
off Hb values. This study also showed that mean Hb values were higher in PD patients 
compared to HD patients.  
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The prevalence of anaemia remains high after transplantation. The overall prevalence 
of anaemia in transplanted patients was reported by six single-centre studies widely 




Figure 5. Prevalence of anaemia in studies that included a transplanted population. The 
number within the bars refers to the proportion of patients with anaemia; the number 




(67) (66) (69) (70) (68) (65) 
Sample 
size 
301 47 77 50 60 162 
95% CI  21-31 0.8-17 18-40 
14-32 
12-30 
37-63 26-50 78-89 
57-71 
 
CI-confidence interval around reported proportion of patients with anaemia presented in Figure 5. The 
order of multiple CIs in the table within the study correspond to the proportions presented in the figure 
in order from left to right.   
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The highest prevalence was reported by single hospital study from the US which used 
Ht values to define anaemia (65), while other studies used Hb. The explanation of a 
higher prevalence of anaemia in studies that used Ht compared to Hb is given in the 
section above. Different inclusion criteria for study populations may also have 
contributed to the variation of the prevalence in transplanted patients. For example, a 
study from a single-hospital in the US (66) might have included healthier transplanted 
patients. This could be because the latter study included patients without structural 
cardiac anomalies and a functioning graft for at least one year with an eGFR >40 
mL/min/1.73 m2. Therefore, selective inclusion of healthier patients may explain the 
fact that the authors reported a lower prevalence of anaemia compared to other studies.  
Another possible explanation for the variation in reported prevalence among 
transplanted and dialysis patients might be the use of different laboratory methods for 
Hb/Ht measurements in various centres. However, the information about the methods 
for Hb/Ht measurements is not provided within the articles and as a result it is not 
possible to identify the potential for misclassification of anaemic/non-anaemic 
patients. It is likely that the majority of centres used the Hb cyanide method for 
determination of Hb in blood, as it is a gold standard reference method (75). It is worth 
noting that other methods, such as automated haematology analyser may have also 
been used. When compared to the reference method, automated haematology analyser 
methods showed a tendency to deviate towards higher Hb values (75, 76). If some of 
the studies used the latter method, they might have reported a lower prevalence 
compared to the studies that used the reference method. For multi-centre and registry 
studies it is possible that a mixture of Hb measuring methods was used and ideally 
standardisation would be required to be applied ensure data are comparable.  
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Other factors may have contributed to differences in reported prevalence of anaemia 
between studies. According to the ESPN/ERA-EDTA registry low ferritin and albumin 
levels and high PTH levels are associated with lower levels of Hb (42). Information 
on the prevalence of these risk factors was not provided in all studies, therefore, it was 
not possible to assess the effect of ferritin, albumin and PTH on the difference in 
reported prevalence of anaemia across the studies. Studies that may have included a 
population of patients with low ferritin, albumin, or high PTH levels, could have 
reported a higher prevalence of anaemia.  
 
2.3.1.2 Prevalence of obesity in patients who initiated RRT in childhood  
Nine4 studies reported the prevalence of obesity including five single-centre and four 
multi-centre studies. Single-centre studies were from the USA (77, 78), Mexico (79), 
Israel (69) and Hungary (80). Four multi-centre studies reported results from national 
and international renal registries, and included the NAPRTCS (54), the USRDS (81), 
the ESPN/ERA-EDTA (37), and a multi-centre study in the USA involving six centres 
(82).  
The sample size of the studies ranged from 32 to 6,658 patients. The mean age ranged 
from 4.3 to 15.7 years. Seven studies defined obesity as BMI ≥95th percentile for age, 
sex and race (54, 77-82), while in two studies obesity was defined as BMI SD scores 
(SDS) >+3 (37) or BMI > 30 kg/m2 (69). Six studies used normative reference data for 
                                                 
4 Five cross-sectional and four cohort studies 
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BMI obtained from the age and sex matched general US population, while information 
about reference centile BMI charts was missing in three studies (79, 80, 82).  
The prevalence of obesity stratified by RRT population and definition of obesity is 
presented in Figure 6. The overall prevalence of obesity among HD, PD and 
transplanted patients was reported by one study performed by the ESPN/ERA-EDTA 
registry (37). Although the ESPN/ERA-EDTA study did not report stratified 
prevalence by RRT modality, the authors stated that the prevalence of obesity was 
higher among transplanted population than among dialysis population (37). Only one 
study reported the prevalence of obesity in a dialysis population (81), whilst the 
remaining studies included patients after kidney transplantation.  
The prevalence of obesity in transplanted patients ranged from 1.5% to 36% across 
studies. The wide variation of the prevalence may be partly explained by the different 
definitions of obesity used in the studies. A single-centre study from Israel (69) 
reported the lowest prevalence of obesity compared to other studies. This is the only 
study that applied the definition used for adults to define obesity in a paediatric 
population. Other studies used age, sex and race dependent percentiles of the general 
population. In children, BMI is dependent on age and sex and it is, therefore, 
recommended that obesity is defined according to the age and sex dependent reference 
percentiles. The application of adult criteria to define obesity in a paediatric population 
is likely to under-estimate the prevalence of obesity in children.  
Increasing prevalence of obesity after kidney transplantation was shown by two studies 
(77, 78). Both of these showed that the pre-transplant prevalence of obesity was lower 
compared to the post-transplant prevalence.  
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Figure 6. Prevalence of obesity in studies that included dialysis and transplanted 
populations. The number within the bars refers to the proportion of patients with 
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Ref-reference, CI-confidence interval around reported proportion of patients with obesity presented in 
Figure 6. The order of multiple CIs in the table within the study correspond to the proportions presented 




One of the possible reasons for post-transplant weight gain may be glucocorticoid 
therapy, which is an immunosuppressive therapy and is initiated after kidney 
transplantation to prevent a graft failure. Glucocorticoids appear to promote the 
differentiation of adipocytes precursor cells into mature fat cells resulting in abdominal 
obesity (83). 
Differences in age distribution between studies might have contributed to the variation 
of the prevalence of obesity reported in transplanted patients. Younger patients 
receiving RRT usually have lower prevalence of obesity compared to older patients 
(37). The NAPRTCS (54) reported a prevalence of 10%, which was lower than the 
13% reported in the other two single-centre studies (77, 78). The lower prevalence 
reported by the NAPRTCS may in part be explained by the study population being 
younger (mean age 4.3 years old) than in the other two studies (mean 13.5 years 
(SD5.3) and median 12.7 years (IQR 2.1-21.8)).  
Moreover, different lengths of follow-up since kidney transplantation across studies 
may have contributed to differences in prevalence of obesity, since longer time after 
kidney transplantation is associated with greater increase in BMI (37). For example, 
Denburg et al. (78) reported that the prevalence of obesity post-transplantation 
increased from 31% at three months to 33% at six months and 36% at three years. 
Additionally, children receiving RRT experience a growth retardation, which is 
influenced by nutritional and metabolic alterations. According to the ESPN/ERA-
EDRA registry, transplanted children with severe and moderate growth retardation 
(height SDS<-3; height SDS between -3 and -1.88 SDS, respectively) have an 
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increased risk of being overweight compared to children with less growth retardation 
(height SDS of ≥-1.88) (37). However, information on patients’ stature was not 
reported in all studies, therefore, it was not possible to assess the effect of this factor 
on variation in obesity prevalence across studies. Studies that may have included 
patients with severe or moderate growth restrictions could have pointed to a higher 
prevalence of obesity.  
2.3.1.3 Prevalence of hypertension in patients who initiated RRT in 
childhood  
Nineteen5 studies described the prevalence of hypertension. Fourteen studies were 
single-centre studies and five were multi-centre studies. Single-centre studies were 
from the USA (66, 84-86), Austria (87), Turkey (88, 89), Canada (90), Mexico (79), 
Serbia (91), Iran (92), Israel (69), Finland (93) and Sweden (94). Multi-centre studies 
were from large national and international renal registries and included the NAPRTCS 
registry (95, 96), the USRDS registry (81), the ESPN/ERA-EDTA registry (64) and a 
multi-centre study from 12 nephrology units in the UK was included (97).  
The sample size of the studies ranged from 17 to 3,337 patients. The mean age ranged 
from 6.9 to 17.4 years at data collection. Included studies were heterogeneous by 
methods of BP measurements and definition of hypertension. Seven studies used 
casual BP, using mostly oscillometric or sphygmomanometer methods (66, 69, 81, 84, 
90, 93, 98), two studies used ambulatory blood pressure monitoring (ABPM) (87, 94) 
while the other five studies measured both casual BP and ABPM (85, 86, 89, 91, 92). 
Information on the methods of BP measurement was not given in five studies (64, 79, 
                                                 
5 Four cohort and fifteen cross-sectional 
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88, 95, 96). To define hypertension 14 studies used measured BP above the 95th 
percentile for age, height and sex of the general US population. Five studies defined 
hypertension based on a combination of BP measurement above the 95th percentile for 
age, height and sex or use of antihypertensive medication. The prevalence of 
hypertension among dialysis populations stratified by method of BP measurement and 
definition of hypertension is summarised in Figure 7. Prevalence of hypertension 




Figure 7. Prevalence of hypertension in studies that included a dialysis population. The 
number within the bars refers to the proportion of patients with hypertension; the 




(85) (86) (96) (81) (64) 
Sample size 24 17 3,437 50 3,337 








CI-confidence interval around reported proportion of patients with hypertension presented in Figure 7. The order 
of multiple CIs in the table within the study correspond to the proportions presented in the figure in order from left 
to right.   
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Two studies that used both casual and ABPM methods to measure BP in their study 
population showed that the prevalence of hypertension was lower when measured by 
casual BP compared to the ABPM method (85, 86). This could be partly explained by 
the fact that ABPM method reveals nocturnal hypertension, since BP is measured 
during 24 or 48 hours (86).  
Among five studies of dialysis patients (64, 81, 85, 86, 96), prevalence of hypertension 
was highest in the studies reported by the USRDS registry (81) and the ESPN/ERA-
EDTA registry (64) . The high prevalence may be partly explained by the definition of 
hypertension that these studies used. Both studies defined hypertension as BP 
levels>95th percentile for age, gender and height or use of antihypertensive medication. 
Inclusion of antihypertensive medication in the definition leads to an increase in 
prevalence of hypertension compared to the use of BP alone because in this case 
patients with controlled BP are classified as hypertensive patients. Moreover, some 
antihypertensive medication (specifically angiotensin-converting-enzyme inhibitors) 
might, in some cases, be prescribed irrespective of BP levels for their nephroprotective 
effect (97). Therefore, their inclusion in the definition might over-estimate prevalence 
of hypertension. 
Another possible explanation for the difference in the reported prevalence might be 
the difference in timing of BP measurements relative to the dialysis procedure. Due to 
the volume overload, pre-dialysis BP readings tend to be higher compared to post-
dialysis. Therefore, studies that measured BP before dialysis might have overestimated 
the prevalence of hypertension compared to the studies that measured BP after the 
dialysis procedure. However, the timing of the BP measurement relative to dialysis 
therapy was rarely reported, therefore, it was not possible to compare the prevalence 
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of hypertension by timing of BP readings. Only two studies mention this: the USRDS 
registry (81) and the ESPN/ERA-EDTA registry (64). The USRDS registry (81) used 
mean of the pre- and post-dialysis BP measurements for their analysis. The authors 
have reported that 8% of patients would be re-categorised from hypertensive pre-
dialysis to normotensive post-dialysis. The ESPN/ERA-EDTA registry (64) stated that 
the registry usually requests pre-dialysis BP measurements; for this reason, this study 
might have overestimated the prevalence of hypertension in the dialysis population.  
Table 5 shows the prevalence of hypertension among transplanted populations 
stratified by method of BP measurement and definition of hypertension. The overall 
prevalence ranged from 18% to 87%. Three studies measured both casual BP and 
ABPM (89, 91, 92). All three studies showed a lower prevalence of hypertension 
measured by casual BP compared to ABPM method. There was no clear difference in 
prevalence of hypertension between studies that used exclusively casual BP versus 
those studies that used exclusively ABPM and between combined definition of BP 
levels with medication versus the use of BP alone.  
The information on BP measurement method was missing in five studies: two studies 
from the NAPRCS (95, 96); one the ESPN-ERA-EDTA (64) and two single-centre 
studies (79, 88). It is likely that in the multi-centre studies a mixture of ABPM and 
casual BP measurement methods was used. Since the authors did not report on methods 
of BP measurement, it is not possible to examine the potential for misclassification of 
hypertensive/non-hypertensive patients.  
In addition to variation in definition of hypertension and method of BP measurement, 
duration of RRT could contribute to the heterogeneity in hypertension prevalence 
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between studies. Different studies measured the prevalence of hypertension in 
population of patients with different duration of RRT. According to the ESPN/ERA-
EDTA, shorter duration of RRT is associated with a higher risk of hypertension (64). 
Therefore, studies that may have included populations with shorter duration of RRT 
might have reported a higher prevalence of hypertension. The information on overall 
duration of RRT, including time on dialysis before transplantation was not reported in 
the majority of the studies, as a result, it was not possible to compare the prevalence 
of hypertension based on the duration of RRT.  
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Table 5. Method of BP measurement, definition and prevalence of hypertension in transplanted population 
Method of BP 
measurement 
Definition of hypertension Author  
(year) 
Sample size Prevalence of 
hypertension % 
(95% CI) 




casual BP  
SBP or DBP>95th percentile for age, height and sex Gulhan et al. (2014)89 29 76 (60-91)  
by ABPM 
21 (5.8-35)  
by casual BP  
mean 24.6 (SD 22.2) 
months 
Paripovic et al. (2010)91 41 68 (54-82) 
by ABPM 
42 (27-57) 
by casual BP  
median 2.5 (IQR 0.8 to 
4.6) years 
SBP or DBP ≥95th percentile for age, height and sex or use 
of antihypertensive medication 
Basiratnia et al. (2011)92 66 76 (65-86) 
by ABPM 
57 (45-69) 
by causal BP 
6 months  
Casual BP  SBP>2 SD above the mean  Feber et al. (2008)90 23 69 (51-88) mean 116 (SD16) days  
87 (73-100) mean 3.35 (SD 2.8) 
years  
SBP or DBP>95th percentile for age, sex and height Bullington et al. (2006)66 47 43 (29-57) median 14 (IQR 12–18) 
months 
Mitsnefes et al. (2003)84 159 62 (54-70)  1 year  
Sinha et al. (2012)97 564 27 (24-31) 6 months  
27 (24-31) 1 year  
26 (22-30) 2 years  
26 (23-29) 5 years  
>2SD for age, sex and height or use of antihypertensive 
medication 
Kaidar et al. (2014)69 77 52 (41-63) 2 months  
28 (18-37) 6 months  
22 (12-31) 2 years  
SBP or DBP ≥95th percentile for age, height and sex or use 
of antihypertensive medication 
Tainio et al. (2014)93 210 87 (82-91) 1.5 years  
62 (55-69) 5 years  
ABPM Mean day-time or night-time SBP or DBP>95th percentile for 
age, height and sex  
Cameron et. al. (2014)94 68 65 (54-76) 1 year  
Kitzmueller et al. (2004)87 39 58 (43-73)  3 months  
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Method of BP 
measurement 
Definition of hypertension Author  
(year) 
Sample size Prevalence of 
hypertension % 
(95% CI) 
Time of BP 
measurement post 
transplantation 
Not reported SBP or DBP ≥95th percentile for age, height and sex Ramirez-Cortes et al. 
(2009)79 
32 53 (36-70) 2 years  
Baluarte et al. (1994)95  277 40 (34-46) 1 month  
29 (24-34) 6 months  
26 (21-31) 12 months  
18 (13-23) 24 months  
Not reported Mir et al. (2005)88 72 38 (26-49)  3 months  
53 (42-65) 1 year  
SBP or DBP ≥95th percentile for age, height and sex or use 
of antihypertensive medication 
Kramer et al. (2011)64 3,337 67 (65-68) not reported 
BP- blood pressure, ABPM-ambulatory BP monitoring, SBP-systolic BP, DBP-diastolic BP, SD-standard deviation, IQR-interquartile range. Number is superscript refers to the study 




2.3.1.4 Prevalence of dyslipidaemia in patients who initiated RRT in 
childhood  
Nine6 studies described the prevalence of dyslipidaemia in patients who initiated RRT 
in childhood. Almost all studies were from a single centre with only one multi-centre 
study performed by ESPN/ERA-EDTA registry (40). Single-centre studies were from 
the USA (99, 100), Turkey (88), Israel (68, 69) Canada (90), Finland (93) and Mexico 
(79). 
The sample size of studies ranged from 23 to 210 patients. The mean age ranged from 
6.9 to 15.8 years. Eight studies included a transplanted population and one study 
included both dialysis and transplanted patients. One study did not report the definition 
of dyslipidaemia (88). Cut-off values for lipid levels showed a variation among the 
studies that reported the definition of dyslipidaemia. Cut-off levels for 
hypercholesterolemia ranged from 170 to 200 mg/dl (4.4 to 5.2 mmol/l). Cut-off levels 
for hypertriglyceridemia ranged from 100 to 200 mg/dl (1.1 to 2.3 mmol/l). Cut-off 
levels for low high-density lipoprotein (HDL) ranged from 35 to 40 mg/dl (0.9 to 1.0 
mmol/l), while cut-off levels for high low-density lipoprotein (LDL) ranged from 100 
to 145 mg/dl (2.6 to 3.7 mmol/l). Only one study included the use of cholesterol 
lowering medication in the definition of dyslipidaemia (90).  
Table 6 summarises the definition and prevalence of hypercholesterolemia and 
abnormal lipids fractions. The prevalence of hypercholesterolemia among transplanted 
patients ranged from 15 to 58%. When stratified by definition of hypercholesterolemia, 
studies that used lower cut-off cholesterol levels do not report higher prevalence of 
                                                 
6 five cross-sectional and five cohort studies 
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hypercholesterolemia than those that used higher cut-off points. The overall 
prevalence of low HDL-cholesterol, high non-HDL cholesterol and 
hypertriglyceridemia ranged from 5% to 18.7% (40, 68, 79, 93), 10% to 31% (40, 68, 
93) and 8% to 54% (40, 68, 69, 79, 88, 93, 99, 100), respectively. As with 
hypercholesterolemia, there is no clear trend that the studies that used lower cut-off 
levels report a higher prevalence.  
Possible explanations for the variation of the prevalence across studies may be 
different populations. For instance, among three studies that used the same threshold 
of > 200 mg/dl (68, 99, 100) two US studies (99, 100) reported a higher prevalence 
compared to the study from Israel (68). This might be explained by the fact that the 
general paediatric population in the US has the highest prevalence of obesity compared 
to the European population. A cross-sectional survey on adolescents from the general 
population of 13 European countries, Israel and the US showed that the highest 
prevalence of overweight/obesity was found in the US (101).  
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Prevalence of high 
total cholesterol  





Prevalence of low 
HDL- cholesterol 
% (95% CI) 
 
Prevalence 
of high TG 
% (95% CI) 
Time of lipids measurements  
Transplanted Silverstein et el. 
(2000)99  
62 52 (39-64)  NR  NR 52 (39-64)  mean 6.7 years (SD 3.1) post 
Tx 
Chavers et al. (2003)100 59 34 (22-46)  NR  NR 54 (41-67) pre-Tx 
46 (33-59) 36 (24-48) 1 year post Tx 
58 (45-70) 29 (17-41) 3 year post Tx 
41 (28-54) 14 (5.1-23) 5 years post Tx 
Becker-Cohen et al. 
(2006)68 
60 15 (5.9-24) 10 (2.4-18)  15 (5.9-24) 8 (1.1-14) mean 5.1 (SD 3.4) years post 
Tx 
Kaidar et al. (2014)69 77 49 (38-60)  NR  NR 50 (39-61) 2 months post Tx 
 40 (29-50) 47 (36-58) 6 months post Tx 
 22 (13-31) 12 (4.7-19) 2 years post Tx 
Feber et al. (2008)90 23 44 (24-64)  NR  NR  NR mean time of 116 (SD 16) days 
 47 (27-67) 
 
mean time of 3.35 (SD 2.8) 
years  
post Tx  
Ramirez-Cortes et al. 
(2009)79 
32 25 (10-40)  NR 19  (5.2-32) 38 (21-54) 2 years post Tx 
Tainio et al. (2014)93 210 39 (32-46) 31 (25-37) 8 (4.3-12) 34 (28-40) 1 year post Tx  
31 (25-37) 24 (18-30) 5 (2.1-7.9) 28 (22-34) 5 years post Tx 









Prevalence of high 
total cholesterol  





Prevalence of low 
HDL- cholesterol 
% (95% CI) 
 
Prevalence 
of high TG 
% (95% CI) 
Time of lipids measurements  
Transplanted
HD and PD 
Bonthuis et al. (2014)40 976  NR 55 (51-58) PD 24 (21-26) PD 74 (71-77) 
PD 
 NR 
24 (21-28) HD 38 (35-41) HD 61 (57-64) 
HD 
23 (20-25) Tx 13 (11-15) Tx 45 (42-48) 
Tx 
HD-haemodialysis, PD-peritoneal dialysis; Tx-transplantation; TG-triglycerides; HDL-cholesterol-high density lipoprotein cholesterol; SD-standard deviation, NR-not reported. Number 
is superscript refers to the study identifier; CI-confidence interval 
 Total cholesterol >200 mg/dl  
 Total cholesterol >180 mg/dl  
 Total cholesterol >170 mg/dl  




Non-HDL cholesterol >145 
mg/dl  
 
Non-HDL cholesterol >130 
mg/dl  
 Definition of high non-HDL 
cholesterol not reported 
 
HDL cholesterol <40 mg/dl  
 
HDL cholesterol <10th 
percentile for age and sex 
 
Definition of low HDL 
cholesterol not reported 
 
TG>200 mg/dl 
 TG>150 mg/dl 
 
TG>140 mg/dl 
 TG>100 mg/dl 
 








Given that the high BMI is associated with a less favourable lipid profile (40) the US 
studies may have reported a higher prevalence of dyslipidaemia. Unfortunately, 
information on mean BMI was not provided by the authors, therefore, it was not 
possible to compare their results by BMI level.  
Different definitions of dyslipidaemia could also in part explain the difference in the 
reported prevalence. For example, two studies from Canada (90) and Mexico (79) used 
simillar cut-off values of >170 mg/dl, however, the Canadian study reported a higher 
prevalence compared to the Mexican study. This is in part because Canadian study 
(90) included the use of cholesterol lowering medication in the definition of 
dyslipidaemia. In this case, patients with controlled lipids levels may have been 
classified as dyslipidaemic. Two studies from Turkey (88) and Finland (93) did not 
report the cut-off levels for the definition of hypercholesterolemia, therefore, it was 
not possible to compare their estimates with other studies.  
The variation of the prevalence of hypercholesterolemia across studies might be 
additionally explained by pre-transplant hypercholesterolemia. Pre-transplant 
hypercholesterolemia is associated with increased cholesterol levels post-kidney 
transplantation (82). However, the information on the pre-transplant 
hypercholesterolemia was not available in all studies, therefore, it was not possible to 
assess the effect of this factor on the difference in prevalence of hypercholesterolemia 
across studies.  
Only one study compared the prevalence of lipid fractions by type of RRT (40). Using 
data from the ESPN/ERA-EDTA registry this study showed that the prevalence of high 
non-HDL cholesterol, low HDL-cholesterol and hypertriglyceridemia was higher 
93 
 
among dialysis patients compared to transplanted patients (40). Specifically, patients 
receiving PD had a higher prevalence of high non-HDL cholesterol and 
hypertriglyceridemia compared to HD and transplanted patients. The high glucose load 
from the dialysis fluid may explain the higher prevalence of dyslipidaemia among PD 
patients. Previous research has shown a correlation between serum lipids and 
intraperitoneal glucose absorption (102).  
The variation of the prevalence of lipid fractions across all studies might be 
additionally explained by the use of medication. Thiazide diuretics and beta-adrenergic 
blockers, that are used to reduce a high BP, have been shown to raise serum lipids 
levels (82). However, medication use was also not reported in all studies and, therefore 
it was not possible to assess the effect of medication on the prevalence of 
dyslipidaemia in the studies.  
Moreover, information on the method of lipids measurements was not reported in all 
studies. It is expected that the majority of studies have measured lipids following an 
overnight fast, as it is a common and accurate method (103). However, if lipids were 
measured under non-fasting conditions there may be an underestimation of the real 
prevalence of HDL-cholesterol, as the levels of non-fasting HDL-cholesterol tend to 
be lower compared to the measurements taken post an overnight fast (103). By 
contrast, the prevalence of hypertriglyceridemia might be overestimated if measured 
in non-fasting conditions as the level of non-fasting triglycerides increases compared 
to the fasting state (103).  
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2.3.1.5 Prevalence of abnormal mineral metabolism in patients who 
initiated RRT in childhood 
Since the literature search strategy did not include specific search terms for abnormal 
mineral metabolism, it is probable that not all relevant papers were identified. As a 
result, the studies that were incidentally identified, and which are summarised below, 
are a selected group. Three studies were identified and included (69, 104, 105). Two 
studies were from large national registries, the USRDS (104) and the ESPN/ERA-
EDTA registry (105), while one study was a single-centre study (69). The sample sizes 
were 77 (69), 588 (104) and 1,237 (105). Two studies reported the mean (SD) age, 
which was 15.8 (104) years and 11.4 (69) years, while another study reported the age 
range (0-18 years) (105). Studies were heterogeneous in terms of RRT population. The 
ESPN/ERA-EDTA registry and the single-centre study included patients post-kidney 
transplantation (69, 105), while the study conducted by the USRDS registry included 
HD patients (104).  
The ESPN/ERA-EDTA registry (105) used GFR dependent cut–off values for PTH 
and age dependent for serum Ca and P (Table 7). Single-centre study from Israel only 
reported high PTH levels, defined as PTH> 108 pg/ml (69). The USRDS registry also 






Table 7. Definition of abnormal mineral metabolism reported in the ESPN/ERA-
EDTA study (105) 




GFR (ml/min per 1.73 m2)  Age (year)   
>59 10-65 0-2 8.8-11.3 4.8-7.4 
29<GFR≤59 10-65 3-5 9.4-10.8 4.5-6.5 
15 ≤ GFR≤29 130-195 6-12 9.4-10.3 3.6-5.8 
<15 130-195 13-18 8.8-10.2 2.3-4.5 
PTH-parathyroid hormone, Ca-serum calcium, P/serum phosphorus 
Figure 8 presents the prevalence of abnormal mineral metabolism stratified by type of 
RRT. The prevalence of high PTH levels in transplanted patients was 25% (69) and 
41% (105) in the study from Israel and the ESPN/ERA-EDTA study, respectively. 
Varying duration post kidney transplantation at the time of the study may contribute 
to the variation of the reported prevalence as longer time post kidney transplantation 
is associated with lower risk of high PTH levels (105). However, it was not possible 
to compare the results of the two studies as the ESPN/ERA-EDTA (105) did not report 
the duration of time post kidney transplantation at the time of the study. The prevalence 
of high PTH level in the study from Israel (69) was reported at two months, six months 
and two years post kidney transplantation with the lowest prevalence reported at the 








Figure 8. Prevalence of abnormal mineral metabolism in dialysis and transplanted 
populations. The number within the bars refers to the proportion of patients with 
abnormal mineral metabolism; the number in parentheses refers to the reference 
number of the study 
 
Study reference (104) (69) (105) 
Sample size 588 77 1,237 








CI-confidence interval around reported proportion of patients with abnormal mineral metabolism 
presented in Figure 8. The order of multiple CIs in the table within the study correspond to the 
proportions presented in the figure in order from left to right.   
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Serum Ca and P levels were reported in one study conducted by the ESPN/ERA-EDTA 
(105). Abnormal serum P levels were observed in 25% (14% hypophosphatemia and 
11% hyperphosphatemia) and altered serum Ca in 30% (19% hypocalcaemia, 11% 
hypercalcemia) of transplanted patients. The authors have stated that female sex, pre-
emptive transplantation and longer time since transplantation are associated with lower 
risk of having mineral levels above the target range.  
2.3.1.6 Prevalence of metabolic syndrome in patients initiated RRT in 
childhood 
Three studies (79, 82, 93) described prevalence of multiple CVRFs in patients post- 
kidney transplantation. All three studies described the prevalence of metabolic 
syndrome (MeS). This was defined as present if children had at least three of the 
following five risk factors: overweight, hypertension, low HDL-cholesterol, elevated 
triglycerides or elevated fasting glucose. Table 8 describes the definitions of the risk 
factors and the prevalence of MeS reported in the studies. 
A single-centre study from Finland (93) reported the lowest prevalence of MeS 
compared to a multi-centre study from the US (82) and a single-centre study from 
Mexico (79). This could be partly explained by the different dosing of 
immunosuppressive medication among studies. The study from Finland (93) focused 
on the maintenance phase, when the immunosuppressive drug dosing was already 
reduced to a minimum, while the other two studies reported higher doses of 
immunosuppressive medication. It has been shown in previous studies that 
immunosuppressive medication (glucocorticoids) is associated with post-transplant 
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weight gain (83). As higher BMI is associated with higher prevalence of MeS (106), 
this may partly explain a higher prevalence of MeS in the other two studies.  
The different study population provides another possible explanation of the difference 
of the prevalence of MeS between studies. The US study (82) reported a higher 
prevalence compared to the study from Finland (93). As the US population is more 
overweight compared to the European population (101), they are more prone to having 
a higher prevalence of MeS compared to European population. The Mexican study 
(79) is the only study that reported the patterns of multiple CVRFs. The more frequent 
combination was hypertension + hypertriglyceridemia + low HDL in four patients and 
one patient in each of the following combinations: hypertriglyceridemia + waist >95% 
+ hypertension; glucose intolerance + waist >95 +low HDL; glucose intolerance + 
hypertriglyceridemia + low HDL. 
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Table 8. Definition and prevalence of metabolic syndrome reported in the studies 
Authors 
(year) 
Definition of risk factors Prevalence 













BP>95th percentile for 
age and sex of the 
general US 
population or use of 
antihypertensive 
medication 
NR Fasting glucose>100 mg/dL 19 (14-24) 1.5 years  





percentile for age 
and sex 
HDL<5th percentile and TG>95th 
percentile for age and sex, or on lipid-
modifying therapy.  
 
Fasting glucose>100 mg/dL, or 
requirement for insulin or oral 
hypoglycemic therapy. 







>95% (75 cm)  
BP>95th percentile for 
age and sex 
HDL cholesterol< 10th percentile for 
age and sex, TG>90th percentile for 
age and sex 
Fasting glucose>140 mg/dL 25 (9.9-40) 2 years  
MeS-metabolic syndrome, HDL-cholesterol-high density lipoprotein cholesterol, TG-triglycerides, BMI-body mass index, BP-blood pressure, TX-transplantation. NR-not reported,  




2.3.2 Part 2. Association of cardiovascular risk factors with all-cause 
mortality and cardiovascular outcomes in patients who initiated RRT in 
childhood. Systematic review  
This systematic review presents results of the associations between CVRFs with all-
cause mortality and CVD outcomes in patients who initiated RRT in childhood. 
Detailed characteristics of the studies included in the systematic review are presented 
in Table 4.  
2.3.2.1 The association of anaemia or haemoglobin with all-cause 
mortality in patients who initiated RRT in childhood 
Three studies (22, 71, 72) reported the association between anaemia or Hb levels and 
all-cause mortality. The number of patients in the studies ranged from 677 to 1,942. 
All three studies reported data collected from national and international renal registries 
such as the NAPRTCS (71), the USRDS (72) and the IPPN (22). The mean age ranged 
from 10.2 to 16 years. The studies were heterogeneous in terms of the incident or 
prevalent RRT population. Incident RRT patients are new patients who started RRT 
within a specified period (62). Prevalent RRT patients are patients who have already 
started RRT at a specified point in time (62). The NAPRTCS study included incident 
RRT patients who started on dialysis (PD and HD) (71). The USRDS included 
prevalent HD patients (72) and the IPPN study included incident and prevalent PD 
patients (22). The definitions of anaemia differed among the three studies. The 
NAPRTCS study defined anaemia as Ht<33% 30 days after initiation of dialysis (71). 
The USRDS defined anaemia as Hb<11 g/dl (72). The IPPN used Hb values as a 
continuous variable in their analysis (22).  
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A summary of the findings of the included studies of anaemia or Hb with all-cause 
mortality is presented in Table 9. The studies consistently showed that patients with 
lower Hb/Ht values had a higher risk of all-cause mortality compared to patients with 
higher levels of Hb/Ht. 
Table 9. Results of included studies describing the association of anaemia or Hb and 

























hazards regression model 
with RRT as a time-
varying covariate 
Amaral et al. 
(2005)72 




















0.23 per g/dl,  
p<0.003, CI not 
reported 
Cox proportional-hazards 
regression model with 
time-varying covariates 
NAPRTCS- North American Pediatric Renal Transplant Cooperative Study, USRDS-United States Renal data system, IPPN- 
International Pediatric Peritoneal Dialysis Network, SD-standard deviation, IQR-inter quartile range, CI-confidence interval, Hb-
haemoglobin, Ht-haematocrit. Number is superscript refers to the study identifier 
The NAPRTCS study reported crude mortality rate in anaemic patients of 2.2 per 100 
person-years (p/y) and in non-anaemic patients of 0.7 per 100 p/y. Anaemic patients 
receiving RRT had a 52 % higher risk of all-cause mortality compared to non-anaemic 
patients during a median follow-up of 2.6 years (IQR not reported) (71). The USRDS 
study reported mortality rate in anaemic patients to be 5.0 per 100 p/y and in non-
anaemic patients to be 1.9 per 100 p/y. Non-anaemic patients had a 62% lower risk of 
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all-cause mortality compared to anaemic patients during a mean follow-up time of 2.1 
years (SD 1.3) (72). The IPPN study reported 46 deaths but did not report a mortality 
rate. The authors modelled Hb as a continuous variable and showed that each 1 g/dl 
increase in Hb was associated with 77% lower risk of all-cause mortality (22) during 
a median follow-up of 0.8 years ((IQR) 0.22-1.56). The CI for the reported HR was 
not provided by authors. The large effect reported by the latter study could be in part 
explained by the method that was used in their analyses. The authors modelled Hb as 
a time-varying variable, meaning that Hb measurements of patients who died were 
taken close to patient`s date of death. Therefore, those measurements represent 
measurements taken from a sicker RRT population. In this case it may have led to an 
overestimation of the real association.  
2.3.2.2 The association of BMI with all-cause mortality in patients who 
initiated RRT in childhood 
Two observational studies (54, 107) described the association between BMI and all-
cause mortality. The first study performed by the USRDS registry included 1,949 
patients (107). The second study included data for 6,658 patients registered in the 
NAPRTCS registry (54). The studies differed in terms of type and duration of RRT 
and categorisation of BMI. The USRDS study included prevalent transplanted and 
dialysis patients at baseline (107), while the NAPRTCS study started follow-up at the 
time of transplant (54). The USRDS study reported BMI as SDS to standardise these 
with respect to age and sex. The resulting SDS for each individual patient reflects the 
number of SDs that the BMI of the patient differs from the average age and sex 
adjusted BMI from the general population (107). These calculated scores were 
modelled as a continuous variable in their analysis. The NAPRTCS study treated BMI 
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as a binary variable, defining obesity as a BMI greater than the 95th percentile for age 
and sex of the general population at time of transplantation (54). Both studies used 
normative reference data for BMI obtained from the age- and sex-matched general US 
population (108). 
The results of these studies are presented in Table 10. The USRDS study reported 189 
deaths, but did not report the mortality rate. The authors showed a U-shaped 
association between BMI and risk for all-cause mortality (p=0.001). Using the 
reference BMI SDS of 0.50, moving either above or below this point by one, two and 
three SDSs was associated with a 6%, 26% and 67% increased risk for all-cause 
mortality, respectively (107). The NAPRTCS study reported 385 deaths, but also did 
not report the mortality rate. Results from this study showed no difference in overall 
survival between obese and non-obese participants. However, stratified analysis by 
age groups showed an increased risk of all-cause mortality in 6-12 year old obese 
living donor and cadaver donor transplant recipients as compared to kidney donor 
recipients of the same age with a normal BMI, HR 3.65 (95 CI, 1.46-9.11) and 2.94 
fold (95 CI, 1.53-5.63), respectively. The most common cause of death in this patient 
group was cardiopulmonary disease. No significant associations were found between 
obesity and all-cause mortality in patients younger than six or older than 12 years of 
age (54). The authors have stratified their analysis by donor source, presumably 
because other studies reported a higher risk of death in cadaver donor transplant 
recipients compared to living donor transplant recipients in children receiving RRT 
(109, 110).  
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Table 10. Results of included studies describing the association between BMI and all-
















Continuous Referent BMI SDS=0.50.  
aRR at ±1 SDS=1.06 
(0.95-1.18);  
aRR at ±2 SDS= 1.26 
(1.01-1.57); 


















2-5 years old  
aRR=0.38 (0.09-1.65) for 
living donor recipients and 
0.45 (0.17-1.17) for 
cadaver donor recipients; 
6-12 years old  
aRR=3.65 (1.46-9.11) for 
living donor recipients and 
2.94 (1.53-5.63) for 
cadaver donor recipients; 
13-17 years old  
aRR=1.03 (0.36-2.94) for 
living donor recipients and 
0.44 (0.11-1.81) for 
cadaver donor recipients 
All ages  
aRR=1.15 (0.63-2.11) for 
living donor recipients and 
1.17 (0.73-1.90) for 





BMI-body mass index, SD-standard deviation, SDS-standard deviation score, aRR-adjusted relative 





2.3.2.3 The association of hypertension with all-cause and 
cerebrovascular mortality in patients who initiated RRT in childhood 
Two observational studies (53, 111) reported the association between hypertension and 
all-cause mortality. The first study, conducted by Groothoff et al. aimed to study and 
evaluate the late physical, social and psychological effects of ESRD (53). The authors 
included 249 patients from the Late Effects of Renal Insufficiency (LERIC) cohort. 
LERIC included all Dutch children younger than 15 years of age who started RRT 
between 1972 and 1992 and who had reached adulthood, defined as aged older than 
18 years old, at the time of the study. The study was based on the National Dutch 
Registry of patients on RRT (53). The National Dutch Registry covers 100% of the 
RRT population in the Netherlands, as registration is compulsory. The second study, 
conducted by Kari et al. aimed to examine risk factors for RRT in children with CKD 
(stage 1-5) in Saudi Arabia (111). The authors included 1,000 children, treated in the 
King Abdulaziz University Hospital in Saudi Arabia between 2006 and 2014 (111).  
These two studies were heterogeneous in terms of distribution of age, race, CKD stages 
and duration of follow-up. The population in the Dutch study (53) was older compared 
to the Saudi study (111), with the mean age at start of RRT being 10.6 years (range 
1.9-14.9) and 4.9 (SD 4.3) years, respectively.  
The Dutch study (53) did not report the race/ethnicity distribution in their study. Just 
over half of the population in the Saudi study (111) was of Saudi ethnicity, but the 
authors did not report the distribution of the other race/ethnic groups. The Dutch study 
(53) included patients receiving RRT (HD, PD, and transplanted patients), while the 
Saudi study (111) included patients with all stages of CKD (stage 1-5), mean eGFR 
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69.2 (SD 44.1) ml/min per 1.73m2. The duration of follow-up was longer in the Dutch 
study (53) compared to the Saudi study (111) due to the fact that the Dutch study 
followed-up their cohort from the start of RRT in childhood into adulthood. The 
follow-up time was 15.5 years (SD not reported) and 1.5 years ((IQR) 0.4-4.0), in the 
Dutch and the Saudi studies, respectively. Both studies investigated the association of 
hypertension with all-cause mortality. The Dutch study (53) additionally explored the 
association of hypertension with cerebrovascular mortality. In both studies 
hypertension was defined as a SBP or DBP measurement above the 95th percentile of 
the general age, sex and height matched US population according to the Task Force on 
Blood Pressure in Children (112). The Dutch study (53) categorised hypertensive 
patients as follows: for each patient a ratio of total number of BPs with values above 
the 95th percentile divided by the total number of BPs with values below the 95th 
percentile was calculated. Patients with a ratio of more than one were categorized as 
patients with a “relatively long standing” hypertension. The Saudi study (111) define 
hypertension based on BPs at the start of follow-up. Results of these studies are 









Table 11. Results of included studies describing the association of hypertension with 
















15.5 years  
 All-cause mortality  
BP >95th 
percentile for age, 
sex and height 
BP≤95th 
percentile  








 Cerebrovascular mortality  
BP >95th 
percentile for age, 













 All-cause mortality  
BP >95th 
percentile for age, 
sex and height 
BP≤95th 
percentile  






BP-blood pressure, aRR-adjusted relative risk, IQR-interquartile range. Both studies reported 
association of hypertension with all-cause mortality, Groothoff et al additionally reported association 
of hypertension with cerebrovascular mortality. Number is superscript refers to the study identifier 
Both studies reported that hypertensive patients had a higher risk of all-cause mortality 
compared to non-hypertensive patients. Additionally the Dutch study did not find a 
statistically significant association between hypertension and cerebrovascular 
mortality. Relative risk (RR) was 3.1 (95 CI, 2.1–4.6) and 2.5 (95 CI, 1.0-6.7) for all-
cause and cerebrovascular mortality, respectively (53). The Saudi study reported that 
patients with hypertension had 2.46 times higher risk of all-cause mortality compared 
to patients with a normal BP, RR 2.46 (95 CI, 1.66-3.65)) (111). The authors did not 
provide a stratified analysis by CKD stages.  
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2.3.3 Quality assessment of the studies included in the literature and 
systematic review 
The quality assessment of the studies included in the literature and systematic reviews 
was conducted using the CASP checklist. The questions of the CASP checklist were 
applied to assess the internal validity of the studies by identifying the potential for 
random error, selection and information bias in the studies, the role of confounding 
factors, as well as the assessment of the external validity of the studies. Questions 
relating to confounding factors were not applicable to studies reporting the prevalence 
of CVRFs included in the literature review. Table 12 shows a detailed description of 
the quality assessment of the studies included in the systematic review. The quality of 
the studies included in the literature and systematic reviews is discussed in the 
following section. 
2.3.3.1 Internal validity of the studies 
Internal validity of the studies can be affected by random error (chance), systematic 
error (bias) and confounding factors.  
Potential role of chance or random error in the studies 
None of the studies included in the literature review reported 95% CI for the 
prevalence estimates. It is, therefore, not possible to assess how precise their 
estimation is. Almost all studies included in the systematic review reported 95% CIs 
for HRs of the associations between CVRFs and all-cause and cerebrovascular 
mortality. Some 95% CIs were broad which means that there was not a reasonable 
statistical precision around the reported HRs. Moreover, there is a possibility of chance 
finding (Type 1 error) in the NAPRTCS study that reported the association of obesity 
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with all-cause mortality among transplanted patients as the authors performed multiple 
tests (54). The finding of the study of the higher risk of all-cause mortality in 6-12 year 
old obese compared to kidney donor recipients of the same age with a normal BMI 
may be due to chance. One of the approaches to minimise the possibility for random 
error to occur is to establish stricter threshold of the significance level, 99% CI or p 
<0.01.  
There is a possibility of Type 2 error in the Dutch study (53) that investigated the 
association of hypertension with cerebrovascular mortality. The authors did not find a 
statistically significant association that might be due to the lack of statistical power as 
the number of cerebrovascular events was too small (n=15) out of total 249 patients. 
This is reflected in a wide CI around obtained effect estimate (HR=2.5; 95% CI 1.0-
6.7).  
Only one study did not report the CI for the reported HR (22) making it difficult to 
determine the potential for random error. However, the authors did present the 






Table 12. Quality assessment using CASP checklist of the studies included in the systematic review 
 
Question Warady 
et al. (2003) 
Amaral  
et al. (2005) 
Borzych-
Duzalka  
et al. (2012) 
Wong et al.  
(2000) 
Hanevold  
et al. (2005) 
Groothoff  
et al. (2002) 
Kari  
et al (2015) 




















Did the study 
address a clearly 
focused issue? 
Yes Yes Yes Yes Yes Yes Yes 
Was the cohort 
recruited in an 
acceptable way? 
Yes Yes Yes Yes Yes Yes Yes 
Was the exposure 
accurately measured 
to minimise bias? 





et al. (2003) 
Amaral  
et al. (2005) 
Borzych-
Duzalka  
et al. (2012) 
Wong et al.  
(2000) 
Hanevold  
et al. (2005) 
Groothoff  
et al. (2002) 
Kari  
et al (2015) 
Was the outcome 
accurately measured 
to minimise bias? 
Yes Yes Yes Yes Yes Yes Yes 
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et al. (2003) 
Amaral  
et al. (2005) 
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et al. (2002) 
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List the ones you 
think might be 
important, that the 
author missed 












Was the follow up 
of subjects complete 
enough? 






(numbers of lost 
to follow-up not 
reported) 
Yes No 
Was the follow up 
of subjects long 
enough? 
Yes Yes Yes Yes Yes Yes Yes 




















et al. (2003) 
Amaral  
et al. (2005) 
Borzych-
Duzalka  
et al. (2012) 
Wong et al.  
(2000) 
Hanevold  
et al. (2005) 
Groothoff  
et al. (2002) 
Kari  
et al (2015) 
Do you believe the 
results? 
Yes Yes Yes Yes Yes Yes Yes 
Can the results be 
applied to the local 
population? 
Yes  Yes Yes Yes Yes Yes Yes 
Do the results of this 
study fit with other 
available evidence?  
Yes Yes Yes Yes Yes Yes Yes 




Potential role of systematic (bias) error in the studies 
Bias can arise from the methods used to select the study population, factors affecting 
the study participation (selection bias) or from inaccuracy of the methods used when 
collecting information about an exposure or an outcome (information bias). Bias can 
lead to conclusions that underestimate or overestimate the true association between 
exposure and outcome (113). Potential for selection and information bias was 
identified in the majority of the studies included in the literature and systematic review.  
Selection bias  
Selection bias occurs when characteristics of individuals who were eligible for the 
study but not included are related to the exposure and, independently from the 
exposure, to the outcome. As a result, the association between exposure and outcome 
differs between individuals included in the study and non-participants (113). The 
potential for several types of selection bias was identified in the studies included in the 
literature and systematic review and include: incidence-prevalence bias (Neyman bias 
or survival bias); volunteer bias; and loss to follow-up bias.  
Incidence-prevalence bias 
Incidence-prevalence bias is a type of selection bias that occurs when we try to 
estimate the risk of a disease on the basis of data collected at a given time point in a 
series of survivors rather than on data gathered during a certain time period in a group 
of incident cases (113).  
The majority of the studies included in the literature review were cross-sectional 
studies of patients with varying duration of RRT (prevalent RRT) who are, by 
definition, survivors to the time of the study. Some studies in the systematic review 
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also included prevalent RRT populations (22, 72, 107, 111).  Excluded patients who 
started RRT at the same time as patients included in the study but who have died before 
reaching the study point might be left out of the study. It is not possible to know 
whether characteristics of patients at start of RRT differ between those who survived 
to participate in the studies and those who did not because the information is not 
provided by the authors. For this reason, it is impossible to identify the direction of 
selection bias and its possible effect on the internal validity of the studies. If the 
patients that were left out of the study were sicker and had a higher prevalence of 
CVRFs compared to patients who were included in the study, the authors may have 
underestimated the true prevalence of CVRFs. On the other hand, the authors might 
have overestimated the true prevalence of CVRFs if prevalence of CVRFs increases 
with duration of RRT. Similarly, the associations of anaemia (22, 72), obesity (107) 
and hypertension (111) with all-cause mortality might have been underestimated or 
overestimated depending on the direction of the bias. 
The Dutch study (53) that investigated the association of hypertension with all-cause 
and cerebrovascular mortality by design is affected by survival bias. The authors 
included patients who started RRT in childhood and reached 18 years old by the time 
of the study. If patients who died before reaching adulthood were hypertensive, 
exclusion of non-survivors might have led to underestimation of the true association 







Volunteer bias (or self-selection bias) occurs when individuals who volunteer for a 
study differ in relevant clinical characteristics from those who do not (113). There may 
be a potential source for volunteer bias in the studies that involved voluntary 
contribution of data to registries such as in the NAPRTCS and IPPN registries (22, 54, 
71). As participating centres of both registries are asked to provide clinical data of 
consenting patients, there might be a potential for both patient and centre-level 
volunteer bias. According to Ganguli et al. (114) mortality rate is much lower in 
volunteers from the general population than in those who are recruited through 
intensive enrolment efforts. However, in the population of sick children it might be 
that the parents of ill children are more willing to volunteer and participate in the study, 
as they may be more conscious in regard to the health of their children. On the other 
hand, parents may be less likely to consent if their child is critically ill, as they may be 
too anxious and stressed to want to join a study. The information about the non-
participating patients/centres was lacking and because of this it was not possible to 
identify the effect of volunteer bias on the internal validity of the studies. In both 
scenarios the prevalence of anaemia (22, 71), obesity (54) and hypertension (96) and 
the associations of anaemia (22, 71) and obesity (54) with all-cause mortality reported 
by these registries would be different in participants compared to the broader 
population of children receiving RRT.  
Loss to follow-up bias 
Loss-to-follow-up bias frequently occurs in prospective cohort studies (113). The 
potential for loss to follow-up bias has been identified in one study form Saudi Arabia 
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included in the systematic review (111). There were 37.3% of patients who were lost 
to follow-up. If the proportion of deaths was higher among those lost to follow-up and 
more of these patients were hypertensive, the true HR of the association between 
hypertension and all-cause mortality would be underestimated. However, due to the 
lack of the information about patients who were lost to follow up, it was not possible 
to identify the direction of the loss to follow-up bias and its effect on the internal 
validity of the study.  
There may be a potential source for selection bias in the studies included in the 
literature and systematic review conducted by the USRDS registry (72, 107) given that 
the outcome data (deaths and hospital admissions) are only available for patients who 
have Medicare coverage. Patients without Medicare coverage were not included in the 
studies and might represent significantly sicker patients with a higher prevalence of 
CVRFs because of the delay with the start of RRT compared to patients who started 
RRT on time. Moreover, these patients might have died before they became eligible 
for Medicare coverage and initiated their RRT treatment. In this case the true HRs of 
the association might have been underestimated. However, according to the USRDS 
registry, 92% of US patients have Medicare coverage, therefore, it is unlikely that a 
large underestimation of the true association could have occurred (17). The 
characteristics of other 8% of patients are not reported by the registry.  
Patients with missing data were excluded from analyses in the majority of the studies 
included in the literature review. However, the characteristics of the excluded patients 
are not provided by all studies, it was therefore, not possible to identify the direction 
of selection bias and its effect on the internal validity of the studies. In the systematic 
review missing data were reported in two studies, the IPPN study (22) and the USRDS 
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study (107). The IPPN study (22) investigated the association of Hb with all-cause 
mortality. The authors stated that the information on Hb was available for all patients. 
However, the data on ESA (erythropoiesis-stimulating agents) dose were missing in 
25% of participants. As the association of Hb and all-cause mortality in this study was 
adjusted for ESA dose, 25% of patients were not included in regression models 
adjusted for this variable. The association may be underestimated if excluded patients 
represented those who had lower Hb values due to poor treatment and had an increased 
risk of death compared to included patients. However, if excluded patients had 
adequate treatment and, therefore, higher Hb levels and additionally had lower death 
rate compared to included patients the association might be overestimated. 
Unfortunately, the characteristics of patients with missing data were not described by 
the authors. In contrast, the USRDS study provided information about 40% of the 
patients that they excluded from the analysis due to missing patient identifier, key 
demographic data or height/weight measurements (107). The authors reported that 
there were no statistically significant differences between the two groups in mortality 
rate and patient characteristics (115). Therefore, it is unlikely that exclusion of patients 
with missing data may have biased their results.  
Information bias  
Information bias occurs during data collection with the most common type being 
misclassification bias, which occurs when the detection of the exposure status or 
outcome (disease) assessment is biased. Exposed/diseased patients are classified as 
non-exposed/non-diseased and vice-versa. Misclassification can be differential or non-
differential. In differential misclassification, the exposure or outcome identification 
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differs between comparison groups, while in non-differential misclassification it is the 
same in both groups (113).  
The potential for misclassification of exposure status might occur in 
multicentre/registry studies if some participating centres have used laboratory and/or 
instrumental methods that might lead to misclassification of exposure status. Detailed 
description of different methods of Hb/Ht determination and BP measurements are 
described in the literature review. Since automated haematology analyser and casual 
BP tend to underestimate the true prevalence of anaemia and hypertension compared 
to Hb cyanide method and ABPM methods, the resulting prevalence of risk factors 
might be underestimated in the studies included in the literature review. In terms of 
the studies included in the systematic review, this misclassification is likely to be non-
differential, which leads to attenuation of the effect size towards the null.  
Additionally, there may be potential for overestimation of BMI, BP and anaemic status 
in studies including dialysis patients due to fluid overload and shifts in plasma volume 
(73). Unfortunately, the information about the timing of the measurement relative to 
the timing of dialysis was only available in a small number of studies. Studies 
conducted by the ESPN/ERA-EDTA registry (37, 64) that are included in the literature 
review, reported that the registry collects dry body weight. Dry weight is the body 
weight at the end of dialysis at which the patient can remain normotensive until the 
next dialysis (116). Therefore, it is unlikely that the BMI would be overestimated. 
However, the authors might have potentially overestimated the prevalence of 
hypertension, as the registry collects pre-dialysis BP. The USRDS study (107) 
included in the systematic review reported that the USRD registry also collects dry 
body weight in dialysis patients. Therefore, it is unlikely that the large overestimation 
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of BMI occurred. If authors overestimated the BMI of the dialysis patients, the 
misclassification is likely to be non-differential among those with the outcome and 
those without, biasing the HR of the association between BMI and all-cause mortality 
towards one.  
In terms of the potential misclassification of the outcome data in the studies included 
in the systematic review, it is unlikely that the all-cause mortality would be 
misclassified among participants who were not lost to follow-up. All included national 
registries collect mortality data obtained from the medical records and submitted by 
the participating centres. However, there is always a potential for misclassification of 
cause-specific mortality on deaths certificates. There was only one study conducted by 
Groothoff et al. (53) that studied cerebrovascular disease mortality. The authors visited 
37 hospitals in the Netherlands in order to collect all available information from 
medical records on the cause of death and so their classification is likely to have been 
valid.  
Confounding  
Confounding exists where an apparent association between an exposure and an 
outcome of interest is partly or entirely explained by a third variable. It is important to 
identify relevant confounders and adjust for the confounding effect as much as 
possible. There are three criteria that need to be fulfilled to determine whether a 
variable could be considered a potential confounder: 
 the variable needs to be associated with the exposure 
 the variable needs to be associated with the outcome  
 the variable should not be an intermediate variable on the causal pathway 
between exposure and outcome 
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In observational studies confounding can be minimised during the design of a study 
by restriction or matching, or if this is not possible, it can be controlled during the 
analysis by stratification or adjustment (117). 
Adjustment for a variety of potential confounders was performed in six out of seven 
studies included in the systematic review, but only the Dutch study (49) reported crude 
effect estimates. Age at start of RRT, type of RRT and duration of RRT were adjusted 
for in all studies of the systematic review where appropriate.  
Age at start of RRT was taken into account in all studies, as younger age is associated 
with a higher prevalence of anaemia and hypertension, while obesity and 
dyslipidaemia are more common among older children. Also, younger children 
receiving RRT have a higher risk of death compared to older children (118). 
Additionally, age is not on the causal pathway in the association between CVRFs and 
all-cause mortality.  
Two studies of the systematic review adjusted their analyses for type of RRT, the 
NAPRTCS (71) and the USRDS (107) studies, as both included a mixed RRT 
population (HD, PD and transplanted patients). However, this variable might be on the 
causal pathway, as sicker patients with comorbidities are more likely to start on HD 
and healthier patients are more likely to receive a kidney transplant. Presumably, the 
authors aimed to investigate the associations of anaemia (71) and obesity (107) with 
all-cause mortality independently from the type of RRT. However, by adjusting for 
variable that is on the causal pathway the intermediate effect that goes through this 
variable is removed (117).  
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Three studies adjusted their analyses for duration of RRT: two studies from the 
USRDS (72, 107) and the IPPN (22) registry, as the authors included prevalent RRT 
populations with varying durations of therapy. The NAPRTCS (54) also adjusted their 
analysis for duration of dialysis before receiving a kidney transplantation as they 
included transplanted population (119).  
PRD is another important confounding factor (120) but, only three out of six studies 
adjusted for it (71, 72, 111). The use of iron and ESA medication was adjusted for in 
all three studies describing the association of anaemia with all-cause mortality (22, 71, 
72). However, this variable might lie in the causal pathway in this association, as 
patients with lower Hb values are more likely to be prescribed iron or ESA medication 
compared to patients with normal Hb levels. Similarly, the NAPRTCS (54) might have 
over-adjusted their analysis by controlling the association of obesity with all-cause 
mortality for the use of antihypertensive drugs as hypertension might lie on a potential 
causal pathway (61).  
The Saudi study that investigated the association of hypertension with all-cause 
mortality (111) included patients with different stages of CKD. However, the authors 
did not control their analyses for eGFR level. Furthermore, this study also did not 
account for BMI level. It is known that obesity is associated with both high BP (64) 
and all-cause mortality (107) in children receiving RRT and it is not on the causal 
pathway in this association.  
2.3.3.2 External validity of the studies 
Unfortunately, it was not possible to assess the external validity of the single-centre 
studies included in the literature and systematic reviews. It is hard to draw conclusions 
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about the generalisability of their results due to the lack of the information about the 
national coverage of the general population in their countries by the single centres. If 
single-centres are not representative of the whole RRT population of their country the 
results obtained by these studies cannot be generalizable to a wider RRT population of 
the whole country. 
Moreover, a single-centre study conducted by Kari et al. (111) included in the 
systematic review, comprised children with all stages of CKD (1-5). However, it might 
be that those patients with early stages of CKD who were referred to their hospital 
might represent a more ill CKD population, as early stages of the disease are usually 
asymptomatic (121). Therefore, the results might not be generalizable to all patients 
with early stages of CKD. Additionally, 53.9% of patients in this study were Saudi 
nationality and, therefore, the results of this study may not be generalizable to a 
population of patients with different ethnic distribution. 
The multi-centre studies included in the literature and systematic reviews were mainly 
performed by the national renal registries, the ESPN/ERA-EDTA, the USRDS, the 
NAPRCTS, the IPPN and the National Dutch Registry. The detailed description and 
the coverage of the general population by the ESPN/ERA-EDTA, the USRDS, the 
NAPRCTS and the IPPN are presented in the “Introduction” chapter. Briefly, the 
ESPN/ERA-EDTA registry reported a high coverage of the general European 
population by the registry and, therefore, their results might be broadly generalizable 
to the European countries participating in the registry and to the entire European 
population of patients receiving RRT (18). The USRDS registry covers all patients 
with ESRD in the US. However, the specific types of analyses are restricted to 
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Medicare patients (17) and, therefore, the results of this registry can only be 
extrapolated to the Medicare eligible population.  
The IPPN and the NAPRTCS are both voluntarily collected data. The response 
proportion in the IPPN registry differed between countries (10% US; 19% Turkey; 
31% European countries; 59% Canada; 80-90% Chile, Korea, Argentina; 100% China, 
Finland, Singapore, Macedonia, Nicaragua, Uruguay) (22). The information of the 
coverage by the NAPRTCS is not reported. For both registries it is difficult to say how 
representative they are to the total paediatric RRT population of the participating 
countries as I have not found such information available either on the websites or in 
their publications. Moreover, participating countries in the IPPN registry differ, 
therefore, generalisability of overall results to specific countries might be difficult.  
The study performed by Groothoff et al. (49), described in the systematic review, used 
data from the National Dutch Registry of patients on RRT. The authors included all 
Dutch patients as the registration in the registry is compulsory. Therefore, this study 
represents a good generalisability of their results to all paediatric RRT patients who 
survive to adulthood in the Netherlands.  
The majority of studies included in the literature review of the prevalence of CVRFs 
included transplanted patients. Three studies (14, 15, 17) reporting the association 
between anaemia or Hb levels and all-cause mortality included only dialysis 
populations. The NAPRTCS study describing the association of obesity with all-cause 
mortality included patients after kidney transplantation. Therefore, the results of these 
studies are not representative to the entire population of patients who initiated RRT in 
childhood. The Dutch study investigating the association of hypertension with all-
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cause and cerebrovascular mortality included patients who started RRT in childhood 
and reached 18 years old by the time of the study, therefore, the results cannot be 






2.4.1. Findings of the literature review and limitations of the studies  
The identified studies reported a high prevalence of CVRFs in patients who initiated 
RRT in childhood. Although the prevalence of CVRFs is high, the overall range of the 
prevalence was broad across studies for all CVRFs. The fact that the studies differed 
largely from each other in terms of their inclusion criteria of the study population, RRT 
population, definition of the exposure and the methods used to determine the CVRFs 
likely contributed to this heterogeneity, making it difficult to compare findings across 
studies. Furthermore, due to the potential for selection and misclassification bias, 
identified in all studies, their internal validity might be compromised, resulting in 
overestimation or underestimation of the reported prevalence. 
Most of the identified studies were from single hospitals and included selected RRT 
populations either receiving dialysis or after kidney transplantation with the majority 
of information available from the studies on transplanted patients. Furthermore, the 
timing of kidney transplantation differed largely across studies making it difficult to 
extrapolate the results to patients after receiving a kidney transplant. The fact that the 
majority of studies included transplanted patients might be explained by the fact that 
over time the majority of patients with ESRD receive a kidney transplant. Only studies 
performed by the ESPN/ERA-EDTA registry included both dialysis and transplanted 
population and reported the prevalence of hypertension, obesity and dyslipidaemia 
stratified by RRT modality. Their results showed that the prevalence of hypertension 
and dyslipidaemia was higher among the dialysis population compared to transplanted 
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population, while prevalence of obesity was higher after kidney transplantation 
compared to dialysis population. However, this registry showed the prevalence of 
anaemia only in dialysis patients. No studies showed that the prevalence of anaemia 
differs by type of RRT.  
Few studies described the combinations of traditional CVRFs combined in MeS 
(hypertension, overweight, dyslipidaemia and increased fasting glucose). No studies 
described the combinations of traditional and uraemia-related CVRFs. Therefore, it is 
not clear whether the prevalence and combinations of traditional and uraemia-related 
CVRFs differs between patients receiving dialysis and after kidney transplantation.  
 2.4.2. Findings of the systematic review and limitations of the studies 
Despite the high prevalence of CVRFs a limited number of studies were found that 
investigated the associations of anaemia, obesity and hypertension with all-cause 
mortality in patients with childhood-onset RRT. No studies reported the association 
between dyslipidaemia and all-cause mortality. Furthermore, there is a big gap in the 
literature about the associations of CVRFs with CVD outcomes. Only one study was 
found that reported the association between hypertension and cerebrovascular 
mortality.  
In general, the studies included in the systematic review were heterogeneous by RRT 
type, inclusion of incident or prevalent patients, characterisation of the exposure and 
adjusted covariates. Therefore, it would be inappropriate to combine the data to obtain 
overall summary effect estimates. Furthermore, the follow-up was relatively short in 
most studies. Moreover, insufficient information on aspects such as characteristics of 
non-participants and methods of CVRFs measurements prevented identification of 
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possible bias. For example, the lack of information about the numbers and 
characteristics of missing patients and patients who were lost to follow-up made it 
impossible to identify the role of selection bias in majority of the studies. Also the 
information on methods of measurements of CVRFs was not available in all studies, 
probably due to the lack of such records in the registries. Most studies accounted for 
important confounding factors, however, some other important confounders (for 
example eGFR level) were not taken into account by the authors. Similar to the studies 
included in the literature review, most of the studies of the systematic review were 
performed on a selected RRT population either receiving dialysis, or after kidney 
transplantation or specific age group, which limits generalisability of their results to 
all RRT population. 
The lack of studies describing association between CVRFs and all-cause mortality or 
CVD outcomes is partly explained by the rarity of ESRD in children and a small 
number of deaths limiting the power of the studies. Additionally it can be explained 
by the lack of access to cause specific mortality data in patients with childhood-onset 
RRT to reliably describe cause-specific mortality. Moreover, there might be a potential 
for publication bias, as studies that failed to achieve statistically significant results 
might not be published. The investigators of identified studies were not contacted to 
request any unpublished results. Therefore, it might be that non-significant results 
were not published and only significant association was reported in publications. 
No RCTs were identified by our search strategy. However, RCTs would be valuable 
in order to know whether lowering BP to less than 95th percentile of age and sex 
specific values by using antihypertensive therapy, or achieving Hb levels higher than 
11 g/dl by using EPO reduces risk of all-cause or CV mortality. The lack of placebo 
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controlled RCTs can be explained by the ethical reasons that cannot allow children to 
be left untreated. Another option would be to conduct no-placebo controlled trials 
testing whether different dosage of drugs will achieve the target BP and Hb levels. Due 
to the lack of such trials in children receiving RRT current guidelines on management 
of CVRFs in these patients are extrapolated from data collected in adults with ESRD.  
2.4.3. Limitations of the literature and systematic review  
One search strategy was used for both parts of the literature review. This search was 
specifically designed to systematically search for papers reporting on the associations 
of CVRFs with outcomes of interest. However, the papers that were identified through 
this search strategy reporting the prevalence of CVRFs were included in the literature 
review. Therefore, given the non-comprehensive search for studies reporting the 
prevalence of CVRFs, it is possible that relevant papers on prevalence of CVRFs in 
populations with childhood-onset RRT may not have been identified by the search 
strategy. However, studies performed by large national and international renal 
registries that reported the prevalence of CVRFs have been identified by the search 
suggesting that key information has been included in the literature review. 
Additionally, the specific search terms to identify studies reporting the prevalence of 
abnormal mineral metabolism in patients with childhood-onset RRT were not included 
in the search strategy and, therefore, included studies might represent selective papers 
reporting this information.  
Other databases such as the nursing data base CINAHL, the Latin American database 
LILACS and the Chinese databases were not searched, and only English language 
papers were sought. Therefore, not all relevant studies might have been identified. 
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However, most relevant studies in this area are likely to be published in English and 
in journals that are included in Medline or Embase because the major registries studies 
are within English speaking countries or European countries where scientific research 
is usually published in English language journals. Moreover, the annual reports of the 
national and international renal registries were read as the grey literature; however, 
they did not add any relevant information.  
2.4.4. Future research 
Study design and sample size of future studies 
Since ESRD in children is a rare condition, it is extremely difficult to recruit a 
sufficient number of patients to RCTs and prospective cohort studies. Therefore, the 
most feasible study design for future research would be retrospective cohort studies 
using routine national renal registry data. In order to increase a sample size of future 
studies data from several national renal registries should be combined.  For example, 
one of the best sources of routinely collected clinical data of patients who initiated 
RRT in childhood in Europe is the ESPN/ERA-EDTA registry, which collects data via 
the national and regional renal registries. Currently 38 European countries provide 
their data to the registry. The international nature of the registry allows including large 
number of patients to the studies. The main limitations of this study design are: the 
retrospective nature of the study and possibility of missing relevant data; the restriction 
to only those countries that collect the relevant routine renal data.  
Data to be collected by the registries for future research 
The individual national renal registries have to collect data on CVRFs such as BP, 
BMI, lipids, Ca, P, PTH and Hb for all patients at the start of RRT. Measuring CVRFs 
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at the start of RRT is important in order to minimise incident-prevalence bias in future 
research. Furthermore, data on medications (antihypertensive medication, iron and 
EPO use, statins, and immunosuppressive medication) has to be recorded to adjust for 
it in future analyses. Previous studies included in the literature review used different 
definitions of CVRFs making it difficult to compare findings between each other. For 
example, inclusion of antihypertensive medication into the definition of hypertension 
may have resulted in overestimation of the prevalence of hypertension as patients with 
controlled BP are categorised as hypertensive compared to studies that used BP level 
alone. In future, renal registries should choose a standard definition of hypertension in 
order to improve comparability of their findings. Adopting a definition of hypertension 
without including antihypertensive medication would be more appropriate to avoid 
any overestimation of the estimates. The same applies to the definitions of other 
CVRFs, for example, anaemia and dyslipidaemia.   
Furthermore, previous studies varied by methods of measurements of CVRFs, which 
also resulted in variability of reported estimates. For example, some studies used pre-
dialysis BP, while other studies used post-dialysis. Pre-dialysis BP measurements tend 
to overestimate the prevalence of hypertension due to fluid overload compared to post-
dialysis BP measurements. Similarly, studies that used Ht rather than Hb 
measurements to define anaemia reported a higher prevalence as Ht is less accurate 
method. Therefore, renal registries should also standardise methods of measurements 
of CVRFs. Collecting post-dialysis rather than pre-dialysis BP measurements and Hb 
rather than Ht will allow to minimise bias in future research and improve comparability 
between studies.  
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Not all confounding factors were accounted for in previous studies. In future, renal 
registries have to collect data on main confounding factors such as PRD, 
comorbidities, race/ethnicity and social-economic status.  
There is a big gap in current knowledge about CVD incidence among children 
receiving RRT. It might be because access to morbidity data was difficult to gain for 
previous studies. Therefore, in future, it is important to establish a data linkage 
between routine renal registries data and hospital admissions data in order to study 
CVD incidence in this population. 
2.5 Conclusion  
In conclusion, the literature review showed that the information about the prevalence 
of CVRFs in patients with childhood-onset RRT is sparse and derived from selected 
populations of patients, mostly after kidney transplantation, performed by single-
centre studies. Available studies are heterogeneous by RRT population, definition and 
methods used to determine CVRFs. Additionally, to my knowledge, no studies exist 
describing the combinations of traditional and uraemia-related CVRFs in patients with 
childhood-onset RRT.  
The systematic review identified limited evidence for the association of CVRFs with 
all-cause mortality. Available studies included a selected population of RRT patients 
and with a relatively short follow-up period. Additionally, there is a big gap in 
knowledge about the associations of CVRFs with CVD outcomes (morbidity and 
mortality) in patients with childhood-onset RRT. 
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The next chapter of my thesis is the ESPN/ERA-EDTA registry analyses that describes 
the prevalence and patterns of CVRFs and their association with all-cause and CV 








Chapter 3. Prevalence and patterns of cardiovascular risk factors and 
their association with all-cause and cardiovascular mortality in young 
European RRT patients; ESPN/ERA-EDTA registry analysis 
This chapter introduces the ESPN/ERA-EDTA registry and gives a justification for 
using this data source. It also describes the methods used for the data analysis, results 
obtained and contains a discussion of the findings. 
3.1 Introduction 
The results of the literature review presented in the previous chapter showed that only 
limited information is available about the prevalence and patterns of CVRFs in patients 
who initiated RRT in childhood. Most of the available information about the 
prevalence of CVRFs is based on single-centre studies with the majority only including 
kidney transplant patients. Therefore, the available studies do not represent the whole 
RRT population. The results of the systematic review showed that only a few studies 
have investigated the association between CVRFs and all-cause mortality. Most of the 
available studies were conducted in selected RRT populations either including dialysis 
or kidney transplant patients. In most studies only a short follow-up was available. 
Moreover, there is a very limited knowledge about the association of CVRFs with CV 
morbidity and mortality in patients who initiated RRT in childhood. To illustrate, the 
systematic review identified only one study reporting the association of hypertension 
with cerebrovascular mortality in patients who initiated RRT in childhood and 
survived into adulthood (29).  
Some of the identified gaps in the literature will be addressed in this chapter by 
analysing data from a large international paediatric renal data source-the ESPN/ERA-
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EDTA registry. This is an international renal registry, based in Amsterdam, the 
Netherlands, which annually collects information on patients from 0 to 20 years of age, 
receiving RRT (dialysis and kidney transplantation) in Europe. Currently, 38 European 
countries voluntarily provide data to the registry. The data collection comprises 
information on date of birth, sex, PRD, treatment modality, date of first RRT, changes 
of RRT, death and cause of death, as well as a variable set of anthropometric, 
biochemical and medication-related data. All data are collected during routine clinical 
care (18).  
To analyse the ESPN/ERA-EDTA registry data I submitted a project proposal to the 
registry board in order to request permission. The ESPN/ERA-EDTA registry data can 
only be accessed from their office in Amsterdam as part of their data protection policy. 
I received permission to access the ESPN/ERA-EDTA data in Amsterdam for a 
restricted time period, from 1st of March until 31st of May 2015.  
I focused my analyses on the following four CVRFs - hypertension, abnormal BMI, 
dyslipidaemia and anaemia. These four CVRFs were chosen due to practical reasons. 
First, because of restricted time of the data access in Amsterdam I needed to limit the 
number of CVRFs of interest. Second, these four CVRFs were the most complete 
recorded variables in the ESPN/ERA-EDTA registry. Data on Ca, P and PTH levels 
was not very complete. Therefore, abnormal mineral metabolism was not addressed in 
these analyses.  
The specific objectives of this work were as follows: 
1. To describe the prevalence of individual CVRFs (hypertension, abnormal BMI, 
dyslipidaemia and anaemia) in patients registered in the ESPN/ERA-EDTA registry. 
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2. To describe combinations of multiple CVRFs in patients registered in the 
ESPN/ERA-EDTA registry. 
3. To investigate the association between individual CVRFs and all-cause and CV 
mortality in patients registered in the ESPN/ERA-EDTA registry.  
3.2. Methods 
3.2.1 Patients 
For the current study, data regarding age at start of RRT, sex, PRD, type of RRT, SBP 
and DBP, use of antihypertensive medication, BMI, Hb, total cholesterol, HDL 
cholesterol, TG, cause and date of death were extracted from the ESPN/ERA-EDTA 
registry. Only for a small proportion of the patients CVRFs measured at the start of 
RRT were available. Therefore, incident and prevalent RRT patients and all their 
available CVRFs measurements during the period from the start of RRT until 31st 
December 2012 were included in the analyses. This resulted in the inclusion of 7,845 
out of a total of 12,140 patients registered in the ESPN/ERA-EDTA registry, who had 
at least one CVRF measurement (Figure 9).  
Weight and height measurements were most complete, while the largest proportion of 
missing data was among lipid fractions. 7,446 patients were included in the BMI 
analysis; 5,698 patients in the analysis of anaemia; 4,840 patients in the hypertension 
analysis; 1,638 patients were included for the dyslipidaemia analysis. For the 
description of the prevalence of multiple CVRFs and their combinations, patients who 




Figure 9. Flow chart describing availability of CVRFs measurements in patients 




Data from 33 European countries reported between 1992 to 2012 were included for 
the current study. This included data from the following countries and periods: Albania 
(2010-2012), Austria (2010-2012), Belgium (1996-2012), Bulgaria (2008-2012), 
Belarus (2008-2012), Switzerland (1980-2012), Czech Republic (2007-2012), 
Germany (2010-2012), Denmark (2000-2012), Estonia (2008-2012), Spain (1991-
2012), Finland (1992-2011), France (2004-2012), Greece (1997-2012), Croatia (2008-
2010), Hungary (2008-2012), Iceland (2002-2010), Italy (1995-2012), Lithuania 
(2007-2012), Moldova (2011), Montenegro (2008), Macedonia (2007-2012), the 
Netherlands (2004-2012), Norway (2006-2012), Poland (2008-2012), Portugal (2007-
2012), Romania (2008), Serbia (2007-2012), Russia (2007-2012), Slovenia (2008-
2012), Slovakia (2007-2012), Turkey (2010-2012), and the UK (1992-2012). Data 
from five countries (Cyprus, Georgia, Israel, Latvia and Sweden) were excluded from 
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the present analyses as these countries did not have any records of CVRFs 
measurements.  
For the analysis, different European countries were combined into four European 
regions based on the genetic similarities of the European population (122) as follows: 
East: Albania, Austria, Belarus, Bulgaria, Croatia, Czech Republic, Estonia, 
Macedonia, Greece, Hungary, Lithuania, Moldova, Montenegro, Poland, Romania, 
Russia, Serbia, Slovakia, Slovenia, Turkey 
West: Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany 
North: Denmark, Finland, Iceland, Norway 
South: Spain, Portugal, Italy 
Coverage of general population by individual registries  
The majority of the individual European registries which provide data to the 
ESPN/ERA-EDTA cover 100% of the eligible population of the country, except Czech 
Republic, Poland and Russia, which cover 99%, 98% and 99% of the eligible 
population, respectively (123). However, for the current analyses patients have been 
selected based on the available data on the CVRFs of interest.  
3.2.3 Age groups 
Patients and young adults were categorised into four age groups, using categories used 
in previous ESPN/ERA-EDTA publications: 0-<2 years old; 2-<6 years old; 6-<12 and 
12-20 years old. The youngest category of 0-<2 years old was kept separately as 
previous studies have shown a higher mortality risk in this age group compared to 
older patients (118). Other age groups have been classified based on the periods of a 
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child`s development: preschool 2-<6 years old, school age 6-<12 years old and 
teenagers and young adults 12-20 years old (37, 40). Furthermore, using the previous 
used ESPN/ERA-EDTA age categories makes comparisons between earlier published 
results possible. 
3.2.4 Definitions of CVRFs 
Definition of dyslipidaemia 
Dyslipidaemia was defined by the presence of at least one of the following criteria 
based on definitions derived from guidelines for CV health and risk reduction in 
children and adolescents (124): 
 Hypertriglyceridaemia: 
(a) 0-9 years: TG >100 mg/dL (>1.1 mmol/L)  
(b) 10-20 years: TG >130 mg/dL (>1.5 mmol/L)  
 Low HDL cholesterol: <40 mg/dL or <1.0 mmol/L 
 High non-HDL cholesterol calculated as total cholesterol minus HDL-
cholesterol: >145 mg/dL or >3.7 mmol/L 
Definition of hypertension 
Hypertension was defined according to the Fourth report on the diagnosis, evaluation, 
and treatment of high BP in children and adolescents (125): 







Definition of underweight and overweight/obesity 
BMI was calculated as weight (kg)/height (m)2. For 0–<2 year old patients BMI was 
categorised according to age- and sex-specific criteria of the World Health 
Organization (WHO) (126-128):  
 underweight (BMI SDS ≤ −2 SDS)  
 normal weight (−2 < BMI SDS ≤ +2) 
 overweight (+2 < BMI SDS ≤ +3)  
 obesity (BMI SDS > +3)  
The WHO reference is based on the United States` children. The SDS were already 
calculated in the dataset I received for the analysis.  
To categorise BMI for patients older than 2 years old, cut-off values from the 
International Obesity Task Force were used (129, 130). These age- and sex-specific 
cut-off values are based on centile curves passing through adult health related cut-off 
points for underweight (BMI of <17 kg/m2), overweight (BMI of 25-29.9 kg/m2) and 
obesity (BMI of >30 kg/m2) at the age of 18 years.  
Definition of anaemia 
Anaemia was defined based on an amalgamation of the European guidelines for 
patients on PD (131), the 2011 UK National Institute for Health and care Excellence 
(NICE) guidelines for patients with CKD (132), the European guidelines for adults 
and the Food and Drug Administration (FDA) guidelines (133): 
 Hb<10.5 g/dL for patients younger than 2 years  
 Hb<11.0 g/dL for patients of 2 years or older 
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3.2.5 Causes of death 
Individual national registries defined causes of death according to the ERA-EDTA 
coding system, which are subsequently classified into the following groups; CV, 
infection, malignancies, haemorrhage, other and unknown (123). 
The present analyses are focused on CV mortality that included the following causes 
of death: 
 Myocardial ischaemia and infarction 
 Hyperkalaemia  
 Haemorrhagic pericarditis  
 Other causes of cardiac failure  
 Cardiac arrest / sudden death 
 Hypertensive cardiac failure  
 Hypokalaemia  
 Fluid overload / pulmonary oedema  
 Pulmonary embolus  
 Cerebrovascular accident 
 Mesenteric infarction 
3.2.6 Statistical analysis 
For each patient Hb, BP, TG and non-HDL-cholesterol values above the normal range 
or below for HDL-cholesterol were coded as 1, where values in normal range were 
coded as 0. BMI measurements were first classified into three groups as underweight, 
normal weight and overweight/obesity. After that I created two variables. To indicate 
underweight measurements normal and overweight/obese BMI measurements were 
coded as 0 and underweight measurements as 1. To indicate overweight/obese 
143 
 
measurements normal and underweight measurements were coded as 0 and 
overweight/obese measurements as 1.  
To summarise the prevalence of CVRFs from repeated measurements, the sum of each 
binary definition was divided by the total number of available measurements for this 
specific patient. This resulted in a weighted average. For example, if a patient had three 
BP measurements, of which two were in the hypertensive range and one in the 
normotensive range, these measurements were summarised as (1+1+0)/3 = 0.67. 
Values equal to or above 0.5 were used to identify hypertension. A similar process was 
used for the other CVRFs and RRT modality. A similar approach to summarise 
repeated measurements into one weighted value was used in a previous analysis (29).  
Chi square tests were used to investigate any differences in prevalence of CVRFs 
between groups of patients. When more than 20% of the expected numbers were less 
than 5, Fisher`s exact tests were used (134).  
To describe the association between CVRFs and all-cause and CV mortality, Kaplan-
Meier plots were used to describe crude survival probabilities. In the analyses focusing 
on the association of CVRFs with CV mortality patients who died from other causes 
of death were censored. 
Cox proportional-hazards models were used to estimate the relative mortality risk of 
patients with the CVRF compared to patients without the CVRF. Patients without the 
CVRF of interest were chosen as the reference category due to the lower risk of 
mortality based on the reviewed literature. The main assumption in the Cox model is 
the proportionality of hazards which means that the survival curves must have hazard 
functions that are proportional over time (135). The proportional hazard assumption 
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was evaluated graphically using log minus log plots. The log minus log plots should 
result in parallel curves if the proportional assumption is not violated. Where the 
proportionality assumption was violated, the follow-up period was split according to 
the crossing point of survival curves (135). 
Each CVRF was assessed in a crude (univariate) Cox proportional hazards model. 
Thereafter, multivariable analyses investigating the association of the individual 
CVRFs with all-cause and CV mortality were conducted. Since there were no CV 
deaths in the non-dyslipidaemic group it was not possible to perform Cox proportional 
hazards analysis to determine the association between dyslipidaemia and CV 
mortality. Figure 10 illustrates the approach taken to adjust for potential confounding 
factors (136). In this figure tick means that the confounding factor is associated with 
the exposure and with the outcome, while cross means that the confounding is not on 
the causal pathway of this association. Each individual association of CVRFs with all-
cause and CV mortality was adjusted for age at start of RRT, sex, PRD, type and 
duration of RRT and European region. Associations of hypertension with all-cause and 
CV mortality and dyslipidaemia with all-cause mortality were additionally adjusted 
for overweight/obesity. This is justified because obesity is associated with higher risk 
of hypertension and dyslipidaemia and independently from them it is associated with 
higher risk of mortality. Furthermore, obesity is not on the casual pathway in these 
associations, therefore, it is a potential confounding factor. In contrast, the association 
of obesity with all-cause and CV mortality has not been adjusted for hypertension and 
dyslipidaemia as they might be part of the causal pathway of this association. 
Adjusting for the variable that lies in the casual pathway might lead to underestimation 
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or overestimation of the true HR. Results of the crude and adjusted models are 
presented as unadjusted and adjusted HRs, respectively.  
The start of the follow-up period was the date of the first measurement of the CVRFs 
and the end of follow-up was December 31st 2012 (the most recent available end-
point), death, loss to follow-up, or reaching 20 years of age, whichever came first. It 
was not possible to extend the follow-up period after patient reaching 20 years of age, 
as the ESPN/ERA-EDTA only collects data on patients receiving RRT from 0 to 20 
years old. Data for patients older than 20 years old are collected through the adult part 
of the ERA-EDTA registry. However, due to the absence of data linkage between the 
paediatric and adult parts of the ERA-EDTA registries it was not possible to describe 




Figure 10. Schematic overview of adjusting for potential confounding factors in the 
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3.2.7 Planned sensitivity analysis 
For the primary analyses all available CVRFs measurements per patient during follow-
up were included in the analysis. However, measurements of CVRFs recorded close 
to death are not likely to be representative predictors of the outcome but rather a marker 
of the severity of the underlying pathology. Therefore, a broad window of six months 
has been chosen to make sure that measurements that were taken close to death will 
not influence the results. A planned sensitivity analysis was conducted excluding 
measurements taken in the last six months before death. If patients had CVRFs 
measurements taken within six months before death and longer, only the CVRFs 
measurements in the six months window before death were excluded. In case patients 
had all their CVRFs measurements taken within six month before death, these patients 
were excluded from the sensitivity analysis. This resulted in the exclusion of 84 
patients whose CVRFs measurements were only available in the last six months before 
death. The prevalence of CVRFs and survival analysis were then repeated after 
exclusion of those measurements and patients and results have been compared to the 
primary analysis.  
 3.3 Results  
3.3.1 Patient characteristics 
An overview of the collected data on CVRFs measurements collected by participating 
countries which are included in the current study is presented in Table 13. The UK, 
Spain, Italy, France, Russia and Switzerland contributed the majority of the data. In 
total 20 countries contributed data for all four CVRFs. For the other 13 countries data 
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Table 13. Number and proportion of patients in the ESPN/ERA-EDTA Registry, who have at least one measurement of one CVRF by 31 
December 2012 stratified by country 
Country N  Start 
year 
HDL % Chol % TG % SBP % DBP % Use of AHT  
% 
BMI % Hb % Countries  
with all  
CVRFs 
Albania 5 2010       100   
Austria 127  2010 - - - - - 98.4 98.4 21.3  
Belgium 168 1996 - - - 71.4 71.4 - 99.4 -  
Bulgaria 31  2008 - - - - - - 100 -  
Belarus 46  2008 19.6 43.5 43.5 52.2 52.2 52.2 100 43.5 + 
Switzerland 314  1980 1.3 3.5 3.2 63.7 63.7 29.3 98.1 61.5 + 
Czech Republic 52  2007 19.2 38.5 36.5 63.5 63.5 50.0 100 40.4 + 
Germany 35  2010 31.4 31.4 25.7 80.0 80.0 80.0 100 80.0 + 
Denmark 216  2000 29.2 32.9 29.6 - - - - 99.5  
Estonia 3  2008 100 100 100 100 100 100 100 100 + 
Spain 1283 1991 - - - 63.7 63.7 84.8 99.8 64.4  
Finland 287  1992 81.5 86.4 81.2 95.5 95.5 - 99.7 82.3 + 
France 660 2004 - - - - - - 90.7 94.5  
Greece 96  1997 44.8 86.5 86.5 85.4 85.4 62.5 98.9 86.5 + 
Croatia 5  2008 40.0 40.0 60.0 100 100 20.0 100 100 + 
Hungary 48  2008 33.3 70.8 70.8 79.2 79.2 83.3 93.7 89.6 + 
Iceland 4  2002 - - - 100 100 - 100 100  
Italy 759  1995 - - - 86.9 7.8 81.8 94.3 53.2  
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Country N  Start 
year 
HDL % Chol % TG % SBP % DBP % Use of AHT  
% 
BMI % Hb % Countries  
with all  
CVRFs 
Lithuania 20  2007 60.0 80.0 70 85.0 85.0 80.0 100 85.0 + 
Moldova 1  2011 - - - - - - 100 -  
Montenegro 3  2008 - - - - - - 100 -  
Macedonia 6  2007 - 100 100 100 100 83.3 100 100 + 
Netherlands 188  2004 73.9 79.3 80.9 98.4 98.4 98.9 100 74.5 + 
Norway 88  2006 80.7 87.2 - 97.7 97.7 100 96.6 100 + 
Poland 227 2008 66.9 76.2 73.1 95.2 95.2 4.8 99.6 80.6 + 
Portugal 109  2007 86.2 88.9 88.1 88.1 88.1 85.3 100 89.9 + 
Romania 30  2008 - - - 100 100 100 100 100  
Serbia 37  2007 - 83.8 83.8 81.1 81.1 86.5 100 94.6 + 
Russia 420 2007 - - - - - - 99.7 19.8  
Slovenia 14  2008 85.7 85.7 85.7 100 100 100 100 100 + 
Slovakia 29  2007 20.7 41.4 41.4 41.4 41.4 41.4 100 41.4 + 
Turkey 242  2010 - 36.4 35.9 73.6 73.9 51.7 91.7 48.3 + 
United Kingdom 2292  1992 - 59.5 42.8 90.9 72.6 60.8 98.4 93.4 + 
Total 7845  10.1 31.4 25.0 66.3 60.8 51.2 94.8 72.7 20 
N-total number of patients, HDL-high density lipoprotein cholesterol, Chol-total cholesterol, TG-triglycerides, AHT-antihypertensive medication, SBP-systolic blood pressure, DBP-diastolic blood pressure, 
BMI-body mass index, Hb-haemoglobin
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The characteristics of the total cohort of patients (N=7,845) are summarised in Table 
14. The mean age of the included patients was 9.5 years (SE 0.06). The majority of 
patients were between 12 and 20 years old (39.8%) and 58.9% of the patients were 
male. PD was the most common type of dialysis therapy at the start of RRT (44.8%) 
and the most common PRD was CAKUT (40.8%).  
Characteristics of the subset of patients with available CVRFs compared to those with 
missing CVRFs data are summarised in Table 15. Patients with missing data were 
slightly older compared to those with available data. Patients with missing data in all 
groups of CVRFs more often started on HD compared to those with available CVRF 
data. The proportion of pre-emptively transplanted patients was higher in patients with 
available BP and Hb compared to patients with missing BP and Hb. In contrast, the 
proportion of pre-emptively transplanted patients was lower in patients with available 
BMI and dyslipidemia compared with patients with missing data on those CVRFs. The 
proportion of deaths was larger among patients with missing data in all groups of 
CVRFs compared to patients with available data. Patients with missing lipids and Hb 
measurements had significantly higher proportions of deaths from CV disease, 
haemorrhage, infection and malignancies compared to patients with available records 










Table 14. Baseline characteristics of patients 
Characteristics N (%) 
Age at start of RRT (years)  
0-<2 1,210 (15.4) 
2-<6 1,205 (15.4) 
6-<12 2,300 (29.3)   
12-20 3,123 (39.8) 
Missing 7 (0.1) 
Sex  
Male 4,617 (58.9) 
Initial type of RRT  
HD 2,775 (35.4) 
PD 3,518 (44.8) 
Tx 1,359 (17.3) 
Unknown/missing  193 (2.5) 
PRD  
CAKUT 3,202 (40.8) 
GN 1,237 (15.8) 
Cystic Kidney Disease 787 (10.0) 
Hereditary Nephropathy 594 (7.6) 
Ischaemic Renal Failure 137 (1.7) 
HUS 314 (4.0) 
Metabolic Disorders 273 (3.5) 
Vasculitis 171 (2.2) 
Miscellaneous 578 (7.4) 
Unknown/missing 552 (7.0) 
N-total number of patients who had at least one measurement of one of the four CVRFs, n-number of patients in 
subgroups, RRT- renal replacement therapy; HD- haemodialysis; PD- peritoneal dialysis; Tx- renal transplant; 
PRD-primary renal disease, CAKUT-congenital anomalies of the kidney and urinary tract; GN-glomerulonephritis, 




Table 15. Characteristics of the study population with and without available CVRFs measurements. Characteristics are presented in 
percentages apart from mean age at start of RRT and total number of death 






























N=2, 147  
 
Mean age at start of RRT in years (SE) 8.6 (0.08)  10.9 (0.1) 9.4 (0.07) 11.5 (0.31) 8.2 (0.14) 9.8 (0.07) 9.2 (0.08) 10.2 (0.11) 
Missing 0.1 0.1 0.1 - 0.1 0.1 0.1 0.1 
Sex         
Female 41.0 41.4 41.2 40.4 42.3 40.8 41.2 40.9 
Male 59.0 58.6 58.8 59.6 57.7 59.2 58.8 59.1 
Initial type of RRT*         
HD 29.0 45.6 34.7 47.1 26.4 42.0 33.0 41.8 
PD 50.5 35.7 45.6 30.3 55.4 37.7 46.0 41.6 
Tx 18.8 14.9 17.3 18.5 15.8 17.7 18.0 15.5 
Unknown/missing 1.7 3.8 2.4 4.0 2.4 2.6 3.0 1.2 
PRD         
CAKUT 41.7 39.3 41.3 30.1 39.3 41.1 40.1 42.7 
GN 15.7 15.7 15.6 18.7 14.4 16.1 15.8 15.4 
Cystic Kidney Disease 10.7 8.9 10.2 6.7 9.8 10.1 9.7 10.8 
Hereditary Nephropathy 8.3 6.2 7.6 5.5 12.2 6.3 7.7 7.0 
Ischaemic Renal Failure 2.1 1.2 1.7 1.0 1.8 1.7 1.8 1.3 
HUS 3.8 4.2 4.1 4.0 3.2 4.2 3.9 4.1 
Metabolic Disorders 3.5 3.3 3.5 2.7 2.8 3.6 3.2 4.1 
Vasculitis 1.9 2.5 2.1 4.5 1.6 2.3 2.1 2.4 
Miscellaneous 6.2 9.1 7.2 9.7 7.8 7.2 7.5 6.8 
Unknown/missing 5.7 9.1 6.5 16.7 6.7 7.1 7.7 5.0 
Proportion of all-cause death* 3.3 6.5 4.3 9.0 2.6 5.1  3.8 6.7  
Distribution of cause of death*         
Total number of deaths (N) 162  195  321 
 
36  43  
 
 
314  214  143  
Cardiovascular  24.1 21.5 14.6 19.4 16.3 23.5 18.2 29.4 
Hemorrhage  3.7 5.1 4.7 2.8 2.3 4.8 3.3 6.3 
Infection  20.9 18.9 19.3 16.7 9.3 21.3 16.8 24.5 
Malignancies  6.8 4.6 5.9 2.8 2.3 6.1 4.7 6.9 
Other known cause  19.1 25.6 22.4 25.0 25.6 22.3 27.6 15.4 
Unknown  25.3 24.1 23.7 33.3 44.2 21.9 29.4 17.5 
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N-total number of patients, RRT-renal replacement therapy, SE-standard error, HD-haemodialysis, PD-peritoneal dialysis, Tx-transplantation, PRD-primary renal disease, CAKUT-
congenital anomalies of kidney and urinary tract, GN- glomerulonephritis, HUS-haemolytic uremic syndrome, BP-blood pressure, AH medication- antihypertensive medication, BMI-
body mass index, Hb-haemoglobin, *indicates statistically significant association (p<0.05) between groups of comparison (distribution of causes of death was <0.05 only between 
patients with missing lipids and Hb measurements compared to patients with available records of lipids and Hb). 
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3.3.2 Prevalence of single CVRFs in young European RRT patients  
The overall prevalence of dyslipidaemia, hypertension, anaemia, overweight and 
underweight is presented in Table 16.  
 




Dyslipidaemia 1638 87.5 
Hypertension 4840 79.3 
Anaemia 5698 36.0 
Overweight/obesity 7446 29.9 
Underweight 7446 4.3 
CVRFs-cardiovascular risk factors 
The prevalence of CVRFs stratified by sex, age groups at start of RRT, type of RRT, 
PRD and European region is presented in Figures 10-13 and Table 17.  
No significant sex differences were found in the prevalence of dyslipidaemia, however 
there was a statistically significant larger proportion of female patients among 
hypertensive, anaemic, overweight/obese and underweight patients (Figure 11). When 
stratified by age at start of RRT, dyslipidaemia, anaemia and underweight were more 
common among younger patients compared to older ones, while older patients were 
more frequently hypertensive and overweight/obese compared to younger patients 





Figure 11. Prevalence of CVRFs stratified by sex 
 







The prevalence of CVRFs stratified by modality of RRT (see Methods section page 
141 for more information) is depicted in Figure 13. Most CVRFs were more prevalent 
among patients receiving dialysis compared to transplanted patients, while 
overweight/obesity was more common in patients after kidney transplantation.  
Figure 13. Prevalence of CVRFs stratified by modality of RRT 
 
The stratified analysis of the prevalence of CVRFs by European region is shown in 
Figure 14. Dyslipidaemia and anaemia were more prevalent among Western and 
Eastern parts of Europe compared to the Southern and Northern part of Europe. The 
prevalence of hypertension was similar across the regions except a lower prevalence 
in the Southern region. Overweight/obesity was found to be more prevalent among 
Western and Northern European regions, compared to Eastern and Southern regions. 
The proportion of underweight patients was higher in Eastern and Southern regions, 
compared to Western and Northern European regions.  
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Figure 14. Prevalence of CVRFs stratified by European region 
 
Table 17 shows the prevalence of the CVRFs by PRD. Patients with vasculitis and GN 
had a higher prevalence of hypertension and anaemia compared to patients with other 
types of PRD. Patients with cystic kidney disease and CAKUT were more frequently 
overweight/obese, while dyslipidaemia and underweight were more common among 




Table 17. Prevalence of CVRFs stratified by PRD 
PRD Dyslipidaemia* Hypertension* Anaemia* Overweight/ 
obesity* 
Underweight 
 % % % % % 
CAKUT 89.1  72.6  31.3  32.6  3.2  
GN 90.3  89.7  42.1  27.4  4.0  
Cystic Kidney Disease 84.5  80.7  30.9  35.4  4.3  
Hereditary Nephropathy 81.5  84.9  37.7  23.1  6.3  
Ischaemic Renal Failure 90.0  68.0  29.0  24.1  10.5  
HUS 90.6  82.4  38.7  19.5  3.7  
Metabolic Disorders 100  80.1  38.4  31.7  3.4  
Vasculitis 92.6  92.5  45.8  27.5  2.6  
Miscellaneous 82.8  81.9  40.9  25.6  5.8  
Unknown/missing  84.7  83.4  43.7  30.3  7.6  
PRD-primary renal disease, CAKUT-congenital anomalies of kidney and urinary tract, GN-glomerulonephritis, HUS-haemolotic uraemic syndrome,  
* p value<0.05 for the difference in the prevalence of CVRFs between PRD groups 
160 
 
In summary, the results show that dyslipidaemia, hypertension, anaemia and 
overweight/obesity are common among young European RRT patients. Younger 
patients have a higher prevalence of dyslipidaemia, anaemia and underweight 
compared to older ones, while older patients were more frequently hypertensive and 
overweight/obese compared to younger patients. Dyslipidaemia, anaemia, 
hypertension and underweight were more prevalent among patients receiving dialysis, 
while overweight/obesity was more common in patients after kidney transplantation. 
Eastern Europe had the highest prevalence of all CVRFs apart from 
overweight/obesity. The prevalence of overweight/obesity was higher among Western 
and Northern Europe compared to Eastern and Southern regions of Europe. 
3.3.3 Prevalence and patterns of multiple CVRFs in European patients 
receiving RRT  
As described in the methods the patterns of multiple CVRFs are studied in a cohort of 
patients with data available for all four CVRFs. The characteristics of this sub-cohort 
are compared to the excluded patients for whom at least one CVRFs measurement was 
missing (Table 18). There were no statistically significant differences between patients 
with missing data and available data in terms of sex and PRD distribution. However, 
patients with all available CVRFs were significantly younger at the start of RRT and 
started more frequently on PD compared to excluded patients. Also, a lower proportion 
of patients with all available CVRFs had received pre-emptive transplantation 
compared to patients with at least one missing measurement of CVRFs.  
Figure 14 shows the numbers of CVRFs stratified by type of RRT. This figure shows 
that combinations of two and three CVRFs were more common, compared to none, 
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one and all four CVRFs on dialysis and after kidney transplantation. Dialysis patients 





Table 18. Characteristics of patients who had all CVRFs measurements available 
compared to patients with missing CVRFs data 












2-<6 250 (19.3) 712 (10.9) 
6-<12 375 (29.0) 1530 (23.4) 
12-20 366 (28.3) 3942 (60.2) 
Missing 1 (0.1) - 
Sex   
Male 743 (57.4) 3874 (59.1) 
Initial type of RRT*   
HD 324 (25.1) 2451 (37.4) 
PD 762 (58.9) 2753 (42.0) 
Tx 180 (13.9) 1179 (18.0) 
Unknown/missing  28 (2.1) 168 (2.6) 
PRD   
CAKUT 505 (39.0) 2,697 (41.2) 
GN 198 (15.3) 1039 (15.8) 
Cystic Kidney Disease 125 (9.7) 662 (10.1) 
Hereditary Nephropathy 180 (13.9) 414 (6.3) 
Ischaemic Renal Failure 27 (2.1) 110 (1.7) 
HUS 51 (3.9) 263 (4.0) 
Metabolic Disorders 34 (2.6) 239 (3.7) 
Vasculitis 20 (1.5) 151 (2.4) 
Miscellaneous 89 (6.9) 489 (7.4) 
Unknown/missing 65(5.0) 487 (7.4) 
N-total number of patients, n-number of patients in subgroups, RRT-renal replacement therapy; HD-
haemodialysis; PD-peritoneal dialysis; Tx-renal transplant; PRD-primary renal disease, CAKUT-
congenital anomalies of the kidney and urinary tract; GN-glomerulonephritis, HUS-haemolytic-uremic 
syndrome, *indicates statistically significant association (p<0.05) between groups.  
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 Figure 15. Number of CVRFs stratified by type of RRT 
 
The combinations of CVRFs stratified by type of RRT are presented in Venn diagrams 
(percentages are not proportional to a corresponding areas of the eclipses) (Figures 16 
and 17). For more detailed information about the numbers of patients within each 
stratum in patients on dialysis and after kidney transplantation can be found in 
Appendix 1, Tables 1 and 2, page 354. After stratifying by type of RRT the 
combination of dyslipidaemia, hypertension and overweight/obesity was more 
common among transplanted patients than among patients on dialysis (25.6% and 
11.0% respectively), while the combination of dyslipidaemia, hypertension and 
anaemia was more common among dialysis than in transplanted patients (28.0% and 






Figure 16. Venn diagram of multiple CVRFs prevalence in dialysis  patients 
 
 






In summary, the results show that combinations of two and three CVRFs are more 
common, compared to none, one and all four CVRFs. The combination of 
dyslipidaemia, hypertension and overweight/obesity was more common among 
transplanted patients, while the combination of dyslipidaemia, hypertension and 
anaemia was more common among dialysis patients.  
3.3.3 All-cause mortality and association between CVRFs and all-cause 
and CV mortality in patients who initiated RRT in childhood 
Among all 7,845 patients there was a total of 37,494 patient-years of follow-up. The 
median follow-up was 3.7 years (IQR 1.7-6.8) and in total 357 patients died. The 
overall crude mortality rate was 9.5 (95% CI 8.5-10.5) per 1000 p/y. Mortality rates 
for different causes of death are presented in Table 19. Among known causes of death 
CVD and infections were the most common causes of death. Among other causes of 
death patients more often died from uraemia caused by graft failure and withdrawal of 
ESRD treatment for medical reasons.  
Table 19. Numbers and cause-specific mortality rates of patients included in the 
ESPN/ERA-EDTA registry by 31 December 2012 
Cause of death N Crude MR per 1000 p/y (95%CI) 
All-cause  357 9.5 (8.5-10.5) 
CVD  81 2.1 (1.6-2.6) 
Infections 71 1.9 (1.5-2.3) 
Malignancies 20 0.5 (0.3-0.7) 
Haemorrhage 16 0.4 (0.2-0.6) 
Other 81 2.1 (1.6-2.6) 
Unknown 88 2.3 (1.8-2.8) 
N-number of deaths, CVD-cardiovascular disease, MR-mortality rate 
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Table 20 describes the numbers and proportion of different types of CV death for 
patients in the ESPN/ERA-EDTA registry. The most common CV causes of death 
were cerebrovascular accident and cardiac arrest/ sudden death.  
Table 20. Distribution of different types of CV death 
Cause of CV death N (%) 
Myocardial ischaemia and 
infarction 
4 (4.9) 
Hyperkalaemia 1 (1.2) 
Haemorrhagic pericarditis 1 (1.2) 
Other causes of cardiac failure 11 (13.7) 
Cardiac arrest / sudden death 21 (25.9) 
Hypertensive cardiac failure 1 (1.2) 
Hypokalaemia 1 (1.2) 
Fluid overload / pulmonary 
oedema 
8 (9.9) 
Pulmonary embolus 4 (4.9) 
Cerebrovascular accident 25 (31.0) 
Mesenteric infarction 4 (4.9) 
 CV-cardiovascular, N-number   
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3.3.3.1 Association of CVRFs with all-cause mortality 
For all analyses log minus log plots were used to check the proportionality assumptions 
of the Cox proportional hazard models. Only for the association between hypertension 
with all-cause and CV mortality (Appendix 1 Figures 1 and 2, page 356) the 
assumption was violated. The log minus log plots indicated for the association with 
all-cause mortality crossing lines after 2.5 and 6 years follow-up and for the association 
with CV mortality the lines crossed once after 2.5 years follow-up. Therefore, separate 
hazard ratios were derived for the association of hypertension with all-cause and CV 
mortality for these different follow-up periods. 
For all the analyses the patients without the CVRF studied are used as reference 
category. The results of the associations between the individual CVRFs and all-cause 
mortality are depicted in Figures 18-24. More detailed information about HRs and 95% 
CIs is included in Appendix 1, Tables 3 and 4, page 357. Underweight/anaemic 
patients had a higher risk of all-cause mortality compared to non-underweight/non-









Figure 18. Association of underweight with all-cause mortality 
 
 





Overweight/obesity (Figure 20), dyslipidaemia (Figure 21) and hypertension (Figure 
22, 23 and 24) were positively associated with all-cause mortality. However, the 
results were not statistically significant.  
Figure 20. Association of overweight/obesity with all-cause mortality 
 





Figure 22. Association of hypertension with all-cause mortality during first 2.5 years 
of follow-up 
 









3.3.3.2 Association of CVRFs with CV mortality 
The results of the associations between the individual CVRFs and CV mortality are 
depicted in Figures 25-29. A statistically significant association was found between 
anaemia and CV mortality. Anaemic patients had a higher risk of CV mortality 
compared to non-anaemic patients (Figure 25).  
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Figure 25. Association of anaemia with CV mortality 
 
 
The associations between overweight/obesity (Figure 26), underweight (Figure 27) 
and hypertension (Figure 28 and 29) with CV mortality were not statistically 
significant. Since there were no CV deaths in the non-dyslipidaemic group it was not 
possible to perform Cox proportional hazards analysis to determine the association 









Figure 26. Association of overweight/obesity with CV mortality 
 
 














In summary, the results show that among the four CVRFs underweight and anaemia 
were statistically significantly associated with higher risk of all-cause mortality. Only 
anaemia showed a statistically significant association with CV mortality. 
3.3.4 Planned sensitivity analysis 
The exclusion of CVRFs measurements taken in the last six months before death 
resulted in the exclusion of 84 patients, of which 23 deaths were due to a CV cause. 
There was no difference with regard to the baseline characteristics of the total cohort 
before and after exclusion (Table 21). The sensitivity analyses focusing on the 
prevalence of the CVRFs showed that the overall prevalence of CVRFs remained 
similar to the primary analysis (Appendix 1 Table 5, page 359). The survival analysis 
excluding CVRFs measurements taken in the last six months before death showed 
similar findings to the primary survival analysis (Appendix 1 Table 6 and 7, page 360). 
The HRs and their accompanying CIs of the associations between dyslipidaemia and 
all-cause mortality (unadjusted and adjusted) and hypertension with CV mortality 
(adjusted), were twice as high as those obtained in the primary analysis. However, also 










Table 21. Characteristics of cohort used for primary and sensitivity analyses 






Age at start of RRT (years)   
0-<2 1,210 (15.4) 1,167 (15.0) 
2-<6 1,205 (15.4) 1,187 (15.3) 
6-<12 2,300 (29.3)   2,292 (29.5) 
12-20 3,123 (39.8) 3,108 (40.1) 
missing 7 (0.1) 7 (0.1) 
Sex   
Male 4,617 (58.9) 4,571 (58.9) 
Initial type of RRT   
HD 2,775 (35.4) 2,742 (35.3) 
PD 3,518 (44.8) 3,474 (44.8) 
Tx 1,359 (17.3) 1,354 (17.4) 
Unknown/missing  193 (2.5) 191 (2.5) 
PRD   
CAKUT 3,202 (40.8) 3,184 (41.0) 
GN 1,237 (15.8) 1,221 (15.7) 
Cystic Kidney Disease 787 (10.0) 779 (10.0) 
Hereditary Nephropathy 594 (7.6) 584 (7.5) 
Ischaemic Renal Failure 137 (1.7) 135 (1.7) 
HUS 314 (4.0) 310 (4.0) 
Metabolic Disorders 273 (3.5) 270 (3.5) 
Vasculitis 171 (2.2) 169 (2.3) 
Miscellaneous 578 (7.4) 565 (7.3) 
Unknown/missing 552 (7.0) 544 (7.0) 
RRT, renal replacement therapy; HD, haemodialysis; PD, peritoneal dialysis; Tx, renal transplant; PRD-primary 




3.4 Discussion of the ESPN/ERA-EDTA registry analyses 
3.4.1 Summary of findings of the study 
Prevalence and patterns of CVRFs 
The current analyses show that dyslipidaemia, hypertension, anaemia and 
overweight/obesity are common among young European RRT patients. The 
prevalence of CVRFs varied significantly by age, type of RRT and European region. 
Dyslipidaemia, anaemia and underweight were more common among younger patients 
compared to older ones, while older patients were more frequently hypertensive and 
overweight/obese compared to younger patients. Almost all CVRFs were more 
prevalent among patients receiving dialysis, compared to transplanted patients. 
However, overweight/obesity was more common among patients after kidney 
transplantation. Patients from Eastern Europe had the highest prevalence of all CVRFs 
apart from overweight/obesity that was more common in Western and Northern 
regions. The analyses of the combinations of CVRFs showed that the most frequent 
combination of CVRFs among dialysis patients was dyslipidemia, hypertension and 
anaemia and among transplanted children was dyslipidemia, hypertension and 
overweight/obesity. 
Cause of death and the association of CVRFs with outcomes 
This study has found that CVD and infections were the most common causes of death 
in patients under 20 years of age receiving RRT. The most common CV causes of 
death were cerebrovascular accident and cardiac arrest. The survival analyses showed 
statistically significant associations between underweight and all-cause mortality and 
for anaemia with all-cause and CV mortality. These findings persisted even when 
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measurements taken in the last six months of life were excluded suggesting that they 
are not entirely explained by reverse causality. Dyslipidaemia, hypertension and 
overweight/obesity were positively associated with all-cause mortality; however, the 
results were not statistically significant. Similarly, hypertension, overweight/obesity 
and underweight were positively associated with CV mortality, but not statistically 
significant.  
3.4.2 Interpretation of the findings in the context of existing literature 
3.4.2.1 Prevalence and patterns of CVRFs 
Comparison with general pediatric populations 
The prevalence of CVRFs appears to be higher in young RRT patients compared to 
estimates from European paediatric general populations. The overall prevalence of 
hypertension in the current study was 79.3%, while it is only 10.5% and 12.4% in the 
general paediatric population of boys and girls in Switzerland, respectively (137). For 
dyslipidaemia the current study reported an overall prevalence of 87.5% that is higher 
that figures reported in the German general paediatric population. In Germany the 
prevalence of different dyslipidaemia measurements ranged from 18%-27% (138). 
Similarly, the overall prevalence of overweight/obesity of 29.9% found in this analysis 
was higher than the prevalence of obesity and overweight of 7% and 12.8% reported 
in a study including children from the general population (139). The overall prevalence 
of anaemia in the current study was 36.0%, while it is 9.4% in the general population 




Comparison with other paediatric RRT populations 
Anaemia 
The prevalence of anaemia was 50.5% and 21.2% among dialysis and transplanted 
patients in the current study. The failing kidneys that cannot secrete the hormone 
erythropoietin (EPO) can explain the higher prevalence of anaemia among dialysis 
patients. This hormone is a necessary stimulus for normal bone marrow to produce red 
blood cells (141). Low EPO levels cause red blood cell count to drop and anemia to 
develop. In transplanted patients anaemia is attributed to immunosuppression therapy 
used post-transplantation combined with other contributing factors such as viral 
infection. Immunosupression therapy is associated with generalised bone marrow 
suppression involving all cell lines (142). Besides immunosupression therapy 
cytomegalovirus and human herpesvirus infections have also been associated with 
anaemia in renal transplant recipients (142).  
The prevalence of anaemia in dialysis patients (50.5%) found in this analysis was 
lower compared to the NAPRTCS registry of 67.8% (71). This might be partly 
explained by the fact that the authors of the latter study used Ht to define anaemia, 
while in this study Hb was used. Volume overload is common among dialysis patients. 
Hb/Ht values are affected by patients fluid status and hypervolaemic patients might 
have lower Hb/Ht values (73). As a patient’s fluid status impacts Ht more than Hb 
(73), it can in part explain that the NAPRTCS study reported a higher prevalence of 
anaemia. The prevalence of anaemia among transplanted patients found in this analysis 
was similar to another study from the US including transplanted patients using the 
same definition of anaemia (67). The authors reported an anaemia prevalence of 25.5% 
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at 1 year after transplantation. However, another cross-sectional study from Israel (68) 
reported a higher prevalence of anaemia among transplanted patients of 38% after an 
average 5.1 years (SD ±3.4) of follow-up. This might be explained by the use of 
different definitions. In contrast to our analyses the authors of the last study classified 
patients who were prescribed EPO as anaemic. This approach might have resulted in 
overestimation of the prevalence as patients with controlled Hb might be classified as 
anaemic. 
Hypertension  
The reported prevalence of hypertension was 82.3% and 77.1% for dialysis and 
transplanted patients in the current study, respectively. An explanation for higher 
prevalence of hypertension among dialysis patients compared with transplanted 
patients might be a decreased residual diuresis that consequently leads to fluid 
overload. Research has shown that fluid overload is independently associated with 
higher BP (143). In transplanted patients the high prevalence of hypertension could be 
explained by the use of corticosteroids, such as prednisone, to prevent rejection of the 
kidney transplant (144). Mechanisms for steroid-induced hypertension include a direct 
mineralocorticoid action and stimulation of angiotensin II type I receptors, resulting in 
increased sodium and fluid retention, and increased cardiac output and total peripheral 
resistance (144). Other commonly prescribed drugs include EPO, used to manage 
anemia associated with chronic renal failure. Apart from increasing Hb, EPO increases 
the sensitivity to endogenous vasopressors, and may have a direct vasopressor effect 
on the vessels (144). 
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The estimates of the prevalence in the current study are in line with several other 
published studies from different population (81, 89, 92). However, one cross-sectional 
study from the US reported a lower prevalence among dialysis patients of 59% (86). 
This difference can probably be explained by not including the use of antihypertensive 
medication in the definition of hypertension.  
Dyslipidaemia 
This study found a higher prevalence of dyslipidaemia among dialysis patients 
compared to transplanted patients. This might be explained by glucose absorption from 
the dialysis fluid in PD patients (145). Studies in adult patients treated with PD 
reported a correlation between serum lipids and intraperitoneal glucose absorption 
(102). 
According to the literature review, there were no studies describing the prevalence of 
dyslipidaemia among dialysis population apart from the ESPN/ERA-EDTA study 
(63). Therefore, it was not possible to compare this results with other studies. 
Moreover, it was difficult to compare the prevalence of dyslipidaemia in transplanted 
patients with existing studies. Most of the existing studies reported the prevalence of 
hypercholesterolemia, excluding the prevalence of hypertriglyceridemia. Therefore, 
the overall prevalence of dyslipidaemia among transplanted patients reported in the 
current study of 84.5% was higher compared to the other studies. To illustrate, a single-
centre study in Mexico reported the prevalence of hypercholesterolemia of 25%, 
defined as cholesterol >170 mg/dl, at two years after transplantation (79). A single-
centre study conducted in Canada reported the prevalence of hypercholesterolemia of 




The reported prevalence of overweight/obesity in the current study was 20.6% and 
40.6% for dialysis and transplanted patients, respectively. The finding that 
overweight/obesity was more common among patients after kidney transplantation 
might be explained by the use of corticosteroids. It was shown that corticosteroids are 
associated with post-transplant weight gain (77). This analysis also showed that 
overweight/obesity was more common among older patients compared to younger 
ones, and this is at least partly explained by the larger proportion of transplanted 
patients among older compared to younger patients. Analysis of type of RRT stratified 
by age are presented in the Appendix 1, Figure 3, page 364. 
The estimates of this study were higher compared with several other published studies 
from different population. For example, the USRDS registry reported that the 
prevalence of obesity, defined as BMI ≥95th percentile for age and sex, among HD 
patients was 11% (81). Post-transplant prevalence of obesity in two US studies was 
31%-36% in the period between 3 to 36 months post-transplantation (78) and 29% at 
1 year post-transplantation (77). The difference may in part be explained by the 
combined definition of overweight and obesity resulting in a higher prevalence. There 
were no studies describing the prevalence of underweight among patients <20 years of 
age receiving RRT apart from the ESPN/ERA-EDTA study (37) and, therefore, it is 
not possible to compare the current results with other studies.  
Prevalence stratified by European region 
The analysis of the prevalence of CVRFs by European region showed that the 
prevalence of hypertension, dyslipidaemia, anaemia and underweight was the highest 
in Eastern Europe. However, overweight/obesity was more prevalent among Western 
183 
 
and Northern Europe. This might be explained by differences in the distribution of 
RRT modalities with most transplanted patients in Western and Northern Europe and 
the proportion of dialysis patients highest in Eastern Europe (Appendix 1, Table 8, 
page 365). This difference might be explained by disparities in public health 
expenditure and access to kidney transplantation. Recent ESPN/ERA-EDTA study 
showed that eastern Europe had the highest risk of mortality due to restricted public 
health financing compared with wealthier northern, southern and western European 
countries (146).  
Combinations of CVRFs 
Among dialysis patients the most common combination of CVRFs is dyslipidemia, 
hypertension and anaemia. This might be explained by the high risk of fluid overload 
which is associated with higher BP levels and haemodilution (143), resulting in lower 
Hb values (73). Moreover, tissue hypoxia caused by anaemia leads to vasodilation, 
which triggers the activation of sympathetic nervous system and arterial stiffness, 
eventually leading to hypertension (147). A large proportion of transplanted patients 
have a combination of dyslipidemia, hypertension and overweight/obesity. A possible 
explanation is the high prevalence of overweight/obesity among transplanted patients. 
Previous studies in the general paediatric population showed that CVRFs are more 
prevalent in obese than non-obese children. For example, Freedman et al. reported that 
obese children have a higher risk of elevated BP, LDL cholesterol, and TG, low HDL 
cholesterol, and high fasting insulin concentration (148).  
The most common combination of CVRFs (dyslipidemia, hypertension and anaemia) 
in dialysis patients was not possible to compare to other studies as no studies reported 
this information. However, the most common combination of CVRFs (dyslipidemia, 
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hypertension and overweight/obesity) among transplanted children is in line with the 
study conducted by Ramirez-Cortes et al. (79). The authors showed that transplanted 
children who were obese are more likely to suffer from MeS compared to non-obese 
children. MeS was defined as the presence of three or more of the following risk 
factors: hypertension, glucose intolerance, low HDL cholesterol, hypertriglyceridemia 
and overweight (79).  
3.4.2.2 Cause of death  
In this study, CVD was the most common cause of mortality in patients under 20 years 
of age receiving RRT (22.7%) with the most common types of CVD being 
cerebrovascular disease and cardiac arrest. This finding corresponds with a study 
conducted by the USRDS registry including patients from 0 to 30 years of age 
receiving RRT (149). The authors reported that CV mortality accounted for 22.5% of 
all deaths and cardiac arrest was the most common cause of CV death.  
However, two other studies reported a two times higher proportion of CV deaths 
compared to the current study. For example, the study from the Dutch Renal Registry 
and the ANZDATA registry showed that CVD accounted for 41% and 45% of all 
deaths, respectively (28, 53). The proportion of CV death in both studies was higher 
presumably due to the longer follow-up time. The follow up of the current study was 
3.7 years (IQR 1.7-6.8) while the Dutch and ANZDATA studies followed their 
patients over the mean of 15.5 years (SD not reported) and median of 9.7 years (IQR 
not reported), respectively. As CV death is more likely to occur later in life after a 
longer follow-up time, both studies might have reported more CV deaths compared to 
the current study 
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3.4.2.3 The association of CVRFs with outcomes  
The survival analyses showed that anaemic patients had a statistically significantly 
higher risk of all-cause mortality compared to non-anaemic patients. This finding was 
in line with two previous studies conducted in dialysis populations that were discussed 
in details in the systematic review. Briefly, the NAPRTCS registry reported that 
patients with anaemia had an estimated 52% greater risk of death than non-anaemic 
patients (71). The IPPN registry showed that the risk of all-cause mortality was 
independently inversely associated with Hb, adjusted HR of 0.23 per g/dl of Hb (95% 
CI not reported) after a median follow-up of 0.8 year (IQR, 0.22-1.56 years) (22).  
The current study also showed that anaemic patients had a higher risk of CV death 
compared to non-anaemic patients. This is the first study investigating this association 
thus it is not possible to compare these findings with previous studies. However, the 
findings from the current study correspond to studies including adult RRT population. 
For example, a US study including Medicare incident HD patients showed that higher 
Ht values were associated with lower risk of CV morbidity and CV mortality over 
three years follow up (150).  
Results of the current study showed no significant associations between 
overweight/obesity and all-cause and CV mortality which is in line with earlier 
published results from the NAPRTCS study (see for details also the systematic review) 
(54). However, the NAPRTCS study showed increased mortality in obese 6 to 12 year 
old children compared to age matched non-obese children. However, it needs to be 
mentioned that this might be a chance finding due to multiple testing.  
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This study has found that underweight patients had a significantly higher risk of all-
cause mortality compared to non-underweight patients. This finding corresponds to 
another study from the USRDS registry including patients receiving RRT (107) 
discussed in my systematic review. The authors reported a U-shaped association 
between BMI and risk for all-cause mortality (107).  
This study did not find statistically significant associations between hypertension and 
all-cause and CV mortality. However, the Dutch Renal registry study included in the 
systematic review (29) showed different results. The authors showed that hypertensive 
patients had a threefold higher rate of all-cause mortality and a more than two times 
higher risk for cerebrovascular death compared to non-hypertensive patients after the 
mean follow-up of 15.5 years. This difference might be explained by the inclusion of 
older RRT population with longer follow-up in the Dutch study, which allowed the 
latter study to capture more outcome events compared to the current study. 
Similarly, I did not find an association between dyslipidaemia and all-cause mortality. 
There are no studies describing the association of dyslipidaemia with all-cause and CV 
mortality in children receiving RRT, so it was not possible to compare current findings 
with previous studies. However, it was shown previously that in the general paediatric 
population dyslipidaemia persists into adulthood and predicts CVD in later life (151). 
3.4.3 Limitations of the study 
This study had several limitations that should be mentioned and taken into account 
interpreting the results of the study.  
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3.4.3.1 Missing data and selection bias 
Almost all participating countries in the ESPN/ERA-EDTA registry were included in 
the current study. However, due to the fact that some registries have only quite recently 
started their data collection, the number of patients were very low for some countries. 
The results are weighted quite heavily by data from the countries which contributed 
the majority of the data (UK, Russia, Italy, France, Spain, Switzerland). I have 
accounted for the fact that different European countries will be represented to different 
degrees by stratifying the prevalence and adjusting the survival analysis for different 
European regions. However, the results of this study will be mostly representative for 
the countries which were overrepresented in the current study. It might be that 
countries with a better healthcare system will have more complete data on CVRFs and 
causes of death, therefore, the results of these analyses would be biased towards 
wealthier countries. 
Countries with missing CVRFs data were excluded from the analyses. Most of the 
missing data was on lipids measurements, while other CVRFs measurements such as 
BMI, Hb and BP levels were provided by the majority of countries. The proportion of 
transplanted patients was higher in patients with available BP and Hb compared to 
patients with missing data on these CVRFs. This might be because transplanted 
patients require immunosuppressive medication that has adverse effects in terms of 
high BP and low Hb level, therefore, need more frequent monitoring. As the 
prevalence of hypertension and anaemia is lower among transplanted population 
inclusion of larger proportion of transplanted patients might have resulted in 
underestimation of the true prevalence of these CVRFs. Moreover, survival of 
transplanted patients is higher compared to dialysis population. Therefore, the 
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associations of hypertension and anaemia with all-cause and CV mortality might also 
have been underestimated.  
In contrast, the proportion of patients receiving dialysis was higher among patients 
with available BMI measurements compared to patients with missing data. This might 
be because patients receiving dialysis require frequent BMI measurements to control 
dialysis regime to achieve a dry body weight. Patients on dialysis are more frequently 
underweight (152) and less overweight. Therefore, this might have led to 
overestimation of the proportion of underweight patients, but underestimation of the 
prevalence of overweight/obesity. Moreover, dialysis patients have a higher risk of 
death compared to transplanted patients. It might have affected the obtained HRs for 
the associations of underweight with all-cause and CV mortality towards 
overestimation.  
For the analysis of multiple CVRFs I could only analyse a limited number of patients. 
When comparing the included patients with patients with missing data, young patients 
(0-<2 years old) were overrepresented in the included cohort. Moreover, included 
patients were less likely to be pre-emptively transplanted and more frequently started 
on PD, as PD is more common among younger patients. The fact that complete data 
on all CVRFs was available for the younger children might be explained by the fact 
that young children have a higher risk of mortality compared to older children (153) 
and, therefore, require more careful and frequent monitoring. Therefore, the patterns 
of multiple CVRFs might not be generalisable for the entire RRT population of 
children in Europe.   
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Also, there was a high proportion of missing cause of death that were excluded from 
the analysis of CV mortality. If there were more deaths due to CVD among patients 
with missing data CV mortality might be underestimated. However, this is unlikely 
because CV death is expected to be recorded in the death certificates due to awareness 
of high risk of CVD in this population.  
3.4.3.2 Misclassification of patients by exposure and outcome status and 
residual confounding 
Information about specific methods for CVRFs measurements at the participating 
centres was not available in the registry. In particular, information is lacking with 
respect to the timing of BP and BMI measurements in dialysis patients. Use of pre-
dialysis measurements of BMI and BP might overestimate the prevalence of obesity 
and hypertension due to the presence of fluid overload (154). In general, the 
ESPN/ERA-EDTA registry requests pre-dialysis BP readings that possibly partly 
explains the high prevalence of hypertension in patients on dialysis found in this study. 
However, the registry requests data on dry body weight, therefore, any overestimation 
of BMI is likely to be small. This misclassification of patients with and without CVRFs 
is likely to be non-differential, which tends to bias the association towards the null 
(155). 
Misclassification of all-cause mortality is unlikely because the ESPN/ERA-EDTA 
registry collects mortality data submitted by the participating national registries. 
However, there is definitely a risk of misclassification of the cause-specific mortality. 
It is most likely that the causes of deaths were obtained from death certificates that 
might have led to misclassification of CV causes of death. Previous studies among the 
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general adult population have shown that death certificates tend to overestimate CV 
causes of death compared to deaths that were validated by autopsy (156).  
Information about the presence of comorbidities, which can increase the risk of death 
(157) was not available in the registry. Comorbidities might be important confounding 
factors in these associations. The IPPN registry reported that out of 1,830 children 
receiving PD 32.9% of patients had at least one comorbidity. The most common type 
of comorbidity was cognitive abnormality (15.5%) followed by motor abnormality 
(12.6%). The authors showed that compared with patients not having a comorbidity, 
those with any comorbidity had a significantly lower survival rate (73% vs 90%, 
p<0.0001) (157).  
3.4.3.3 Limitation of methods used 
Due to the lack of baseline measurements of CVRFs (taken at the start of RRT) in the 
majority of patients, both incident and prevalent RRT patients were included in the 
current study. This resulted in the inclusion of patients with highly variable duration 
of RRT, median 2.3 years (IQR 0.5-5.6). To control for this the analysis was adjusted 
for the period from the start of RRT to the time of first CVRF measurement.  
Moreover, I used a simplistic methodological approach to summarise the repeated 
CVRFs measurements and changes in RRT modality into one derived summary 
measure. This method may not have sufficiently captured the change in measures over 
time and the effect this may have had on the outcome. Additionally, the summarised 
repeated measurements did not allow to classify patients with available BMI 
measurements into three categories: underweight, normal weight and 
overweight/obese. This method only allows to categorise patients into two groups: 
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overweight/obese versus non-overweight/obese and underweight versus non-
underweight.   
Another limitation related to the methods of the study was that all available CVRFs 
measurements per patient during follow-up time were included in the primary analysis. 
This approach was chosen to be able to include as many patients as possible to the 
study. However, such an approach may mean that CVRFs measurements, measured 
soon before death, are not predictors of death but are rather markers for the severity of 
the underlying renal pathology (158). However, a sensitivity analysis excluding 
patients whose measurements were taken in the last six months before death led to 
similar results to those obtained in the primary analysis.  
Finally, due to the observational nature of the study it is not possible to claim any 
causal relationships for the factors that were found to be associated with all-cause and 
CV mortality. Nevertheless, this large scale European study provides important 
knowledge which will help to optimise CVD management in children receiving RRT.  
3.4.4 Strengths of the study 
3.4.4.1 Sample size and generalisability of results 
This is the first study focusing on CVRFs in young patients receiving RRT. One of the 
biggest strengths of this study is the use of the European international dataset that 
allowed to include a large number of patients who initiated RRT in childhood. 
Furthermore, most European countries participating in the ESPN/ERA-EDTA registry 
were included in the analysis with all regions of Europe represented in the registry. 
This shows high generalisability of the obtained results to the European population 
under 20 years of age receiving RRT. Previous studies are predominantly from the US 
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(54, 72, 159, 160) or from a single European country (29). The finding of the US 
studies might be difficult to extrapolate to the European population due to the 
differences in health care systems and a higher proportion of black people in the US 
compared to Europe. It has been shown in previous studies in adults with ESRD that 
black patients have a higher risk of ESRD compared to white patients (161).  
Furthermore, this is the first European study including patients with all age groups 
from 0-20 years of age and both dialysis and transplanted patients. This makes it 
possible to explore differences in prevalence of CVRFs between sub-groups of patients 
by age at start of RRT and type of RRT. Furthermore, this makes obtained results 
generalisable to the entire RRT population of patients from 0-20 years old. In contrast, 
most of the previous studies discussed in the systematic review included selected 
population of RRT patients, either on dialysis (72, 160, 162) or after kidney 
transplantation (54) or certain age groups (72).  
3.4.4.2. Follow-up period 
Another strength of this study is the relatively long follow-up period when comparing 
with other available studies. For example considering anaemia this is the study with 
longest follow-up of 3.7 years (IQR 1.7-6.8) Until now, the association between 
anaemia and outcome was investigated in the NAPRTCS registry with 2.6 years 
follow-up available (160).  
3.4.4.3 Novel findings 
This is the first study using data from the ESPN/ERA-EDTA registry that described 
several CVRFs, their patterns and regional difference of prevalence of CVRFs. 
Previous studies only focused on describing the prevalence of single CVRFs. 
193 
 
Additionally, there is the gap in the literature about the association of dyslipidaemia 
with all-cause mortality. This is the first study that described this association in 
children receiving RRT.   
Most importantly, the access to cause specific mortality records allowed to study the 
association of CVRFs with CV mortality. This study, therefore, provides an important 
and novel contribution, since there are no studies describing the association of CVRFs 
with CV mortality. As shown in my systematic review there was only one study 
performed by the Dutch Renal Registry (29) that examined the association between 
hypertension and cerebrovascular disease mortality. However, this study only included 
a selected RRT population of survivors into adulthood and only reported crude RRs. 
3.5 Conclusion and future research 
In conclusion, the current study has added novel insights and results to this research 
field. This study showed that dyslipidaemia, hypertension, anaemia and 
overweight/obesity are common among young European patients receiving RRT. The 
prevalence of the majority of CVRFs was lower in transplanted than among dialysis 
patients. This finding underlines the beneficial effects of transplantation in terms of 
improved CVRF profile. In addition, the combination of dyslipidemia, hypertension 
and anaemia was most common in dialysis patient and the combination of 
dyslipidemia, hypertension and overweight/obesity was most common in transplanted 
patients. Patients who were underweight/anaemic had a higher risk of all-cause 
mortality compared to non-underweight/non-anaemic patients. Anaemic patients had 
a higher risk of CV mortality compared to non-anaemic patients. Future research is 
needed to clarify whether treatment of anaemia will reduce CVD and death in patients 
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who initiated RRT in childhood. Detailed discussion about future study designs that 
could be performed to answer this remaining question are presented in the overall 
discussion chapter (Chapter 7). 
As the ESPN/ERA-EDTA registry was limited in follow-up of patients up to reaching 
20 years of age, further research is needed that would follow patients up from 
childhood into adulthood and look at the longer-term survival. Furthermore, lack of 
CVD morbidity data within the ESPN/ERA-EDTA registry did not allow to describe 
CVD incidence in this population. These limitations should be addressed by using 
registry data with the access to CVD morbidity records. Both main limitation of the 
ESPN/ERA-EDTA analyses I addressed by using the SRR registry data. The SRR 
follows patients up from childhood into adulthood and has an opportunity to link 
individual patient data with the national registry of causes of death and hospital 
admissions. These advantages allowed me to describe a longer-term survival and CVD 
incidence in patients who initiated RRT in childhood. The following chapter provides 
a literature review focusing on longer-term survival, CVD incidence and the 
association of age at start of RRT, sex, PRD, type of RRT and period of start of RRT 
with all-cause mortality and CVD incidence in patients who initiated RRT in childhood 
(Chapter 4). This literature review informed my SRR analysis presented in Chapters 5 







Chapter 4. Survival, all-cause mortality and cardiovascular disease 
outcomes in patients who initiated renal replacement therapy in 
childhood; a literature review 
4.1 Introduction 
ESRD in children is rare but important health problem, often requiring RRT. The 
ANZDATA registry showed that all-cause mortality rates in patients who started RRT 
from 0 to 19 years old were 30 times higher compared to an age- and sex-matched 
general population (118). CVD is one of the most common causes of death in patients 
who initiated RRT in childhood. Information about long-term survival and CVD 
incidence in these patients is limited. The systematic review presented in Chapter 2 
described the association of CVRFs (anaemia, hypertension, obesity and 
dyslipidaemia) with all-cause and CV mortality to inform the ESPN/ERA-EDTA 
analyses. This literature review was performed in conjunction with the SRR analyses 
to describe the long-term survival and CVD incidence among patients who initiated 
RRT in childhood. The aims of this literature review were: 
1. To identify, synthesise and critically appraise the existing literature about 
survival/all-cause mortality and CVD incidence of patients who initiated RRT in 
childhood. 
2. To identify, synthesise and critically appraise determinants for all-cause mortality 
and CVD incidence in patients who initiated RRT in childhood, such as age at 
initiation of RRT, sex, PRD, type of RRT and period of initiation of RRT. These 
particular determinants were of interest partly because these were the risk factors that 
would be investigated within the SRR analyses. 
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4.2 Methods  
4.2.1 Search strategy 
Medline and Embase electronic literature databases were searched using a 
comprehensive search strategy comprised of Medical Subject Heading terms and 
keywords for paediatric, renal disease, survival, all-cause mortality and CVD 
outcomes. The search was limited to the last 5 years (from 2011 to 2016) due to time 
limitations. The search strategy is presented in Appendix 1 page 366. The reference 
lists of the relevant papers and annual reports of national and international renal 
registries were also searched to identify relevant papers and information.  
4.2.2 Inclusion and exclusion criteria for study identification for this 
review 
4.2.3.1 Inclusion criteria  
Types of studies: 
RCTs and observational studies that report survival and/or CVD incidence, and/or 
association of age at start of RRT, sex, PRD, type of RRT and period of initiation of 
RRT with all-cause and/or CVD incidence of children with ESRD or patients who 
initiated RRT in childhood were included. 
Types of participants: 





Types of exposure: 
Among studies reporting on determinants associated with all-cause mortality/CVD 
incidence, exposures of interest were age at start of RRT, sex, PRD, type of RRT and 
period of initiation of RRT. 
Types of outcome: 
1. All-cause mortality  
2. CVD outcome: fatal and non-fatal CVD events (coronary artery disease, 
cardiomyopathy, cardiac arrest, valvular heart disease, arrhythmia, cerebrovascular 
disease, peripheral vascular disease). 
4.2.3.2 Exclusion criteria  
Studies that report survival and/or CVD outcomes and/or association of age at start of 
RRT, sex, PRD, type of RRT and period of initiation of RRT with all-cause and/or 
CVD incidence in patients with adult-onset RRT were excluded.  
Studies that reported CV surrogate end-points obtained from non-invasive imaging 
techniques, such as left ventricular hypertrophy, carotid intima-media thickness, 
coronary artery calcification or coronary intravascular ultrasound plaque volume were 
excluded. 
4.2.3 Data extraction and assessment of risk of bias and confounding 
I screened the results of the search strategy to identify relevant studies for inclusion, 
first by title and abstract and then by full text. Data from relevant full-text studies were 
extracted: author/s; year of publication; data sources and settings; study population; 
length of follow-up; categorisation of exposure; incident/prevalent RRT population; 
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statistical techniques used; and results of the study analysis (crude/adjusted effect 
estimates and confidence intervals). Results are presented in tables and forest plots. 
The results were summarised in a narrative synthesis.  
4.3 Results 
The flow diagram of included and excluded studies is presented in Figure 30. In total, 
after excluding duplicate records, 2,757 records were identified through two database 
searches. After screening titles and abstracts 2,706 records were excluded, leaving 51 
relevant papers for full-text review. Additional 11 papers were identified from the 
reference lists. Ultimately, 57 full-text articles were retrieved and assessed for 




Figure 30. Flow diagram of included studies in the literature review of survival, CVD 
outcomes and the associations of age at initiation of RRT, sex, PRD, type of RRT and 
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4.3.1 Characteristics of included studies describing survival/all-cause 
mortality and CVD outcomes in patients who initiated RRT in childhood  
Table 22 presents characteristics of the included studies (number in superscript refers 
to the study identifier). All studies were observational cohort studies. Almost all 
studies used data from national or multi-national renal registries, apart from one single 
hospital study from Canada (109). Multi-centre studies were from the USRDS (120, 
149, 163, 164), the ESPN/ERA-EDTA (30, 31), the National Dutch Registry of 
patients on RRT (29, 165), the Canadian Paediatric ESRD registry (14, 110), the ERA-
EDTA (166), the ANZDATA (118), the NAPRTCS (167), the UK renal registry (168) 
and one study combined data from the ESPN/ERA-EDTA, IPPN and ANZDATA 
registries (169). Sample size ranged from 87 to 23,401 participants. Studies generally 
included children aged up to 18 years of age at initiation of RRT, while three studies 
included patients up to two years of age (14, 167, 169) and two studies included 
children and young adults after reaching at least 18 years of age (120, 149). There was 
a larger proportion of males than females across all studies. Six studies reported 
race/ethnicity distribution showing that the proportion of white patients was higher in 
all studies compared to patients of other race/ethnicity groups. CAKUT and GN were 
the most common types of underlying ESRD almost in all studies. Studies were 
heterogeneous in terms of the RRT population. Ten studies included both dialysis and 
transplanted ESRD populations, while five studies were limited to children/young 
adults receiving dialysis and one study was limited to a transplanted population. The 
majority of studies included incident RRT populations. Not all studies reported median 
follow-up period. Among the 10 studies with reported follow-up, it ranged from 1.2 to 
25.5 years.  
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Table 22. Characteristics of included studies describing survival, all-cause mortality and CVD outcomes in patients who initiated RRT in 
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National 1,634 0-19  
Mean NR 
56.0 NR NR PD  
HD 
Tx 
Incident  Median 9.7 years 
(IQR 4.1-17.6) 
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1,697 0-19  
Mean NR 


















6,473 0-18  
Mean NR 
56.1 NR CAKUT 32.4 
GN 18.3 







Incident  10,910  




NR 193 0-2 
Mean NR 













Incident  Median 14.6 (IQR 
NR) months  
N=total population, PRD-primary renal disease, NAPRTCS- North American Pediatric Renal Transplant Cooperative Study, ANZDATA-Australia and New Zealand dialysis and transplant registry, USRDS-
United States Renal data system, IPPN- International Pediatric Peritoneal Dialysis Network, GN-glomerulonephritis, FSGS-focal segmental glomerulosclerosis, CAKUT-congenital anomalies of the kidney 
and urinary tract, CNS- congenital nephrotic syndrome, ARPKD-autosomal recessive polycystic kidney disease, HUS-haemolytic-uremic syndrome, PD-peritoneal dialysis, HD-haemodialysis, Tx-
transplanted patients, SD-standard deviation, IQR-interquartile range, p/y- person years. *Age is presented in years unless otherwise specified. NR-not reported  
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4.3.2 Mortality/long-term survival and CVD occurrence in patients who 
initiated RRT in childhood  
4.3.2.1 All-cause mortality rate/survival in patients who initiated RRT in 
childhood  
This section summarises the results of all-cause mortality rates and/or survival 
reported by the included studies. Ten studies described all-cause mortality rates and/or 
described survival in patients who initiated RRT in childhood (Table 23). Studies in 
Table 23 are organised based on RRT population and age at initiation of RRT. The 
overall crude all-cause mortality rate among dialysis populations ranged from 2.8 to 
9.8 per 100 p/y. Crude all-cause mortality rates among studies that included both 
dialysis and transplanted patients ranged from 1.6 to 4.7 per 100 p/y. Most studies 
reported on a 5-year or shorter follow-up period. One- and five- year survival ranged 
from 79.8% to 99.4% and from 74.9% to 96.3% across all studies, respectively. Only 
three studies reported very long-term follow-up. The ANZDATA registry (118), 
Canadian Paediatric ESRD registry (110) and Dutch Renal registry (29) reported 10-
year survival ranging from 78.0% to 85.8%. Twenty-year survival of 66.0% (95% CI 
63-69%) was reported by the ANZDATA registry (118), while the Dutch registry (29) 
reported a higher 20-year survival of 78.0% (95% CI not reported). It was not possible 
to assess whether this difference is statistically significant due to the lack of 95% CI 
in the Dutch study.   
Patients in the youngest age groups showed the highest mortality rates/lowest survival. 
For example, the USRDS study reported a mortality rate of 9.8 per 100 p/y (120) in 
the youngest age strata of patients <5 years of age. The Canadian Paediatric ESRD 
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registry (14) reported the lowest one- and five-year survival of 79.8% (95% CI 71.6-
88.8%) and 74.9% (95% CI 66.1-84.8%), respectively. The high mortality rate/low 
survival among the youngest patients might be explained by delayed transplantation 
until the child weighs 10 kg or is two years old. The primary reason for this delay is 
that renal transplantation is technically difficult in children <2 years old due to the 
small size of the child compared with the relatively large (usually adult) donor kidney 
and the small blood vessel calibre of the recipient (14).  
The lowest mortality rate of 1.6 per 100 p/y was reported by the Dutch registry (29). 
The study was limited to patients who initiated RRT in childhood and survived into 
adulthood by the time of the study initiation. Included patients may be healthier 
compared to those who did not survive until adulthood, therefore, the lower mortality 
rates in this study compared to other studies is likely to reflect survival bias.  
Longer-term survival (10- and 20-year) was reported by the ANZDATA, Canadian 
and Dutch renal registries studies (29, 110, 118). The lowest 10- and 20-year survival 
was reported by the ANZDATA registry (118) presumably due to the inclusion of 
patients who started RRT in earlier periods (from 1963 onwards) compared to the 
Canadian (110) and Dutch (29) registries which started in 1972 and 1992, respectively. 
Improvement in dialysis and transplantation techniques in later periods compared to 
earlier years might have resulted in better survival of patients included in the Dutch 
and Canadian studies.  
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Table 23. Results of included studies reporting overall crude all-cause mortality rate/ 






rate per 100 p/y (95% 
CI) 
Overall survival  
% (95% CI) 
 Age range 0-21 years old 
Wong et al. 
(2001)163 
93 3.2 (NR) NR 
Mitsnefes et al. 
(2013)120 
<5 years old 
705 
>5 years old 
2270 
<5 years old 
9.8 (NR) 




Chesnaye et al. 
(2016)30 
306 2.8 (NR) 1 year- 96.6 (96.0-97.0) 
5 year- 89.5 (87.7-91.0) 
Groothoff et al. 
(2002)29 
63 1.6 (NR) 5 year-87 (NR) 
10 year-82 (NR) 
20 year-78 (NR) 
 
McDonald et al. 
(2004)118 
436 2.4 (NR) 5 year- 86.0 (84.0-88.0) 
10 year-78.0 (76.0-80.0) 
20 year-66.0 (63.0-69.0) 
 
Kramer et al. 
(2009)166 
76 NR 1 year- 99.4 (99.1-99.7) 
5 year- 96.3 (95.3-97.4) 
Samuel et al. 
(2011)110 
107 1.8 (1.5-2.1) 5 year-91.7 (89.8-93.7) 
10 year-85.8 (82.8-88.8) 
Chesnaye et al. 
(2014)31 
NR 2.0 (NR) NR 
 Age range 0-2 years old 
Alexander et al. 
(2011)14 
23 4.7 (2.8-6.6) 1 year-79.8 (71.6-88.8) 
5 year-74.9 (66.1-84.8) 
Van Stralen et al. 
(2012)169 
45 NR 5 year- 76.4 (NR) 
p/y-patient years, CI-confidence interval, NR-not reported. Number in superscript refers to the study identifier




4.3.2.3 CVD incidence and/or CV mortality rate in patients who initiated 
renal replacement therapy in childhood 
Table 24 summarises CV mortality rates and/or CVD incidence reported by the 
included studies. Only three studies reported CV mortality rates. The Dutch renal 
registry study (29) reported the overall crude CV mortality rate of 0.95 per 100 p/y 
(95% CI not reported) in all Dutch children who started RRT between 1972 and 1992 
and who survived to adulthood. Another publication using the same cohort with 
extended follow-up period reported lower CV mortality rates in patients who started 
RRT from 2000 to 2010 compared to patients who started RRT from 1972 to 1989, 
0.22 per 100 p/y (95% CI 0.06-0.56) (165). The authors explained the trend of 
decreased CV mortality over the last decade by an increased awareness of the burden 
of CVD in renal patients among clinicians, which may have resulted in better treatment 
and consequently better survival. Another possible explanation could be a better 
availability of living-related donors and pre-emptive transplantation in recent decades 
compared to earlier decades which may in part result in better survival. The USRDS 
registry (120) reported higher CV mortality rates compared to the Dutch studies of 
3.54 and 1.45 per 100 p/y among patients less than 5 years old and older than 5 years 
old, respectively. The healthier and older study population of RRT patients, who 
survived into adulthood included in the Dutch studies might explain this difference. 
Furthermore, the ESRDS registry included dialysis patients only, while the Dutch 
studies included also transplanted patients who have better survival compared to 
dialysis population, partly explaining this difference.  
210 
 
Four studies reported data on types of CVD causing the fatal events. The proportion 
of deaths attributed to CVD ranged from 27.1% to 41.0%. Cerebrovascular accident 
and cardiac arrest were the most common causes of death from CVD (Table 24). 
 Despite the high CV mortality in patients who initiated RRT in childhood limited 
knowledge exists about CVD incidence in this population. Only two studies described 
incidence of fatal and non-fatal CVD events. The USRDS study (164) only described 
cardiac events and excluded cerebrovascular disease events. This study included 1,454 
incident patients who started dialysis between 0 and 19 years of age. Among them, 
452 (31.1%) developed a cardiac-related event (Table 24). Arrhythmia was the most 
common (19.6%), followed by valvular disease (11.7%), cardiomyopathy (9.6%) and 
cardiac arrest (3%). A single centre study from Toronto, Canada (109) included 418 
patients who received a kidney transplant. The Canadian authors defined CVD 
incidence as the first fatal or non-fatal CVD event obtained from a hospital admission 
administrative dataset. CVD events were defined as myocardial infarction, congestive 
heart failure, cardiac arrest, stroke and transient ischaemic attack. A total of 33 (12.0%) 
patients had CVD events over mean follow-up of 6.4 years (SD 5.1). Cerebrovascular 
events accounted for 43% of all CVD events observed. It was impossible to compare 
this two studies by follow-up period as this data was lacking in the USRDS study 
(164). It is probable that the study with the longest follow-up period would have 







Table 24. Results of included studies describing overall crude CV mortality rates and 





Crude overall CV 
mortality rate or 




CV deaths or 
CVD events 
% 













Cardiac arrest 7.7 
Pericarditis 3.8 




<5 years old 
246 
>5 years old 
852 
<5 years old 
3.45  
>5 years old 
1.45 
<5 years old 
27.1 
>5 years old  
35.9 
<5 years old 
Cardiac arrest 53 
Other 47 
>5 years old  

















452 NR 31.1 Arrhythmia 19.6 
Valvular heart disease 
11.7 
Cardiomyopathy 9.6 
Cardiac arrest 3.0 





33 1.07 (NR) 12.0 Cerebrovascular accident 
43 
Congestive heart failure 
33 
Myocardial infarction 24 
p/y-patient years, CV-cardiovascular, CVD-cardiovascular disease, CI-confidence interval, NR-not reported. Number in 
superscript refers to the study identifier 
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4.3.3 Associations of age at start of RRT, sex, PRD, type of RRT and 
period of initiation of RRT with all-cause mortality and CVD outcomes 
This section summarises the results of the associations of age at start of RRT, sex, 
PRD, type of RRT and period of start of RRT with all-cause mortality and CVD 
outcomes (fatal and/or non-fatal CVD) reported by the included studies.  
4.3.3.1 Association of age at start of RRT with all-cause mortality and 
CVD outcomes in patients who initiated RRT in childhood 
Nine studies described the association of age at start of RRT with all-cause mortality 
and one study described the association of age at death with cardiac mortality (Table 
25). Studies were heterogeneous in terms of categorisation of age. The youngest age 
category varied from <1 years old to <5 years old, while the oldest category varied 
from >5 years old to 15-19 years old. The results of the studies consistently showed 
that patients in the youngest age category had a higher risk of all-cause mortality 
compared to patients in older age category. The USRDS study showed no statistically 
significant association of age at death with fatal cardiac events among patients who 







Table 25. Results of included studies describing the association of age at start of RRT 





Effect estimate (95% CI) Summary of findings 








Older patients had a lower risk of all-





>5 years  
<5 years  
 
1.00 
3.4 (1.8- 6.4) 
Patients started RRT less than 5 years of 
age had a higher risk of all-cause 
mortality compared to older patients.  
Parekh et al. 
(2002)**149 
Continuous 
Increasing age at death for 
each 10 years 
1.22 (1.00-1.44) 
There is no statistically significant 
association between age at death and 
cardiac mortality.  
Kramer et al. 
(2009)*166 










There is no statistically significant 
association between age at start of RRT 













Patients started RRT at the age of less 
than 3 months had a higher risk of all-
cause mortality compared to those who 
started RRT from 1 to 2 years old.  












Patients who started dialysis at the age of 
less than 1 year had a higher risk of all-
cause mortality compared to those started 






<5 years HR/year 0.75 
(0.70-0.80) 
>5 years HR/year 1.00 
(0.99-1.02) 
Each one-year increase in age in patients 
started RRT less than 5 years old was 
associated with a lower risk of all-cause 
mortality.  
Pruthi et al. 
(2013)*168 










Patients started RRT from 0 to 3 years old 
had a higher risk of all-cause mortality 












The youngest age group had the highest 
risk of all-cause mortality compared to the 







Effect estimate (95% CI) Summary of findings 
Carey et al. 
(2016)*167 





There is no statistically significant 
association between age at start of RRT 
and all-cause mortality.  
CI-confidence interval, RRT-renal replacement therapy, * effect estimates presented as adjusted hazard ratios,** effect estimates 
presented as adjusted odds ratios, number in superscript refers to the study identifier 
4.3.3.2 Association of sex with all-cause mortality and CVD outcomes in 
patients who initiated RRT in childhood 
Six studies described the association of sex with all-cause mortality (Figure 31) and 
one with cardiac mortality (149). Almost all studies showed no statistically significant 
association of sex with all-cause mortality apart from the USRDS that reported that 
male patients had a 20% significantly lower risk of all-cause mortality compared to 
female patients among those who started RRT older than five years old. However, the 
authors did not find a significant association among patients younger than five years 
old (120).  
The only USRDS study that described the association of sex with cardiac mortality 
(not in the Figure, described in the text only) showed no statistically significant 
association among patients who initiated RRT between 0 and 30 years old, OR 1.17 
(95% CI 0.9-1.5) (149).  
 
 
    Association of age at start of RRT with all-cause mortality, 
  Association of age at death with cardiac mortality (myocardial infarction, cardiac arrest, cardiomyopathy, 





Figure 31. Association of sex with all-cause mortality reported in the studies 
 
4.3.3.3 Association of PRD with all-cause mortality and CVD outcomes in 
patients who initiated RRT in childhood 
Seven studies described the association of PRD with all-cause mortality and one with 
cardiac mortality (149) in patients who initiated RRT in childhood (Figure 32). Three 
studies reported a statistically significant association showing that patients with 
CAKUT have a lower risk of all-cause mortality compared to other PRD. For example, 
the Dutch study showed that patients with Goodpasture’s syndrome, oxalosis, 
cystinosis or autosomal recessive polycystic kidney disease had a higher risk of all-
cause mortality compared to patients with CAKUT, HR 2.4 (95% CI 1.1-5.1) (29). The 
USRDS study showed that patients with GN and patients with PRD other than GN or 
focal segmental glomerulosclerosis had a higher risk of all-cause mortality compared 
to patients with CAKUT, HR 1.49 (95% CI 1.08-2.04) and HR 1.35 (95% CI 1.11-
1.63), respectively (120). Similarly, the NAPRTCS study also reported that patients 
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with CAKUT had a lower risk of all-cause mortality compared to patients with other 
PRD, HR 0.67 (95% CI 0.45-0.98) (167).  
The only study that described the association of PRD with CVD outcome was the 
USRDS study (149). The authors categorised PRD as glomerular or other types of 
PRD, which included diabetes, hypertension, polycystic kidney disease, obstructive 
uropathy/dysplasia and other. The authors did not find a statistically significant 
association between PRD and cardiac mortality. 




Figure 32. Association of PRD with all-cause mortality and CVD outcomes reported 
in the included studies 
 
4.3.3.4 Association of type of RRT with all-cause mortality and CVD 
outcomes in patients who initiated RRT in childhood 
Eight studies described the association of type of RRT with all-cause mortality (Figure 
33) and three described the association of type of RRT with CVD outcomes (Figure 
34). Studies that included both dialysis and transplanted populations consistently 
showed that patients receiving pre-emptive transplantation or a kidney transplant 
during follow-up period had a lower risk of all-cause mortality compared to patients 
only receiving dialysis. There were two studies including dialysis populations that 
investigated the association of PD and HD with all-cause mortality, the ESPN/ERA-
EDTA (30) and the USRDS (120). Only the ESPN/ERA-EDTA study showed 
statistically significant results, reporting that patients who initiated RRT with HD had 
a higher risk of all-cause mortality compared to patients initiated RRT with PD. One 
of the limitations of the ESPN/ERA-EDTA study was a short median follow-up period 
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of 2.17 years (IQR not reported). The USRDS registry did not report the follow-up 
period.  
 
Figure 33. Association of type of RRT with all-cause mortality 
 
Three studies described association of type of RRT with CVD outcomes (Figure 34). 
All three studies used different CVD outcomes. Two studies used only fatal CVD 
events (29, 149). The Dutch study used cerebrovascular mortality (29), while the 
USRDS study (149) used cardiac mortality, defined as myocardial infarction, cardiac 
arrest, cardiomyopathy, arrhythmias, pericarditis, valvular heart disease and other 
cardiac causes. The Canadian study used fatal and non-fatal CVD events as their 
outcome (109).  
The Dutch and the USRDS studies both showed that transplanted patients had a lower 
risk of cerebrovascular and cardiac mortality, respectively, compared with dialysis 
patients. However, the Canadian study did not find a statistically significant difference 
in CVD incidence between transplanted patients who started on dialysis and pre-
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emptively transplanted patients possibly due to the small sample size (N=274) and 
small number of CVD events (N=33) resulted in low statistical power.  
Figure 34. Association of type of RRT with CVD outcomes 
 
 
4.3.3.5 Association of period of initiation of RRT with all-cause mortality 
and CVD outcomes in patients who initiated RRT in childhood  
Five studies described the association of period of initiation of RRT with all-cause 
mortality and three with CV mortality. (Table 26). However, only three studies found 
statistically significant results (118, 120, 165). These results showed that patients who 
initiated RRT in recent periods had a lower risk of all-cause and CV mortality 
compared to patients who initiated RRT in earlier periods. The ANZDATA registry 
(118) reported that patients commencing RRT from 1963 to 1982 had a significantly 
higher risk of all-cause mortality compared to those who started RRT from 1993-2002. 
The USRDS (120) included patients who started RRT from 1990 to 2010 reporting 
that each 5 year increment in calendar year of dialysis initiation is associated with a 
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lower risk of all-cause and CVD mortality. The Dutch study (165) showed that patients 
who started RRT from 1990 to 2010 had a lower risk of CVD mortality compared to 
























Table 26. Results of included studies describing the association of period of initiation 














There is no difference in all-cause 
and CV mortality between patients 
who started RRT in the period from 
1982 to 1991 compared to those who 

















Patients commencing RRT from 
1963 to 1982 had a significantly 
higher risk of all-cause mortality 










There is no difference in all-cause 
mortality between patients started 
RRT in the period from 2000 to 
2007 compared to those who started 






HR per 5 years increment in 
calendar year of RRT initiation 
Patients <5 years old 
0.82 (0.77-0.87) 
Patients >5 years old 
0.88 (0.85-0.92) 
Each 5 years increment in calendar 
year of dialysis initiation is 
associated with a lower risk of all-
cause and CV mortality 
Patients <5 years old 
0.54 (0.47-0.63) 









0.09 (0.02-0.45)  
0.26 (0.10-0.66) 
1.00 
Patients who started RRT from 1990 
to 2010 had a lower risk of CV 
mortality compared to those who 
started RRT from 1972 to 1989 






There is no difference in all-cause 
mortality between patients who 
started dialysis from 1992 to 1998 
compared to patients who started 
from 1999 to 2005  
HR hazard ratio, RRT-renal replacement therapy, CV-cardiovascular, ESRD-end stage renal disease, CI-confidence interval, 
number in superscript refers to the study identifier 
   Association of period of start of RRT with all-cause mortality 




4.3.4 Quality assessment of the included studies 
4.3.4.1 Internal validity of the studies 
Volunteer bias  
Studies by van Stralen et al. (169) and Carey et al. (167) may have been affected by 
volunteer bias as both studies used voluntary registries, the IPPN and the NAPRTCS, 
respectively. Both registries have been described in more detail in previous chapters. 
Since there is no information available about non-participating centres it is difficult to 
predict the direction of the selection bias.  
Selection bias 
Most of the studies included all eligible patients, apart from a few studies that excluded 
patients from the analyses due to missing data or loss to follow-up. For example, the 
two studies performed by the USRDS registry excluded 12.3% (163) and 6% (149) of 
patients with missing data from the analyses. The ANZDATA registry study (118) 
excluded 2% of patients who were lost to follow-up in their analyses. The Canadian 
study (109) that reported the association of type of RRT with CVD incidence excluded 
5% of patients with missing ID that was necessary for data linkage.  
The characteristics of patients with missing data that were excluded from the analyses 
were not provided in all studies. Therefore, it is impossible to predict the direction of 
any selection bias and its effect on the internal validity of the studies. However, it is 
unlikely that such small proportion of excluded patients from the analyses would 




Misclassification bias  
It is unlikely that misclassification of all-cause mortality would occur in the studies; 
however, cause specific mortality might be misclassified. Most studies used registry 
data submitted by participating centres through death certificates, which tend to 
overestimate CV cause of death compared to deaths that were validated by autopsy 
(156).  
Survival bias  
The potential source for survival bias was identified in the majority of studies. Two 
Dutch studies by Groothoff et al.(29) and Vogelzang et al.(165) used the same cohort 
of patients who started RRT in childhood and survived into adulthood defined as older 
than 18 years old by the time of the study initiation. Another study from the ERA-
EDTA (166) that also selected patients who started RRT in childhood and reached the 
age of 18 years. Inclusion of healthier population of RRT patients results in better 
survival and likely explains the lower mortality rates reported by these studies.  
The studies that included the youngest patients (14, 167, 169) and/or patients receiving 
dialysis (30, 120, 163, 164, 167) are also subject to survival bias because over time 
older and healthier children receive a kidney transplantation. Inclusion of sicker RRT 
populations might partly explain the higher mortality rates in these studies. Survival 
bias may also affect the studies with short follow period (14, 31, 168) as most deaths 
usually occur among the youngest patients and within the first year after start of RRT.   
Confounding 
Most studies adjusted their associations for important confounding factors. However, 
some studies might over-adjust their results. For example, in the association of sex 
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with all-cause mortality age at start of RRT is not a confounding factor as it is 
associated with the outcome but not with the exposure. Therefore, it represents another 
risk factor and should not be adjusted for. In the association of PRD with all-cause 
mortality type of RRT might be in a causal pathway, as patients with more severe PRD 
might start with dialysis and healthier patients might receive a kidney transplant.  
4.3.4.2 External validity of the studies 
The ESPN/ERA-EDTA (30, 31), the ERA-EDTA (166), the National Dutch Registry 
of patients on RRT (29, 165), the Canadian Paediatric ESRD registry (14, 110), the 
ANZDATA (118) and the UK renal registry (168) studies have a high generalisability 
of their findings due to national coverage of these registries and very low proportion 
of excluded patients from their analyses. However, the results of the USRDS studies 
(120, 163, 164) can only be extrapolated to the Medicare eligible population as the 
analyses was restricted to Medicare patients registered in the USRDS registry.  
The only single centre study from the Sick Kids hospital in Province of Ontario, 
Canada reported that their hospital performs all paediatric kidney transplants in 
Ontario which covers 40% of the population of Canada (109). It is not possible to say 
whether patients who were transplanted in this hospital are representative to all 
paediatric patients receiving a kidney transplantation in Canada as the authors do not 






4.4.1 Summary of findings of the literature review and limitations of the 
studies  
All-cause mortality/survival and fatal/non-fatal CVD outcomes  
This literature review including 16 observational studies mostly from known renal 
registries (14, 29-31, 110, 118, 120, 149, 163-169) showed that all-cause mortality 
rates varied widely across studies (1.6-9.8 per 100 p/y) partly due to the heterogeneous 
study populations. The studies either included dialysis or transplanted patients or 
patients from specific age group. Studies that included dialysis or younger RRT 
populations reported higher mortality rates compared to the studies that included 
transplanted or older RRT populations. Most studies reported five-year survival or 
shorter, while only few studies described very long-term survival. The results of these 
studies may suffered from survival bias due to inclusion of selected RRT populations 
that also limits generalisability of their results to a wider paediatric RRT populations. 
Only a few studies reported CV mortality rates. Despite the fact that CVD was one of 
the most common causes of death only very limited information was identified through 
this literature review. The most commonly reported fatal and non-fatal CVD events in 
the studies were cerebrovascular disease and cardiac arrest/arrhythmias.  
Association of age at initiation of RRT, sex, PRD, type of RRT and period 
of start of RRT with all-cause mortality and CVD outcomes 
Data about the associations between determinants and all-cause mortality is sparse. A 
few studies showed that patients with CAKUT, receiving a kidney transplant, older 
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age at start of RRT and initiating RRT in recent periods are associated with a lower 
risk of all-cause mortality. Only a few studies described the associations between 
determinants and CVD outcomes. The studies mostly used fatal CVD events as the 
outcome, with the definition varying between studies as CVD mortality, 
cerebrovascular mortality and cardiac mortality. Only two studies, the Canadian (109) 
and the USRDS (164), used non-fatal and fatal CVD events, while only the Canadian 
study (109) described the association of RRT with CVD incidence and included only 
transplanted RRT populations. Therefore, I have identified that there is a very limited 
information published about the associations of age at initiation of RRT, sex, PRD, 
type of RRT and period of start of RRT with all-cause mortality and CVD incidence 
in patients who initiated RRT in childhood.  
Since completion of this literature review one recent additional paper has been 
identified performed by the UK renal registry (170). This study included patients who 
started RRT from 11 to 30 years old between 1999 and 2008. The authors reported that 
five year survival was worse among older patients (26-30 years old) compared to 
younger patients. This is explained by the older RRT population included in this study 
compared to the studies described in this literature review. The authors reported a 
changing pattern from CAKUT in childhood to increasing diabetes, hypertension and 
renovascular diseases in adulthood. The proportion of ESRD due to diabetes in patients 
from 26 to 30 years old was 17.4%. This study also showed that patients with diabetes 
have an increases risk of all-cause mortally compared to patients with glomerular 
diseases (170).  
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4.4.2 Limitations of the literature review 
Due to time restrictions, only papers published from 2011 to 2016 were searched. 
Therefore, papers published earlier than 2011 were not identified by the search. 
However, I successfully identified articles based on data from the known national and 
international registries, which are likely to be the key sources of the highest quality 
data in studies reporting on this topic. Furthermore, inclusion of recent papers to the 
review reflects current clinical practice compared to older papers. The results from 
older papers could be difficult to extrapolate to the current clinical practice due to 
change in RRT population over time and improvement in dialysis techniques and 
transplantation. Therefore, I expect that I identified the major large and most valid 
studies. Similarly to the systematic review in Chapter 2, other databases, such as the 
nursing data base CINAHL, the Latin American database LILACS and the Chinese 
databases were not searched, and only English language papers were sought. 
Therefore, not all relevant studies might have been identified. However, most relevant 
studies in this area are likely to be published in English and in journals that are included 
in Medline or Embase because the major registries studies are within English speaking 
countries or European countries where scientific research is usually published in 
English language journals. 
Since this literature review was performed to inform the SRR analyses (Chapter 5 and 
6) the particular determinants (age at start of RRT, sex, PRD, type of RRT and period 
of start of RRT) were of interest partly because these were the risk factors that are 
available and would be investigated within the SRR analyses. Another important risk 
factor for mortality that was not included in this review is race/ethnicity. Previous 
research from the ESPN/ERA-EDTA registry showed that Asian patients had higher 
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overall mortality risk on RRT compared with white patients (HR, 2.50; 95% CI, 1.14-
5.49) (171).   
4.5 Conclusion and future research 
There is little data available on the long- to very long-term survival and CVD incidence 
among patients who initiated RRT in childhood. The available studies might suffer 
from selection/survival bias as they generally are based on selected RRT populations 
and followed patients up for five years or less. The information about CVD incidence 
and the associations of age at start of RRT, sex, PRD, type of RRT and period of start 
of RRT with all-cause mortality and CVD incidence is limited. Therefore, future 
studies are needed reporting on very long-term survival, CVD incidence and the 
association between the determinants and all-cause mortality and CVD incidence to 
provide relevant information on prognosis for sub-groups of paediatric RRT 
populations.  
To be able to address identified gaps in the literature the SRR was chosen as a source 
of routine data for adult and paediatric patients who receive RRT for ESRD in 
Scotland. The SRR provides the opportunity to follow-up patients over a long period 
of time, including into adulthood. Moreover, the SRR contains patient data such as 
sex, date of birth, initial RRT modality, start of RRT date, switches of RRT, PRD, date 
of death and cause of death. The SRR can be linked to other national registries such as 
hospital admissions and mortality records to study CVD incidence in this population. 
Therefore, the SRR data were used to describe the long-term survival, all-cause 
mortality and CVD incidence in patients who initiated RRT in childhood. The results 
of these analyses are presented in the next chapters. Chapter 5 is a methodology 
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chapter that describes SRR and the linkage of the SRR data with hospital admissions 
and mortality records. Chapter 6 presents analyses of SRR data on survival/mortality 
and the associations of age at start of RRT, sex, PRD, type of RRT and period of start 
of RRT and with all-cause mortality in patients who initiated RRT in childhood in 
Scotland. Chapter 7 presents data on CVD incidence and the associations between the 
same set of determinants and CVD incidence in patients who initiated RRT in 








Chapter 5. Scottish Renal Registry: data linkage, cohort selection and 
analytical approach  
5.1 Background and aim of the study 
The literature review presented in Chapter 4 showed that limited knowledge exists 
about long-term survival in patients who initiate RRT in childhood. The available 
studies generally included selected RRT populations either limited to people receiving 
dialysis or to kidney transplant recipients or to specific age groups. This means that 
these studies could not assess the difference in mortality between patients receiving 
different RRT type or between younger and older patients. I found a few studies that 
included both dialysis and transplanted patients as well as patients of all age groups 
from 0 to 18 years old. However, these studies were limited to short follow-up. 
Furthermore, few data are available about the association of age at initiation of RRT, 
sex, type of RRT, PRD and period of start of RRT with all-cause mortality among 
children who receive RRT. Selection bias in some studies might have led to 
underestimation or overestimation of the associations that were described. Moreover, 
information on causes of death might be biased due to misclassification as almost all 
studies had missing data on causes of death. Therefore, the overall aim of this study is 
to describe the long-term survival, all-cause mortality, causes of death and CVD 
incidence in a nationally representative cohort of patients who initiated RRT in 
childhood.  
The specific objectives are: 
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1. To describe the demographic characteristics, long-term survival, all-cause mortality, 
cause of death and CVD incidence in patients who initiated RRT in childhood in 
Scotland;  
2. To describe the association of age at initiation of RRT, sex, type of RRT, PRD and 
the period of commencing RRT with all-cause mortality/CVD incidence in patients 
who initiated RRT in childhood in Scotland.  
I used an extract of the SRR (described below) linked to the national registry of causes 
of death and hospital admissions to address this aim and the objectives.   
5.2 Choice of Scottish Renal Registry and comparison with other renal 
registries  
The SRR is a national registry of both adult and paediatric patients receiving RRT for 
ESRD in Scotland. Data from Scottish renal units are available from 1961, which is 
the year routine RRT for ESRD started in Scotland. Up to 31st December 2015, 16,741 
patients have started RRT in Scotland. Compared to the ESPN/ERA-EDTA, the SRR 
dataset includes a much smaller sample size as it only collects data from Scotland. 
However, one of the advantages of the SRR is the long-term follow-up as the SRR 
includes data for children who receive RRT and continues to collect data for survivors 
to adulthood who remain under follow-up in Scotland. 
In comparison to other known national and international renal registries (17, 19, 22) 
the SRR was considered the best options for this thesis for several reasons. The first 
reason to use the SRR is that all National Health Service (NHS) renal units contribute 
fully to the SRR leading to national coverage of patients receiving RRT for ESRD in 
Scotland and its results are generalisable to all patients who initiate RRT for ESRD in 
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Scotland. In contrast, the USRDS registry limits their analyses to Medicare patients 
only (17) and the coverage of the IPPN registry differs widely between participating 
countries (22). This means their results are not generalisable to the entire RRT 
population. Also, the incidence of RRT is higher among the US population compared 
to the European population (17, 172), therefore, it would be inappropriate to directly 
extrapolate the USRDS registry results to the European population.  
Furthermore, the major advantage of using SRR data is the feasibility of data linkage. 
Data linkage systems exist in only a handful of countries or regions including 
Australia, Canada, Norway, Sweden, Finland, England, Scotland and most recently in 
Wales (173). It was possible to obtain data on incident CVD events of patients 
registered in the SRR through linking their records with causes of death and CVD 
hospital admissions data. 
5.3 Data request and data linkage 
A request form for the release of data from the SRR was submitted to the SRR steering 
group (Appendix 2, page 382). Additionally, a Self-Audit Checklist for Level 1 Ethical 
Review for PGR projects, Centre for Population Health Sciences research ethics 
subgroup was submitted (Appendix 2, page 390). I completed data governance training 
as a requirement for accessing the data (see Appendix 2 page 396 for certificates). I 
applied to the Public Benefit and Privacy Panel for Health and Social Care (PBPP) for 
permission to use SRR data linked to causes of death and hospital admissions records 
(Appendix 2 page 398). All applications were approved. PBPP is a governance 
structure of NHS Scotland, which undertakes information governance scrutiny of 
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requests to access NHS Scotland-originated data for a variety of purposes, one of 
which is data linkage with other sources.  
SRR datasets were sent to the Electronic Data Research and Innovation Service 
(eDRIS) indexing team with The Community Health Index (CHI) numbers for all 
patients in the file. CHI number is used to link records from different datasets. The 
CHI number is the unique patient identifier used in all primary health care activities 
and hospital based clinical information systems, throughout NHS Scotland (174). To 
ensure that privacy is maintained researchers can only see the final results from the 
data linkage via Scotland’s safe havens (Figure 35).  
Figure 35 An overview of the data linkage process  
 
Source of image: “A Health and Biomedical Informatics Research Strategy for 
Scotland. Enhancing research capability in health informatics for patient and public 




For the purpose of this thesis the SRR data has been linked with the Scottish Morbidity 
Records (SMR01) and causes of death (174). The CHI numbers were replaced with 
the Master Index number on the SRR, death and hospital admission datasets. I could 
then use this number to link the data files from SRR, mortality records and hospital 
admission data. Records of causes of death and CV hospital admissions were available 
from 1 January 1981 to 31 December 2015 because electronic information on death 
records and hospital admissions is available from 1981 onwards.  
All patient data were anonymised before being released to me for the analyses. Date 
of birth was given as month and year, to protect confidentiality. The costs for data 
access to the Safe Haven were covered by my and my supervisor`s (Sarah Wild) 
research funds (total £3,509). 
5.4 Cohort design and study time frames 
Study time frames 
As the SRR analyses is focused on patients who initiated RRT in childhood I requested 
data on all 479 patients registered in the SRR who initiated RRT from 0-<18 years of 
age between January1961 and 31st December 2013. The end date of 31st December 
2013 reflected the most recent available mortality linked data at the time of the data 
request. Causes of death and CVD hospital admissions are available from 1981, hence 
the analyses of cause of death and CVD incidence were limited to the 403 patients who 






As the aim of this study is to describe mortality/CVD incidence and associated risk 
factors over a follow-up period a cohort study is the best suitable study design as 
opposed to cross-sectional or case-control studies which measure the association 
between exposure and outcome at a certain time point. Furthermore, cross-sectional 
studies are subject to survival bias as patients who may have died before the beginning 
of the study would not be included to the study. This is a retrospective cohort study 
because conducting a prospective cohort study would not be possible as I would need 
to start including participants into the study from the beginning of my PhD onwards. 
Due to the rarity of RRT in children and small number of events (death and CVD 
events) it was not feasible. The cohort is open as patients could enter and exit the study 
at any time point within the observation period. 
Longitudinal data 
One of the challenges related to the longitudinal nature of the study is handling 
repeated measurements. For example, in the ESPN/ERA-EDTA analysis presented in 
Chapter 3 I summarised repeated CVRFs measurements into one summary value. In 
contrast, this study is not focused on CVRFs, however, patients could change RRT 
modalities over follow-up period. The approach chosen to handle RRT changes over 




Figure 36 Flow chart describing numbers of included and excluded patients for the 
final analysis of all-cause mortality, cause of death and CVD incidence among children 
receiving RRT and registered in the SRR 
  
479 patients initiated RRT 
<18 years of age from 1961 
to 2013  
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missing date of 
initiation of RRT) 
449 patients included 
in analyses of 
association of age at 
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403 patients who started 
RRT from 1981 to 2013 and 
had linked records of causes 
of death and CVD hospital 
admissions  
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primary analysis of CVD 
incidence  
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missing PRD 
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5.5 Period of follow-up  
Patients were followed from the start of RRT until death for the analysis of all-cause 
mortality or first CVD event for the analysis of CVD incidence, or the end of 
observation period (December 31st, 2015) or lost to follow-up, whichever came first 
(Figure 37, 38).  
Figure 37 A diagram of depicting how patients are included in follow-up or lost to 
follow-up for all-cause mortality analysis 
 
Figure 38 A diagram of depicting how patients are included in follow-up or lost to 




5.6 Data collection within SRR and missing data 
Each renal unit elects one consultant nephrologist to submit data electronically to SRR. 
Within the SRR, data on individual RRT patients are collected annually, including 
information on date of birth, sex, PRD, type of RRT, date of first RRT, changes of 
RRT, and date and cause of death. Almost all variables were complete apart from PRD 
which was missing in 6.2% of patients. Imputation of missing data could not be 
performed as one of the main assumption for imputation is that data are missing at 
random. It might be that patients with missing PRD were more complicated patients 
with the PRD diagnoses that could not be confirmed without further 
instrumental/laboratory tests. Therefore, at the moment of data submission this 
information could be missing. Thus, it is likely that data were missing not at random. 
For this reason, a complete case analysis was performed. The patients with missing 
data were excluded from all survival analyses (Cox regression and Kaplan-Meier) 
(Figure 36). To check whether these exclusions might introduce bias, the 
characteristics of patients with missing data were compared to the sub-cohort with 
complete data. 
5.7 Definition of outcomes 
5.7.1 All-cause mortality 
The SRR has data on vital status for all 479 patients. Therefore, this information was 
used to describe all-cause mortality rate.  
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5.7.2 Cause of death 
Cause of death was assigned using information given in the primary position of death 
certificates. Cause of death was classified according to the ERA-EDTA coding system 
(172), to again facilitate comparisons with previous studies: circulatory disease, 
infection, malignancies, renal and other. International classification of diseases ICD-9 
(175) and ICD-10 (176) codes for each category are presented in Table 27.  
Table 27. ICD-9 and ICD-10 codes used for definition of causes of death 
Cause of death ICD-9 Codes ICD-10 Codes 
Circulatory disease 390-459 
 
I00-I99 





Malignancies  140-239 
 
C00-D48 
Renal 580-599, 753 
 
N00-N39, Q60-Q64 
Other 240-389, 470-478, 490-558, 
570-579, 600-752, 754-999 
D50-H95, J30-J99, K00-
K64, K70- M99, N40-
N99, O00-Q56, Q65-Z99 
 
 
Deaths due to circulatory diseases listed in any position of death certificates were also 
identified and were grouped as follows: Ischaemic heart disease, cerebrovascular 
disease, heart failure, cardiac arrest/arrhythmias, cardiomyopathy and other diseases 
of circulatory system. ICD-9 and ICD-10 codes for each category is presented in Table 
28. These groups were chosen to make the results of this study comparable with other 
literature as most of the previous research picked these CVD events, which are also 





Table 28. ICD-9 and ICD-10 codes used for classification of causes of death due to 
circulatory disease 
Type of CV death ICD-9 Codes ICD-10 Codes 
Ischaemic heart disease 410-414 I20-I25 
Cerebrovascular disease 430-438 I60-I69 
Heart failure 428 I50 
Cardiac arrest/arrhythmias 427 I46-I49 
Cardiomyopathy 425 I42, I43 
Other diseases of 
circulatory system 
390-405, 415-417, 
420-424, 426, 429, 
440-459 
I00-I15, I26-I28, I30-
I41, I44, I45, I51, I52, 
I70-I99 
 
5.7.2 CVD incidence 
CVD incidence was defined as the first CVD event, either fatal or non-fatal, whichever 
came first. Fatal CVD events were defined as any circulatory disease as identified from 
ICD-9 (390-459) codes on death records before 1997 and ICD-10 (I00-I99) codes for 
subsequent years. Non-fatal CVD events were defined similarly but with exclusion of 
codes for hypertensive disease (401, 403, and 405 for ICD-9 and I10, I12, I15 for ICD-
10) and arteriovenous fistula (447 for ICD-9 and I77.0 for ICD-10). CVD codes were 
identified from any position listed in the diagnoses in hospital admissions records or 
death certificates. Table 38 presents ICD-9 and ICD-10 codes for selected key CVD 
sub-types of ischaemic heart disease, cerebrovascular disease, heart failure, cardiac 




Table 29. ICD-9 and ICD-10 codes used for fatal and non-fatal CVD events 
CVD events Non-fatal CVD events Fatal CVD events 
ICD-9  ICD-10  ICD-9  ICD-10  
Ischaemic heart 
disease 
410-414 I20-I25 410-414 I20-I25 
Cerebrovascular 
disease 
430-438 I60-I69 430-438 I60-I69 
Heart failure 428 I50 428 I50 
Cardiac arrest/ 
arrhythmias 
427 I46-I49 427 I46-I49 
























I45, I51, I52, 
I70-I99 
 
5.7.2.1 Secondary analysis of CVD incidence  
A secondary analysis was performed in two steps: first, applying a stricter definition 
of CVD incidence by excluding the group of other non-fatal diseases of the circulatory 
system from the definition (Table 39).  
Table 30. ICD-9 and ICD-10 codes used for fatal and non-fatal CVD events in the 
secondary analysis 
CVD events  Non-fatal CVD events Fatal CVD events 
ICD-9  ICD-10  ICD-9  ICD-10  
Ischaemic heart 
disease 
410-414 I20-I25 410-414 I20-I25 
Cerebrovascular 
disease 
430-438 I60-I69 430-438 I60-I69 
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Heart failure 428 I50 428 I50 
Cardiac 
arrest/arrhythmias 
427 I46-I49 427 I46-I49 
Cardiomyopathy 425 I42, I43 425 I42, I43 
Other diseases of 
circulatory system 






I44, I45, I51, 
I52, I70-I99 
 
Second, as some of the CVD outcomes included in the “other diseases of circulatory 
system” might be relevant to CVD outcomes a less strict definition of CVD incidence 
was applied by excluding only diseases of veins, lymphatic vessels and lymph nodes 
as they could be haematological rather than CV outcome. 
The rationale for the secondary analysis is that the first non-fatal CVD event might be 
mild or found by investigations such as ultrasound scan or magnetic resonance 
imaging. In addition, this group (non-fatal other CVD) includes heterogeneous 
conditions with uncertain clinical significance. Therefore, it was decided to restrict the 
secondary analysis to what are assumed to be more severe CVD events with clinical 
manifestation. Based on this stricter/less strict definitions of CVD events, the CVD 
incidence rates were re-calculated and survival analyses repeated and compared to the 
primary analysis. 
5.7.2.2 Planned sensitivity analysis of CVD incidence  
There were 22 patients with prevalent CVD at the time of start of RRT. People with 
existing CVD are more likely to have another (recurrent) CVD event. Therefore, these 
patients were excluded from the primary analysis (Figure 36). To test the effect of this 
group these 22 patients were included in the sensitivity analysis and survival analyses 
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were repeated and compared to the primary analysis. All the associations in the 
sensitivity analyses were additionally adjusted for a binary variable of history of CVD.  
5.8 Definition of exposures 
5.8.1 Age at start of RRT 
Patients were categorised into the following four age groups: 0-<2 years old, 2-<6 
years old, 6-<12 years old and 12-<18 years old. These age categories were chosen to 
be consistent with those used in the ESPN/ERA-EDTA studies to facilitate 
comparisons. 
5.8.2 PRD 
PRD was classified according to the ERA-EDTA coding system. In the current 
analyses CAKUT and GN are used as separate categories. Cystic kidney disease, 
hereditary nephropathy, ischaemic renal failure, haemolytic-uraemic syndrome 
(HUS), metabolic disorders, vasculitis and miscellaneous are grouped together in the 
‘Other’ category because the numbers are too small to study separate categories.  
5.8.3 Initial type of RRT 
Initial type of RRT was categorised as HD, PD and pre-emptively transplanted (pre-
Tx).  
5.8.4 Changes of RRT during follow-up 
As many patients receive a kidney transplant after initial treatment with dialysis, RRT 
patterns over follow-up were classified into four categories: started on HD and not 
transplanted during follow-up (abbreviated to HD+Tx-), started on PD and not 
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transplanted during follow-up (PD+Tx-), pre-emptively transplanted (pre-Tx) and 
transplanted ever after initiation RRT with dialysis (D+Tx+).  
5.8.5 Period of initiation of RRT 
The period of initiation of RRT was divided into three periods: 1961-1990, 1991-2000 
and 2001-2013. Ideally, time periods would have been categorised into similar length 
periods such as decades, but because relatively few patients initiated RRT in the period 
1961-1980, this time period was combined with the following decade to create 
approximately similar distributions of numbers of patients in each time period.  
In the analysis of CVD incidence the period of initiation of RRT was divided into: 
1981-1990, 1991-2000 and 2001-2013. 
5.9 Statistical analysis 
5.9.1 Descriptive analyses  
Demographic, clinical characteristics and types of CVD event were described as 
proportions for categorical variables. Continuous variables that are normally 
distributed were described as mean and SD, while median and IQR was used when the 
distribution was skewed. Differences in distribution of PRD and type of RRT by age 
at start of RRT and sex were tested by Chi square tests. When more than 20% of the 
expected numbers were less than 5 for comparisons of proportions, Fisher`s exact test 
was used. A significance level of 0.05 was used in all statistical tests.  
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5.9.2 Survival/mortality and CVD incidence analyses 
Crude all-cause mortality and CVD incidence rates were calculated per 100 p/y of 
follow-up for all patients and stratified by: age at start of RRT; sex; PRD; type of RRT; 
and period of initiation of RRT.  
Survival was calculated as proportion of people with the relevant amount of follow-up 
time who were alive at 10 years and 20 years. The Kaplan-Meier method was used to 
describe survival for each subgroup, with differences between groups assessed using 
the log rank test.  
Cox proportional hazard models were used to examine the association of age at 
initiation of RRT, sex, PRD, type of RRT and period of initiation of RRT with all-
cause mortality/CVD incidence. The proportional hazard assumption was evaluated 
graphically using log minus log plots (Appendix 1, Figures 4-8, page 368). The log 
minus log plots should result in approximately parallel curves if the proportional 
assumption is not violated. Reference groups for age, sex, PRD, initial type of RRT 
and period of start of RRT were the groups of patients with the lowest risk of all-cause 
mortality/CVD incidence based on the reviewed literature and the reference group for 
RRT during follow-up was the group with the largest number of patients, as follows:  
 For age: patients in the oldest age group (12-<18 years of age) 
 For sex: females 
 For PRD: patients with CAKUT 
 For initial type of RRT: pre-emptively transplanted patients 
 For RRT during follow-up: patients in the D+Tx+ group  
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 For calendar period: patients who started RRT in the most recent period 
(2001-2013) 
 
Crude and adjusted models in the Cox regression analysis are based on the sub-group 
of patients with complete data (see Figure 36). Characteristics of patients with missing 
data versus complete data were compared. 
The associations were corrected for confounding factors including age at start of RRT, 
sex, initial type of RRT and period of start of RRT. These variables were chosen as 
potential confounding factors based on previous literature that found them to be 
associated with both exposures and risk of all-cause mortality. Figure 39 schematically 
depicts the approach taken to adjust for appropriate confounding factors, where tick 
means that the confounding factor is associated with the exposure and with the 
outcome, while cross means that the confounding is not on the causal pathway of this 
association.  
The association of sex with all-cause mortality was not adjusted for age at start of RRT 
because there was no association between sex and age at start of RRT. When a variable 
is not associated with the exposure but is associated with outcome it is considered as 
another risk factor and should not be adjusted for (117).  
The initial type of RRT might be on the causal pathway in the associations of PRD, 
age at start of RRT and period of start of RRT with all-cause mortality as the choice 
of treatment might depend on these factors. The reason for adjusting for a variable that 
may lie on the causal pathway was to study the effect of the mentioned exposures on 
the outcome independently from the initial type of RRT. However, by adjusting for 
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the variable that is on the causal pathway the intermediate effect that goes through this 






Figure 39. Schematic overview of adjusting for potential confounding factors the 
associations between age at start of RRT, sex, PRD, type of RRT and period of start 
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5.9.3 One and five-year all-cause mortality/CVD incidence 
 In order to compare mortality/CVD incidence across time periods standard follow-up 
periods of one and five years were applied. One year follow-up data were available for 
all children. However, only patients who started RRT from 1961 to 2010 and from 
1981 to 2010 were included in the analyses of five-year mortality/CVD incidence, 
respectively, in order to allow all patients to have the opportunity for five-years of 
follow-up.  
5.10 Checklist for reporting the SRR study 
This study was reported following the EQATOR collaboration (RECORD) guidelines 
for observational studies using routinely collected health data. The checklist is 
presented in Appendix 1 page 376.  
The next two chapters present results from the SRR analyses. In particular, Chapter 6 
describes characteristics of patients registered in the SRR who started RRT in 
childhood between 1961 and 2013, their mortality and the association of age at start 
of RRT, sex, PRD, type of RT and period of start of RRT with all-cause mortality. 
Chapter 7 describes CVD incidence and its association with age at start of RRT, sex, 
PRD, type of RT and period of start of RRT in patients who initiated RRT between 





Chapter 6. All-cause mortality and causes of death in patients who 
initiated renal replacement therapy in childhood in Scotland between 
1961 and 2013; an analysis of Scottish Renal Registry data  
6.1 Results  
6.1.1 Characteristics of patients who initiated RRT in childhood 
Between 1961 and 2013, 479 children <18 years of age were recorded as starting RRT 
in Scotland. The characteristics of the total cohort are presented in the first two 
columns of Table 29. Over half of the patients started RRT when they were older than 
12 years of age. There was a higher proportion of boys than girls. CAKUT accounted 
for almost half of the underlying PRD with the next two most common causes being 
GN and cystic kidney disease. Almost 90% of patients started RRT by receiving 
dialysis. There was a slightly higher proportion of patients initiating RRT with HD 
than by PD.  
Table 29 presents the cohort characteristics by period of initiation of RRT. The 
proportion of boys increased over time. The proportion of patients who started RRT 
from zero to five years old increased in 1991-2000 compared to 1961-1990 and 
decreased slightly in 2001-2013 compared to 1991-2000. The proportion of patients 
with GN decreased in 1991-2000 compared to 1961-1990 and increased slightly in 
2001-2013 compared to 1991-2000. The proportion of patients who received HD as 
the first type of RRT decreased in 1991-2000 compared to 1961-1990 and slightly 
increased in 2001-2013 compared to 1991-2000. The proportion of patients who 
started on PD increased in 1991-2000 compared to 1961-1990 and slightly decreased 
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in 2001-2013 compared to 1991-2000, while the proportion of pre-emptively 



















Table 31. Characteristics of patients who initiated RRT<18 years old in the period 
from 1961 to 2013 in Scotland 
 Total 1961-1990 1991-2000 2001-2013 
Characteristics N (%) N (%) N (%) N (%) 
All patients  479 214 133 130 
Sex*     
Male 265 (55.3) 107 (50.0) 74 (55.6) 83 (63.8) 
Age at start of RRT 
(years)* 
    
0-<2 30 (6.3) 9 (4.2) 12 (9.0) 9 (6.9) 
2-<6 50 (10.4) 12 (5.6) 23 (17.3) 15 (11.5) 
6-<12 113 (23.6) 49 (22.9) 32 (24.1) 32 (24.6) 
12-<18 284 (59.3) 144 (67.3) 66 (49.6) 74 (56.9) 
missing  2 (0.4) - - - 
PRD      
CAKUT 231 (48.2) 103 (48.1) 60 (45.1) 66 (50.8) 
GN 80 (16.7) 41 (19.2) 18 (13.5) 21 (16.2) 
Other 140 (29.3) 57 (26.6) 46 (34.6) 37 (28.5) 
Unknown/missing 28 (5.8) 13 (6.1) 9 (6.8) 6 (4.5) 
Initial type of RRT*     
HD 220 (45.9) 138 (64.5) 37 (27.8) 45 (34.6) 
PD 207 (43.2) 66 (30.8) 79 (59.4) 62 (47.7) 
Tx 50 (10.4) 10 (4.7) 17 (12.8) 23 (17.7) 
Unknown/missing  2 (0.4) - - - 
PRD-primary renal disease, CAKUT-congenital anomalies of kidney and urinary tract, GN-
glomerulonephritis, RRT-renal replacement therapy, HD-haemodialysis, PD-peritoneal dialysis, 
Tx-transplanted, *p<0.05. Two patients with missing start date of RRT were excluded from the 





The characteristics of the 30 patients who were excluded from the Cox regression 
analysis due to missing data compared to patients with complete data is presented in 
Table 30. There were higher proportions of females and older patients (12-<18 years 
old) and a lower proportion of pre-emptively transplanted patients among patients with 


















Table 32. Characteristics of patients with complete data and with missing data 
 With complete data With missing data  
Characteristics N (%) N (%) 
All patients  449 30  
Sex   
Male 254 (56.6) 12 (40.0) 
Age at start of RRT (years)   
0-<2 29 (6.5) 1 (3.3) 
2-<6 49 (10.9) 1 (3.3) 
6-<12 111 (24.7)  2 (6.7) 
12-<18 260 (57.9) 24 (80.0) 
PRD    
CAKUT 229 (51.0) 2 (6.6) 
GN 80 (17.8) - 
Other 140 (31.2) - 
Initial type of RRT    
HD 206 (45.9) 14 (46.7) 
PD 194 (43.2) 13 (43.3) 
Pre-Tx 49 (10.9) 1 (3.3) 
Period of start of RRT   
1961-1990 201 (44.7) 13 (43.3) 
1991-2000 124 (27.6) 9 (30.0) 
2001-2013 124 (27.6) 6 (20.0) 
N of deaths 119 (26.5) 7 (23.3) 
PRD-primary renal disease, GN-glomerulonephritis, RRT-renal replacement therapy, HD-




6.1.2 Distribution of primary renal disease by sex and age at start of RRT  
There was no statistically significant difference in distribution of PRD by sex (Figure 
40). However, the distribution of PRD significantly differed by age at start of RRT. 
Figure 41 shows that PRD other than CAKUT and GN formed the largest sub-group 
among the youngest age category. CAKUT was the largest category of PRD in all age 
groups older than two years old. GN was more common among patients older than two 
years old compared to the youngest patients.  








Figure 41. Distribution of underlying PRD stratified by age at start of RRT 
 
6.1.3 Distribution of initial type of RRT by sex and age at start of RRT  
There was no statistically significant difference in distribution of initial type of RRT 
by sex (Figure 42). However, the distribution of first RRT type significantly differed 
by age (Figure 43). The proportion of patients who received PD as the first RRT type 
decreased with age, whereas the proportion of those who started with HD increased 
with age. There were no patients who received pre-emptive kidney transplantation in 








Figure 42. Distribution of initial type of RRT stratified by sex 
 
 
Figure 43. Distribution of initial RRT modality stratified by age at start of RRT 
 
6.1.4 First switch of RRT 
The majority (N=410) of patients switched RRT type at least once over the follow-up 
period. The first switch is depicted in Figure 44. The most frequent first RRT changes 
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were from HD to transplantation and from PD to transplantation. The switch from one 
dialysis type to the other was less common, while the transition from transplant to 
dialysis was very rare as was expected. Patients who received their first transplant 
following a period on dialysis spent a median time of 1.4 (IQR 0.7-2.8) years on 
dialysis. Patients who started RRT less than two years old had the longest time to their 
first transplant compared to older patients (Table 31).  
Figure 44. First switch of type of RRT 




















Table 33. Time on dialysis to first transplant stratified by age at start of RRT for the 
sub-group of patients who received dialysis as their first treatment and subsequently 
received a transplant 
Age at start of RRT 
(years) 
 
N Time on dialysis in years 
to first transplant 
Median (IQR)  
0-<2  17 2.7 (1.3-4.4) 
2-<6  40 1.8 (0.8-3.4) 
6-<12  86 1.3 (0.7-3.2) 
12-<18 227 1.3 (0.6-2.3) 
RRT-renal replacement therapy, IQR-interquartile range 
6.1.5 Type of RRT during follow-up time in patients initiating RRT with 
dialysis stratified by sex and age at start of RRT 
Of the 427 patients initiating RRT with dialysis 371 (86.9%) received a kidney 
transplant after a period of dialysis (abbreviated to D+Tx+). The proportion of those 
who received a kidney transplant following a period on dialysis was slightly higher 
among females compared to males (Figure 45) and among older patients compared to 





Figure 45. Type of RRT during follow-up stratified by sex in patients who initiated 
RRT with dialysis 
 
 
Figure 46. Type of RRT during follow-up in patients initiating RRT with dialysis 




6.1.6 Survival and all-cause mortality of patients who started RRT in 
childhood 
In total, 479 patients were followed for a median of 18.3 years (IQR 8.7-27.0 years), 
giving 8,867 p/y of follow-up. During the study period 126 patients died. The overall 
crude mortality rate was 1.42 per 100 p/y (95% CI 1.17-1.67). The overall survival 
among patients requiring RRT was 87.3% (95% CI 84.3-90.3) at 10 years and 77.6% 
(95% CI 73.8-81.3) at 20 years. In the sub-group of patients with complete data 119 
patients died during 8,363 p/y. The overall crude mortality rate among patients with 
complete data was similar to the total cohort and was 1.42 per 100 p/y (95% CI 1.16-
1.67).  
Table 32 presents crude mortality rates in sub-groups of patients of the total cohort. 
The youngest patients, males and patients with CAKUT as PRD had the highest 
mortality rates compared to older patients, females and patients with GN and other 
PRD, respectively. Within the treatment categories the mortality rate was the highest 
among patients who started with HD and lowest among those who were pre-emptively 
transplanted. Patients who started on dialysis and did not receive a transplant during 
follow-up had higher mortality compared to patients who received a kidney transplant. 








Table 34. Number of deaths, person-years of follow-up (p/y) and crude mortality rates 
(MR) for different subgroups of the total cohort 
Sub-group characteristics Number of 
deaths  
p/y Crude MR per 100 p/y 
(95% CI) 
Age at start of RRT (years)    
0-<2 11 349.2 3.15 (1.32-4.98) 
2-<6 10 800.0 1.25 (0.47-2.02) 
6-<12 27 2109 1.28 (0.80-1.76) 
12-18 77 5620 1.37 (1.16-1.67) 
Sex    
Female  56 1600 3.50 (2.59-4.40) 
Male 70 1732 4.04 (3.11-4.97) 
PRD     
CAKUT 54 1381 3.91 (2.88-4.93) 
GN 22 1732 1.27 (0.74-1.79) 
Other 44 2340 1.88 (1.32-2.43) 
Initial type of RRT    
HD 77 4638 1.66 (1.29-2.03)  
PD 44 3464 1.27 (0.89-1.64)  
Pre-Tx 4 754.7 0.53 (0.01-1.05) 
Type of RRT during follow-up     
HD +Tx-  17 135.0 12.59 (6.99-18.18) 
PD+Tx- 17 115.0 14.78 (8.29-21.26) 
Pre-Tx 4 754.7 0.53 (0.01-1.05) 
D+Tx+ 87 7837 1.11 (0.87-1.34)  
PRD-primary renal disease, GN-glomerulonephritis, CAKUT-congenital anomalies of kidney and 
urinary tract, RRT-renal replacement therapy, HD-haemodialysis, PD-peritoneal dialysis, Tx- 
transplanted, pre-Tx-pre-emptive transplantation, MR-mortality rate, CI-confidence interval, 
HD+Tx- started on HD and not transplanted during follow-up, PD+Tx- started on PD and not 
transplanted during follow-up, D+Tx+ transplanted ever after starting on dialysis. 
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6.1.7. Associations between age at start of RRT, sex, PRD and type of 
RRT at start and during follow-up with all-cause mortality 
Kaplan-Meier survival curves differed significantly by patterns of RRT during follow-
up (p<0.0005) (Figure 47). 
Figure 47. Kaplan-Meier survival curves stratified by patterns of RRT during follow-
up 
 
Number at risk       
351 284 188 69 12 -  D+Tx+ 
48 31 14 1 - -  Pre-Tx 
29 3 - - - -  HD+Tx- 
21 3 2 - - -  PD+Tx- 
 
PD+Tx- started on PD and not transplanted during follow up, HD+Tx- started on HD and not transplanted during 




Figure 47 shows that patients who started on either form of dialysis and did not receive 
a kidney transplant over the study period had worse survival compared to those who 
were pre-emptively transplanted and those who received a kidney transplant after they 
started RRT with dialysis. Kaplan-Meier survival curves did not differ significantly by 
age at start of RRT, sex, PRD groups and initial type of RRT.  
Table 33 presents results of the associations between age at start of RRT, sex, PRD 
and type of RRT with all-cause mortality. The youngest patients and patients with PRD 
other than CAKUT or GN had significantly higher risk of all-cause mortality compared 
to the oldest patients and patients with CAKUT, respectively. Patients in the HD+Tx- 
and PD+Tx- groups had significantly higher risk of all-cause mortality compared to 
patients in the D+Tx+ group. The associations of sex and initial type of RRT with all-













Table 35. Crude and adjusted hazard ratios for associations between age at start of 
RRT, sex, PRD and type of RRT with all-cause mortality among children who started 
RRT in Scotland 1961-2013 with complete data available 
Variable Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Age at start of RRTa   
0-1 2.09 (1.07-4.08) 2.50 (1.19-5.25) 
2-5 0.85 (0.42-1.71) 1.24 (0.58-2.67) 
6-11 0.87 (0.55-1.35) 0.95 (0.59-1.52) 
12-<18 1.00 1.00 
Sexb   
Males 1.30 (0.90-1.88) 1.37 (0.95-1.98) 
Females 1.00 1.00 
PRDc   
GN 0.98 (0.59-1.63) 0.97 (0.58-1.62) 
Other 1.54 (1.04-2.31) 1.58 (1.05-2.39) 
CAKUT 1.00 1.00 
Type of RRT at startd   
HD 2.97 (1.08-8.16) 2.64 (0.94-7.38) 
PD 2.27 (0.81-6.35) 2.11 (0.74-6.03) 
Pre-Tx 1.00 1.00 
Type of RRT at follow-upe   
HD+Tx- 14.6 (8.11-26.5) 19.4 (10.38-36.37) 
PD+Tx- 15.2 (8.43-27.5) 19.5 (9.65-39.56) 
Pre-Tx 0.55 (0.20-1.52) 0.65 (0.24-1.78) 
D+Tx+ 1.00 1.00 
 
PRD-primary renal disease; GN-glomerulonephritis, CAKUT-congenital anomalies of kidney and urinary tract; 
RRT-renal replacement therapy; HD-haemodialysis; PD-peritoneal dialysis; pre-Tx-pre-emptively transplanted; 
HD+Tx- started on HD and not transplanted during follow-up, PD+Tx- started on PD and not transplanted during 
follow-up, D+Tx+ transplanted ever after starting on dialysis. HR-hazard ratio, CI-confidence interval. Only 
patients with complete data included in unadjusted and adjusted analyses (N=449). N of death=119; Adjusted for a 
sex, PRD, type of RRT at start and period of start of RRT; b PRD, type of RRT at start and period of start of RRT; 
cage at start of RRT, sex, type of RRT at start and period of start of RRT; d age at start of RRT, sex, PRD and period 




6.1.8. One-year and five-year all-cause mortality  
In total, 18 deaths occurred within the first year after initiation of RRT in the total 
cohort. Thirty seven deaths occurred in the period of five years from the start of RRT 
among 450 patients who started RRT from 1961 to 2010. The baseline characteristics 
of the group with five year follow-up data were similar to the total cohort. In a sub-
cohort with complete data 17 and 33 deaths occurred after one and five years from 
start of RRT, respectively.  
Characteristics of patients who died within one and five years after start of RRT in the 
sub-group of patients with complete data are presented in Table 34. The distribution 
of deaths within one- and five-years differed significantly by age at start of RRT and 
type of RRT during follow-up. Patients in the youngest age group and patients who 
started RRT on dialysis and who did not receive a kidney transplant during follow-up 
had higher proportions of deaths during these periods compared to older patients and 
patients who received a kidney transplant after starting on dialysis, respectively. There 
was no significant difference in the proportion of deaths within one- and five-years by 
sex and initial type of RRT. The proportion of deaths significantly differed by PRD 
after five-years from start of RRT, but not after one-year.  
Table 35 presents crude and adjusted HRs and 95% CIs for the associations of period 
of start of RRT with one- and five-year all-cause mortality. One-year mortality was 
non-significantly higher among patients who initiated RRT in the periods 1961-1990 
and 1991-2000 compared to those who started RRT in 2001-2013. Five-year mortality 
was higher among patients who initiated RRT in the period of 1961-1990 compared to 
those who started RRT in 2001-2010, but the association was not statistically 
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significant. Five-year mortality did not differ between patients who started RRT in the 




Table 36. One and five year mortality/survival following start of RRT for sub-groups of patients the sub-group of patients with complete data 
Characteristics One year after start of RRT Five years after start of RRT 
 Dead Alive p Dead Alive p 
All patients  17 432  33 392  
Age at start of RRT (years)   <0.0005   <0.0005 
0-<2 6 (20.7) 23 (79.3)  7 (29.2) 17 (70.8)  
2-<6 3 (6.1) 46 (93.9)  5 (11.1) 40 (88.9)  
6-<12 2 (1.8) 109 (98.2)  8 (7.4) 100 (92.6)  
12-<18 6 (2.3) 254 (97.7)  13 (5.2) 235 (94.8)  
Sex   0.13   0.09 
Female  5 (2.6) 190 (97.4)  10 (5.3) 179 (94.7)  
Male 12 (4.7) 242 (95.1)  23 (9.7) 213 (90.3)  
PRD    0.6   0.003 
CAKUT 8 (3.5) 221 (96.5)  9 (4.2) 206 (95.8)  
GN 2 (2.5) 78 (97.5)  5 (6.6) 71 (93.4)  
Other 7 (5.0) 133 (95.0)  19 (14.2) 115 (85.8)  
 
Initial type of RRT 
   
0.3 




Characteristics One year after start of RRT Five years after start of RRT 
 Dead Alive p Dead Alive p 
HD 10 (4.9) 196 (95.1)  15 (7.7) 181 (92.3)  
PD 7 (3.6) 187 (96.4)  17 (9.1) 169 (90.9)  
Pre-Tx 0 49 (100)  1 (2.3) 42 (97.7)  
       
Type of RRT during follow-
up  
  <0.0005   <0.0005 
HD+Tx- 9 (30.0) 21 (70.0)  12 (54.5) 10 (45.5)  
PD+Tx- 7 (31.8) 15 (68.2)  12 (75.0) 4 (25.0)  
Pre-Tx 0 49 (100)  1 (2.3) 42 (97.7)  
D+Tx+ 1 (0.3) 347 (99.7)  8 (2.3) 336 (97.7)  
PRD-primary renal disease, CAKUT-congenital anomalies of kidney and urinary tract, GN-glomerulonephritis, RRT-renal replacement therapy, HD-
haemodialysis, PD-peritoneal dialysis, pre-Tx-pre-emptive transplantation. HD+Tx- started on HD and not transplanted during follow-up, PD+Tx- started on PD 




Table 37. Crude and adjusted HRs and 95% CI for the association of the period of initiation of RRT with one-year and five-year all-cause 
mortality after start of RRT 
One-year mortality Five-year mortality 
Period of 
initiation of RRT 
Crude Adjusted* Period of 
initiation of RRT 
Crude Adjusted* 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
1961-1990 2.06 (0.57-7.52) 3.32 (0.78-14.02) 1961-1990 2.07 (0.78-5.52) 2.53 (0.93-6.94) 
1991-2000 1.33 (0.29-5.96) 1.66 (0.33-8.29) 1991-2000 1.31 (0.43-4.01) 0.99 (0.32-3.11) 
2001-2013 1 1 2001-2010 1 1 
Only patients with complete data were included in unadjusted and adjusted analyses. For one-year mortality: N=449, 17 deaths. For five-year mortality: N=425, 33 deaths. *adjusted for 
age at start of RRT, sex, PRD and type of RRT at start.  
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6.1.9 Causes of death for the cohort of patients who started RRT from 
1981 to 2013 
As mentioned in the methods section the analyses for causes of death only included 
data from patients who started RRT from 1981 to 2013 and whose data were linked to 
the national registry of causes of death, resulting in a cohort of 403 patients. Their 
characteristics were similar to the total cohort. Overall 83 deaths occurred over a total 
of 6,658 p/y. Median follow up was 16.5 (IQR 7.9-24.5) years. Circulatory disease 
accounted for 21.7% of all deaths when mentioned as a primary cause of death in death 
certificates (Table 36). However, when described from any position of death 
certificates circulatory disease was recorded for 51.2% (N=43) of all deaths. 
Cerebrovascular disease and cardiac arrest/ arrhythmias followed by ischaemic heart 
disease were the most common specific types of circulatory disease (Table 37). The 
main cause of death in the other category was congenital malformations.  
Table 38. Numbers and cause-specific mortality rates for primary cause of death 
derived from death certificates for children who received RRT in Scotland 1981-2013 
Cause of death N (%) Crude MR per 100 p/y 
(95% CI) 
   
Circulatory disease 18 (21.7) 0.27 (0.14-0.39) 
Infections 4 (4.8) 0.06 (0.001-0.12) 
Malignancies 6 (7.2) 0.09 (0.02-0.16) 
Renal 32 (38.6) 0.48 (0.31-0.64) 
Other 23 (27.7) 0.35 (0.21-0.49) 





Table 39. Distribution of different types of circulatory disease derived from any 
position of the death certificates 
Types of circulatory diseases N (%) 
Total 43 (100) 
Cerebrovascular disease 8 (18.6) 
Cardiac arrest/arrhythmias 8 (18.6) 
Ischaemic heart disease 6 (14.0) 
Heart failure  4 (9.3) 
Cardiomyopathy  2 (4.7) 




6.2.1 Summary of findings of the study 
The SRR data provided the opportunity to describe characteristics and survival of 
patients who initiated RRT in childhood in Scotland between 1961 and 2013. Key 
findings are summarised below followed by comparison with the existing literature 
and discussion of the strengths and limitations of the work. 
This study showed that PRD, initial type of RRT and type of RRT during follow-up 
differed significantly by age at start of RRT. Distribution of patient characteristics such 
as age at initiation of RRT, sex and initial type of RRT have also changed over time.  
Age at start of RRT, PRD and type of RRT during follow-up were significantly 
associated with all-cause mortality in patients who initiated RRT in childhood. The 
associations of sex, initial type of RRT and period of start of RRT with all-cause 
mortality were not statistically significant.  
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Circulatory disease was mentioned in any position on just over 50% of death 
certificates. Cerebrovascular disease and cardiac arrest/arrhythmias were the most 
common specific types of circulatory disease mentioned on death certificates.  
6.2.2 Interpretation of the findings in the context of existing literature 
The findings obtained in the current study were generally concordant with the existing 
literature that are described in details in the following section. 
6.2.2.1 Patient characteristics and changes over time 
The finding that higher proportions of older patients start on HD, while PD is the most 
common first RRT modality among younger patients could be explained by the fact 
that HD for infants is limited due to technical difficulties related to patient size, 
provision of adequate vascular access, and the need for highly skilled nursing staff 
(177). As a result, PD is the modality of choice in young children with ESRD. This 
study has also shown that there were no patients who received a pre-emptive 
transplantation before two years of age. This is because transplantation is often delayed 
until the child weights 10 kg or is 2 years old. The primary reason for this delay is that 
kidney transplantation is technically difficult in very young children (<2 years old) due 
to the small size of the child compared with the relatively large (usually adult) donor 
kidney and the small blood vessel calibre of the recipient (177). Van Stralen et al. (169) 
analysed data from the ESPN/ERA-EDTA, ANZDATA and IPPN registries on 
patients who started RRT at less than 2 years of age reporting that 91.7% of patients 
had PD as their initial RRT modality.  
The finding of the current study that older patients are more likely to receive a kidney 
transplant is in line with the data from the ESPN/ERA-EDTA registry (31) which 
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showed that the probability of children aged 0-4 years receiving a kidney transplant 
within four years after starting RRT was 35% lower than that of those aged 5-9 years 
old (HR 0.65, 95% CI 0.57-0.74).  
An increase in the proportion of patients who started RRT at a young age over the 
study period was probably largely due to improved treatment resulted in better survival 
of young children with CKD prior to the commencement of RRT. This trend was in 
line with the ANZDATA registry study (118) that also showed that the proportion of 
young children under five years of age at the start of RRT has increased between 1963 
and 2002. The ERA-EDTA registry study (166) showed a similar trend in distribution 
of patient characteristics between 1985 and 2004. Increasing proportions of pre-
emptively transplanted patients over time could be explained by a more proactive 
policy towards pre-emptive transplantation in children with ESRD (personal 
communication with Glasgow paediatric nephrologists). In addition, the increase in 
the number of young children receiving RRT over time, as well as a more frequent use 
of PD in children in general, has led to a higher proportion of children receiving PD 
as the first type of RRT. 
6.2.2.2 Long-term survival in patients who initiated RRT in childhood 
This study reported a crude overall mortality rate of 1.42 per 100 p/y (95% CI 1.17-
1.67) over a median of 18.3 years (IQR 8.7-27.0 years) follow-up. This was slightly 
lower in comparison with the ESPN/ERA-EDTA registry study reporting overall crude 
mortality rate of 2.0 per 100 p/y over median follow-up of 2.17 years (IQR not 
reported) (31). This difference might partly be due to a shorter follow-up period in the 
ESPN/ERA-EDTA study compared to the current study as more deaths occur within a 
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first year after start of RRT. Furthermore, the inclusion of countries with lower public 
health expenditure compared to Scotland in the ESPN/ERA-EDTA study (146), 
however, it is not possible to explore as the ESPN/ERA-EDTA registry does not 
provide country specific mortality rates.  
Ten and 20 year survival reported by the current study were 87.3% (95% CI 84.3-90.3) 
and 77.6% (95% CI 73.8-81.3) respectively. Only a small number of studies reported 
the longer-term survival that could be compared with the current results. The Canadian 
Paediatric ESRD Database study (110) reported a similar 10 year survival of 85.8% 
(95% CI 82.8-88.8). However, the ANZDATA registry study (118) reported slightly 
lower 10 and 20 years survival of 78% (95% CI 76-80) and 66% (95% CI 63-69), 
respectively. This difference may in part be explained by the earlier time period of 
RRT initiation in the latter study (1963 to 2002) because mortality has probably 
declined over time.  
6.2.2.3 Association of age at start of RRT, type of RRT and PRD with all-
cause mortality 
The current study has found that the youngest patients had higher risk of all-cause 
mortality compared to older patients. This finding might be affected by survival bias 
because of delayed kidney transplantation in patients younger than two years old and 
not all of these patients survive until they receive a kidney transplant. This finding was 
in line with the ESPN/ERA-EDTA study (31). The authors showed that the youngest 
age group (0-4 years old) had the poorest 4 year survival rate, with a HR 4.4 (95% CI 
2.8-7.0) for all-cause mortality compared to the oldest age group (15-19 years old). 
Similarly, data from the ANZDATA registry (118) showed that patients who initiated 
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RRT at less than 1 year of age had 3.7 times higher risk of all-cause mortality compared 
to 15-19 year olds over median follow-up of 9.7 years (IQR 4.1-17.6). 
The finding that patients who started on dialysis and did not receive a kidney transplant 
over the study period had a higher risk of all-cause mortality compared to those who 
received a kidney transplant following period on dialysis might be due to survival bias 
as healthier patients are more likely to receive a kidney transplant, while patients with 
comorbidities, some of which may be associated with increased risk of mortality (157), 
remain on dialysis (178). Observational studies are the main source of evidence 
showing that successful kidney transplantation increases quality of life and survival as 
compared with long-term dialysis treatment (29, 31, 118). The ANZDATA registry 
study (118) and the USRDS study (163) showed that receiving dialysis rather than a 
kidney transplantation was associated with increased risk of all-cause mortality. 
Similarly, survival comparison by dialysis modality (HD versus PD) can only be 
conducted in observational studies as conducting a RCT in this population is extremely 
difficult. An example of this is the RCT that aimed to compare the survival and quality 
of life between HD and PD among adult incident dialysis patients in the Netherlands 
(179). The main limitation of this RCT was low incidence and low response rate. The 
vast majority of patients refused to participate because of a preference for one of the 
modalities. After an inclusion period of more than 3 years, only 38 patients had been 
randomised. Since no dramatic changes in the inclusion rate were expected the steering 
group decided to stop recruitment as an extension with another 5 to 6 years was not 
considered to be feasible. Although the RCT was underpowered, the authors reported 
that after 5 years of follow-up patients who started with HD had a higher risk of all-
cause mortality as compared with patients started with PD, HR 3.8 (95% CI 1.1-12.6). 
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The authors also concluded that observational studies are needed for comparison of 
both modalities in a larger number of patients (179). 
The current study showed that patients with PRD other than GN or CAKUT had higher 
risk of all-cause mortality compared to patients with CAKUT. This finding may in part 
be explained by the fact that the group of ‘other’ types of PRD included diagnoses that 
cause damage in multiple organs, such as heart, brain and kidneys. For example, the 
group of vasculitic disorders includes diagnoses such as Wegener's granulomatosis, 
polyarteritis nodosa, lupus erythematosus, Henoch-Schonlein purpura, and systemic 
sclerosis (scleroderma). These are systemic disorders that involve inflammation and 
damage of small- and medium-size vessels in multiple organs. Other diagnoses 
included in the group of other PRD are Henoch-Schonlein purpura (Immunoglobulin 
A vasculitis) and (HUS). Both are types of PRD that are characterised by 
thrombophilia (activation of coagulation system) causing endothelial damage of 
internal organs (180, 181). Therefore, the observed multi morbidity in patients 
included in the category of other PRD might contribute to their higher risk of mortality. 
The Dutch study (29) showed that patients with PRD affecting other vital organs 
(oxalosis, Goodpasture’s syndrome, cystinosis or autosomal recessive cystic disease) 
had a crude RR 2.4 (95% CI 1.1-5.1) of all-cause mortality compared to patients with 
other causes of PRD.  
This study did not find an association between period of start of RRT and all-cause 
mortality. Improved health care is expected to result in better survival in recent 
periods, however, this may be offset by the increasing proportion of younger patients 
over time that may have resulted in worse survival in recent periods. In contrast to this 
study the USRDS registry (120) study on patients who initiated RRT on dialysis at 
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younger than 21 years between 1990 and 2010 showed that each 5-year increment in 
calendar year of dialysis initiation was associated with a higher risk of all-cause 
mortality. Adjusted HR for mortality for each 5-year increment among children 
younger than 5 years at initiation were 0.80 (95% CI, 0.75-0.85) and 0.88 (95% CI, 
0.85-0.92) among those 5 years and older. The authors of this study did not suggest an 
explanation for this finding.  
6.2.2.4 Cause of death 
The most common cause of death in children who started RRT in Scotland 1981-2013 
was renal disease. Circulatory diseases accounted for 21.7% of all deaths when cause 
of death was identified from primary position on death certificates. Circulatory 
diseases were mentioned in any position of the death certificates in 51.8% of all deaths. 
The ESPN/ERA-EDTA registry reported a similar proportion of CV death to this study 
of 23.0% when described as a primary cause of death. However, cause of death was 
missing for 41% of deaths in the ESPN/ERA-EDTA study (31). The authors might 
have underestimated CV mortality if there were a larger proportion of CV deaths 
among patients with missing data. However, it is unlikely that a large underestimation 
occurred as missing data on cause of death is probably likely to be random.  
6.2.3 Limitations of the study 
This study had several limitations which are described in the following paragraphs.  
6.2.3.1 Role of chance  
As ESRD is rare in children and young adults the sample size of this study is small 
and small numbers of events precluded stratified analysis. For example, it was not 
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possible to describe whether cause of death differs between young and older patients. 
Furthermore, the small sample size may have resulted in a low statistical power of the 
study which reduces precision of estimates and is reflected in wide 95% CI. Therefore, 
it was not possible to detect clinically relevant differences. For example, this study did 
not show a statistically significant association between initial type of RRT and all-
cause mortality. In contrast, the ESPN/ERA/EDTA registry showed that patients who 
initiated RRT with HD or PD had a higher risk of all-cause mortality compared to 
patients who were pre-emptively transplanted, HR 6.6 (95% CI 2.9-15.2) and 6.5 (95% 
CI 2.9-14.9), respectively (31). The small number of one- and five-year deaths among 
the small study population precluded derivation of any meaningful conclusions about 
improved survival over time. The USRDS registry (120) study reporting improved 
survival during their study period included a much bigger sample size of 23,401 
patients. 
 
It was also not possible to split the “other” category of PRD in to more specific 
diagnoses due to small numbers within each category. Therefore, it was decided to 
separate the two biggest PRD categories CAKUT and GN and combine the rest into 
one broad category. However, such an approach does not allow me to investigate 
effects of other PRD.  
6.2.3.2 Missing data  
Another limitation is related to missing data in the SRR. Patients with missing data 
were excluded from the analyses. This study showed that there were more older 
patients among excluded compared to the complete cohort which might have resulted 
281 
 
in biased study population. Older patients are more likely to receive a kidney 
transplant, therefore, have better survival. Exclusion of patients with better survival 
might have resulted in mortality being overestimated. However, the proportion of 
excluded patients was very small (6.3%), therefore, it is unlikely that a large 
overestimation occurred.  
Cause of death was not available for all patients in the SRR, therefore, the data were 
linked with the registry of causes of death. The data on cause of death was only 
available from 1981, so only patients who started RRT from 1981 to 2013 were 
included for this part of the analyses. Even though their characteristics were similar to 
the total cohort I expect that mortality rate for CV death would be higher among 
patients who started RRT from 1961 to 1980 compared to the included sub-cohort due 
to improvement of dialysis techniques, better availability of kidney transplantation and 
increased awareness of the burden of CVD in renal patients among physicians that 
may have resulted in better survival in recent years compared to earlier years.   
Race/ethnicity was missing in the majority of patients, as a result potential racial or 
ethnic differences in survival could not be explored. The USRDS registry study (163) 
showed that black patients had a higher risk of all-cause mortality compared to white 
patients. According to the data from the 2011 census published in the national Records 
of Scotland website 96.0% of the population in Scotland is white. The numbers of 
children from non-white ethnic groups is small and there would have been extremely 
limited power to explore racial/ethnic differences in outcomes.  
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6.2.3.3 Misclassification of causes of death 
Similarly to the ESPN/ERA-EDTA analyses, there is a potential for overestimation of 
CV mortality when obtained from death certificates (156). See Chapter 3, page 187 for 
more details.  
6.2.3.4 Unrecorded confounding factors 
Again, similarly to the ESPN/ERA-EDTA analyses (Chapter 3) it was impossible to 
assess effect of co-morbidity on mortality as this information was also lacking in the 
SRR (see page 187 for more details).  
6.2.4 Strengths of the study 
Despite the limitations, to my knowledge, this is the first study with the longest follow-
up period among available studies in Europe that has described changes of 
characteristics of the population over time, survival, all-cause mortality and cause of 
death in patients who started RRT in childhood. This study included both dialysis and 
transplanted patients as well as patients from 0 to 18 years old at start of RRT and was 
able to compare the risk of death between sub-groups of patients. These factors also 
improve generalisability of the results. In contrast, previous studies included a selected 
RRT population and generally only were based on short-term follow-up.  
Another major strength of this study is data linkage. This study described cause of 
death in a sub-cohort with complete data on causes of death due to the ability to link 
SRR data with the national registry of causes of death.  
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6.2.5 Generalisability of the study findings 
This study included almost all patients receiving RRT in Scotland due to national 
coverage of the SRR and a very small proportion was excluded because of missing 
data. This study might potentially miss deaths that occurred outside of Scotland. 
However, it is unlikely that patients with ESRD receiving dialysis would travel, 
meaning that such loss to follow-up is unlikely. Therefore, the results obtained in this 
study could be considered representative of the entire population of patients who 
initiated RRT from 0 to <18 years of age in Scotland during the study period.  
6.2.6 Future research 
Future observational cohort studies are needed that include a bigger sample size 
compared to the current study, perhaps, combining data from several national registries 
to achieve a sufficient statistical power to be able to overcome the major limitation of 
this study. Ideally, more complete data is needed to avoid selection bias which could 
affect obtained results. Detailed discussion of future research is presented in the overall 
discussion chapter (Chapter 7).  
6.2.7 Conclusion  
This study demonstrates that the characteristics and treatment history of patients who 
started RRT in childhood have changed in the period from 1961 and 2013. CVD 
accounted for 51.8% of all deaths that occurred in patients who started RRT between 
1981 and 2013. Young age at start of RRT, PRD other than CAKUT or GN and 
receiving dialysis was associated with a higher risk of all-cause mortality compared to 




This study suggests that CVD is common among children who receive RRT. 
Therefore, further information is required about CVD incidence and risk factors 
associated with development of CVD after start of RRT in childhood. The next Chapter 
presents the analyses of the SRR data linked with CV hospital admissions describing 
CVD incidence and the association of age at start of RRT, sex, PRD, type of RRT and 







Chapter 7. Cardiovascular disease incidence among patients who 
initiated RRT in childhood in Scotland between 1981 and 2013: an 
analysis of the Scottish Renal Registry linked to causes of death and 
cardiovascular hospital admissions  
7.1 Results 
7.1.1 Characteristics of patients who started RRT in childhood from 1981 
to 2013 in Scotland 
In total 381 patients without existing CVD started RRT before the age of 18 years 
between 1981 and 2013 in Scotland. Their characteristics are similar to the total cohort 
described in Chapter 5. Characteristics of patients with complete and missing data are 
presented in Table 40. Patients with missing data were older and there were slightly 
more females than males compared to patients with complete data. Furthermore, 
patients with missing data in comparison to patients with complete data were less 








Table 40. Characteristics of patients with complete data and with missing data who 
started RRT between 1981 and 2013 in Scotland 
Characteristics Patients with 
complete data 
N (%) 
Patients with missing 
PRD 
N (%) 
All patients 356 25 
Age at start of RRT 
(years) 
  
0- <2 28 (7.9) 1 (4.0) 
2- <6 46 (12.9) 1 (4.0) 
6- <12 88 (24.7) 2 (8.0)  
12- <18 194 (54.5) 21(84.0) 
Sex   
Male 209 (58.7) 9 (36.0) 
PRD    
CAKUT 185 (52.0) - 
GN 59 (16.6) - 
Other 112 (31.5) - 
Initial type of RRT   
HD 143 (40.2) 12 (48.0) 
PD 168 (47.2) 12 (48.0) 
Pre-Tx 45 (12.6) 1 (4.0) 
PRD-primary renal disease, GN-glomerulonephritis, RRT-renal replacement therapy, HD-
haemodialysis, PD-peritoneal dialysis, Tx- transplanted, Pre-Tx-pre-emptively transplanted. % 




7.1.2 CVD incidence in patients who started RRT in childhood in Scotland 
1981-2013 
In total, 381 patients were followed for a median of 12.9 (IQR 5.6-21.5) years, giving 
5,223 p/y of follow-up. During follow-up 134 (35.2%) patients developed CVD 
identified using the broad definition. Mean age at CVD incidence was 21.5 years (SD 
9.5). The majority of patients with CVD had a non-fatal CVD event as their first event 
(N=120), while a fatal CVD event was the first CVD event for 14 patients. In the sub-
group of patients with complete data 128 patients developed CVD during 4,909 p/y. 
The overall crude CVD incidence was 2.6 (95% CI 2.2-3.0) and 1.9 (95% CI 0.4-3.4) 
among patients with complete and incomplete data, respectively. Table 41 presents the 
crude CVD incidence rates for sub-groups of patients with complete data. The 
differences in all sub-groups were not statistically significant, as indicated by 
overlapping 95% CIs in all sub-groups.  
The most common types of first CVD event were other diseases of the circulatory 
system accounting for 62.7% of the CVD events, followed by cerebrovascular disease 
and heart failure (Figure 48). Among the groups of other diseases of the circulatory 
system (‘other’ group in Figure 48) the most common form was other forms of heart 
disease (29.7%) (Table 42). Within the latter group valvular heart disease (41.4%) and 
cardiomegaly (38.0%) were the most common types of CVD, while pericarditis 






Table 41. CVD incidence rate in sub-group of patients who started RRT between 1981 
and 2013 in Scotland 





rate per 100 p/y 
(95% CI) 
Age at start of RRT    
0-<2 8 (6.0) 285 2.8 (0.9-4.7) 
2-<6 14 (10.4) 636 2.2 (1.1-3.3) 
6-<12 24 (17.9) 1,360 1.8 (1.1-2.5) 
12-18 88 (65.7) 2,941 3.0 (2.4-3.6) 
Sex    
Male 79 (59.0) 2,700 2.9 (2.3-3.5) 
Female 55 (41.0) 2,523 2.2 (1.6-2.8) 
PRD     
CAKUT 65 (48.5) 2,538 2.6 (1.9-3.2) 
GN 24 (17.9) 944 2.5 (1.5-3.5) 
Other 39 (29.1) 1,426 2.7 (1.8-3.5) 
Missing  6 (4.5) 314 1.9 (0.4-3.4) 
Therapy modality at  
start of RRT 
   
HD 66 (49.3) 2,152 3.1 (2.4-3.8) 
PD 56 (41.8) 2,469 2.3 (1.7-2.9) 
Tx 12 (9.0) 601 2.0 (0.9-3.1) 
Period of start of RRT    
1981-1990 70 (52.2) 2,428 2.9 (2.2-3.6) 
1991-2000 40 (29.9) 1,966 2.0 (1.4-2.6) 
2001-2013 24 (17.9) 828 2.9 (1.8-4.0) 
 
CVD-cardiovascular disease, PD-peritoneal dialysis, HD-haemodialysis, RRT-renal replacement 





Figure 48. Distribution of first non-fatal and fatal CVD events (broad definition) 
 
 
Table 42. Distribution of types of ‘other’ group in Figure 46 (fatal and non-fatal)  
Type of other diseases of the circulatory 
system 
N  (%) 
Other forms of heart disease 25 29.7 
Diseases of veins, lymphatic vessels and 
lymph nodes 
23 27.3 
Other and unspecified disorders of the 
circulatory system 
14 16.6 
Diseases of arteries and arterioles 11 13.3 
Hypertensive heart disease 5 5.9 
Disease of pulmonary circulation 4 4.8 
Chronic rheumatic heart disease 2 2.4 





In the secondary analysis there were 80 patients who developed CVD defined using 
strict definition. Of these CVD events 60 were non-fatal and 20 fatal CVD events. The 
CVD incidence was 1.4 (95% CI 1.1-1.7) per 100 p/y, which was significantly lower 
compared to the incidence CVD using the broader definition in the primary analysis. 
The most common types of CVD events were cerebrovascular disease followed by 
heart failure, cardiac arrest and arrhythmias (Figure 49). Cardiomegaly (55%) and 
endocarditis (27%) were the most common fatal types of CVD in the other category.  
Figure 49. Distribution of first non-fatal and fatal CV events in the secondary analysis 
with a “stricter” definition of CVD 
 
After applying a less strict definition of CVD incidence (only excluding diseases of 
veins, lymphatic vessels and lymph nodes) 96 patients developed CVD. Of these CVD 
events 79 were non-fatal and 17 fatal CVD events.  The most common CVD types 
were other diseases of the circulatory system (29.2%), followed by cerebrovascular 
disease (20.1%) and heart failure (12.3%). 
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7.1.3 Associations of age at start of RRT, sex PRD and type of RRT with 
CVD incidence (broader definition) 
Kaplan-Meier survival curves differed significantly by RRT modality patterns during 
follow-up (p=0.04) (Figure 50).  
Figure 50. Kaplan-Meier survival curves for CVD incidence among children starting 
RRT in Scotland stratified by type of RRT during follow-up 
 
Number at risk      
260 191 101 17 -  D+Tx+ 
49 29 9 1 -  Pre-Tx 
24 1 - - -  HD+Tx- 
23 2 2 - -  PD+Tx- 
PD+Tx- started on PD and not transplanted during follow up, HD+Tx- started on HD and not transplanted during 




Figure 50 shows that patients in the PD+Tx- and HD+Tx- groups were more likely to 
develop CVD incidence compared to those who were pre-Tx and D+Tx+ 
(abbreviations are explained below Figure 50). Kaplan-Meier survival curves were 
similar by age at start of RRT, sex, PRD groups and initial type of RRT.  
Table 43 presents crude and adjusted HRs and 95% CIs for the associations between 
age at start of RRT, sex, PRD and type of RRT at start and RRT modality patterns 
during follow-up with CVD based on the broader definition. The adjusted analysis 
showed that patients who started RRT from six to 11 years of age had a significantly 
lower risk of CVD incidence compared to patients in the oldest age group. Patients in 
the PD+Tx- group had a significantly higher risk of CVD incidence compared to the 
D+Tx+ group. Patients in the HD+Tx- had a non-significantly higher risk of CVD 
compared to patients in the D+Tx+ group. Associations between PRD, type of RRT at 
start and sex with CVD incidence were not statistically significant.  
The secondary analysis with a less strict definition was similar to the primary analysis 
when a broad definition of CVD incidence was applied. Secondary analysis with a 
strict definition of CVD incidence showed that patients in the PD+Tx- and HD+Tx- 
groups had a significantly higher incidence of this definition of CVD compared to the 
D+Tx+ group. In contrast to the primary analysis, the association of age at start of 
RRT with more strictly defined CVD incidence was no longer statistically significant. 
Male patients had a higher risk of CVD compared to females. Patients with PRD other 





Table 43. Crude and adjusted HRs and 95% CIs of the associations between age at start of RRT, sex, PRD and type of RRT with CVD in the 
primary and secondary analyses based on broader and stricter definition of cardiovascular disease incidence among children who started RRT 
in Scotland 1981-2013 
Variable Primary analysis (broad CVD definition)* Secondary analysis (strict CVD 
definition)** 
 Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Age at start of RRTa     
0-<2 0.91 (0.44-1.89) 0.95 (0.44-2.05) 0.71 (0.23-1.98) 0.86 (0.29-2.53) 
2-<6 0.74 (0.42-1.29) 0.82 (0.44-1.52) 0.54 (0.23-1.26) 0.76 (0.31-1.89) 
6-<12 0.59 (0.34-0.94) 0.59 (0.36-0.96) 0.63 (0.35-1.12) 0.72 (0.39-1.31) 
12-18 1.00 1.00 1.00 1.00 
Sexb     
Males 1.26 (0.88-1.80) 1.32 (0.92-1.90) 1.45 (0.90-2.32) 1.69 (1.05-2.74) 
Females 1.00 1.00 1.00 1.00 
PRDc     
GN 1.00 (0.62-1.60) 0.95 (0.59-1.55) 1.16 (0.63-2.18) 1.12 (0.59-2.19) 
Other 1.05 (0.71-1.57) 1.14 (0.75-1.71) 1.45 (0.87-2.42) 1.72 (1.02-2.91) 
CAKUT 1.00 1.00 1.00 1.00 
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Variable Primary analysis (broad CVD definition)* Secondary analysis (strict CVD 
definition)** 
 Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Initial type of RRTd     
HD 1.54 (0.83-2.87) 1.39 (0.74-2.63) 2.04 (0.86-4.79) 1.44 (0.57-3.61) 
PD 1.09 (0.58-2.04) 1.20 (0.63-2.29) 1.14 (0.47-2.76) 1.74 (0.73-4.16) 
Pre-Tx 
 
1.00 1.00 1.00 1.00 
Type of RRT during follow-upe     
PD+Tx- 2.52 (1.02-6.22) 3.32 (1.24-8.88) 4.35 (1.55-12.19) 7.30 (2.30-23.16) 
HD+Tx- 2.20 (0.95-5.13) 2.14 (0.87-5.23) 5.55 (2.42-12.76) 8.38 (3.31-21.23) 
Pre-Tx 0.82 (0.45-1.49) 0.82 (0.45-1.51) 0.74 (0.32-1.73) 0.74 (0.32-1.73) 
D+Tx+ 1.00 1.00 1.00 1.00 
PRD-primary renal disease; GN-glomerulonephritis, CAKUT-congenital anomalies of kidney and urinary tract; RRT-renal replacement therapy; HD-haemodialysis; PD-peritoneal dialysis; 
Pre-Tx-pre-emptively transplanted; HR-hazard ratio, CI-confidence interval. PD+Tx- started on PD and not transplanted during follow up, HD+Tx- started on HD and not transplanted 
during follow-up, D+Tx+ started on dialysis and received a transplant during follow-up. Only patients with complete data included in unadjusted and adjusted analyses (N=356). *CVD 
events N=128; ** CVD events N=75; Adjusted for a sex, PRD, type of RRT at start and period of start of RRT; b PRD, type of RRT at start and period of start of RRT; c sex, age at start of 
RRT, RRT at start and period of start of RRT; d sex, age at start of RRT, PRD and period of start of RRT; e sex, age at start of RRT, PRD and period of start of RRT; 
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7.1.4 One- and five-year CVD incidence 
Fifteen patients developed CVD defined using the broader criteria within the first year 
after initiation of RRT. Forty-eight patients out of the 335 patients with five-year 
follow-up and complete data developed CVD within five years after initiation of RRT. 
Characteristics of patients for whom five-year follow-up was available (i.e. those who 
started RRT from 1981 to 2010) were similar to the main cohort.  
Proportions of patients who developed CVD within one and five years after starting 
RRT by key characteristics are presented in Table 44. A statistically significantly 
higher proportion of patients in the PD+Tx- and HD+Tx- groups developed CVD 
compared to those in the pre-Tx and D+Tx+ groups. No other significant differences 
between groups were found.  
In the secondary analysis with a stricter definition of CVD nine and 23 patients 
developed CVD within one and five years after start of RRT, respectively. As in the 
primary analysis higher proportions of patients in the PD+Tx- and HD+Tx- groups 
developed CVD compared to those who were in the pre-Tx or the D+Tx+ groups.  
Cox regression analyses did not show a statistically significant association between 
period of start of RRT with one-year and five-year CVD incidence (Table 45). 
However, patients who started RRT in the earliest decade had a lower risk of one-year 
and five-year CVD defined using the broader definition compared to patients who 
started RRT in the latest decade. In contrast, the reverse pattern was found in the 
analysis based on the stricter definition of CVD.  
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Table 44. Proportions of patients who developed CVD one and five years after starting 
RRT by key characteristics 
 One-year Five-year 
Characteristics CVD+  CVD - CVD+ CVD - 
All patients  15 341 48 287 
Age at start of RRT     
0-<2 2 (7.1) 26 (92.9) 4 (16.7) 20 (83.3) 
2-<6 4 (8.7) 42 (91.3) 8 (19.0) 34 (81.0) 
6-<12 2 (2.3) 86 (97.7) 9 (10.6) 76 (89.4) 
12-18 7 (3.6) 187 (96.4) 27 (14.7) 157 (85.3) 
Sex     
Female  5 (3.4) 142 (96.6) 15 (10.6) 126 (89.4) 
Male 10 (4.8) 199 (95.2) 33 (17.0) 161 (83.0) 
PRD      
CAKUT 9 (4.9) 176 (95.1) 22 (12.7) 151 (87.3) 
GN 2 (3.4) 57 (96.6) 10 (18.2) 45 (81.8) 
Other 4 (3.6) 108 (96.4) 16 (15.0) 91 (85.0) 
Initial type of RRT     
HD 9 (6.3) 134 (93.7) 21 (15.8) 112 (84.2) 
PD 5 (3.0) 163 (97.0) 24 (14.9) 137 (85.1) 
Pre-Tx 1 (2.2) 44 (97.8) 3 (7.3) 38 (92.7) 
Type of RRT during 
follow-up * 
    
HD+Tx- 3 (12.5) 21 (87.5) 4 (25.0) 12 (75.0) 
PD+Tx- 2 (11.1) 16 (88.9) 4 (30.8) 9 (69.2) 
Pre-Tx 1 (2.2) 44 (97.8) 3 (7.3) 38 (92.7) 
D+Tx+ 9 (3.3) 260 (96.7) 37 (14.0) 228 (86.0) 
 
CAKUT-congenital anomalies of kidney and urinary tract, GN-glomerulonephritis, RRT-renal replacement 
therapy, HD-haemodialysis, PD-peritoneal dialysis, pre-Tx-pre-emptive transplantation, PD+Tx- started on PD and 
not transplanted during follow up, HD+Tx- started on HD and not transplanted during follow-up, D+Tx+ started 
on dialysis and received a transplant during follow-up. CVD-cardiovascular disease. Patients with complete data 




Table 45. Crude and adjusted HRs and 95% CIs for the associations between period of starting RRT with CVD incidence in the primary 
analysis and secondary analysis based on broader and stricter definition of cardiovascular disease incidence among children who started RRT 
in Scotland 1981-2013 
  Primary analysis (broad definition)*   Secondary analysis (strict definition)* 





HR (95% CI) 
Adjusted 




HR (95% CI) 
Adjusted 
HR (95% CI) 
One year CVD        
1981-1990 3 0.44 (0.11-1.77) 0.38 (0.09-1.57) 3 1.34 (0.22-7.99) 1.49 (0.22-9.79) 
1991-2000 6 0.95 (0.31-2.94) 1.11 (0.35-3.57) 4 1.92 (0.35-10.46) 1.85 (0.30-11.43) 
2001-2013 6 1.00 1.00 2 1.00 1.00 
       
Five year CVD        
1981-1990 14 0.59 (0.29-1.21) 0.58 (0.28-1.19) 11 1.68 (0.58-4.85) 1.67 (0.56-4.92) 
1991-2000 17 0.76 (0.39-1.49) 0.74 (0.27-1.46) 7 1.11 (0.35-3.49) 1.05 (0.33-3.37) 
2001-2010 17 1.00 1.00 5 1.00 1.00 
       
Total number of patients include for one year CVD incidence =356. Total N of patients include for five year CVD incidence =335; n- total number of CVD events;  
*Broad definition of CVD, **Strict definition of CVD. Adjusted for age at start of RRT, sex, PRD, type of RRT at start; CVD-cardiovascular disease;  
RRT-renal replacement therapy; HR-hazard ratio, CI-confidence interval.   
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7.1.5 Planned sensitivity analysis 
Among 22 patients with prevalent CVD the most common CVD diagnoses were other 
forms of circulatory disease (86%), with the most common type within this category 
being diseases of veins and arterioles (36%). Cardiomyopathy, ischaemic heart disease 
and cerebrovascular disease accounted for 4.5% per each category. Sensitivity analysis 
after inclusion of 22 patients with prevalent CVD showed similar results to the primary 
analysis. The results of the sensitivity analysis are presented in Appendix 1, Table 9, 
page 374.  
7.2 Discussion 
7.2.1 Summary of findings of the study 
The SRR data linked with the national registry of CV hospital admissions and causes 
of death provided an opportunity to fulfil one of the major gaps in current knowledge 
about CVD incidence in patients who initiated RRT in childhood. This study has 
shown that over a third of patients developed incident CVD over a median follow-up 
of 12.9 (IQR 5.6-21.5) years after initiating RRT in childhood in Scotland from 1981 
to 2013. The most common category of CVD within the broad definition was other 
diseases of the circulatory system. Valvular heart disease and cardiomegaly were the 
most common specific CVD types within this category. When the stricter definition of 
CVD incidence was applied the most common specific types were cerebrovascular 
disease, followed by heart failure, cardiac arrest and arrhythmia.  
The primary analyses based on the broad definition of CVD showed that age at start 
of RRT and type of RRT during follow-up were significantly associated with CVD 
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incidence. Patients who started RRT from six to 11 years of age had a significantly 
lower risk of CVD incidence compared to patients who started RRT when they were 
between 12 and 18 years old. Patients in the PD+Tx- group had a significantly higher 
risk of CVD compared to patients in the D+Tx+ group. Patients in the HD+Tx- group 
had a non-significantly higher risk of CVD compared to patients in the D+Tx+. 
Associations between PRD, type of RRT at start, period of start of RRT and sex with 
CVD incidence were not statistically significant.  
The secondary analyses based on the stricter definition of CVD showed slightly 
different results. Higher risk of CVD compared to patients in the D+Tx+ group was 
also found among patients in the HD+Tx- group as well as in the PD+Tx- group. Male 
patients had a significantly higher risk of CVD incidence compared to female patients. 
Patients with PRD other than CAKUT or GN had a significantly higher risk of CVD 
incidence compared to patients with CAKUT. In contrast to the primary analyses, the 
association of age at start of RRT with CVD incidence was no longer statistically 
significant. 
7.2.2 Interpretation of the findings in the context of existing literature  
7.2.2.1 Incidence of CVD  
According to the literature review described in Chapter 4 there is only one study that 
used a comparable definition of CVD incidence with the current study (109). This 
single-centre Canadian study included 418 pre-emptively transplanted patients and 
patients who received a kidney transplant following a period on dialysis. CVD 
incidence in this study was defined as first fatal or non-fatal CVD event obtained from 
hospital admission administrative dataset. The authors reported an incidence of 1.07 
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per 100 p/y (95% CI not reported) in their study, which was similar to the CVD 
incidence of the current study among transplanted patients of 1.2 (95% CI 0.8-1.5) per 
100 p/y. The follow-up in the Canadian study was approximately half as long (mean 
6.4 (SD 5.1) years) as in the current study (mean 13.7 (SD 9.4) years).  
7.2.2.2 Types of CVD 
The finding of the current study that cardiomegaly was one of the most common types 
of CVD in the primary analysis could be explained by cardiac remodelling that results 
from hypertension, volume and sodium overload. This leads to LVH as a response to 
mechanical or haemodynamic overload (182). Previous research has shown that at 
initiation of maintenance dialysis 69–82% of paediatric patients have LVH (183).  
When the CVD definition was based on stricter criteria the most common type of CVD 
was cerebrovascular disease. This could be explained by vascular injury, the second 
key process involved in the development of CVD in patients receiving RRT. Patients 
receiving RRT experience abnormal mineral metabolism including increased calcium 
and phosphate ion product or hyperphosphatemia which may be key factors underlying 
development of coronary artery calcification (CAC). The mechanisms include either 
stimulation of the uptake and precipitation of calcium and phosphate into the vessel or 
a decrease of the inhibitory process that prevents these ions from precipitation (184). 
This finding was in line with the Canadian study that classified CVD events as 
cerebrovascular accident, myocardial infarction, congestive heart failure and sudden 
cardiac arrest. The authors reported that cerebrovascular events were the most common 
type of incident CVD events accounting for 43% of all CVD events in patient who 
were younger than 18 years old at the time of transplantation (109). The distribution 
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of CVD types in the Canadian study was similar to the current study, i.e. 
cerebrovascular disease was the most common and was flowed by heart failure and 
cardiac arrest. A Dutch study similarly reported that death from cerebrovascular 
accidents accounted for 41% of all deaths among patients who started RRT in 
childhood and survived until they were at least 18 years old (29). Another study that 
reported non-fatal CVD events was a USRDS study including only patients receiving 
dialysis that limited their analyses to cardiac-related events defined as arrhythmia, 
cardiac arrest, valvular heart disease and cardiomyopathy. The authors reported that 
arrhythmia was the most common type of cardiac event (19.6%) followed by 
cardiomyopathy (9.6%) (164).  
7.2.2.3 Association of age at start of RRT, sex, PRD, type of RRT and 
period of start of RRT with CVD incidence  
The literature review presented in Chapter 4 showed that limited knowledge exists 
about the association of age at start of RRT, sex, PRD, type of RRT and period of start 
of RRT with CVD outcomes. The available studies mostly used fatal CVD events as 
the primary outcomes of interest in their analyses. In contrast, the current study used 
both fatal and non-fatal CVD events. In general, the findings of the associations 
between potential risk factors with CVD incidence were in line with previous studies 
reporting only on fatal CVD events. However, different definitions of CVD outcomes 
made it difficult to directly compare the current findings with previous studies. Ideally, 
it would be desirable to re-run the analyses using a similar definition of CVD outcome 
to match the obtained results with the other authors. However, small number of fatal 
CVD events observed in the current study resulted in insufficient statistical power to 
identify difference in associations of risk factors with fatal CVD events.  
302 
 
7.2.2.3.1 Association of age at start of RRT with CVD incidence 
The primary analysis based on the broader definition of CVD showed that patients 
who started RRT from six to 11 years of age had a significantly lower risk of CVD 
incidence compared to patients in the oldest age group (12-18 years old). This finding 
may be explained by the fact that patients who start RRT in older age live longer 
compared to those who start RRT in younger age. Therefore, older patients have a 
higher chance to survive until development of CVD compared to younger patients. 
Alternatively, this finding might be a chance finding due to multiple testing because 
after applying a “strict” definition the association was no longer statistically 
significant. However, there may be limited statistical power due to smaller number of 
CVD events when using the stricter definition. 
The USRDS study including incident paediatric dialysis patients from 1991 to 1996 
showed that the proportion of non-fatal cardiac-related incident events was 
significantly higher in the oldest patients (15-19 years old) compared to younger ones 
(0-4 years old) (164). In contrast, another study from the USRDS registry using cardiac 
death as outcome showed no association between age at death and cardiac mortality 
(185).  
7.2.2.3.2 Association of sex with CVD incidence 
In the current analysis no association between sex with CVD incidence using the broad 
definition is found. This is in line with the USRDS registry study that analysed 1,380 
deaths from 1990 to 1996 among patients who started RRT as children and died before 
30 years of age (185). However, the results of the secondary analysis using stricter 
definition showed that male patients had a borderline significantly higher incidence of 
CVD compared to female patients. This was in line with ERA-EDTA study in adult 
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RRT population showing that female patients have a lower risk of CV mortality 
compared to men (186). Bearing in mind that these results are borderline significant 
and might be due to chance this finding should be interpreted with caution.  
7.2.2.3.3 Association of PRD with CVD incidence 
This study has shown that patients with PRD other than CAKUT and GN had a 
significantly higher risk of CVD incidence compared to patients with CAKUT. The 
explanation of this finding is presented in previous Chapter 5, page 265. Briefly, the 
group of ‘other’ types of PRD included diagnoses that are characterized by 
arteriopathies and thrombophilia. Research among children in the general population 
has shown that the presence of arteriopathies and thrombophilia are associated with 
increased risk of arterial ischaemic stroke compared to children without these 
conditions (187). The inflammation and damage of small- and medium-size vessels in 
many organs, including kidney, heart and brain (180, 181) might contribute to the 
higher risk of CVD incidence.  
The only other study that explored the association of PRD with CVD outcome in 
children receiving RRT is the USRDS study (185). The authors did not find a 
statistically significant association between PRD and cardiac mortality.  
7.2.2.3.4 Association of type of RRT with CVD incidence 
This study has shown that patients in PD+Tx- and HD+Tx- groups had a significantly 
higher risk of CVD compared to patients in the D+Tx+ group. This finding might be 
explained by referral bias which has been previously introduced in Chapter 5, page 
265 (178). The association between RRT patterns and CVD incidence was in line with 
the Dutch (29) and the USRDS (185) studies. However, the Canadian study (109) did 
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not find a statistically significant difference in CVD incidence between transplanted 
patients who started on dialysis and pre-emptively transplanted patients. The 
difference might be due to the fact that the Canadian study had a shorter follow-up 
time compared to the current study and they only analysed type of RRT at the time of 
initiation, while the current study took into account changes in RRT modality during 
follow-up.  
7.2.2.3.5 Period of start of RRT with CVD incidence 
This study did not find an association between periods of start of RRT with one- and 
five-year CVD incidence. There was limited power to detect differences as the 
numbers of one- and five-year CVD incident events were small, as reflected in the 
wide 95% CIs around the estimates. In contrast, the USRDS study that included 1,064 
fatal CVD events reported that patients who started RRT in later time periods had a 
lower risk of CV mortality compared to patients who started RRT in earlier periods 
(120). The larger number of events provided much greater statistical power compared 
to the current study. Better awareness of high risk of CVD in this population and better 
management of CVRFs might have resulted in improved CVD-free survival. 
7.2.3 Limitations of the study 
7.2.3.1 Limitations resulting from data linkage 
As data on causes of death and hospital admissions required to identify outcomes are 
only available in Scotland from 1981 the study was limited to patients who started 
RRT from 1981 to 2013. The aim of the study was to look at new onset CVD, therefore, 
patients with prevalent CVD were excluded from the analysis of CVD incidence in the 
main analysis. However, it is possible that some CVD events occurred among the study 
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population prior to 1981. It would have been ideal to have access to full records for 
everyone from birth in order to identify all CVD events prior to RRT. The sensitivity 
analysis including patients with recurrent CVD showed that patients with a prior 
history of CVD had a higher risk of CVD compared to patients who were CVD-free at 
the start of RRT. If patients with recurrent CVD events were included in the analysis 
of CVD incidence then the incidence and the associations of determinants with CVD 
might be overestimated. However, it is unlikely that the number of patients for whom 
prevalent CVD status was misclassified would be large. 
7.2.3.2 Limitation of the CVD coding 
For the primary analysis using the broad definition of CVD almost all codes for 
diseases of the circulatory system were used apart from those for hypertension and 
arteriovenous fistula. Hypertensive disease was excluded from the definition of non-
fatal CVD events, as for the purpose of this study it is considered as a risk factor rather 
than the outcome. However, if a patient died from hypertensive disease it was included 
in the definition of CVD in order to maximise the power of the study. The 
arteriovenous fistula procedure codes were excluded from the definition of CVD as 
this is a standard procedure which is a part of the preparation for HD treatment.  
The biggest group of CVD events was “other disease of the circulatory system”, and 
included heterogeneous types of CVD categories that might represent less severe CVD 
events. Therefore, these outcomes were not included in the secondary analysis using a 
stricter definition for CVD. Results of the secondary analysis showed slightly higher 
HRs suggesting stronger association between determinants with more severe types of 
CVD events.  
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7.2.3.3 Bias and confounding factors 
Similarly to the ESPN/ERA-EDTA (Chapter 3) and the SRR all-cause mortality 
analyses (Chapter 5) CV death may be overestimated when obtained from death 
certificates (156). This overestimation may result in the overall overestimation of CVD 
incidence, as the definition of CVD incidence included fatal and non-fatal CVD events.  
It was not possible to adjust for comorbidities and proteinuria as important 
confounding factors because these data are not available in the SRR and information 
on comorbidities was not requested in the linked data.  
7.2.3.4 Missing data 
Patients with missing data were excluded from the analysis. Excluded patients were 
older compared to the complete cohort. The explanation of the possible effect it could 
have on the estimates are presented in previous chapter section 5.4.3.2.  
7.2.3.5 Time limitation 
Originally I planned to use another renal dataset called Strathclyde Electronic Renal 
Patient Record (SERPR) in addition to the SRR. The SERPR is a hospital-based renal 
database, which contains biochemistry, haematology, radiology, pathology, 
microbiology test results and medication data of patients with all stages of CKD in 
Scotland. It is a relatively new renal system, which was introduced in adult renal 
services in Scotland in June 2010 and saw the amalgamation of paediatric data in May 
2012. Since the SERPR contains much detailed clinical data on CVRFs than the SRR 
it was planned to use these data to describe the association of CVRFs (hypertension, 
obesity, dyslipidaemia and anaemia) with CVD. However, the SERPR data have never 
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been used for research purpose before and the data manager had to learn new 
programming skills in her spare time in order to extract the data from the database. 
This resulted in significant delay in my receiving data for analyses. Therefore, it was 
decided to restrict my analysis to the SRR data.  
7.2.4 Strengths of the study  
The main strength of this study is the linkage of the SRR data with the causes of death 
and CV hospital admissions to be able to describe CVD incidence in patients who 
initiated RRT in childhood in Scotland. To my knowledge, this is the first study that 
has described fatal and non-fatal incident CVD events in children who have received 
RRT in Europe. Furthermore, this study had the longest follow-up period among 
available studies and included both dialysis and transplanted patients to make a 
comparison between sub-groups. Most of the available studies used only fatal CVD 
events, included selected RRT populations and had short follow-up periods.  
This is the first study that has explored the associations of age at start of RRT, sex, 
PRD, type of RRT and period of start of RRT with CVD incidence over a long follow-
up period. Only a very small proportion of patients was excluded from the analysis 
due to missing PRD which is unlikely to have a large influence on these results.  
7.2.5 Conclusion and future research 
This study highlights the fact that CVD is common among patients who initiated RRT 
in childhood in Scotland. Cerebrovascular disease is the most common specific type 
of CVD in this population. Male sex, PRD other than CAKUT or GN and receiving 
dialysis are significantly associated with a higher risk of developing CVD after 
initiation of RRT compared to females, patients with CAKUT and patients receiving 
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a kidney transplantation, respectively. Further research is needed to clarify whether 
treatment of CVRFs will reduce the risk of CVD in this specific patient population.  
However, the small sample size and limited statistical power of the study precluded 
the potential to draw meaningful conclusions for clinical practice. Future studies are 
needed with a large sample size to validate these findings. Moreover, studies with data 
on CVRFs are needed to explore the association of hypertension, obesity, 
dyslipidaemia and anaemia with CVD incidence in children receiving RRT. A detailed 














Chapter 8. Discussion 
This chapter begins with a summary of the results from the different parts of the thesis: 
the two literature reviews and the analyses performed in the ESPN/ERA-EDTA and 
the SRR data. This is followed by the strengths and limitations of the thesis. This 
chapter also addresses the implications of the findings for clinical practice and future 
research and proposes recommendations for how the ESPN/ERA-EDTA and SRR can 
be further enhanced for use in research, followed by an overall conclusion of the thesis.   
8.1 Summary of principal findings of the thesis 
8.1.1 Findings from the literature review on the prevalence of CVRFs and 
their association with all-cause mortality and CVD outcomes  
The literature review presented in Chapter 2 showed that little knowledge exists about 
the prevalence and patterns of CVRFs and their association with all-cause and CV 
mortality in children who receive RRT. In total, 38 studies were included for the 
literature review of the prevalence of CVRFs. Most of the available studies were 
performed by single centre studies from the US (65-67, 77, 78, 84-86, 99, 100), Israel 
(68, 69), Australia (70), Mexico (79), Hungary (80), Austria (70, 87), Turkey (88, 89), 
Canada (90), Serbia (91), Iran (92), Finland (93) and Sweden (94). Multicentre studies 
were mostly performed using data from the national and international renal registries 
(22, 37, 40, 42, 54, 64, 71, 72, 81, 95, 96). The included studies showed that 
hypertension, anaemia, dyslipidaemia and overweight/obesity are common in patients 
who initiated RRT in childhood. However, the prevalence estimates of CVRFs varied 
widely across the studies. No studies described combinations of traditional and 
uraemia-related CVRFs.  
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The heterogeneity between studies in terms of their inclusion criteria of the study 
population and definition of the CVRFs made it difficult to directly compare findings 
across studies. Several common issues in terms of study quality reporting the 
prevalence of CVRFs were identified. Potential selection bias and misclassification 
may have affected the results of the included studies. For example, the majority of the 
studies were cross-sectional. Therefore, the findings are potentially affected by 
survival bias. If the patients that were left out of the study were sicker and had a higher 
prevalence of CVRFs compared to patients who were included in the study, the authors 
may have underestimated the true prevalence of CVRFs. On the other hand, the authors 
might have overestimated the true prevalence of CVRFs if prevalence of CVRFs 
increases with duration of RRT. Additionally, most studies were from single centres 
with a small sample size that may have resulted in imprecise estimates of the 
prevalence and may have limited generalisability of their results to wider populations 
of patients who initiated RRT in childhood within countries or in other countries.  
The systematic review of the association of CVRFs with all-cause mortality included 
limited numbers of studies: three studies for anaemia/Hb (22, 71, 72), two for BMI 
(54, 107) and two for hypertension (53, 111). Only one study reported on the 
association between hypertension and cerebrovascular mortality (53). Most studies 
were based on data collected through national and international renal registries (22, 
53, 54, 71, 72, 107), except one single-centre study from Saudi Arabia (111). Results 
showed that patients with anaemia, hypertension and overweight/obesity have a higher 
risk of all-cause mortality compared to non-anaemic, non-hypertensive and non-
overweight/obese patients, respectively. The only identified study with CV mortality 
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as the outcome (53) showed that hypertensive patients have a non-significantly higher 
risk of cerebrovascular mortality compared to non-hypertensive patients.  
The quality assessment of the articles included in the systematic review showed that 
available studies might suffer from selection bias due to exclusion of patients with 
missing data and the voluntary nature of some registries such as the NAPRTCS and 
the IPPN. This might have led to underestimation or overestimation of the reported 
associations between CVRFs and outcomes of interest. However, the characteristics 
of patients/centres that could not be included in the studies were not provided by the 
authors, therefore, it was not possible to identify the likely direction of any bias. 
Furthermore, there might be misclassification of CVRF status among studies that 
included dialysis populations since patients receiving dialysis experience fluid 
overload which may have affected the levels of Hb/Ht, BP and body weight (154). 
This misclassification is likely to be non-differential and bias the reported association 
towards the null. Despite the limitations the studies included in the systematic review 
have been performed mostly by the large national and international renal registries that 
included a large population of patients who initiate RRT in childhood, therefore, offer 
the best quality data available.  
8.1.2 Findings from the literature review of survival and CVD outcomes  
My second literature review of survival, CVD outcomes and the association of age at 
start of RRT, sex, PRD, type of RRT and period of initiation of RRT with all-cause 
mortality and CVD outcomes (Chapter 4) included 16 observational cohort studies. 
Most studies used data from national or international renal registries (14, 29-31, 110, 
118, 120, 149, 163-169). There was only one single hospital study from Canada (109).  
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Seven studies showed that patients of young age have a higher risk of all-cause 
mortality compared to older patients (14, 31, 53, 110, 120, 163, 168). Four studies 
reported that patients receiving pre-emptive transplantation or a kidney transplant 
during follow-up period had a lower risk of all-cause mortality compared to patients 
only receiving dialysis (31, 53, 118, 166). Two studies found a statistically 
significantly higher risk of all-cause mortality in patients with a PRD other than 
CAKUT compared to patients with CAKUT (120, 167). Three studies showed that 
patients who initiated RRT in early years had a statistically significantly higher risk of 
all-cause mortality compared to patients who initiated RRT in recent years (118, 120, 
165).  
The majority of the studies reported that CVD was one of the most common causes of 
death in this population. However, only two studies were found that described 
incidence of non-fatal CVD events. The USRDS study (164) reported that 31.2% 
developed a cardiac-related event (mean follow-up not reported) among 1,454 dialysis 
patients from 0 to 19 years of age. Arrhythmia was the most common type of CVD in 
this study. Another single centre study from Canada (109) reported that 12.0% of 418 
transplanted patients developed CVD during a mean follow-up period of 6.4 years (SD 
5.1). Cerebrovascular disease was the most common CVD event. When reviewing the 
published literature of the association of age at start of RRT, sex, PRD, type of RRT 
and period of start of RRT with CVD very limited information was found. Only one 
study explored the association of type of RRT with CVD and the authors did not find 
a statistically significant association (109).  
The major limitations of the available studies are short follow-up period and a low 
number of events (deaths and CVD incidence) resulting in limited statistical power. 
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Furthermore, the included studies might suffer from selection bias due to exclusion of 
patients with missing data from their analyses. Almost all studies had a high proportion 
of missing data on causes of death. This might have resulted in an underestimation of 
the CV mortality if there were higher proportion of CV deaths among patients with 
missing data. However, it is unlikely that a large underestimation occurred as missing 
data on cause of death is probably likely to be random.  
8.1.3 Findings from the ESPN/ERA-EDTA and the SRR analyses 
Data on longer-term survival, CVRFs and CVD incidence is scarce in patients with 
childhood-onset RRT in part because ESRD is rare in children and young adults. This 
results in low incidence of RRT which leads to small sample sizes and consequently 
low number of events (death and CVD events) compared to studies performed in adult 
patients receiving RRT. Moreover, access to morbidity data is necessary to study non-
fatal CVD events, which might have been difficult to gain for previous studies. This 
makes it challenging to perform studies in these populations. In the sections below the 
findings, limitations and strengths of the ESPN/ERA-EDTA and SRR analyses are 
summarised.  
8.1.3.1 Findings from the ESPN/ERA-EDTA analyses 
The analyses of the ESPN/ERA-EDTA registry data covering 33 European countries 
(Chapter 3) found that hypertension, anaemia, dyslipidaemia and overweight/obesity 
are common among European patients who initiated RRT from 0 to 20 years old. My 
findings confirm significant differences in prevalence of the CVRFs by type of RRT. 
The prevalence of hypertension, dyslipidaemia and anaemia was higher among 
dialysis patients compared to transplanted patients, while overweight/obesity was 
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more common among transplanted patients compared to patients receiving dialysis. 
The most frequent combination of CVRFs among dialysis patients was dyslipidemia, 
hypertension and anaemia. The combination of dyslipidemia, hypertension and 
overweight/obesity was most common among transplanted patients. 
In the analyses of the association of CVRFs with all-cause and CV mortality I found 
that anaemic patients had a statistically significantly higher risk of all-cause and CV 
mortality compared to non-anaemic patients. Underweight patients had a statistically 
significantly higher risk of all-cause mortality compared to non-underweight patients. 
I did not find a statistically significant association between dyslipidaemia, 
hypertension or overweight/obesity and all-cause mortality. Similarly, I found no 
associations between hypertension, overweight/obesity and underweight with CV 
mortality. The strengths and limitations of the ESPN/ERA-EDTA analyses are 
summarised in section 7.3.  
8.1.3.2 Findings from the SRR analyses 
The analyses of the SRR dataset (Chapter 5 and 6) showed that almost 80% of children 
who started RRT in Scotland between 1961 and 2013 were still alive after 20 years of 
follow-up. Furthermore, incident CVD was common developing in 35.2% of the sub-
set of children who initiated RRT between 1981 and 2013 (median follow-up 12.9 
years (IQR 5.6-21.5)). The results also suggest that patients with PRD other than 
CAKUT or GN had a higher risk of all-cause mortality and CVD incidence compared 
to patients with CAKUT. Receiving dialysis rather than a kidney transplantation was 
associated with a higher risk of all-cause mortality and CVD incidence. Younger age 
at start of RRT was significantly associated with a higher risk of all-cause mortality. 
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Males compared to females had a higher risk of CVD incidence. The strengths and 
limitations of the SRR analyses are summarised in section 7.3.  
8.2 Strengths and limitations of the thesis 
This section summarises the main strengths and limitations of the thesis. More detailed 
and specific discussions of strengths and limitations regarding the literature reviews 
and analyses have been presented in each previous chapter.  
8.2.1 Strengths of the literature reviews 
Before conducting the analyses in the ESPN/ERA-EDTA and SRR, specific 
systematic literature searches including critical appraisal of the identified papers have 
been performed. The main strength of the systematic review of CVRFs is inclusion of 
several CVRFs (hypertension, dyslipidaemia, anaemia and abnormal BMI) and several 
outcomes (all-cause mortality, CV mortality and morbidity). Furthermore, besides the 
searches in Medline and Embase I have also screened annual reports of the national 
renal registries published on their websites (17, 19) to ensure that also relevant 
information from this source is reviewed.  
8.2.2 Strengths of the ESPN/ERA-EDTA and the SRR analyses 
A common strength for both the ESPN/ERA-EDTA and the SRR analyses is the 
inclusion of incident RRT patients, avoiding survival bias. In contrast the majority of 
previous studies included prevalent RRT populations subject to survival bias.  
Another strength of the ESPN/ERA-EDTA and the SRR analyses is that the data from 
both dialysis and transplanted patients were included while previous studies mostly 
focused on mortality risk of either dialysis or transplantation instead of throughout the 
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entire RRT trajectory. As the majority of children with ESRD receive a kidney 
transplant, the dialysis studies are subject to selection bias due to inclusion of patients 
who may have been identified as unsuitable for kidney transplantation in addition to 
those awaiting a donor. Since patients who remain on dialysis are generally sicker with 
comorbidities the estimates of mortality would be higher compared to patients who 
received a kidney transplant. Furthermore, inclusion of both dialysis and transplanted 
populations permits investigation of potential differences in CVD and mortality by 
RRT modality, both at initiation of RRT and during follow-up. 
A relatively long follow-up period in the ESPN/ERA-EDTA and the SRR analyses 
increases the power of the study and, specifically for SRR, facilitates long-term follow-
up. In contrast, previous studies in general had relatively short-term follow-up and 
could be subject to survival bias as most deaths occur in the first year after start of 
RRT with the majority of deaths occurring among children less than 2 years old due 
to delayed kidney transplantation (169). This may result in overestimation of mortality 
rates.  
8.2.3 Limitations of the literature reviews 
There were several limitations of the literature reviews related to the search terms, 
restriction by year of publication, population and language. Due to that I might 
potentially miss some relevant papers. First, I did not develop a search strategy 
specifically to identify papers reporting the prevalence of CVRFs (see Chapter 2 
section 2.2.1 for a detailed description). However, I expect that the most relevant data 
about the prevalence of CVRFs has been included and reviewed because I identified 
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studies performed by large national and international renal registries reporting this 
information.  
Another limitation of the search strategy for the systematic review is that I did not 
include narrower search terms for cardiovascular and cerebrovascular disease, for 
example, coronary heart disease, ischaemic heart disease, stroke, myocardial infarction 
or ischaemia. However, the medical Subject Headings (MeSH) term “Cardiovascular 
Diseases” was exploded in the search. This has the effect of including all of the 
narrower MeSH in the hierarchy, which is a very sensitive and inclusive approach to 
retrieving records in this broad area of topics. For the complete list of terms included 
within the exploded heading, see Appendix 3. Relying on MeSH for these areas does 
depend on the database indexers correctly applying the relevant MeSH, and it is 
recognised that there is human error or inconsistency in the application of MeSH. This 
scope for error or inconsistency could have been mitigated against in my search by the 
use of free-text searches for all of the specific CVD outcomes. This would have been 
a time-consuming process. Furthermore, as CVD is rare in paediatric RRT population 
it is unlikely that studies will have sufficient number of patients with specific CVD 
events to be included in the study and to obtain clinically meaningful results.  
In my search I used .mp. rather than .tw. which is more sensitive and in Medline looks 
for a word or phrase in the title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word and unique identifier. "Textword" (.tw.) 
searching looks for a word or phrase in the titles or abstracts of the articles only.  
318 
 
For the second literature review focusing on survival/mortality and CVD incidence 
(Chapter 4) the search only focused on papers published in the last five years. It was a 
pragmatic approach as inclusion of papers published in recent years would reflect the 
current clinical situation. Older papers would differ by study population and survival 
compared to recent papers since improvement in transplantation and dialysis 
techniques resulted in increased survival in recent years.  
I have restricted my search strategy to children. However, adult populations were not 
excluded in the search. Studies potentially about both child and adult populations 
would have been captured by the search.  
I only included papers published in English. I might potentially miss non-English 
papers. However, most relevant studies in this area are likely to be published in English 
because the major registries studies are within English speaking countries or European 
countries where scientific research is usually published in English language journals. 
In order to estimate the volume of non-English literature that I missed when 
conducting my systematic review I used Search Fields in Ovid to isolate any records 
added to Medline since the completion of systematic review (August 2015). In order 
to do that I used the format YYYYMMDD with truncation to pick up whole months 
or years – e.g. 201508$ to pick up whole of August. Then I excluded the records added 
from August 2015 to obtain the same number of papers that I got in July 2015. Then I 
separated the English language and non-English language results (see search strategy 




8.2.4 Methodology of the ESPN/ERA-EDTA and the SRR analyses 
Repeated measurements 
In my analyses of the ESPN/ERA-EDTA data I summarised repeated CVRFs 
measurements into one summary measure. This method did not allow me to study 
whether CVRFs may have a different effect on short-term survival than on long-term 
survival. One of the approaches to study the effect of the length of follow-up is by 
reporting mortality rates separately for each year of follow-up (188). For example, 
Snyder et al. assessed effect of BMI as a fixed risk factor at the start of PD on mortality 
by reporting yearly mortality rates in 41,197 incident adult PD patients. The authors 
showed that the effect of obesity at the start of PD on mortality increased over time 
(189). A Cox regression analysis can also be used to study the effect of a risk factor 
whose value changes over time. Such risk factors are called time-varying risk factors 
or time-dependent covariates. In a time-dependent analysis, the follow-up time for 
each patient is divided into different time windows. A separate Cox analysis is carried 
out for each time window. After that, a weighted average of all the time window 
specific results is calculated and presented as one RR. Time-dependent Cox regression 
model takes into account that risk factors may change over time. However, a time 
dependent Cox regression provides an answer to a different research question 
compared with a traditional Cox analysis with only fixed baseline risk factors. A 
traditional Cox analysis also addresses the relatively long-term effects of a risk factor 
on mortality, while a time-dependent Cox analysis only addresses relatively short-term 





I used a complete case analyses for both the ESPN/ERA-EDTA and the SRR data 
analyses. Within each analysis I have excluded patients with missing data relevant to 
the particular analysis. For the ESPN/ERA-EDTA the percentage of missing data 
differed for each variable. For example, BMI measurements were quite complete 
(95%) but only 20% of patients had data on lipids. Excluding patients with missing 
data might have biased the estimates of the prevalence of CVRFs and their association 
with all-cause and CV mortality (see complete and more specific explanation in the 
discussion section of Chapter 3).  
In the SRR analyses 6% of patients with missing PRD and/or date of initiation of RRT 
were excluded. This may have resulted in exaggeration of the estimates of mortality 
rate and the strength of the association of age at start of RRT with all-cause mortality 
partly because excluded patients were older compared to the complete cohort. Older 
patients are more likely to receive a kidney transplant, therefore, have better survival. 
However, the small proportion of patients with missing data in the SRR analyses 
means that it is unlikely that there was much exaggeration of the estimates.  
Alternative method to deal with missing data would be to perform a multiple 
imputation of missing data (190). A multiple imputation procedure replaces each 
missing value with a set of plausible values that represent the uncertainty about the 
right value to impute. The multiply imputed data sets are then analysed by using 
standard procedures for complete data and combining the results from these analyses 
(190). To be able to perform the imputation of missing data the data have to be missing 
at random. However, in clinical datasets it is most likely that the data is missing not at 
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random. For example, more complicated patients with comorbidities are more likely 
to get their BP, BMI, Hb levels to be measured for better monitoring and treatment of 
CVRFs, while in healthier patients they would not be not measured or measured less 
frequently. Therefore, it was not possible to perform multiple imputation of missing 
data in my analyses. For that reason a complete case analysis was performed.  
Comorbidities 
Another common limitation is potential residual confounding. Both the ESPN/ERA-
EDTA registry and the SRR registry do not include information about comorbidities. 
Extrarenal comorbidity is common in the paediatric RRT population. The UK Renal 
Registry reported that at the onset of RRT (2009–2013), 19.3% of children had at least 
one and 9.5% had two or more comorbidities. The most common types were 
syndromic diagnosis (8%), developmental delay (7%), and congenital abnormality 
(7%) (168). The IPPN and the NAPRTCS registries reported that comorbidity is an 
important predictor of mortality especially for patients with cognitive, cardiac and 
pulmonary abnormalities in addition to renal disease (157, 191). 
8.2.5 Specific limitations of the ESPN/ERA-EDTA analyses 
CVRF status might be misclassified particularly among dialysis patients due to fluid 
overload which might have affected Hb, BP and BMI measurements. Furthermore, 
information about methods of CVRF measurements was lacking in the registry. A 
more detailed discussion is presented in Chapter 3. This misclassification is likely to 
be non-differential which might have biased the association of CVRFs with all-cause 
and CV mortality towards the null.  
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Although incident patients are included in the ESPN/ERA-EDTA registry, the 
measurements of CVRFs were taken at different time points from the start of RRT 
date. If prevalence of CVRFs increases with duration of RRT the strength of the 
association between CVRFs and mortality may differ between patients whose 
measurements were taken at the start of RRT compared to those whose measurements 
were taken after initiation of RRT. Therefore, to account for that I adjusted my 
analyses for the time period from start of RRT to the date of first CVRF measurement. 
Finally, this study design could not clarify whether CVRFs are modifiable risk factors 
for all-cause and CV mortality or whether all or some of them are acting as markers of 
the severity of the underlying renal disease.  
8.2.6 Specific limitations of the SRR analyses 
The main limitation of the SRR analyses is the small sample size and consequently 
low event rates. This is reflected in borderline statistically significant results and wide 
95% CIs for the associations of PRD with all-cause mortality (HR 1.58 (95% CI 1.05-
2.39)) and CVD incidence (HR 1.72 (95% CI 1.02-2.91)), and for sex with CVD 
incidence (HR 1.69 (95% CI 1.05-2.74)). The small number of events occurred despite 
the median follow-up 18.3 years (IQR 8.7-27.0) for all-cause mortality and 12.9 years 
(IQR 5.6-21.5) for CVD incidence. Low event rates are of course good for the patients, 
but does introduce limitations for epidemiological studies.  
Another limitation of the SRR analyses is that the records of causes of death and 
hospital admissions are only available in Scotland from 1981 onwards. For this reason, 
I had to restrict the study sample to patients who initiated RRT between 1981 and 
2013. Even though the characteristics of the linked cohort were similar to the total 
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cohort I expect that improvement in dialysis techniques and better availability of 
living-related donors after 1990 in Scotland (personal communication with Glasgow 
paediatric nephrologists) in part would result in lower CVD incidence compared to the 
period from 1961 to 1981. Furthermore, inclusion of more recent data is valuable as it 
reflects the current situation in clinical practice.   
8.2.7 Generalisability of SRR findings 
The findings of the SRR analysis can be extrapolated to paediatric RRT populations 
of countries with population, healthcare system and level of income similar to 
Scotland. It would be inappropriate to extrapolate the SRR findings, for example, to 
the US population because the population and healthcare system of the US is different 
from Scotland. The population of Scotland is mainly white with a very low proportion 
of black people, while the proportion of black people in the US is higher compared to 
Scotland. Previous research in adult RRT populations showed that the incidence of 
ESRD is significantly higher in black compared to white population. Scotland has a 
universal healthcare system that provides health care to all citizens of Scotland. In 
contrast, the USA has health insurance programs called Medicare and Medicaid which 
do not cover the whole US population. Approximately 16% of the US population is 
uninsured. People with and without health insurance may differ in terms of socio-
economic status and health conditions. The uninsured people are usually people who 
cannot afford insurance due to financial difficulties and therefore may be sicker 
compared to people with health insurance.  
Furthermore, it is inappropriate to extrapolate the SRR findings to European countries 
with lower income compared to Scotland, for example, to eastern European countries. 
324 
 
The ESPN/ERA-EDTA registry previously reported that an increase in public health 
expenditure was associated with a decreased mortality risk (HR per SD increase 0.69, 
95% CI 0.52-0.91) (146). Lower quality of health care system in lower income 
countries results in poorer accessibility to RRT compared to higher income countries.    
 
8.3 Implication of the findings of the thesis for clinical practice 
Implications of the ESPN/ERA-EDTA findings for clinical practice 
In this paragraph the implications of the findings of the thesis for clinical practice are 
discussed. First, the findings from the ESPN/ERA-EDTA registry have demonstrated 
a high prevalence of anaemia and its association with increased risk of all-cause and 
CV mortality. One of the main challenges in using these findings to inform clinical 
practice is the lack of evidence for the effect of treating anaemia in children receiving 
RRT to reduce the risk of CVD. The systematic review I presented in Chapter 2 
showed that there are no RCTs available showing the effect of achieving higher Hb 
levels on risk of CVD and mortality in children receiving RRT. In the absence of such 
evidence current guidelines for children receiving RRT are extrapolated from evidence 
collected in the adult RRT population. In particular, the evidence from cohorts of 
adults receiving dialysis show that each 1 g/dL decrease in mean Hb is associated with 
increased odds of LVH (OR 1.46 (95% CI not reported) and recurrent cardiac failure 
(RR 1.20 (95% CI not reported) (192). The current K/DOQI guidelines recommend 
treating children with CKD including those treated with dialysis or after kidney 
transplantation with ESA in order to achieve target Hb levels of 10-12 g/dl (73).  
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Another finding from the ESPN/ERA-EDTA analyses was the high prevalence of 
hypertension, dyslipidaemia and obesity in the young European RRT population. Even 
though this study did not find an association between these CVRFs with all-cause and 
CV mortality the high prevalence should not be neglected. It might be that these 
CVRFs have their effect on all-cause and CV mortality after longer-term follow-up 
into adulthood. This was not possible to describe within the ESPN/ERA-EDTA study 
because patients were censored when they reach 20 years of age. Previous research in 
Dutch patients who started RRT in childhood and survived into adulthood showed that 
hypertensive patients had a higher risk of all-cause and cerebrovascular mortality 
compared to non-hypertensive patients (53).  
No RCTs have been performed in children receiving RRT to demonstrate the efficacy 
of BP management in preventing CVD. Children with CKD 2-4 in the CKiD study 
who were treated with angiotensin-converting enzyme (ACE) inhibitor therapy had 
better control of BP compared to patients who did not receive these classes of agents 
(193). Research in general paediatric population showed that ACE inhibitor therapy 
resulted in reduction of LVH (194). Based on these data K/DOQI recommends ACE 
inhibitors as a preferred antihypertensive agents in children with ESRD and target BP 
should be lower than the 90th percentile for age, sex and height (73).  
In terms of treatment of dyslipidaemia, there is no evidence in the literature of the 
influence of statin treatment on the development of CVD in children with ESRD. A 
recent meta-analysis showed that in adults with CKD stage 2-4 statin treatment seems 
to reduce the risk of CVD, but not in dialysis populations (195). This might be 
explained by the fact that intimal atherosclerosis, which is most likely to be influenced 
by lipid levels is an important risk factor for CVD in patients with mild to moderate 
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CKD. Medial calcification becomes an important risk factor for CVD in advanced 
stages of CKD and is influenced by factors other than lipids levels (196). K/DOQI 
guideline recommends screening for dyslipidaemia in children with CKD (including 
those treated with chronic dialysis and kidney transplantation) to introduce dietary 
recommendation without initiating treatment with statins (197).  
The ESPN/ERA-EDTA analyses found that underweight patients have a higher risk of 
all-cause mortality compared to non-underweight patients. The aetiology of 
malnutrition in RRT patients is complex and may include many factors. For example, 
low food intake may result from anorexia, nausea and vomiting due to uraemic toxicity 
(152, 198). In addition, bacterial contamination of the dialysis liquid is associated with 
chronic inflammation (199) which in turn is associated with malnutrition and protein-
energy wasting (152). Research in adults receiving dialysis showed that improvement 
in the bacterial quality of the dialysate is associated with improved nutritional status 
(200). Therefore, these findings imply that adjusting dietary and caloric intake is 
needed as well as control of inflammatory and infectious complications in order to 
maintain BMI and normal growth in children receiving RRT. The NAPRTCS registry 
showed that growth failure in the paediatric RRT population is associated with 
increased mortality. The authors reported that mortality risk was twice as high in 
children with a height SDS<2.5 compared with those of normal height (159).  
Implications of the SRR findings for clinical practice 
The SRR findings show that the incidence of CVD is high among paediatric RRT 
patients in Scotland. Therefore, efforts should be made to minimize risk factors for 
CVD in this population. Most of the CVRFs in the general population, including 
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hypertension, dyslipidemia, obesity and anaemia are also risk factors for CVD in RRT 
patients. CVD risk reduction strategies should include: lipid management, control of 
BMI, BP and Hb level in paediatric RRT population.  
The SRR analyses showed an increased risk of mortality in patients receiving dialysis 
compared to patients following kidney transplantation. The beneficial effect of kidney 
transplantation on the quality of life and survival of patients with ESRD implies that 
efforts should be made to increase kidney donation so that more patients could be pre-
emptively transplanted or receive a kidney transplant following period of dialysis. 
Policy makers and clinicians should encourage people to donate their kidneys by 
informing the public about the need for living donors, and the living donation process. 
Having accurate and detailed information makes a person more likely to become a 
donor when they hear that a friend or family member requires a kidney transplantation. 
Efforts also should be made to increase the number of deceased donor kidneys by 
encouraging people to register as donors.   
The SRR findings also showed that despite the beneficial effect of kidney 
transplantation mortality rate is still higher among transplanted patients compared to 
the general population. To improve patient and graft survival among transplanted 
patients it is important to monitor graft function regularly by performing screening for 
eGFR level. Detecting kidney allograft dysfunction as soon as possible will allow 
timely diagnosis and treatment that may improve outcomes.  
The SRR findings showed that the risk of mortality was the highest among the 
youngest RRT patients (<2 years old) who are technically challenging to perform 
dialysis or a kidney transplantation due to small body size. Therefore, it is particularly 
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important for the youngest patients to manage PRD. Screening for eGFR, proteinuria 
and microhaematuria may result in early diagnosis and treatment of PRD that may be 
beneficial. Furthermore, it is important to control for complications of RRT (infection) 
and comorbidities in order to allow them the best chance of surviving to receive a 
kidnay transplant. An international collaboration between the IPPN, ESPN/ERA-
EDTA and the ANZDATA registries reported a five-year survival of 76% and a 
transplant probability of 55% among patients <2 years of age. The authors concluded 
that relatively good medium-term survival may be achieved in patients <2 years of age 
despite the high presence of comorbidities (73%) (169).  
8.4 Future research 
The results of this thesis have added novel and important knowledge to the existing 
literature describing CVRF prevalence, CVD incidence, all-cause and CVD mortality 
in patients who initiated RRT in childhood, but there is a scope for future research that 
is discussed in this section.  
Ideally, RCTs would be performed to inform evidence based guidelines for treatment. 
However, conducting placebo controlled RCTs would not be ethical. The unethical 
issue of placebo controlled RCT are based on the 1964 Declaration of Helsinki of the 
World Medical Association that the interest of patients must come before the interests 
of science and society (201). For example, it would be unethical to use a placebo in a 
trial of anaemia management because treatments for anaemia that are known to be 
effective to improve quality of life and reduce mortality in adult RRT population 
already exist (202). Instead, future trials could potentially test the effect of different 
doses of ESA on CVD as well as on Hb. Intermediate outcomes such as LVH rather 
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than hard CVD outcomes would be more feasible for conducting RCTs. The main 
advantage of RCTs over nonexperimental studies is their ability to control 
confounding by indication (203). Confounding by indication is a bias that occurs from 
the differences in prognosis between patients given different therapies in normal 
clinical practice. It is likely that higher ESA doses will be offered to patients with more 
severe anaemia. Even if the higher ESA doses are highly effective, the mortality rate 
among those who receive it could be greater than that among those receiving lower 
ESA doses, because those who get the higher dose are at the highest risk. This problem 
can be controlled by the random assignment that is possible in a RCT (203). 
Despite the strengths of RCTs there are some important limitations. As ESRD is rare 
in children it would be challenging to recruit a sufficiently large sample size to provide 
meaningful results. Furthermore, paediatric patients receiving RRT are heterogeneous 
in terms of underlying PRD. It will be extremely difficult to include a sufficient 
number of patients with particular PRD diagnoses due to very low number of patients 
within specific PRD. In addition, RCTs are often limited to selected populations of 
patients from unrepresentative centres of care. Multi-centre trials with long follow-up 
periods are required for adequate numbers of outcomes which will be very expensive.  
Taking into account the limitations of RCTs, the most feasible study design in this 
population of patients at present is to perform retrospective cohort studies using 
routinely collected data from national and international renal registries linked to 
hospital admission and mortality records where this is feasible. The benefit of using 
registry data is that in most cases there is national coverage and these studies are 
usually less expensive compared to RCTs. This will lead to quicker results because 
there is no need to wait until CVD occurs. Furthermore, registry studies might be able 
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to provide long follow-up if the registry has existed for a long time. However, this can 
also mean that the data collected in earlier years are not always representative for 
current clinical practice due to change of treatment during follow-up period. Thus, I 
recommend that retrospective cohort studies using national or sub-sets of international 
registry data that can be linked to morbidity and mortality data are used to validate and 
extend the findings of this thesis. In addition, more and better quality data are needed 
in order to improve the quality of future studies (recommendations for that are 
described in section 7.6). However, realistically, this study design is also challenging 
to perform. Even one of the largest renal registries such as the ESPN/ERA-EDTA not 
able to fulfil the requirements for this study design as it lacks the access to morbidity 
data for all participating countries. It might be possible to undertake a study in the sub-
group of European renal registries that are able to link registry and routine hospital and 
death record data. Methods for analysing such data without needing data to leave the 
country of origin are increasingly being used to avoid the problems of international 
data sharing (204). The USRDS registry might be a potentially good source for future 
research as this registry has access to morbidity data. I identified one study from this 
registry that described incidence of cardiac related events in dialysis patients younger 
than 20 years old (164).  
Reverse causality 
The ESPN/ERA-EDTA findings of the association of anaemia with CV mortality 
might be due to reverse causality. Reverse causality refers to a causal relationship that 
is opposite to what is apparent, e.g., while the observed causal relationship is that F 
causes Y, the true, actual relationship is that Y causes F (62). It is possible that anaemia 
is a risk factor for CV mortality in patients with ESRD. However, it is also possible 
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that CVD causes anaemia. In my analysis of the ESPN/ERA-EDTA data I partly 
addressed this issue of reverse causality by performing a sensitivity analysis excluding 
CVRFs measurements taken in the last six months before death. The results of 
sensitivity analysis were similar to the main results, which means that the association 
is not entirely explained by reverse causality.   In order to investigate weather anaemia 
is a true risk factor for CVD future prospective cohort studies should include general 
paediatric populations who are free from CVD and anaemia at the time of the study 
and follow them up until occurrence of CVD with regular screening for Hb levels. This 
would allow to explore whether anaemia preceded CVD or CVD caused anaemia.   
Another question that remained unanswered within this thesis and could be addressed 
by future studies is whether hypertension, dyslipidaemia and obesity play a role in risk 
of CVD in later life after patients who receive RRT as children reach adulthood. The 
ESPN/ERA-EDTA registry is planning to link paediatric and adult parts of the registry 
which will enable to investigate the longer-term effects of hypertension, obesity and 
dyslipidaemia.  
There is also scope for future research about paediatric patients receiving RRT in 
lower-income countries. The studies that I identified in the literature reviews are from 
middle-income and high-income countries as well as included in my analyses of the 
ESPN/ERA-EDTA and the SRR. This means that the information that is currently 
available about children receiving RRT could be biased towards underestimation of 
mortality due to inclusion of wealthier countries. A few studies available in lower-
income countries, where renal registries are often lacking, confirm these disparities. In 
two tertiary hospitals in Vietnam between 2001 and 2005, only 27% of admitted 
paediatric ESRD patients received RRT. The remainder were treated conservatively 
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due to a lack of financial resources (205). In a tertiary hospital in South-West Nigeria 
the median survival time of 51 admitted paediatric ESRD patients was only 47 days 
between 2005 and 2012. Of these, 82% had received an acute session of dialysis. 
However, chronic RRT could not be carried out after discharge due to financial 
constraints, often resulting in death within months after diagnosis of ESRD (206). In 
a tertiary care hospital in India, 21% of admitted paediatric ESRD patients were treated 
conservatively and 40% opted against further treatment due to the high cost of RRT, 
resulting in death (207). In addition, differences in a country’s ability to accept and 
successfully treat children may be one of the main reasons of disparities in incidence 
of RRT. Lower-income countries have a lower incidence of RRT compared to middle- 
and higher-income countries as non-acceptance to RRT results in an underestimation 
of the incidence of RRT. To illustrate, the incidence of RRT in Nigeria for the years 
2009-2012 among children aged≤14 years was 4.4 per MARP (206), while in Europe 
the incidence of RRT in patients aged 0-14 years was 6.5 per MARP in 2007 (26). 
Furthermore, country differences in transplant rates, donor source, and time on the 
transplant waiting list may also affect patient survival indirectly. To conclude, data 
from middle- and lower-income countries remain scarce. Collecting global data for the 
paediatric RRT population is essential to determine international disparities in access 
to RRT and mortality rates and provide evidence for policy change for countries of 
different levels of income.  
8.5 Recommendations for the ESPN/ERA-EDTA and the SRR registries  
In this section recommendations for enhancing the data collected within the 
ESPN/ERA-EDTA and the SRR are discussed. To date, both registries provide the 
best quality of data available on patients receiving RRT for ESRD in Scotland and in 
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Europe. However, during the data analyses process I have encountered some 
limitations within both registries that could be addressed to improve the quality of 
future studies. First, as retrospective cohort studies rely on existing records stored in 
the registry database, important information may be missing or unavailable resulting 
in selection bias. Records with missing data had to be excluded from my analyses of 
the ESPN/ERA-EDTA and the SRR. There were large proportions of missing data on 
CVRFs within the ESPN/ERA-EDTA registry. Only a small number of patients had 
CVRFs measured at the start of RRT, which made it impossible to select a sufficient 
number of incident RRT patients for my analyses. Therefore, the ESPN/ERA-EDTA 
registry should collect CVRFs data at the start of RRT for all patients. This will allow 
researchers to select incident RRT patients and minimise incident-prevalent bias in 
future studies. However, it is still under debate whether start of RRT should be 
considered as the first day of RRT initiation. Some studies in adult RRT populations 
recommend to measure CVRFs at three months after start of RRT. It is because during 
the first three month after start of RRT the body is adjusting for new therapy, therefore, 
CVRFs may fluctuate a lot. There are no studies in paediatric RRT populations 
describing the changes of CVRFs over time after start of RRT. Furthermore, there are 
no studies exploring whether CVRFs measurements taken at the start of RRT or later 
play a significant role in prediction of mortality and CVD incidence. Therefore, I 
recommend for the ESPN/ERA-EDTA registry to collect CVRFs data taken at the start 
of RRT and monthly within the first year after start of RRT to explore these 
uncertainties. Furthermore, more data on CVRFs are needed. For example, data on 
serum Ca, serum P and PTH are available for a very limited number of patients 
registered in the ESPN/ERA-EDTA registry. For that reason, it was not possible to 
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explore whether abnormal mineral metabolism is significant risk factor for CV 
mortality in paediatric RRT patients within my thesis. Also, data on lipids, Hb and BP 
were incomplete with the registry, which might have biased my results. Therefore, the 
ESPN/ERA-EDTA registry should collect data on Hb, BP, lipids, serum Ca, P and 
PTH for all patients in the registry to minimise bias in future studies and to be able to 
explore remaining research questions.  
Second, the methods of CVRF measurement in the ESPN/ERA-EDTA is not provided 
by participating centres. For example, different centres may use different methods of 
Hb, BP, lipids and BMI measurements which may introduce misclassification bias in 
the study.  
To address the issue regarding the lack of data on methods of CVRFs measurements 
the registry could either recommend the method of CVRFs measurement that 
participating centres should use in order to provide their results to the registry. 
Alternatively a sub-set of samples from each centre could be measured at a central 
laboratory as well as at the local laboratory in order to calibrate measurements from 
different laboratories against each other. However, both requirements could be 
challenging to fulfil for participating centres. The most feasible recommendation 
would be for the registry to gather information about the methods of measurements so 
attempts can be made to correct for different methods in future analyses. 
One of the ways to improve the data quality is to show paediatric nephrologists, policy 
makers and funders the importance of the research that is based on the routine data 
collected by the renal registries. Paediatric nephrologists should be encouraged by 
disseminating the findings of the research to them. They could be expected to be more 
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enthusiastic in providing more and better quality data to the registry if they know that 
the data are going to be used for research that eventually will improve the health of 
their patients. Policy makers and funders should also be encouraged to promote the 
collection of more data by informing them that data collection enhancement could 
provide higher quality information to patients and parents as well as contributing to 
higher quality evidence on the prevention of CVD in this population.  
The findings of my thesis have been disseminated to paediatric nephrologists in 
Scotland. I have presented the findings of the ESPN/ERA-EDTA analyses of the 
prevalence of CVRFs at the Scottish Renal Association (SRA) annual meeting in 
Dundee on the 2nd October 2015 (oral presentation). I presented the SRR findings in 
the SRA annual meeting in Inverness on the 28th October 2016 and during a 
multicentre meeting combining paediatric nephrologists from Glasgow, Newcastle and 
Belfast held in Glasgow on the 31st May 2017 (both oral presentations). Furthermore, 
I will present the findings of the SRR analyses in an oral presentation at the upcoming 
annual ESPN/ERA-EDTA congress in Glasgow on the 7th September 2017.  
8.6 Conclusion  
My analyses of the ESPN/ERA-EDTA data show that the prevalence of anaemia, 
hypertension, dyslipidaemia and hypertension is high among young European patients 
receiving RRT. Being anaemic/underweight is associated with increased risk of all-
cause/CV mortality. The SRR analyses showed that CVD is common among patients 
who initiated RRT in childhood. Younger age at start of RRT, male sex, PRD other 
than CAKUT or GN and receiving dialysis rather than a kidney transplantation are 
associated with increased risk of all-cause mortality/CVD in patients who initiated 
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RRT in childhood. These findings highlight the need for further research to clarify 
whether treatment of CVRFs is associated with reduced risk of CVD and mortality in 
this population. RRT for ESRD in children is a rare condition and is challenging to 
study because of the small sample size and low events rate. This means that future 
studies should use multi-national renal registries data with long follow-up period and 
with links to morbidity data where possible. Renal registries should attempt to further 
enhance the quality of their data to minimise bias in future research. Collecting global 
data on paediatric patients receiving RRT is essential as a first step in addressing 
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MEDLINE search strategy (1946 to July Week 2 2015)  
1. (chronic kidney or chronic renal or CKD or impaired renal function or end stage 
renal disease or ESRD or renal replacement therapy or RRT or dialysis or hemodialysis 
or haemodialysis or peritoneal dialysis or renal transplantation or kidney 
transplantation).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
2. exp renal replacement therapy/ or exp renal dialysis/ or exp kidney transplantation/ 
3. exp renal insufficiency, chronic/ or exp kidney failure, chronic/ 
4. 1 or 2 or 3 
5. (death or mortality or all- cause mortality or all-cause death or overall mortality or 
overall death).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
6. (cardiovascular mortality or cardiovascular death or cerebrovascular mortality or 
cerebrovascular death).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
7. exp Mortality/ 
8. exp Cardiovascular Diseases/ or exp Cerebrovascular Disorders/ or cerebrovascular 
morbidity.mp. or cardiovascular morbidity.mp. 
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9. 5 or 6 or 7 or 8 
10. (cardiovascular risk factors or risk prediction score or risk prediction model).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
11. exp risk factors/ 
12. exp hypertension/ or exp hypertension, renal/ or (hypertension or blood 
pressure).mp . 
13. (Obes$ or overweight or BMI or body mass index or underweight).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
14. exp Obesity/ or exp Overweight/ or exp Body Weight/ 
15. (anemia or anaemia or target hemoglobin or haemoglobin or iron deficiency).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
16. exp Anemia/ 
17. (dyslipidemia or dyslipidaemia or hyperlipidemia or hyperlipidaemia or 
dyslipoproteinemia or dyslipoproteinaemia or abnormal lipid profile or 
hypercholesterolaemia or hypercholesterolemia or cholesterol or triglycerides).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
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keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
18. exp dyslipidemias/ or exp hyperlipidemias/ 
19. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20. (child* or paediatric or pediatric or teen* or adolescen* or young adult*).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
21. exp Child/ 
22. 20 or 21 
23. 4 and 9 and 19 and 22 



















Anaemia N (%) 
0 no no no no no 5 (0.9) 
1 yes     28 (5.0) 
  yes    15 (2.7) 
    yes  1 (0.2) 
     yes 0 
   yes   0 
Total      44 (7.9) 
2 yes yes    155 (27.8) 
  yes   yes 16 (2.9) 
 yes    yes 12 (2.2) 
 yes   yes  10 (1.8) 
  yes  yes  6 (1.1) 
 yes  yes   2 (0.4) 
    yes yes 1 (0.2) 
Total      202 (36.3) 
3 yes yes   yes 156 (28.0) 
 yes yes  yes  61 (11.0) 
 yes yes yes   13 (2.3) 
 yes   yes yes 7 (1.3) 
  yes  yes yes 3 (0.5) 
 yes  yes  yes 1 (0.2) 
Total      241 (43.3) 
4 yes yes  yes yes 51 (9.2) 
 yes yes yes  yes 14 (2.5) 
















Anaemia N (%) 
0 no no no no no 4 (0.5) 
1 yes     63 (8.5) 
  yes    61 (8.3) 
     yes 2 (0.3) 
    yes  2 (0.3) 
   yes   1 (0.1) 
Total      129 (17.5) 
2 yes yes    195 (26.5) 
 yes   yes  47 (6.4) 
  yes  yes  19 (2.6) 
 yes    yes 16 (2.2) 
  yes   yes 13 (1.8) 
  yes yes   1 (0.1) 
 yes  yes   1 (0.1) 
Total      292 (39.6) 
3 yes yes  yes  189 (25.6) 
 yes yes   yes 64 (8.7) 
 yes   yes yes 9 (1.2) 
  yes  yes yes 4 (0.5) 
 yes yes yes   2 (0.3) 
Total      268 (36.4) 
4 yes yes  yes yes  







Figure 1. Adjusted Log minus log plot for the association between hypertension 





Figure 2. Adjusted Log minus log plot for the association between hypertension 




Table 3. Hazard ratios for the association of individual CVRFs with all-cause 
mortality  
CVRFs N/n Crude 
 HR and 95% CI 
Adjusted*  
HR and 95% CI  
Overweight/Obesity    
Reference group 5222/249 1 1 
Overweight/Obese  2224/72 0.62 (0.48-0.81) 1.11 (0.85-1.47) 
Underweight     
Reference group 7125/ 273 1 1 
Underweight  321/ 48 5.22 (3.84-7.09) 1.81 (1.30-2.53) 
Hypertension  First 2.5 years of follow-up 
Reference group 1000/ 12 1 1 
Hypertensive 3840/ 62 1.29 (0.69-2.39) 1.10 (0.57-2.12) 
  2.5 to 6 years of follow-up 
Reference group 1000/ 12 1  
Hypertensive 3840/ 26 0.59 (CI 0.29-1.19) 0.64 (0.30-1.36) 
  After 6 years of follow-up 
Reference group 1000/ 7 1 1 
Hypertensive 3840/ 43 1.97 (0.84-4.64) 1.82 (0.94-3.52) 
Anaemia    
Reference group 3649/ 84 1 1 
Anaemic 2049/ 130 3.62 (2.74-4.77) 2.19 (1.64-2.93) 
Dyslipidaemia     
Reference group 204/ 2 1 1 
Dyslipidaemic 1434/ 41 3.64 (0.87-15.18) 2.09 (0.46-9.44) 
N-number of patients, n-number of deaths, HR-hazard ratio, CI-confidence interval. *Adjusted for age, 
sex, PRD, type and duration of RRT and European region, associations of hypertension with all-cause 
and dyslipidaemia with all-cause mortality were additionally adjusted for overweight/obesity. 




Table 4. Hazard ratios for the association of individual CVRFs with CV mortality  
CVRFs N/n Crude 
HR and 95% CI 
Adjusted*  
HR and 95% CI  
Overweight/Obesity    
Reference group 5222/57 1 1 
Overweight/Obese  2224/17 0.66 (0.39-1.12)  1.44 (0.81-2.55)  
Underweight     
Reference group 7125/ 61 1 1 
Underweight  321/ 13 5.39 (2.97-9.79)  1.85 (0.97- 3.52)  
Hypertension  First 2.5 years of follow-up 
Reference group 1000/ 2 1 1 
Hypertensive 3840/ 12 1.57 (0.35-7.04)  1.89 (0.40-8.90)  
  After 2.5 years of follow-up 
Reference group 1000/ 7 1  
Hypertensive 3840/ 18 0.71 (0.29-1.70)  0.69 (0.28-1.75)  
Anaemia    
Reference group 3649/ 13 1 1 
Anaemic 2049/ 26 4.37 (2.25- 8.49)  2.55 (1.27-5.12)  
N-number of patients, n-number of deaths, HR-hazard ratio, CI-confidence interval. *Adjusted for age, 
sex, PRD, type and duration of RRT and European region, associations of hypertension with CV 
mortality was additionally adjusted for overweight/obesity. Reference group is the group of patients 









Table 5. Prevalence of CVRFs for patients included in primary analyses 
compared with patients included in sensitivity analyses 




Dyslipidaemia 87.5 87.6 




Overweight/obesity 29.9 29.9 













Table 6. Hazard ratios for the independent association of CVRFs with all-cause mortality for patients included in primary analyses 
compared with patients included in sensitivity analyses 
  Cohort primary analysis  Cohort sensitivity analysis 
CVRFs N/n Unadjusted HR 
and 95% CI 
Adjusted HR 
and 95% CI  
N/n Unadjusted HR 
and 95% CI 
Adjusted HR and 
95% CI  
Non 
Overweight/Obese  
5222/249 1 1 5163/190 1 1 








Non Underweight  7125/ 273 1 1 7064/212 1 1 








Hypertension  First 2.5 years of follow-up    
Non Hypertensive 1000/ 12 1 1 998/10 1 1 








  2.5 till 6 years of follow-up    
Non Hypertensive 1000/ 12 1 1 998/11 1 1 
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  After 6 years of follow-up    
Non Hypertensive 1000/ 7 1 1 998/6 1 1 








Non Anaemic 3649/ 84 1 1 3633/68 1 1 








Non Dyslipidaemic 204/ 2 1 1 203/1 1 1 













Table 7. Hazard ratios for the independent association of CVRFs with CV mortality for patients included in primary analyses 
compared with patients included in sensitivity analyses. 
  Cohort primary analyses  Cohort sensitivity analysis 
CVRFs N/n Unadjusted HR and 
95% CI 
Adjusted HR 
and 95% CI  
N/n Unadjusted HR 
and 95% CI 




5222/57 1 1 5163/44 1 1 








Non Underweight  7125/ 61 1 1 7064/44 1 1 








Hypertension  First 2.5 years of follow-up    
Non Hypertensive 1000/ 2 1 1 998/1 1 1 








  After 2.5 years of follow-up    
Non Hypertensive 1000/ 7 1 1 998/7 1 1 
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3821/18 0.71 (0.29-1.70) 
p=0.44 
0.69 (0.27-1.75) p=0.44 
Non Anaemic 3649/ 13 1 1 3633/9 1 1 































Dyslipidaemia     
transplanted 18.4 67.7 75.9 27.4 
dialysis 81.6 32.3 24.1 72.6 
Hypertension     
transplanted 32.5 71.1 79.3 45.4 
dialysis 67.5 28.9 20.7 54.6 
Anaemia     
transplanted 21.1 53.2 74.4 47.7 
dialysis 78.9 46.8 25.6 52.3 
BMI     
transplanted 28.5 53.6 72.5 42.0 
dialysis 71.5 46.4 27.5 58.0 
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MEDLINE search strategy  
1. (end stage renal disease or ESRD or renal replacement therapy or RRT or dialysis 
or hemodialysis or haemodialysis or peritoneal dialysis or renal transplantation or 
kidney transplantation).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading]  
2. exp Kidney Failure, Chronic/ or exp Renal Replacement Therapy/ or exp Kidney 
Transplantation/ or exp Renal Dialysis/  
3. 1 or 2  
4. (child* or paediatric or pediatric or teen* or adolescen*).mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading]  
5. exp Child/ 
6. 4 or 5 
8. (survival or long-term survival or death or mortality or all- cause mortality or all-
cause death or overall mortality or overall death).mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword, floating subheading] 
9. exp survival/ 
10. (cardiovascular disease incidence or cardiovascular disease or cardiovascular death 
or cardiovascular mortality or cerebrovascular disease or cerebrovascular death or 
cerebrovascular mortality or cardiac death or cardiac events).mp. [mp=title, abstract, 
367 
 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading] 
11. exp cardiovascular disease/ 
12. 8 or 9 or 10 or 11 
13. 3 and 6 and 12 

























Figure 8. Log-log plot for the association of pattern of RRT modality with all-









Figure 9. Log-log plot for the association of age at start of RRT with CVD 
incidence  
  































Table 9. Crude and adjusted HRs and 95% CIs of the associations between age at start of RRT, sex, PRD and type of RRT with CVD in the 
sensitivity analyses 
Variable Primary analysis* Secondary analysis** 
 Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Age at start of RRTa     
0-<2 0.90 (0.45-1.79) 1.14 (0.55-2.37) 0.58 (0.21-1.61) 0.77 (0.26-2.25) 
2-<6 0.72 (0.42-1.23) 0.92 (0.52-1.65) 0.48 (0.21-1.14) 0.74 (0.29-1.82) 
6-<12 0.54 (0.35-0.84) 0.61 (0.38-0.96) 0.66 (0.38-1.16) 0.79 (0.44-1.43) 
12-18 
 
1.00 1.00 1.00 1.00 
Sexb     
Males 1.35 (0.96-1.87) 1.43 (1.01-2.02) 1.23 (0.78-1.95) 1.61 (1.01-2.56) 
Females 
 
1.00 1.00 1.00 1.00 
PRDc     
GN 1.02 (0.65-1.60) 0.96 (0.61-1.53) 1.33 (0.87-2.44 1.23 (0.67-2.29) 
Other 1.13 (0.78-1.64) 1.22 (0.83-1.79) 1.45 (0.88-2.36) 1.76 (1.05-2.95) 
CAKUT 1.00 1.00 1.00 1.00 
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Variable Primary analysis* Secondary analysis** 
 Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Initial type of RRTd     
HD 1.59 (0.87-2.87) 1.19 (0.64-2.22) 2.75 (1.17-6.47) 1.90 (0.79-4.52) 
PD 1.15 (0.63-2.08) 1.52 (0.82-2.81) 1.38 (0.57-3.32) 1.56 (0.63-3.88) 
Pre-Tx 
 
1.00 1.00 1.00 1.00 
Type of RRT during follow-upe     
PD+Tx- 2.94 (1.35-6.36) 3.82 (1.61-9.07) 1.77 (0.71-4.41) 5.86 (2.02-17.04) 
HD+Tx- 2.19 (1.00-4.79) 2.49 (1.08-5.73) 1.97 (0.94-4.12) 6.68 (2.77-16.12) 
Pre-Tx 0.80 (0.45-1.42) 0.82 (0.45-1.47) 0.55 (0.24-1.28) 0.69 (0.29-1.61) 
D+Tx+ 1.00 1.00 1.00 1.00 
PRD-primary renal disease; GN-glomerulonephritis, CAKUT-congenital anomalies of kidney and urinary tract; RRT-renal replacement therapy; HD-haemodialysis; PD-peritoneal dialysis; 
Pre-Tx-pre-emptively transplanted; HR-hazard ratio, CI-confidence interval. PD+Tx- started on PD and not transplanted during follow up, HD+Tx- started on HD and not transplanted 
during follow-up, D+Tx+ started on dialysis and received a transplant during follow-up. Only patients with complete data included in unadjusted and adjusted analyses (N=378). *Broad 
definition, CVD events N=142; ** Strict definition, CVD events N=79; Adjusted for a sex, PRD, type of RRT at start and period of start of RRT; b PRD, type of RRT at start and period of 




The RECORD statement – checklist of items that should be reported in 








 1 RECORD 1.1: The type of data used 
should be specified in the title or abstract. 
When possible, the name of the databases 
used should be included. 
 
RECORD 1.2: If applicable, the 
geographic region and timeframe within 
which the study took place should be 
reported in the title or abstract. 
 
RECORD 1.3: If linkage between 
databases was conducted for the study, this 
should be clearly stated in the title or 
abstract. 
Titles of 




2  Chapter 5, 
section 5.1 




4  Chapter 5, 
section 5.4 
Setting 5  Chapter 5, 
section 5.2 
Participants 6 RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided.  
 
RECORD 6.2: Any validation studies of 
the codes or algorithms used to select the 
population should be referenced. If 
validation was conducted for this study and 
not published elsewhere, detailed methods 
and results should be provided. 
 
RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical display to 





including the number of individuals with 
linked data at each stage. 
Variables 7 RECORD 7.1: A complete list of codes 
and algorithms used to classify exposures, 
outcomes, confounders, and effect 
modifiers should be provided. If these 
cannot be reported, an explanation should 
be provided. 
Chapter 5, 






8  Chapter 5, 
section 5.2 
Bias 9   




11   
Statistical 
methods 






 RECORD 12.1: Authors should describe 
the extent to which the investigators had 
access to the database population used to 
create the study population. 
 
RECORD 12.2: Authors should provide 
information on the data cleaning methods 
used in the study. 
Chapter 5, 
section 5.3 
Linkage  RECORD 12.3: State whether the study 
included person-level, institutional-level, 
or other data linkage across two or more 
databases. The methods of linkage and 
methods of linkage quality evaluation 
should be provided. 
Chapter 5, 
section 5.3 
Participants 13 RECORD 13.1: Describe in detail the 
selection of the persons included in the 
study (i.e., study population selection) 
including filtering based on data quality, 
data availability and linkage. The selection 
of included persons can be described in the 
























17  Chapter 7, 
section 7.1.5 




Limitations 19 RECORD 19.1: Discuss the implications 
of using data that were not created or 
collected to answer the specific research 
question(s). Include discussion of 
misclassification bias, unmeasured 
confounding, missing data, and changing 
eligibility over time, as they pertain to the 


























 RECORD 22.1: Authors should provide 
information on how to access any 
supplemental information such as the study 




*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, 
Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee.  The 
REporting of studies Conducted using Observational Routinely-collected health Data 
(RECORD) Statement.  PLoS Medicine 2015; in press. 
 




PRIMA 2009 CHECKLIST 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  47 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  47 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
48 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
48 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
50 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
49 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
335 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
51 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
51 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis.  
52 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Not 
followed 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
52 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
52 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
Not 
followed 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
52-55 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
56-66 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 




Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
94,97,100 




Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  101-115 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
Not-
followed 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
119-121 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
122 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications 
for future research.  
123 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); 




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  





This application should be completed and sent to NSS.isd-
ScotHealthAudits@nhs.net or 
Scottish Healthcare Audits, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
EH12 9EB 
 
1. Please select the project you require information on: 
 
 JAG-Global Rating System 
(JAG/GRS) 
 
 Scottish Arthroplasty Project (SAP) 
 
 Scottish ECT Accreditation Network 
(SEAN) 
 
 Scottish Multiple Sclerosis Register 
(MS)  
 
 Scottish Stroke Care Audit (SSCA) 
   
 The Musculoskeletal Audit (MSk)  
 
 Scottish Audit of Surgical Mortality (SASM)   
 
 Scottish Intensive Care Society Audit Group 
 (SICSAG) 
 
+  Scottish Renal Registry (SRR) 
 




2. Details of person requesting data and who will be responsible for 
them. 
 
Name:  Dinara Galiyeva                          Designation: PhD student 
 
Project:   The prevalence and patterns of cardiovascular risk factors and 
their association with all-cause mortality, cardiovascular mortality and 
cardiovascular morbidity in people who develop end stage renal disease in 
childhood.                                                    
 
Place of Work: The University of Edinburgh, Usher Institute of Population 
Health Sciences and Informatics 
 
Postal Address: The University of Edinburgh, Old medical school, Teviot 
place, Edinburgh                                 Post code:  EH8 9AG                                     
 
Tel No: +44 7557850375                                    Fax No:-   
 
Email: Dinara.Galiyeva@ed.ac.uk  
 
3. Details of other staff involved in the project who will have access to 
confidential data 
 
Name: Professor Sarah Wild       Designation: Professor of Epidemiology 




Project:   The prevalence and patterns of cardiovascular risk factors and 
their association with all-cause mortality, cardiovascular mortality and 
cardiovascular morbidity in people who develop end stage renal disease in 
childhood.                                                                                       
 
Place of Work: The University of Edinburgh, Usher Institute of Population 
Health Sciences and Informatics 
 
Postal Address: The University of Edinburgh, Old medical school, Teviot 
place, Edinburgh                                                                Post code: EH8 
9AG                                                                        
 
Tel No:  0131 651 1630                                 Fax No:  0131 650 6868 
 
Email: Sarah.Wild@ed.ac.uk  
 
Please add details of any other colleagues who will be involved on 
the reverse of this page or below if you are submitting this document 
electronically.  
 
Name: Dr Nynke Halbesma       Designation: Research fellow  
 
Project:   The prevalence and patterns of cardiovascular risk factors and 
their association with all-cause mortality, cardiovascular mortality and 
cardiovascular morbidity in people who develop end stage renal disease in 
childhood.        
 
Place of Work: The University of Edinburgh, Usher Institute of Population 
Health Sciences and Informatics  
Postal Address: The University of Edinburgh, Old medical school, Teviot 
place, Edinburgh                                                                Post code: EH8 
9AG                                                                        
 





Name: Dr Caroline Jackson       Designation: Chancellor’s Fellow 
 
Project:   The prevalence and patterns of cardiovascular risk factors and 
their association with all-cause mortality, cardiovascular mortality and 
cardiovascular morbidity in people who develop end stage renal disease in 
childhood.       
 
Place of Work: The University of Edinburgh, Usher Institute of Population 




Data Requested:  
Please be specific. We will try to provide exactly the information you want 
but this is sometimes very difficult where a request has not been carefully 
specified.  Where linkage is to be requested, which datasets will be 
included? 
 
Informal prior discussion with a member of the relevant steering group is 
usually helpful.  
 
The population of interest is people who developed end-stage renal 
disease in childhood whose data are stored within Scottish paediatric and 
adult renal registries. Outcomes of interest are all-cause and cause-
specific mortality and incidence of cardiovascular disease derived from the 
most recent linkage of SRR to death and hospital admission records. 
Additional data (eg. Lipids fractions measurements, records of 
antihypertensive medication, ESA and lipid lowering therapy may be 
required from the paediatric renal register (Strathclyde Electronic Renal 
Patient Record (SERPR)).  
 
The list of variables requested from renal registries is: 
 





- Scottish Index of Multiple Deprivation or historical postcodes so this 
can be derived by lookup tables 
- Health Board or historical postcodes so this can be derived by 
lookup tables 
 
-primary renal disease 
-eGFR and dates of measurement 
 
-date of start of renal replacement therapy (RRT) 
 
-type of RRT at start 
 
Postal Address: The University of Edinburgh, No.9 Edinburgh Bioquarter, 
9 Little France Road, Edinburgh                                       
Post code: EH16 4AX                                                                        
 
Tel No:  -       Fax No:  - 
 





-changes in RRT and dates of measurement all on the same row 
 
- height and dates of measurement for value recorded closest to start of 
RRT and subsequent annual measurements, in case if the closest to 
starting RRT measurement will not be available within SRR we would 
kindly ask to check if SERPR dataset might provide this measurement 
 
- dry body weight and dates of measurement for value recorded closest to 
start of RRT and subsequent annual measurements, in case if the closest 
to starting RRT measurement will not be available within SRR we would 
kindly ask to check if SERPR dataset might provide this measurement 
 
-BMI and dates of measurement for value recorded closest to start of RRT 
and subsequent annual measurements, in case if the closest to starting 
RRT measurement will not be available within SRR we would kindly ask to 
check if SERPR dataset might provide this measurement 
 
-pre- and post-dialysis systolic and diastolic blood pressure and dates of 
measurement for value recorded closest to start of RRT and subsequent 
annual measurements, in case if the closest to starting RRT measurement 
will not be available within SRR we would kindly ask to check if SERPR 
dataset might provide this measurement 
 
-total cholesterol and dates of measurement for value recorded closest to 
start of RRT and subsequent annual measurements, in case if the 
measurements will not be available within SRR we would kindly ask to 
check if SERPR dataset might provide these measurements 
 
-triglycerides and dates of measurement for value recorded closest to start 
of RRT and subsequent annual measurements, in case if the 
measurements will not be available within SRR we would kindly ask to 
check if SERPR dataset might provide these measurements 
 
-HDL-cholesterol and dates of measurement for value recorded closest to 
start of RRT and subsequent annual measurements, in case if the 
measurements will not be available within SRR we would kindly ask to 
check if SERPR dataset might provide these measurements 
 
-haemoglobin and dates of measurement for value recorded closest to 
start of RRT and subsequent annual measurements, in case if the closest 
to starting RRT measurement will not be available within SRR we would 
kindly ask to check if SERPR dataset might provide this measurement 
 
-ESA use  
 
-antihypertensive medication (types) and date started and stopped, in case 
if the measurements will not be available within SRR we would kindly ask 




- Lipid lowering treatment (types) and date started and stopped, in case if 
the measurements will not be available within SRR we would kindly ask to 
check if SERPR dataset might provide these measurements 
 
- date of death  
 
-cause of death  
- comorbidities at time of death 
 









5. Time Period of interest: 
 
Up to the end of 2013 
6. Frequency of data (monthly, quarterly...etc.): 
 
 Single data extract 
7. Group of Patients involved: 
Requests for data that will or could allow relevant units to be compared, 
should be specifically highlighted and the reason stated.  
 
Data that could allow the performance of /or outcomes in relevant units to 
be identified, requires permission as noted below. 
 
Research projects should be conducted under the guidelines agreed by the 
relevant steering group.  
 
 
All individuals who developed ESRD in childhood (identified from age<18 
years at first renal replacement therapy) 
 
Differences in outcomes by deprivation decile and Health Board will be 








8. To whom should the data be sent? 
 
eDRIS research co-ordinator - Sian Nowell siannowell@nhs.net for linkage to 
paediatric register, mortality and hospital admissions records 
 
(for non-aggregated data please supply an nhs.net address) 
9. Preferred date data required by: 
 
Autumn 2015 
(Please note: completion dates will be managed around core work by a 
member of the Steering Group/Clinical Co-ordinator. 




11. The purpose for which the data are required: 
eg, NHS Board Needs Assessment, local audit, research, manuscript for 
publication, teaching,.. 
 
The data requested will be analysed for research purposes. The results 
obtained will be described in one of the chapters of Dr Galiyeva’s PhD 
thesis and also presented in publications and conferences in collaboration 




12. Description of the methods used to ensure that confidential data 
are stored and handled with at least the same degree of care and 
security as that provided by the Audit, and in accordance with the 
guidelines issued by the Information Services Division of NHS 
Scotland. Please include details of where the data will be stored 
(eg, in a locked filing cabinet in Dr X’s office) and how access is 
controlled (eg, key held only by consultant or department 
secretary …). 
 




13. Proposed presentations or publications using the data: 
A separate guideline describes the audit’s rules and advice on publication 
of data and reports. 
 
The results of the data analysis will be presented in my PhD thesis, 
Scottish Renal Association meetings, ERA-EDTA or ESPN/ERA-EDTA 
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congress and peer reviewed publications, with review of material by SRR 





a) Please specify any non-NHS funds which will be used. 
b) Any funding that will be required by PHI.  
 





15. Do you anticipate that this project will need to be submitted to: 
 
   a)The steering group (see Information Request Flowchart)              Yes 
 
   b) A local research ethics committee?                               No 
 
   c) A multi-centre or national research ethics committee?                No 
 
   d) The Privacy Advisory Committee at PHI?                           Yes 
 
   e) Caldicott Guardians?                                            Yes 
                
   f) Any other regulatory body?                                      /No 
 
If you have answered “Yes” to question b to f please describe your 
plans. It saves time if the submission to these regulatory bodies is 
developed jointly by the team requesting the data. 
Failure to submit an application to a regulatory body at an early stage 
can result in long delays. 
 
This application is being submitted in parallel to the new Public Benefit and 
Privacy Panel (that now covers the function of both the Privacy Advisory 
Committee and Caldicott Guardians) 
 
 
16. Details of any proposed collaboration with commercial companies 














18. Describe the method of destroying confidential data at the end of 
the project: 
Confidential and patient identifiable data must only be retained for the 
duration of the project. Long term storage of raw data may be required in 
order to provide the possibility of validating or checking research methods 
used in publications. In that case paper documents or data files on a non 
re-writeable medium can be deposited with the PHI office for safe storage. 
The envelope should state the project name, the name of the main 
investigator, the date the data were stored, the date in which the data 
should be destroyed, the medium, the file type and any special instruction 
required to read it, the purpose of storing the data (eg, audit trail of 
published data). 
 
Based on eDRIS guidance with appropriate archiving after publication  
 
 
19. Confirmation from You 
I have read, understood and will adhere to the Information 
Governance checklist. 
 
a) I agree to use the data from the audit only for the purpose 
described above in section 11. If further proposals for data 
analysis or data linkage arise I will submit these for consideration. 
 
b) I understand that the research subgroup may: 
i) In some circumstances be able to release information 
without seeking further approval. 
ii) Need to seek approval from the Steering Group. 
iii) Need to seek further approval from the Privacy Advisory 
Committee of PHI. 
 
 
    Signed: …Dinara Galiyeva……………………………………………. 
 










University of Edinburgh, 
Centre for Population Health Sciences 
RESEARCH ETHICS SUBGROUP 
 
Self-Audit Checklist for Level 1 Ethical Review for PGR projects 
See Intra website for further information: 
http://www.cphs.mvm.ed.ac.uk/intra/research/ethicalReview.php 
NOTE to student: Completion of this form should be under the oversight of your supervisor. A good 
strategy would be to complete a draft as best you can, then discuss with your supervisor before 
completing a final copy for your supervisor to sign. 
Proposed Project (State research question and topic area, and briefly describe 
method/ data. Specify also countries in which data will be collected.): 
Research question of the project: 
What is the prevalence and patterns of cardiovascular risk factors (CVRFs) and what 
is their association with all-cause and cardiovascular (CV) mortality and CV morbidity 
in people who develop end stage renal disease (ESRD) in childhood? 
 Background 
CV disease is a major cause of morbidity and mortality in paediatric patients with 
ESRD and is reported as either the first or second most common cause of death, with 
the other being infection [1]. CV disease incidence in paediatric ESRD patients is 
substantially higher compared to the general age-matched population, at least partly 
because ESRD patients have a higher prevalence of both traditional (hypertension, 
dyslipidaemia, obesity) and uraemia-related (anaemia) CVRFs [2].  
Several studies have reported a high prevalence of hypertension [3] [4], dyslipidaemia 
[5], obesity [6] and anaemia [8] [9] in children with ESRD. Hypertension and anaemia 
have also been found to be associated with an increased risk of death in children 
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receiving renal replacement therapy (RRT) [7] [10]. However, no studies have been 
published describing the association of dyslipidaemia, obesity or anaemia with CV 
mortality in this specific patient population. Furthermore, there are no studies which 
describe the prevalence of combinations of CVRFs and their association with all-cause 
and CV mortality in children on RRT.  
Therefore, the aim of this project is to describe the prevalence of single and 
combinations of multiple CVRFs and to investigate the association between CVRFs 
and all-cause and CV mortality and morbidity in people who develop ESRD in 
childhood. 
Methods 
A retrospective cohort study based on secondary analysis of pseudonymised individual 
level data derived from national Scottish paediatric and adult renal registers linked to 
hospital and mortality records will be performed. The proposal will be reviewed by 
the Scottish Renal Register steering group and the national Public Benefit and Privacy 
Panel Prevalence of traditional and uraemia-related CVRFs and their combinations 
will be described using register data. Kaplan-Meier analysis and Cox proportional 
hazards regression will be used to investigate the association between CVRFs (and 
combinations) and all-cause mortality, cardiovascular mortality and cardiovascular 
morbidity in different groups of patients (for example by primary renal disease), 
corrected for possible confounders. No information that might allow individuals to be 







1. Mitsnefes, M.M., Cardiovascular morbidity and mortality in children with 
chronic kidney disease in North America: Lessons from the USRDS and NAPRTCS 
databases. Peritoneal Dialysis International, 2005. 25: p. 120-122. 
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. . National Kidney Foundation. Am J Kidney Dis 
39:S1-S266, 2002 (suppl 1). 
3. Mitsnefes, M. and D. Stablein, Hypertension in pediatric patients on long-term 
dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS). Am J Kidney Dis, 2005. 45(2): p. 309-15. 
4. Kramer, A.M., et al., Demographics of blood pressure and hypertension in 
children on renal replacement therapy in Europe. Kidney Int, 2011. 80(10): p. 1092-8. 
5. Bonthuis, M., et al., Dyslipidaemia in children on renal replacement therapy. 
Nephrol Dial Transplant, 2014. 29(3): p. 594-603. 
6. Bonthuis, M., et al., Underweight, overweight and obesity in paediatric dialysis 
and renal transplant patients. Nephrol Dial Transplant, 2013. 28 Suppl 4: p. iv195-
iv204. 
7. Jaap W Groothoff, M.P.G., Martin Offringa, Jeroen Hutten, Marc R Lilien, 
Nicole J Van De Kar, Eric D Wolff, Jean Claude Davin and Hugo S A Heymans, 
Mortality and causes of death of end-stage renal disease in children: A Dutch cohort 
study. Kidney International (2002)61,: p. 621–629;. 
8. NAPRTCS 2011 Annual Dialysis Report. 2011. 
9. van Stralen, K.J., et al., Prevalence and predictors of the sub-target Hb level in 
children on dialysis. Nephrol Dial Transplant, 2012. 27(10): p. 3950-7. 
10. Warady BA, M.H., Morbidity and mortality in children with anemia at 
initiation of dialysis. Pediatr Nephrol, 2003. 18: p. 1055–1062. 
 
1. Bringing the University into disrepute 
Is there any aspect of the proposed research which might bring the University into 
disrepute? NO 
2. Data protection and consent 
Are there any issues of DATA PROTECTION or CONSENT which are NOT adequately  
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These include well-established sets of undertakings. For example, a ‘No’ 
answer is justified only if: 
(a) There is compliance with the University of Edinburgh’s Data Protection procedures (see  
    www.recordsmanagement.ed.ac.uk); 
(b) Respondents give consent regarding the collection, storage and, if appropriate, 
archiving and destruction of data; 
(c) Identifying information (eg consent forms) is held separately from data; 
(d) There is Caldicott Guardian approval for (or approval will be obtained prior to) 
obtaining/ analysing NHS patient-data. 
(e) There are no other special issues arising about confidentiality/consent. 
3. Study participants  
Will a study researcher be in direct contact with participants to collect 
data, whether face-to-face, or by telephone, electronic means or post, or 





4. Moral issues and Researcher/Institutional Conflicts of Interest 




(a)  An example of conflict of interest for a researcher would be a financial or 
non-financial benefit for him/herself or for a relative of friend. 
(b)  Particular moral issues or concerns could arise, for example where the 
purposes of research are concealed, where respondents are unable to 
provide informed consent, or where research findings could impinge 
negatively/ differentially upon the interests of participants.  
(c)  Where there is a dual relationship between researcher and participant (eg 
where research is undertaken by practitioners so that the participant might 
be unclear as to the distinction between ‘care’ and research) 
5. Protection of research subject confidentiality 
Are there any issues of CONFIDENTIALITY which are NOT adequately handled by  
normal tenets of confidentiality for academic research?          
 
NO 
These include well-established sets of undertakings that should be agreed with 
collaborating and participating individuals/organisations. For example, a ‘No’ 
answer is justified only if: 
(a) There will be no attribution of individual responses;  
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(b) Individuals (and, where appropriate, organisations) are anonymised in stored 
data, publications and presentation;  
(c) There has been specific agreement with respondents regarding feedback to 
collaborators and publication.  
6. Potential physical or psychological harm, discomfort or stress 
(a) Is there a FORSEEABLE POTENTIAL for PSYCHOLOGICAL HARM or 




(b) Is there a FORSEEABLE POTENTIAL for PHYSICAL HARM or  
 DISCOMFORT for participants? 
 
NO 




Examples of issues/ topics that have the potential to cause psychological harm, 
discomfort or distress and should lead you to answer ‘yes’ to this question 
include, but are not limited to:  
relationship breakdown; bullying; bereavement;  mental health difficulties; 
trauma / PTSD; violence or sexual violence; physical, sexual or emotional 
abuse in either children or adults. 
 
7. Duty to disseminate research findings  
Are there issues which will prevent all relevant stakeholders* having 
access to a clear, understandable and accurate summary of the research 
findings if they 
wish?
  
* If, and only if, you answered ‘yes’ to 3 above, ‘stakeholders’ includes 






 If every answer above is a definite NO, the self-audit has been conducted and confirms the  
ABSENCE OF REASONABLY FORESEEABLE ETHICAL RISKS – please tick box 
This means that regarding this study, as currently self-audited, no further 
ethical review actions  are required within CPHS. However, if in the 
coming weeks/months there is any change to the research plan envisaged 
now (and outlined above), the study should be re-audited against a Level 1 
form, because it may be that the change made negates the absence of 





 If one or more answers are YES, then risks have been identified 
and prior to commencing any data collection formal ethical 
review is required - either: 
 by NHS REC (NB copy of ethics application and decision letter to be 
sent to CPHS Ethics); or  
 if not to be formally reviewed by NHS REC, then CPHS level 2/3 
ethical review required.      [If either of 5 or 7 are answered ‘yes’ 
then almost certainly level 3 is required.] 
Two copies of this form should be taken for inclusion in the final 
dissertation and the original should be returned to the CPHS Ethics 
administrator.  
 
                          





                        











Supervisor Signature * 
* NOTE to supervisor: The CPHS Ethics Subgroup will not check this form (the light touch Level 1 
form means we have insufficient detail to do so). By counter-signing this check-list as truly 
warranting all ‘No’ answers, you are taking responsibility, on behalf of CPHS and UoE, that the 
research proposed truly poses no potential ethical risks. Therefore, if there is any doubt on any issue, 
it would be a wise precaution to mark it as ‘uncertain’ and contact the Ethics Subgroup as to whether 






















Applicants should not fill out this section 
Application Coordinator Sian Nowell 
Application Number 1516-0199 Submitted 
Date 
29.10.2015 
Applicant Name Dinara Galiyeva 
Proposal Name The prevalence and patterns of cardiovascular 
risk factors and their association with all-cause 
mortality, cardiovascular mortality and 
cardiovascular morbidity in people who develop 
end stage renal disease in childhood: a 
retrospective cohort study 
 
 
“Amendment to request causes of death and hospital admission 
data from 1981” 
Chronic kidney disease (CKD) in children is a rare but serious 
condition, as it can progress to end stage renal disease (ESRD), 
which requires initiation of renal replacement therapy (RRT) in the 
form of dialysis or kidney transplantation. Mortality rates among 
children requiring RRT are about 30 times higher than in the age- and 
gender-matched general population (1), (2). The main cause of death 
in children receiving RRT is cardiovascular (CV) mortality, which 
accounts for about 50% of the deaths. Currently we have data on 
causes of death and hospital admissions from 1997 to 2013, however, 
due to the fact that CKD in children is rare condition we need the 
maximum amount of available data on causes of deaths and hospital 
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admissions starting from the beginning of 1981 until the end of 2013 
to improve the power of the current study, specifically in terms of 





1. Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, et al. 
Mortality and causes of death of end-stage renal disease in children: a Dutch cohort 
study. Kidney Int. 2002;61(2):621-9. 
2. Stephen P. McDonald aJCC. Long-Term Survival of Children with End-Stage Renal 
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Note to Applicants 
 
Prior to completing your application form you should: 
 Contact the eDRIS Team, who will assist you - Nss.edris@nhs.net 
or by phone on 0131 275 7333 
 Read and understand the separate Guidance for Applicants 
 
Your application should be typed, not handwritten. Your eDRIS 
application coordinator will inform you how to submit your application 
form and any supporting evidence. Before submitting your completed 
application, you should ensure that: 
 All relevant sections of the application are complete 
 Relevant supporting evidence is attached 
 Individuals named on the form have read and approved its 
submission 
 
Please note that submitted applications may be circulated to panel 
members, administrative colleagues, NHSScotland information 
governance and information security colleagues, Caldicott Guardians, 
the CHI Advisory Group and, where appropriate, non-NHS Scotland 
colleagues from a variety of participating partner bodies, in the course 
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of processing. You must make your eDRIS application coordinator 
aware of any confidential or sensitive information contained in your 
application which you would consider inappropriate for circulation in 
such a manner. Your application could be subject to disclosure or partial 
disclosure under the Freedom of Information (Scotland) Act, and will be 





Section 1 – People 
1.1 Applicant Please read section 1.1 of the guidance 
1.1.01 Full Name:  Dinara Galiyeva 
1.1.02 Title: Miss 




1.1.05 Organisation Name: The University of Edinburgh, Centre for 
population health sciences 
1.1.06 Address: The University of Edinburgh, Old medical 
school, Teviot place, Edinburgh                                  
1.1.07 Postcode: EH8 9AG                                     
1.1.08 Telephone Number: +44 7557850375                                     
1.1.09 Email: Dinara.Galiyeva@ed.ac.uk 




1.1.11 Provide details of the most recent information governance training 
undertaken - a list of training courses is included at Appendix A, 
and you should particularly indicate if you have undertaken any of 
those listed 
 Name of course: MRC Research Data and Confidentiality 
online module 




 Institution: MRC 
 Date completed: October 2015 
 
1.2 Clinical Sponsor/Lead Please read section 1.2 of the guidance  
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1.2.01 Full Name:  Sarah Wild        
1.2.02 Title: Professor 
1.2.03 Position: Professor of Epidemiology and Honorary 





1.2.05 Organisation Name: The University of Edinburgh, Centre for 
population health sciences 
1.2.06 Address: The University of Edinburgh, Old 
medical school, Teviot place, Edinburgh                                  
1.2.07 Postcode: EH8 9AG                                     
1.2.08 Telephone Number: 0131 651 1630                                  
1.2.09 Email: Sarah.Wild@ed.ac.uk 





1.2.11 Provide details of the most recent information governance training 
undertaken - a list of training courses is included at Appendix A, 
and you should particularly indicate if this person has undertaken 
any of those listed 
 Name of course: Safe Researcher Training 




 Institution: ADLS 
 Date completed: June 2013 
 
1.3 Information/Data Custodian Please read section 1.3 of the 
guidance 
1.3.01 Full Name: Sarah Wild 
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1.3.02 Title: Professor 
1.3.03 Position: Professor of Epidemiology/ Hon 




1.3.05 Organisation Name: University of Edinburgh 
1.3.06 Address: Teviot Place 
1.3.07 Postcode: EH8 9AG 
1.3.08 Telephone Number: 0131 651 1630 
1.3.09 Email: Sarah.wild@ed.ac.uk 





1.3.11 Provide details of the most recent information governance training 
undertaken - a list of training courses is included at Appendix A, 
and you should particularly indicate if this person has undertaken 
any of those listed 
 Name of course: Safe Researcher Training 




 Institution: ADLS 
 Date completed: June 2013 
 
1.4 Others with access to identifiable or potentially identifiable data 
Please read section 1.4 of the guidance  
Complete this section if applicable – for each additional person 
















IG Training - Name of course: Safe Researcher Training 
IG Training - Link to course: http://www.adls.ac.uk/safe-researcher-
training/ 
IG Training - Institution: ADLS Date 
completed: 
June 2013 















IG Training - Name of course: MRC Research Data and Confidentiality 
online module 
IG Training - Link to course: http://byglearning.co.uk/mrcrsc-
lms/login/index.php 





1.5 Others Please read section 1.5 of the guidance 
Complete this section if applicable – for each additional person 
Full Name:  Involvement in 
Proposal: 
 





Section 2 – Organisations & Bodies 
2.1 Organisation or Body Leading Proposal Please read section 
2.1 of the guidance  
2.1.01 Organisation or Body Name: University of 
Edinburgh 
2.1.02 Is this organisation or body a registered 
data controller? If ‘Yes’, provide Data 
Protection Registration Number:  
 Yes - Z6426984 
2.1.03 Is this a commercial organisation or 
body?  
No  
2.1.03a If ‘Yes’, please provide a full explanation 
of the organisation or body’s activity and 
industry sector, including any previous 
experience of using NHSScotland data - 
append supporting documentation as 
appropriate 
If applicable 
2.1.04 Is this organisation or body wholly 
funding or paying for the costs of 
conducting the proposal? 
Yes  
 
2.2 Organisation or Body Funding Proposal Please read section 
2.2 of the guidance  
Complete the following section if you answered ‘No’ to question 2.1.4 
2.2.01 Organisation or Body Name: If the organisation here 
is an NHSScotland 
board note this and, go 
directly to section 2.3 
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2.2.02 Is this organisation or body a registered 
data controller? If ‘Yes’, provide Data 
Protection Registration Number: 
Choose an item. 
2.2.03 Is this organisation or body a 
commercial organisation? 
Choose an item.  
2.2.03a If ‘Yes’, please provide a full explanation 
of the organisation or body’s activity and 
industry sector, including any previous 
experience of using NHSScotland data - 








2.3 Other Relevant Organisations or Bodies Please read section 2.3 of 
the guidance  
Complete this section if applicable 
Organisation Name Nature of 
Business/Sector 
Nature of interest in 
proposal 
   
   




 Section 3 – Overview 
3.1 Proposal Essentials Please read section 3.1 of the guidance  
3.1.01 Proposal title/name: The prevalence and patterns 
of cardiovascular risk factors 
and their association with 
all-cause mortality, 
cardiovascular mortality and 
cardiovascular morbidity in 
people who develop end 
stage renal disease in 
childhood: a retrospective 
cohort study 
3.1.02 Is this proposal an extension or 
renewal of an existing approval (for 
example to conduct a study over a 
wider geographic area or for a 
longer period of time)? Please 
provide details, include the reference 
number of the original approval, and 
summarise the changes requested 
No 
3.1.03 Is this new proposal related to a 
previous application (approved or 
not)? Please give details, indicate if 
this is a resubmission, including the 
reference number of the original 
submission 
No 
3.1.04 What is(are) the substantive purpose(s) of the proposal? (tick all 
that apply) 
 ☐ Patient Care ☒ Research 




 ☐ Service 
Planning/Improvement 
☐ Health/Social Care 
Administration 
 ☐ Systems 
Implementation/Testing 
☐ Training/Education 
 ☐ Quality (Clinical, 
Educational, etc) 
 
 If other clearly defined purpose, please give details: 
 
3.1.05 Does the proposal require the use of 
information which can identify or 
potentially identify individuals?  
Yes  
3.1.06 Access is being requested to data from which sources? (tick as 
many as are relevant) 
 ☐  A single NHS Scotland Board (excluding NSS)  
☒  NHS National Services Scotland  
☐  More than one NHS Scotland Board 
☒  A national NHS Scotland system/database 
☒  More than one NHS Scotland system/database 
☐  Community Health Index (CHI) database 
☐  NHS Central Registry 
 
 If other, please give details: 
3.1.07 Provide a full, clear concise outline of the proposal background – 
describe why it is needed, aims and objectives and envisaged 
benefits to the public and/or patients: 
 
Cardiovascular disease (CVD) accounts for about 50% of the 
deaths among paediatric patients with end stage renal disease 
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(ESRD) [1], [2]. In contrast, the proportion of deaths due to CVD in 
the general paediatric population is less than 3% [3]. 
Risk factors for CVD and mortality were first comprehensively 
identified in the Framingham cohort study of an adult general 
population, resulting in the Framingham cardiovascular risk score 
[4], which includes the traditional cardiovascular risk factors 
(CVRFs): hypertension, obesity, dyslipidaemia, diabetes and 
smoking. According to the Kidney Disease Outcome Quality 
Indicators (K/DOQI) clinical practice guidelines for CVD in dialysis 
patients these CVRFs are also common among the adult and 
paediatric ESRD population and contribute to increased risk of CVD 
[1]. Furthermore, during progression to ESRD different pathological 
processes specifically caused by abnormal kidney function lead to 
anaemia, which is also common in the paediatric chronic kidney 
disease population and may also increase risk of CVD.  
 
However, current research conducted in children with ESRD 
provides very little information about the prevalence of CVRFs and 
their association with mortality and cardiovascular outcomes. For 
this reason K/DOQI guidelines for paediatric ESRD population are 
mostly based on research conducted in adults with ESRD. The 
prevalence of traditional and uraemia-related CVRFs in children 
and young adults with ESRD and their association with all-cause, 
cardiovascular mortality and cardiovascular morbidity is unclear.  
 
The main goals of this project are: 
1. To describe the prevalence of individual CVRFs, such as 
hypertension, dyslipidaemia, overweight/obesity and anaemia and 
combination of them in people who develop ESRD in childhood. 
2. To describe the association of above mentioned CVRFs with all-
cause mortality, cardiovascular mortality and cardiovascular 




The work will be conducted in three stages. The first stage will 
describe the prevalence of single and multiple CVRFS in children 
and young adults with ESRD at the start of renal replacement 
therapy. The second step will describe all-cause and cardiovascular 
mortality and cardiovascular disease incidence rates for people who 
developed ESRD in childhood and to compare rates with those for 
the general population available from 
http://www.isdscotland.org/Health-Topics/Heart-
Disease/Publications/data-tables.asp?id=1475#1475. The final 
stage is to describe the association between CVRFs and all-cause 
and cardiovascular mortality and cardiovascular morbidity in people 
who developed ESRD in childhood.  
 
The results of this work will inform further research, clinical practice 
and guidelines in paediatric nephrology with the eventual aim of 
improving outcomes for people who develop ESRD in childhood. 
 
References 
1. K/DOQI Clinical Practice Guidelines for Cardiovascular 
Disease in Dialysis Patients. American Journal of Kidney Diseases, 
2005. 45. 
2. Judith L. Vogelzang, K.J.v.S., Kitty J. Jager and JaapW. 
Groothoff, Trend from cardiovascular to non-cardiovascular late 
mortality in patients with renal replacement therapy since childhood. 
Nephrol Dial Transplant, 2013: p. 2082–2089. 
3. Mitsnefes, M.M., Cardiovascular morbidity and mortality in 
children with chronic kidney disease in North America: Lessons 
from the USRDS and NAPRTCS databases. Peritoneal Dialysis 
International, 2005. 25: p. 120-122. 
4. Ralph B. D'Agostino, S., Ramachandran S. Vasan, Michael 
J. Pencina, Philip A. Wolf, Mark and J.M.M.a.W.B.K. Cobain, 
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General Cardiovascular Risk Profile for Use in Primary Care: The 
Framingham Heart Study American Heart Association, 2008 117: p. 
743-753. 
 
3.1.08 Provide a full, clear and concise outline of the proposal design, 
listing: data sources; sample size; inclusion/exclusion criteria (eg 
involvement in trial/survey; health event, etc); relevant date range; 
need for identifiable or potentially identifiable data; requirement for 
a matched control cohort etc. 
 
Data sources 
The Scottish Renal Register (SRR) and the Strathclyde Electronic 
Renal Patient Record (SERPR) will be used to identify the cohort of 
patients who started renal replacement therapy (dialysis or kidney 
transplant) before they reached 18 years of age and provide risk 
factor data (hypertension and/or overweight/obesity, and/or 
dyslipidaemia and/or anaemia). SERPR dataset is needed to 
provide the data on those risk factors that are not available in SRR, 
such as lipids measurements, antihypertensive medication and 
ESA usage. Outcome data to the end of 2013 are available from 
hospital and mortality records from an existing linkage of SRR data 
to SMR01/NRS records. 
 
Sample size/ inclusion criteria 
Based on all available Scottish data for people developing ESRD in 
childhood 
  
Time Period of interest: 
 
From start of available data – beginning of 1981 to the end of 2015 
 
 
Individual level data will be required for analysis but only 





National age-specific or age-standardised data on all-cause and 
CVD mortality and CVD incidence will be presented for comparison 




1. K/DOQI Clinical Practice Guidelines for Cardiovascular 
Disease in Dialysis Patients. American Journal of Kidney Diseases, 
2005. 45. 
3.1.09 Does the proposal have implications for, or target, sensitive groups 
or vulnerable populations? Please give details 
  
Not from list given below in sections 5 and 6 of appendix 6 
 
3.1.10 Does the proposal seek to use information exclusively about 
deceased persons? Please give details 
  
No, not exclusively, but death is one of the outcomes of interest 
 
3.1.11 Have any members of the public/lay representatives been involved 




3.1.12 Has any peer review of the proposal been undertaken? Please give 
details (for example formal review by a peer organisation or funding 
body, informal internal review, review by a third party) 
  
The main applicant for this proposal is a PhD student of the 
University of Edinburgh, Usher Institute of Population Health 
Sciences and Informatics and this project will be one of the main 
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chapters of the thesis. This project will therefore be reviewed by the 
internal ethics committee and PhD review panels within the Usher 
Institute at the University of Edinburgh. 
 
In addition a very similar project describing the prevalence and 
association of CVRFs and cardiovascular mortality in European 
children receiving RRT conducted by the applicant was approved 
as part of a short-term fellowship within the second year of the 
applicant’s PhD by the European Society for Paediatric Nephrology 
(ESPN) committee. The project was finished on 30.05.2015. The 
results will be also included in the applicant`s thesis and have been 
presented at the Annual Scottish Renal association meeting in 
Dundee in October 2015. The current proposal mainly builds on the 
ESPN project, but the Scottish data will allow extension of the 
eligible cohort into adulthood and will also include cardiovascular 
morbidity as an outcome, which was not possible with the European 
data. 
 
3.1.13 Is there any commercial aspect or dimension to the proposal or its 




3.2 Proposal Geography Please read section 3.2 of the guidance 
☐  Local/Regional (relating to one or more specific areas within Scotland) 
☒  National (relating to the whole of Scotland) 
☐  UK-wide (relating to the whole of the UK, or to UK regions outside 
Scotland) 
☐  International (relating to areas within the EEA) 




3.3 Proposal Duration and Frequency Please read section 3.3 of the 
guidance  
3.3.01 What is the proposed duration of the 
proposal? 
12 months 
3.3.02 Does the proposal require updates of 
information at regular intervals? 
Please give details 
no 
3.3.03 Are you seeking approval to iterate 
the proposal (ie the whole project, 
audit or study) at regular intervals? 
Please give details 
no 
 
3.4 Statutory and Regulatory Context Please read section 3.4 of the 
guidance  
3.4.01 Does your proposal have a statutory 
or regulatory justification - is the 
proposal responding to a statutory or 
regulatory instruction, duty or order? 
Please give details 
No 
3.4.02 Which Data Protection Act schedule 
2 and schedule 3 conditions are 
relevant? (a list of conditions can be 
found at Appendix B) 
Schedule 2, condition 6.  
Schedule 3, condition 3.  
3.4.03 Are there any relevant information 
sharing agreements, protocols or 
contracts in place which support your 
proposal? Please give details and 
attach as supporting documentation 
if available 
If applicable 
3.4.04 Has a Privacy Impact Assessment 
been carried out which supports your 




attach as supporting documentation 
if available 
3.4.05 Has local Caldicott approval been 
given for your proposal at a local 
level? Please give details 
If applicable 
3.4.06 Are approvals from Caldicott 
Guardians outside Scotland pending 
or received? Please give details 
If applicable 
 
3.5 Research and Ethics Governance Please read section 3.5 of 
the guidance 
3.5.01 Has your proposal sought research/ethics 
approval? 
Yes  
3.5.01a If yes, please provide committee details and 
status of approval (ie pending, approved, etc). 
Please attach as supporting documentation if 
available 
Level 1 review 






3.5.01b If no, please explain why research/ethics 




3.6 Safe Havens Please read section 3.6 of the guidance 
3.6.01 Do you intend to access the data 
requested exclusively through a safe 
haven listed at Appendix A? Please 
provide details of which safe haven/s 
Yes NSS National Safe 
Haven 
3.6.02 If you applying to use NHS NSS data 
and you do not intend to do this 
through the National Safe Haven, 








Section 4 – Data & Data Subjects 






Explicit consent sought? If Yes, 
describe how explicit consent being 
sought – provide copies of participant 
consent/registration forms, etc. If No, 
explain why consent is not being 
sought (eg impractical, risk associated 
with seeking consent, etc) 
   
   
   
 
4.2 All Other Datasets / sources Please read section 4.2 of the guidance 
Dataset/source 
Name 








Susan Burns/ NHS Greater 





Mortality records and 
hospital admissions 
ISD Yes 
How were individuals originally informed of the use of their data? (if known) 





For existing dataset/sources for which the data controller is not an 
NHSScotland board, please append evidence of the data controllers 
permission to use the data 
 









CHI number For cohort 
identified from 
renal register 
Yes – for data 
linkage by 
eDRIS, to be 














-eGFR and dates of 
measurement 
-date of start of 
renal replacement 
therapy (RRT) 
-type of RRT at start 














-changes in RRT 
and dates of 
measurement 
- height and dates 
of measurement  
- dry body weight 
and dates of 
measurement  
-BMI and dates of 
measurement  
-pre- and post-
dialysis systolic and 
diastolic blood 
pressure and dates 
of measurement  
-total cholesterol 











-ESA use and date 





and date started 
and stopped  
- Lipid lowering 
treatment (types) 
and date started 
and stopped 
- comorbidities at 
time of death 
-end of follow up 
date/lost to follow 
up, date of 
emigration or date 
of last vital data 
- date of death  
-cause of death  
  
Death registration  - date of death  
-all causes of death  
 











records (ICD-10 I 
chapter codes) 








    
Please justify your need for identifiable or potentially identifiable variables: 
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- Age, sex and race are crucial variables in order to make fair 
comparisons both with mortality in the general population but also for 
comparison within the cohort, for example for people with different types of 
kidney disease. As this is a paediatric population month of birth is needed as 
well as year of birth to improve precision of estimates of age. 
 
To link the data and to control for confounding by age and sex  
 
4.4 NRS/NHSCR Data Sources Please read section 4.4 of the 
guidance  
Complete this section if access to NHSCR is required, or if there is any 
National Records of Scotland involvement 
4.4.01 Does the proposal require access to NHS 
Central Registry as a sampling frame for 
cohorts? 
No  
4.4.02 Does the proposal involve flagging of 
individuals on the NHSCR for long term 
follow up? 
No  
4.4.03 If yes, is flagging necessary: 
 ☐ To trace and contact individuals throughout the UK?  
 ☐ To be informed of fact and cause of death?  
 ☐ To be informed of the incidence of on-going cancers?  
 ☐ To be informed of emigrations prospectively and 
retrospectively?  
4.4.04 Is any other NRS involvement 
required? Please provide 
details 
Yes 
To provide death data 
 




4.5.01 Is any direct contact with any group of individuals 
required? If Yes, please provide details below 
No  
 Contact Group and Method of contact Contact by 
(whom) 




























































4.5.02 Please explain why contact is being made – append copies of 
relevant correspondence as supporting evidence 
 
 If applicable 
 
4.6 Community Health Index (CHI) Database Please read section 
4.6 of the guidance 
Complete this section if access to CHI Database is required 
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4.6.01 What monitoring and audit of 
the use of CHI is planned? 
Please provide details 
Not applicable 
4.6.02 What technical method will be 
used to access CHI (online 
read-only, download, other 
extract, anonymised extract, 
etc)? Please provide details 
 
4.6.03 Have any risks been identified 
in the proposal which relate 







Section 5 – Methodology & Data Processing  
5.1 Methodology Please read section 5.1 of the guidance 
5.1.01 Does the proposal require any of the following: 
☒ Data 
matching/linking 
☐  Use of matched 
controls 
☒ Single anonymised data extract  
 
Other (please specify): 
 
5.1.02 Who is carrying out any indexing/ 
linkage/anonymisation, and where? 
eDRIS 
5.1.03 Which data sources listed at section 4.1 and 
4.2 will NSS/NRS receive identifiers for 
linkage purposes? 
All 
5.1.04 What variables will be provided for linkage?  
 
☒ CHI Number ☐ Forename ☐ Surname 
☒ Date of Birth ☐ Address or 
Postcode 
☐ NHS Number 
Other Please Specify: 
 
 
5.2 Access Please read section 5.2 of the guidance 
Complete the following section if you answered ‘No’ to question 3.6.1 
5.2.01 At what location is identifiable or 
potentially identifiable data being 
accessed? 
Not applicable 
5.2.02 Please provide details of security 




physical and technical environment – 
append supporting documentation  
5.2.03 Does this policy/procedure cover 
password policy in detail? Please provide 
details/ append supporting documentation 
 
5.2.04 Does this policy/procedure cover user 
account management, including review or 
removal of access to sensitive/personal 
data, in detail? Please provide details/ 
append supporting documentation  
 
5.2.05 Will individuals with access to data have 
individual or shared accounts? 
 
5.2.06 Will the data be accessed by staff working 
off site eg staff working from home at any 
time during the duration of the proposal?  
Choose an item.  
5.2.06b If yes, are policies/procedures in place to 
facilitate, monitor and audit this access? 
Please provide details/ append supporting 
documentation 
If applicable 
5.2.07 Provide any additional detail of how data 
is protected from unauthorised access 
If applicable 
 
5.3 Store & Use Please read section 5.3 of the guidance 
Complete the following section if you answered ‘No’ to question 3.6.1 
5.3.01 Where is data being stored and used? 
(location, organisation, address – refer to 
addresses in previous sections if 
appropriate) 
 
5.3.02 Data Protection Registration Number If applicable 
5.3.03 ISO 27001 Cert. No. If applicable 
5.3.04 Please provide details of security 




use of data within this physical and 
technical environment – append supporting 
documentation 
5.3.05 Does this policy/procedure cover the 
implementation of up-to-date controls for 
the detection and prevention of malware? 
Please provide details/ append supporting 
documentation 
 
5.3.06 Does this policy/procedure cover access 
control and auditing of system 
administrator activity? Please provide 
details/ append supporting documentation 
 
5.3.07 Does this policy/procedure cover the 
production of backups and the controls in 
place around these? Please provide 
details/ append supporting documentation 
 
5.3.08 Does this policy/procedure describe the 
controls in place to prohibit unauthorised 
copying of data? Please provide details/ 
append supporting documentation 
 
5.3.09 Does this policy/procedure describe 
physical and site controls? Please provide 
details/ append supporting documentation 
 
5.3.10 Does this policy/procedure cover hardware 
repair, replacement or disposal and 
protection of data from inappropriate 
access during such procedures? Please 
provide details/ append supporting 
documentation 
 
5.3.11 Describe the systems, software and 




please provide details/ append supporting 
documentation 
5.3.12 Is outsourced IT in use? Please give 
details 
 
Please repeat section 5.3 above for each relevant location in the proposal 
– see guidance 
  
 
5.4 Transfer Please read section 5.4 of the guidance 
5.4.01 Please provide details of security 
policy/procedure to ensure that data will be 
transferred in such a way that it is 
protected from inappropriate or 
unauthorised access (mention email 
encryption, secure file transfer protocols 
SFTP, device encryption, physical controls, 
etc, as appropriate) - append supporting 
documentation 
Data will be 
transferred by 
secure file transfer 
5.4.02 At what intervals/ trigger points will data 
transfer take place? 
At start of study 
5.4.03 Will any identifiable or potentially 
identifiable data be transferred outside of 
the UK? 
No  
5.4.03b If yes, please provide details of the country 
of destination, the method of transfer, the 
proposed location and method of storage 
outside of the UK, and details of any further 
onward transfer 
If applicable 
5.4.04 Other than initial transfers from source 
systems, is there any copying of data 






5.5 Dissemination Please read section 5.5 of the guidance 
5.5.01 Will proposal findings be published or 
disseminated beyond the proposal team? 
Yes If you have 
answered ‘No’, go 
directly to section 5.6 
5.5.01a If yes, how will proposal findings be 
published or disseminated, to what 
audience and in what format? Please 
give details 
Abstracts to renal 
conferences and peer 
reviewed papers 
5.5.01b If yes, what steps will be taken to ensure 
that persons cannot be identified in 
published findings (eg disclosure control 
procedures (safe haven), use of aliases, 
numbers, avoidance of small 
geographical areas, avoidance of small 
numbers, etc)? Please give details 
No cells in published 
work will contain 
fewer than 5 
individuals 
5.5.01c If yes, are there any circumstances 
where a living or dead individual would 
be cited? (eg where a person consented 
to their data being used as a case 
study)? Please give details 
No 
5.5.01d If yes, were any permissions to publish 
data required or sought (for example 




5.6 Retain/Dispose Please read section 5.6 of the guidance  
5.6.01 Which information/data/records retention 
policy will you be applying to the proposal 
data (details of the policy and the 
organisation to which it belongs)? 
NSS National Safe 




5.6.02 How long do you intend to retain identifiable 
or potentially identifiable data after the 
conclusion of the proposal (including 
archive/backup copies)? 
As advised by 
eDRIS 
5.6.03 Who will retain the data and where? NSS National Safe 
Haven 
5.6.04 What is the purpose for retaining the data 




5.6.05 What method of disposal or destruction will 
be used when this period has expired 
(including archive/backup copies)? 
NSS National Safe 
Haven destruction 
policy 
5.6.06 What evidence will be obtained that 
destruction has occurred (eg IT supplier 
certificate of destruction, etc)? 




5.7 Review Please read section 5.7 of the guidance 
5.7.01 Describe how the mechanisms which 
safeguard data security will be audited 
and reviewed at regular intervals to ensure 
their continued efficacy 
Data will only be 
accessed by the 
applicants and 
information custodian 
via the safe haven 
5.7.02 Describe any resource implications to any 
of the proposed measures for the 
protection of physical or technical security 
of information which are unresolved at the 
time of this application? (for example 
encryption of devices is an intention not 
yet fulfilled, training is not yet undertaken, 
etc) 
NA 
5.7.03 Describe the breach reporting 
mechanisms to be invoked in the event of 




any inappropriate access to data or other 
information security incident 




Section 6 – Declaration 
 
 I DECLARE THAT this application is accurate, and that, should it be 
successful, any health data made accessible will be used for no 
other purpose, and in no other way, than as described above.  
 I UNDERTAKE TO notify the Public Benefit and Privacy Panel of any 
future changes to the purpose or manner in which data is processed 
in accordance with this application. 
 I UNDERSTAND THAT any future applications by me, or my 
employing or sponsoring organisation, may be refused should any 
health data made accessible be used for any other purpose or in any 
other way than that described above.  
 I CERTIFY THAT all those who have access to health data in this 
proposal are aware of the requirements of confidentiality and 
understand that any breach (eg disclosure of confidential information 
to a person not authorised to receive it) will be reported to the data 
controller, and in the case of NHS Scotland originated data to 
Scottish Government eHealth division. 
 I GUARANTEE THAT no publication will appear in any form in which 
an individual may be identified without the written permission of that 
individual, and that I will apply appropriate disclosure control when 
planning publications involving the data requested. 
 I UNDERSTAND THAT the Data Controller, and agents acting on its 
behalf, reserves the right to inspect the data on the sites where it is 
being processed. 
 
To be signified by the APPLICANT 






 I DECLARE THAT (the applicant named above) is a bona fide worker 
engaged in a reputable project and that the data he/she asks for can 
be entrusted to him/her in the knowledge that he/she will 
conscientiously discharge his/her obligations, including in regard to 
confidentiality of the data, as stated in the declaration above. 
 
To be signified by the INFORMATION CUSTODIAN named in Section 
1.3 above (where the Information Custodian is not the applicant). 




Section 7 - Supporting Evidence  
 
Supporting Evidence Please read section 7 of the guidance  
Please list each piece of supporting evidence which you have 
included with your application in the box below – the name of 
each should clearly indicate what the document/file/reference is 
about 
Application form for data access to Scottish Renal Registry 
CPHS ethical review form 
Information Governance Training Certificates for Dinara 






List of terms included within the exploded heading “cardiovascular 
diseases” 
 
Cardiovascular Diseases [C14]  
 Cardiovascular Abnormalities [C14.240]   
 Cardiovascular Infections [C14.260]   
o Endocarditis, Bacterial [C14.260.249]   
o Syphilis, Cardiovascular [C14.260.500]  
o Tuberculosis, Cardiovascular [C14.260.750]   
 Heart Diseases [C14.280]   
o Arrhythmias, Cardiac [C14.280.067]   
 Arrhythmia, Sinus [C14.280.067.093]   
 Atrial Fibrillation [C14.280.067.198]  
 Atrial Flutter [C14.280.067.248]  
 Bradycardia [C14.280.067.319]  
 Brugada Syndrome [C14.280.067.322]  
 Cardiac Complexes, Premature [C14.280.067.325]   
 Commotio Cordis [C14.280.067.441]  
 Heart Block [C14.280.067.558]   
 Long QT Syndrome [C14.280.067.565]   
 Parasystole [C14.280.067.672]  
 Pre-Excitation Syndromes [C14.280.067.780]   
 Tachycardia [C14.280.067.845]   
 Ventricular Fibrillation [C14.280.067.922]  
 Ventricular Flutter [C14.280.067.961]  
o Carcinoid Heart Disease [C14.280.104]  
o Cardiac Conduction System Disease [C14.280.123]   
o Cardiac Output, High [C14.280.142]  
o Cardiac Output, Low [C14.280.148]  
o Cardiac Tamponade [C14.280.155]  
o Cardiomegaly [C14.280.195]   
o Cardiomyopathies [C14.280.238]   
o Endocarditis [C14.280.282]   
o Heart Aneurysm [C14.280.358]  
o Heart Arrest [C14.280.383]   
o Heart Defects, Congenital [C14.280.400]   
o Heart Failure [C14.280.434]   
o Heart Neoplasms [C14.280.459]   
o Heart Rupture [C14.280.470]   
o Heart Valve Diseases [C14.280.484]   
o Myocardial Ischemia [C14.280.647]   
o Myocardial Stunning [C14.280.671]  
o Pericardial Effusion [C14.280.695]  
o Pericarditis [C14.280.720]   
o Pneumopericardium [C14.280.763]  
436 
 
o Postpericardiotomy Syndrome [C14.280.793]  
o Pulmonary Heart Disease [C14.280.832]  
o Rheumatic Heart Disease [C14.280.874]  
o Ventricular Dysfunction [C14.280.945]   
o Ventricular Outflow Obstruction [C14.280.955]   
 Pregnancy Complications, Cardiovascular [C14.583]   
 Vascular Diseases [C14.907]   
o Aneurysm [C14.907.055]   
o Angiodysplasia [C14.907.075]   
o Angiomatosis [C14.907.077]   
o Angioedema [C14.907.079]   
o Aortic Diseases [C14.907.109]   
o Arterial Occlusive Diseases [C14.907.137]   
o Arteriovenous Malformations [C14.907.150]   
o Capillary Leak Syndrome [C14.907.218]  
o Cerebrovascular Disorders [C14.907.253]   
 Basal Ganglia Cerebrovascular Disease [C14.907.253.061]   
 Brain Ischemia [C14.907.253.092]   
 Carotid Artery Diseases [C14.907.253.123]   
 Cerebral Small Vessel Diseases [C14.907.253.329]   
 Cerebrovascular Trauma [C14.907.253.535]   
 Intracranial Arterial Diseases [C14.907.253.560]   
 Intracranial Embolism and Thrombosis [C14.907.253.566]   
 Intracranial Hemorrhages [C14.907.253.573]   
 Leukomalacia, Periventricular [C14.907.253.612]  
 Sneddon Syndrome [C14.907.253.774]  
 Stroke [C14.907.253.855]   
 Vascular Headaches [C14.907.253.937]  
 Vasculitis, Central Nervous System [C14.907.253.946]   
 Vasospasm, Intracranial [C14.907.253.951]  
o Colitis, Ischemic [C14.907.286]  
o Compartment Syndromes [C14.907.303]   
o Diabetic Angiopathies [C14.907.320]   
o Embolism and Thrombosis [C14.907.355]   
o Hand-Arm Vibration Syndrome [C14.907.440]  
o Hemorrhoids [C14.907.449]  
o Hemostatic Disorders [C14.907.454]   
o Hepatic Veno-Occlusive Disease [C14.907.460]  
o Hyperemia [C14.907.474]  
o Hypertension [C14.907.489]   
o Hypotension [C14.907.514]   
o Mesenteric Ischemia [C14.907.549]  
o Myocardial Ischemia [C14.907.585]   
o Optic Neuropathy, Ischemic [C14.907.601]  
o Peliosis Hepatis [C14.907.609]  
o Peripheral Vascular Diseases [C14.907.617]   
o Prehypertension [C14.907.653]  
o Pulmonary Veno-Occlusive Disease [C14.907.690]  
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o Reperfusion Injury [C14.907.725]   
o Retinal Vein Occlusion [C14.907.760]  
o Scimitar Syndrome [C14.907.780]  
o Spinal Cord Vascular Diseases [C14.907.790]   
o Splenic Infarction [C14.907.795]  
o Stenosis, Pulmonary Vein [C14.907.798]  
o Superior Vena Cava Syndrome [C14.907.800]  
o Telangiectasis [C14.907.823]   
o Thoracic Outlet Syndrome [C14.907.863]   
o Varicocele [C14.907.903]  
o Varicose Veins [C14.907.927]   
o Vascular Fistula [C14.907.933]   
o Vascular Neoplasms [C14.907.936]  
o Vascular System Injuries [C14.907.937]  
o Vasculitis [C14.907.940]   
o Vasoplegia [C14.907.946]  





MEDLINE search strategy (1946 to July Week 2015) excluding records 
added from August 2015 and separating English and non-English 
papers 
1. (chronic kidney or chronic renal or CKD or impaired renal function or end stage 
renal disease or ESRD or renal replacement therapy or RRT or dialysis or 
hemodialysis or haemodialysis or peritoneal dialysis or renal transplantation or 
kidney transplantation).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms]    
2. exp renal replacement therapy/ or exp renal dialysis/ or exp kidney transplantation/    
3. exp renal insufficiency, chronic/ or exp kidney failure, chronic/    
4. 1 or 2 or 3    
5. (death or mortality or all- cause mortality or all-cause death or overall mortality or 
overall death).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms]    
6. (cardiovascular mortality or cardiovascular death or cerebrovascular mortality or 
cerebrovascular death).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms]    
7. exp Mortality/    
8. exp Cardiovascular Diseases/ or exp Cerebrovascular Disorders/ or 
cerebrovascular morbidity.mp. or cardiovascular morbidity.mp.    
9. 5 or 6 or 7 or 8    
10. (cardiovascular risk factors or risk prediction score or risk prediction model).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms]    
11. exp risk factors/    
12. exp hypertension/ or exp hypertension, renal/ or hypertension.mp.    
13. (Obes$ or overweight or BMI or body mass index or underweight).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms]    
14. exp Obesity/ or exp Overweight/ or exp Body Weight/    
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15. (anemia or anaemia or target hemoglobin or haemoglobin or iron deficiency).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms]    
16. exp Anemia/    
17. (dyslipidemia or dyslipidaemia or hyperlipidemia or hyperlipidaemia or 
dyslipoproteinemia or dyslipoproteinaemia or abnormal lipid profile or 
hypercholesterolaemia or hypercholesterolemia or cholesterol or triglycerides).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms]    
18. exp dyslipidemias/ or exp hyperlipidemias/    
19. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18    
20. (child* or paediatric or pediatric or teen* or adolescen* or young adult*).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms]    
21. exp Child/    
22. 20 or 21    
23. 4 and 9 and 19 and 22    
24. limit 23 to (english language and humans)    
25. (201508$ or 201509$ or 20151$ or 2016$ or 2017$).ed.    
26. 23 not 25    
27. limit 26 to humans    
28. limit 27 to english language    
29. 27 not 28 
